Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
HUMAN GENES AND GENE EXPRESSION PRODUCTS
Document Type and Number:
WIPO Patent Application WO/2000/018916
Kind Code:
A2
Abstract:
This invention relates to novel human polynucleotides and variants thereof, their encoded polypeptides and variants thereof, to genes corresponding to these polynucleotides and to proteins expressed by the genes. The invention also relates to diagnostic and therapeutic agents employing such novel human polynucleotides, their corresponding genes or gene products, e.g., these genes and proteins, including probes, antisense constructs, and antibodies.

Inventors:
WILLIAMS LEWIS T
ESCOBEDO JAIME
INNIS MICHAEL A
GARCIA PABLO DOMINGUEZ
SUDDUTH-KLINGER JULIE
REINHARD CHRISTOPH
GIESE KLAUS
RANDAZZO FILIPPO
KENNEDY GIULIA C
POT DAVID
KASSAM ALTAF
LAMSON GEORGE
DRMANAC RADOJE
CRKVENJAKOV RADOMIR
DICKSON MARK
DRMANAC SNEZANA
LABAT IVAN
LESHKOWITZ DENA
KITA DAVID
GARCIA VERONICA
JONES LEE WILLIAM
STACHE-CRAIN BIRGIT
Application Number:
PCT/US1999/022226
Publication Date:
April 06, 2000
Filing Date:
September 23, 1999
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
CHIRON CORP (US)
HYSEQ INC (US)
International Classes:
C12N15/09; C07K14/47; C07K16/18; C12N1/15; C12N1/19; C12N1/21; C12N5/10; C12N15/12; C12Q1/68; (IPC1-7): C12N15/12; C07K14/47; C07K16/18; C12Q1/68
Domestic Patent References:
WO1992020798A11992-11-26
WO1996030389A11996-10-03
WO1999033982A21999-07-08
Other References:
CARMECI ET AL: "Identification of a gene (GPR30) with homolgy to the G-protein-coupled receptor superfamily associated with estrogen receptor expression in breast cancer" GENOMICS,US,ACADEMIC PRESS, SAN DIEGO, vol. 45, no. 3, 1 November 1997 (1997-11-01), pages 607-617-17, XP002099963 ISSN: 0888-7543
YEATMAN, T.J. ET AL.: "Identification of a differentially expressed message associated with colon cancer liver metastasis using an improved method of differential display." NUCLEIC ACIDS RESEARCH,GB,OXFORD UNIVERSITY PRESS, SURREY, vol. 23, no. 19, 1995, pages 4007-4008-8, XP002099962 ISSN: 0305-1048
See also references of EP 1144636A2
Attorney, Agent or Firm:
Blackburn, Robert P. (P.O. Box 8097 Emeryville, CA, US)
Download PDF:
Claims:
We Claim :
1. A library of polynucleotides, the library comprising the sequence information of at least one of SEQ ID NOS : 11079.
2. The library of claim 1, wherein the library is provided on a nucleic acid array.
3. The library of claim 1, wherein the library is provided in a computerreadable format.
4. The library of claim 1, wherein the library comprises a polynucleotide corresponding to a gene differentially expressed in cell of high metastatic potential relative to a control cell, wherein the control cell is a normal cell or a cell of low metastatic potential, and wherein the sequence is selected from the group consisting of SEQ ID NOS : 350, 571, 781, 778, 756, 779, 691, 686, 916, and 969.
5. The library of claim 1, wherein the library comprises a polynucleotide corresponding to a gene differentially expressed in a cancer cell of low metastatic potential relative to a control cell, wherein the control cell is a normal cell or a cell of high metastatic potential, and wherein the sequence is selected from the group consisting of SEQ ID NOS : 34, 57, 103, 110, 113, 189, 214, 359, 521, 532, 533, 536, 547, 549, 554, 555, 558, 561, 562, 572, 582, 584, 587, 589, 590, 591, 592, 599, 603, 607, 609, 623, 624, 635, 636, 637, 641, 646, 647, 648, 650, 653, 654, 656, 657, and 661.
6. An isolated polynucleotide comprising a nucleotide sequence having at least 90% sequence identity to an identifying sequence of SEQ ID NOS : I1079 or a degenerate variant or fragment thereof.
7. A recombinant host cell containing the polynucleotide of claim 6.
8. An isolated polypeptide encoded by the polynucleotide of claim 6.
9. An antibody that specifically binds a polypeptide of claim 8.
10. A vector comprising the polynucleotide of claim 6.
11. A polynucleotide comprising the nucleotide sequence of an insert contained in a clone deposited as ATCC accession number xx, or xx.
12. A method of detecting differentially expressed genes correlated with a cancerous state of a mammalian cell, the method comprising the step of : detecting at least one differentially expressed gene product in a test sample derived from a cell suspected of being cancerous, where the gene product is encoded by a gene corresponding to a sequence of at least one of SEQ ID NOS : 34, 57, 100, 103, 110, 113, 189, 209, 214, 316, 350, 359, 370, 521, 532, 533, 536, 547, 549, 554, 555, 558, 561, 562, 571, 572, 582, 584, 587, 589, 590, 591, 592, 599, 603, 607, 609, 623, 624, 635, 636, 637, 641, 645, 646, 647, 648, 650, 653, 654, 656, 657, 661, 781, 778, 756, 779, 691, 686, 854, 916, and 969 ; wherein detection of the differentially expressed gene product is correlated with a cancerous state of the cell from which the test sample was derived.
Description:
HUMAN GENES AND GENE EXPRESSION PRODUCTS Field of the Invention The present invention relates to polynucleotides of human origin and the encoded gene products.

Background of the Invention Identification of novel polynucleotides, particularly those that encode an expressed gene product, is important in the advancement of drug discovery, diagnostic technologies, and the understanding of the progression and nature of complex diseases such as cancer. Identification of genes expressed in different cell types isolated from sources that differ in disease state or stage, developmental stage, exposure to various environmental factors, the tissue of origin, the species from which the tissue was isolated, and the like is key to identifying the genetic factors that are responsible for the phenotypes associated with these various differences.

This invention provides novel human polynucleotides, the polypeptides encoded by these polynucleotides, and the genes and proteins corresponding to these novel polynucleotides.

Summarv of the Invention This invention relates to novel human polynucleotides and variants thereof, their encoded polypeptides and variants thereof, to genes corresponding to these polynucleotides and to proteins expressed by the genes. The invention also relates to diagnostics and therapeutics comprising such novel human polynucleotides, their corresponding genes or gene products, including probes, antisense nucleotides, and antibodies. The polynucleotides of the invention correspond to a polynucleotide comprising the sequence information of at least one of SEQ ID NOS : 1-1079.

Various aspects and embodiments of the invention will be readily apparent to the ordinarily skilled artisan upon reading the description provided herein.

Detailed Description of the Invention The invention relates to polynucleotides comprising the disclosed nucleotide sequences, to full length cDNA, mRNA genomic sequences, and genes corresponding to these sequences and degenerate variants thereof, and to polypeptides encoded by the polynucleotides of the invention and polypeptide variants. The following detailed description describes the polynucleotide compositions encompassed by the invention, methods for obtaining cDNA or genomic DNA encoding a full-length gene product, expression of these polynucleotides and genes, identification of structural motifs of the polynucleotides and genes, identification of the function of a gene product encoded by a gene corresponding to a polynucleotide of the invention, use of the provided polynucleotides as probes and in mapping and in tissue profiling, use of the corresponding polypeptides and other gene products to raise antibodies, and use of the polynucleotides and their encoded gene products for therapeutic and diagnostic purposes.

Polvnucleotide Compositions The scope of the invention with respect to polynucleotide compositions includes, but is not necessarily limited to, polynucleotides having a sequence set forth in any one of SEQ ID NOS : 1- 1079 ; polynucleotides obtained from the biological materials described herein or other biological sources (particularly human sources) by hybridization under stringent conditions (particularly conditions of high stringency) ; genes corresponding to the provided polynucleotides ; variants of the provided polynucleotides and their corresponding genes, particularly those variants that retain a biological activity of the encoded gene product (e. g., a biological activity ascribed to a gene product corresponding to the provided polynucleotides as a result of the assignment of the gene product to a protein family (ies) and/or identification of a functional domain present in the gene product). Other nucleic acid compositions contemplated by and within the scope of the present invention will be readily apparent to one of ordinary skill in the art when provided with the disclosure here.

"Polynucleotide"and"nucleic acid"as used herein with reference to nucleic acids of the composition is not intended to be limiting as to the length or structure of the nucleic acid unless specifically indicted.

The invention features polynucleotides that are expressed in human tissue, specifically human colon, breast, and/or lung tissue. Novel nucleic acid compositions of the invention of particular interest comprise a sequence set forth in any one of SEQ ID NOS : 1-1079 or an identifying sequence thereof. An"identifying sequence"is a contiguous sequence of residues at least about 10 nt to about 20 nt in length, usually at least about 50 nt to about 100 nt in length, that uniquely identifies a polynucleotide sequence, e. g., exhibits less than 90%, usually less than about 80% to about 85% sequence identity to any contiguous nucleotide sequence of more than about 20 nt. Thus, the subject novel nucleic acid compositions include full length cDNAs or mRNAs that encompass an identifying sequence of contiguous nucleotides from any one of SEQ ID NOS : 1-1079.

The polynucleotides of the invention also include polynucleotides having sequence similarity or sequence identity. Nucleic acids having sequence similarity are detected by hybridization under low stringency conditions, for example, at 50°C and 10XSSC (0. 9 M saline/0. 09 M sodium citrate) and remain bound when subjected to washing at 55°C in IXSSC. Sequence identity can be determined by hybridization under stringent conditions, for example, at 50°C or higher and 0. 1XSSC (9 mM saline/0. 9 mM sodium citrate). Hybridization methods and conditions are well known in the art, see, e. g., USPN 5, 707, 829. Nucleic acids that are substantially identical to the provided polynucleotide sequences, e. g. allelic variants, genetically altered versions of the gene, etc., bind to the provided polynucleotide sequences (SEQ ID NOS : I-1079) under stringent hybridization conditions. By using probes, particularly labeled probes of DNA sequences, one can isolate homologous or related genes. The source of homologous genes can be any species, e. g. primate

species, particularly human ; rodents, such as rats and mice ; canines, felines, bovines, ovines, equines, yeast, nematodes, etc.

Preferably, hybridization is performed using at least 15 contiguous nucleotides (nt) of at least one of SEQ ID NOS : 1-1079. That is, when at least 15 contiguous nt of one of the disclosed SEQ ID NOS. is used as a probe, the probe will preferentially hybridize with a nucleic acid comprising the complementary sequence, allowing the identification and retrieval of the nucleic acids that uniquely hybridize to the selected probe. Probes from more than one SEQ ID NO. can hybridize with the same nucleic acid if the cDNA from which they were derived corresponds to one mRNA. Probes of more than 15 nt can be used, e. g., probes of from about 18 nt to about 100 nt, but 15 nt represents sufficient sequence for unique identification.

The polynucleotides of the invention also include naturally occurring variants of the nucleotide sequences (e. g., degenerate variants, allelic variants, etc.). Variants of the polynucleotides of the invention are identified by hybridization of putative variants with nucleotide sequences disclosed herein, preferably by hybridization under stringent conditions. For example, by using appropriate wash conditions, variants of the polynucleotides of the invention can be identified where the allelic variant exhibits at most about 25-30% base pair (bp) mismatches relative to the selected polynucleotide probe. In general, allelic variants contain 15-25% bp mismatches, and can contain as little as even 5-15%, or 2-5%, or 1-2% bp mismatches, as well as a single bp mismatch.

The invention also encompasses homologs corresponding to the polynucleotides of SEQ ID NOS : I-1079, where the source of homologous genes can be any mammalian species, e. g., primate species, particularly human ; rodents, such as rats ; canines, felines, bovines, ovines, equines, yeast, nematodes, etc. Between mammalian species, e. g., human and mouse, homologs generally have substantial sequence similarity, e. g., at least 75% sequence identity, usually at least 90%, more usually at least 95% between nucleotide sequences. Sequence similarity is calculated based on a reference sequence, which may be a subset of a larger sequence, such as a conserved motif, coding region, flanking region, etc. A reference sequence will usually be at least about 18 contiguous nt long, more usually at least about 30 nt long, and may extend to the complete sequence that is being compared. Algorithms for sequence analysis are known in the art, such as gapped BLAST, described in Altschul, et al. Nucleic Acids Res. (1997) 25 : 3389-3402.

In general, variants of the invention have a sequence identity greater than at least about 65%, preferably at least about 75%, more preferably at least about 85%, and can be greater than at least about 90% or more as determined by the Smith-Waterman homology search algorithm as implemented in MPSRCH program (Oxford Molecular). For the purposes of this invention, a preferred method of calculating percent identity is the Smith-Waterman algorithm, using the following. Global DNA sequence identity must be greater than 65% as determined by the Smith-

Waterman homology search algorithm as implemented in MPSRCH program (Oxford Molecular) using an affine gap search with the following search parameters : gap open penalty, 12 ; and gap extension penalty, 1.

The subject nucleic acids can be cDNAs or genomic DNAs, as well as fragments thereof, particularly fragments that encode a biologically active gene product and/or are useful in the methods disclosed herein (e. g., in diagnosis, as a unique identifier of a differentially expressed gene of interest, etc.). The term"cDNA"as used herein is intended to include all nucleic acids that share the arrangement of sequence elements found in native mature mRNA species, where sequence elements are exons and 3'and 5'non-coding regions. Normally mRNA species have contiguous exons, with the intervening introns, when present, being removed by nuclear RNA splicing, to create a continuous open reading frame encoding a polypeptide of the invention.

A genomic sequence of interest comprises the nucleic acid present between the initiation codon and the stop codon, as defined in the listed sequences, including all of the introns that are normally present in a native chromosome. It can further include the 3'and 5'untranslated regions found in the mature mRNA. It can further include specific transcriptional and translational regulatory sequences, such as promoters, enhancers, etc., including about I kb, but possibly more, of flanking genomic DNA at either the 5'and 3'end of the transcribed region. The genomic DNA can be isolated as a fragment of 100 kbp or smaller ; and substantially free of flanking chromosomal sequence. The genomic DNA flanking the coding region, either 3'and 5', or internal regulatory sequences as sometimes found in introns, contains sequences required for proper tissue, stage- specific, or disease-state specific expression.

The nucleic acid compositions of the subject invention can encode all or a part of the subject polypeptides. Double or single stranded fragments can be obtained from the DNA sequence by chemically synthesizing oligonucleotides in accordance with conventional methods, by restriction enzyme digestion, by PCR amplification, etc. Isolated polynucleotides and polynucleotide fragments of the invention comprise at least about 10, about 15, about 20, about 35, about 50, about 100, about 150 to about 200, about 250 to about 300, or about 350 contiguous nt selected from the polynucleotide sequences as shown in SEQ ID NOS : 1-1079. For the most part, fragments will be of at least 15 nt, usually at least 18 nt or 25 nt, and up to at least about 50 contiguous nt in length or more. In a preferred embodiment, the polynucleotide molecules comprise a contiguous sequence of at least 12 nt selected from the group consisting of the polynucleotides shown in SEQ ID NOS : 1- 1079.

Probes specific to the polynucleotides of the invention can be generated using the polynucleotide sequences disclosed in SEQ ID NOS : I-1079. The probes are preferably at least about a 12, 15, 16, 18, 20, 22, 24, or 25 nt fragment of a corresponding contiguous sequence of SEQ ID

NOS : 1-1079, and can be less than 2, 1, 0. 5, 0. 1, or 0. 05 kb in length. The probes can be synthesized chemically or can be generated from longer polynucleotides using restriction enzymes. The probes can be labeled, for example, with a radioactive, biotinylated, or fluorescent tag. Preferably, probes are designed based upon an identifying sequence of a polynucleotide of one of SEQ ID NOS : 1-1079.

More preferably, probes are designed based on a contiguous sequence of one of the subject polynucleotides that remain unmasked following application of a masking program for masking low complexity (e. g., XBLAST) to the sequence., i. e., one would select an unmasked region, as indicated by the polynucleotides outside the poly-n stretches of the masked sequence produced by the masking program.

The polynucleotides of the subject invention are isolated and obtained in substantial purity, generally as other than an intact chromosome. Usually, the polynucleotides, either as DNA or RNA, will be obtained substantially free of other naturally-occurring nucleic acid sequences, generally being at least about 50%, usually at least about 90% pure and are typically"recombinant", e. g., flanked by one or more nucleotides with which it is not normally associated on a naturally occurring chromosome.

The polynucleotides of the invention can be provided as a linear molecule or within a circular molecule, and can be provided within autonomously replicating molecules (vectors) or within molecules without replication sequences. Expression of the polynucleotides can be regulated by their own or by other regulatory sequences known in the art. The polynucleotides of the invention can be introduced into suitable host cells using a variety of techniques available in the art, such as transferrin polycation-mediated DNA transfer, transfection with naked or encapsulated nucleic acids, liposome- mediated DNA transfer, intracellular transportation of DNA-coated latex beads, protoplast fusion, viral infection, electroporation, gene gun, calcium phosphate-mediated transfection, and the like.

The subject nucleic acid compositions can be used to, for example, produce polypeptides, as probes for the detection of mRNA of the invention in biological samples (e. g., extracts of human cells) to generate additional copies of the polynucleotides, to generate ribozymes or antisense oligonucleotides, and as single stranded DNA probes or as triple-strand forming oligonucleotides.

The probes described herein can be used to, for example, determine the presence or absence of the polynucleotide sequences as shown in SEQ ID NOS : I-1079 or variants thereof in a sample. These and other uses are described in more detail below.

Use of Polvnucleotides to Obtain Full-Length cDNA. Gene, and Promoter Region Full-length cDNA molecules comprising the disclosed polynucleotides are obtained as follows. A polynucleotide having a sequence of one of SEQ ID NOS : I-1079, or a portion thereof comprising at least 12, 15, 18, or 20 nt, is used as a hybridization probe to detect hybridizing members of a cDNA library using probe design methods, cloning methods, and clone selection

techniques such as those described in USPN 5, 654, 173. Libraries of cDNA are made from selected tissues, such as normal or tumor tissue, or from tissues of a mammal treated with, for example, a pharmaceutical agent. Preferably, the tissue is the same as the tissue from which the polynucleotides of the invention were isolated, as both the polynucleotides described herein and the cDNA represent expressed genes. Most preferably, the cDNA library is made from the biological material described herein in the Examples. The choice of cell type for library construction can be made after the identity of the protein encoded by the gene corresponding to the polynucleotide of the invention is known. This will indicate which tissue and cell types are likely to express the related gene, and thus represent a suitable source for the mRNA for generating the cDNA. Where the provided polynucleotides are isolated from cDNA libraries, the libraries are prepared from mRNA of human colon cells, more preferably, human colon cancer cells. even more preferably, from a highly metastatic colon cell, Kml2L4-A.

Techniques for producing and probing nucleic acid sequence libraries are described, for example, in Sambrook et al., Molecular Cloning : A Laboratory Manual, 2nd Ed., (1989) Cold Spring Harbor Press, Cold Spring Harbor, NY. The cDNA can be prepared by using primers based on sequence from SEQ ID NOS : I-1079. In one embodiment, the cDNA library can be made from only poly-adenylated mRNA. Thus, poly-T primers can be used to prepare cDNA from the mRNA.

Members of the library that are larger than the provided polynucleotides, and preferably that encompass the complete coding sequence of the native message, are obtained. In order to confirm that the entire cDNA has been obtained, RNA protection experiments are performed as follows.

Hybridization of a full-length cDNA to an mRNA will protect the RNA from RNase degradation. If the cDNA is not full length, then the portions of the mRNA that are not hybridized will be subject to RNase degradation. This is assayed, as is known in the art, by changes in electrophoretic mobility on polyacrylamide gels, or by detection of released monoribonucleotides. Sambrook et al., Molecular Cloning : A Laboratory Manual, 2nd Ed., (1989) Cold Spring Harbor Press, Cold Spring Harbor, NY.

In order to obtain additional sequences 5'to the end of a partial cDNA, 5'RACE (PCR Protocols. A Guide to Methods and Applications, (1990) Academic Press, Inc.) can be performed.

Genomic DNA is isolated using the provided polynucleotides in a manner similar to the isolation of full-length cDNAs. Briefly, the provided polynucleotides, or portions thereof, are used as probes to libraries of genomic DNA. Preferably, the library is obtained from the cell type that was used to generate the polynucleotides of the invention, but this is not essential. Most preferably, the genomic DNA is obtained from the biological material described herein in the Examples. Such libraries can be in vectors suitable for carrying large segments of a genome, such as P I or YAC, as described in detail in Sambrook et al., 9. 4-9. 30. In addition, genomic sequences can be isolated from human BAC libraries, which are commercially available from Research Genetics, Inc., Huntsville,

Alabama, USA, for example. In order to obtain additional 5'or 3'sequences, chromosome walking is performed, as described in Sambrook et al., such that adjacent and overlapping fragments of genomic DNA are isolated. These are mapped and pieced together, as is known in the art, using restriction digestion enzymes and DNA ligase.

Using the polynucleotide sequences of the invention, corresponding full-length genes can be isolated using both classical and PCR methods to construct and probe cDNA libraries. Using either method, Northern blots, preferably, are performed on a number of cell types to determine which cell lines express the gene of interest at the highest level. Classical methods of constructing cDNA libraries are taught in Sambrook et al., supra. With these methods, cDNA can be produced from mRNA and inserted into viral or expression vectors. Typically, libraries of mRNA comprising poly (A) tails can be produced with poly (T) primers. Similarly, cDNA libraries can be produced using the instant sequences as primers.

PCR methods are used to amplify the members of a cDNA library that comprise the desired insert. In this case, the desired insert will contain sequence from the full length cDNA that corresponds to the instant polynucleotides. Such PCR methods include gene trapping and RACE methods. Gene trapping entails inserting a member of a cDNA library into a vector. The vector then is denatured to produce single stranded molecules. Next, a substrate-bound probe, such a biotinylated oligo, is used to trap cDNA inserts of interest. Biotinylated probes can be linked to an avidin-bound solid substrate. PCR methods can be used to amplify the trapped cDNA. To trap sequences corresponding to the full length genes, the labeled probe sequence is based on the polynucleotide sequences of the invention. Random primers or primers specific to the library vector can be used to amplify the trapped cDNA. Such gene trapping techniques are described in Gruber et al., WO 95/04745 and Gruber et al., USPN 5, 500, 356. Kits are commercially available to perform gene trapping experiments from, for example, Life Technologies, Gaithersburg, Maryland, USA.

"Rapid amplification of cDNA ends,"or RACE, is a PCR method of amplifying cDNAs from a number of different RNAs. The cDNAs are ligated to an oligonucleotide linker, and amplified by PCR using two primers. One primer is based on sequence from the instant polynucleotides, for which full length sequence is desired, and a second primer comprises sequence that hybridizes to the oligonucleotide linker to amplify the cDNA. A description of this methods is reported in WO 97/19110. In preferred embodiments of RACE, a common primer is designed to anneal to an arbitrary adaptor sequence ligated to cDNA ends (Apte and Siebert, Biotechniques (1993) 15 : 890- 893 ; Edwards et al., Nuc. Acids Res. (1991) 19 : 5227-5232). When a single gene-specific RACE primer is paired with the common primer, preferential amplification of sequences between the single gene specific primer and the common primer occurs. Commercial cDNA pools modified for use in RACE are available.

Another PCR-based method generates full-length cDNA library with anchored ends without needing specific knowledge of the cDNA sequence. The method uses lock-docking primers (I-VI), where one primer, poly TV (I-III) locks over the polyA tail of eukaryotic mRNA producing first strand synthesis and a second primer, polyGH (IV-VI) locks onto the polyC tail added by terminal deoxynucleotidyl transferase (TdT) (see, e. g., WO 96/40998).

The promoter region of a gene generally is located 5'to the initiation site for RNA polymerase II. Hundreds of promoter regions contain the"TATA"box, a sequence such as TATTA or TATAA, which is sensitive to mutations. The promoter region can be obtained by performing 5' RACE using a primer from the coding region of the gene. Alternatively, the cDNA can be used as a probe for the genomic sequence. and the region 5'to the coding region is identified by"walking up." If the gene is highly expressed or differentially expressed, the promoter from the gene can be of use in a regulatory construct for a heterologous gene.

Once the full-length cDNA or gene is obtained, DNA encoding variants can be prepared by site-directed mutagenesis, described in detail in Sambrook et al., 15. 3-15. 63. The choice of codon or nucleotide to be replaced can be based on disclosure herein on optional changes in amino acids to achieve altered protein structure and/or function.

As an alternative method to obtaining DNA or RNA from a biological material, nucleic acid comprising nucleotides having the sequence of one or more polynucleotides of the invention can be synthesized. Thus, the invention encompasses nucleic acid molecules ranging in length from 15 nt (corresponding to at least 15 contiguous nt of one of SEQ ID NOS : I-1079) up to a maximum length suitable for one or more biological manipulations, including replication and expression, of the nucleic acid molecule. The invention includes but is not limited to (a) nucleic acid having the size of a full gene, and comprising at least one of SEQ ID NOS : I-1079 ; (b) the nucleic acid of (a) also comprising at least one additional gene, operably linked to permit expression of a fusion protein ; (c) an expression vector comprising (a) or (b) ; (d) a plasmid comprising (a) or (b) ; and (e) a recombinant viral particle comprising (a) or (b). Once provided with the polynucleotides disclosed herein, construction or preparation of (a)- (e) are well within the skill in the art.

The sequence of a nucleic acid comprising at least 15 contiguous nt of at least any one of SEQ ID NOS : 1-1079, preferably the entire sequence of at least any one of SEQ ID NOS : 1-1079, is not limited and can be any sequence of A, T, G, and/or C (for DNA) and A, U, G, and/or C (for RNA) or modified bases thereof, including inosine and pseudouridine. The choice of sequence will depend on the desired function and can be dictated by coding regions desired, the intron-like regions desired, and the regulatory regions desired. Where the entire sequence of any one of SEQ ID NOS : 1- 1079 is within the nucleic acid, the nucleic acid obtained is referred to herein as a polynucleotide comprising the sequence of any one of SEQ ID NOS : 1-1079.

Expression of Polypeptide Encoded bv Full-Length cDNA or Full-Lenzh Gene The provided polynucleotides (e. g., a polynucleotide having a sequence of one of SEQ ID NOS : 1-1079), the corresponding cDNA, or the full-length gene is used to express a partial or complete gene product. Constructs of polynucleotides having sequences of SEQ ID NOS : 1-1079 can also be generated synthetically. Alternatively, single-step assembly of a gene and entire plasmid from large numbers of oligodeoxyribonucleotides is described by, e. g., Stemmer et al., Gene (Amsterdam) (1995) 164 (1) : 49-53. In this method, assembly PCR (the synthesis of long DNA sequences from large numbers of oligodeoxyribonucleotides (oligos)) is described. The method is derived from DNA shuffling (Stemmer, Nature (1994) 370 : 389-391), and does not rely on DNA ligase, but instead relies on DNA polymerase to build increasingly longer DNA fragments during the assembly process.

Appropriate polynucleotide constructs are purified using standard recombinant DNA techniques as described in, for example. Sambrook et al.. Molecular Cloning. A Laboratory Manual, 2ndEd., (1989) Cold Spring Harbor Press, Cold Spring Harbor, NY, and under current regulations described in United States Dept. of HHS, National Institute of Health (NIH) Guidelines for Recombinant DNA Research. The gene product encoded by a polynucleotide of the invention is expressed in any expression system, including, for example, bacterial, yeast, insect, amphibian and mammalian systems. Vectors, host cells and methods for obtaining expression in same are well known in the art. Suitable vectors and host cells are described in USPN 5, 654, 173.

Polynucleotide molecules comprising a polynucleotide sequence provided herein are generally propagated by placing the molecule in a vector. Viral and non-viral vectors are used, including plasmids. The choice of plasmid will depend on the type of cell in which propagation is desired and the purpose of propagation. Certain vectors are useful for amplifying and making large amounts of the desired DNA sequence. Other vectors are suitable for expression in cells in culture.

Still other vectors are suitable for transfer and expression in cells in a whole animal or person. The choice of appropriate vector is well within the skill of the art. Many such vectors are available commercially. Methods for preparation of vectors comprising a desired sequence are well known in the art.

The polynucleotides set forth in SEQ ID NOS : I-1079 or their corresponding full-length polynucleotides are linked to regulatory sequences as appropriate to obtain the desired expression properties. These can include promoters (attached either at the 5'end of the sense strand or at the 3' end of the antisense strand), enhancers, terminators, operators, repressors, and inducers. The promoters can be regulated or constitutive. In some situations it may be desirable to use conditionally active promoters, such as tissue-specific or developmental stage-specific promoters.

These are linked to the desired nucleotide sequence using the techniques described above for linkage to vectors. Any techniques known in the art can be used.

When any of the above host cells, or other appropriate host cells or organisms, are used to replicate and/or express the polynucleotides or nucleic acids of the invention, the resulting replicated nucleic acid, RNA, expressed protein or polypeptide, is within the scope of the invention as a product of the host cell or organism. The product is recovered by any appropriate means known in the art.

Once the gene corresponding to a selected polynucleotide is identified, its expression can be regulated in the cell to which the gene is native. For example, an endogenous gene of a cell can be regulated by an exogenous regulatory sequence as disclosed in USPN 5, 641, 670.

Identification of Functional and Structural Motifs of Novel Genes Screening Against Publicly Available Databases Translations of the nucleotide sequence of the provided polynucleotides, cDNAs or full genes can be aligned with individual known sequences. Similarity with individual sequences can be used to determine the activity of the polypeptides encoded by the polynucleotides of the invention.

Also, sequences exhibiting similarity with more than one individual sequence can exhibit activities that are characteristic of either or both individual sequences.

The full length sequences and fragments of the polynucleotide sequences of the nearest neighbors can be used as probes and primers to identify and isolate the full length sequence corresponding to provided polynucleotides. The nearest neighbors can indicate a tissue or cell type to be used to construct a library for the full-length sequences corresponding to the provided polynucleotides.

Typically, a selected polynucleotide is translated in all six frames to determine the best alignment with the individual sequences. The sequences disclosed herein in the Sequence Listing are in a 5'to 3'orientation and translation in three frames can be sufficient (with a few specific exceptions as described in the Examples). These amino acid sequences are referred to, generally, as query sequences, which will be aligned with the individual sequences. Databases with individual sequences are described in"Computer Methods for Macromolecular Sequence Analysis"Methods in Enzymology (1996) 266, Doolittle, Academic Press, Inc., a division of Harcourt Brace & Co., San Diego, California, USA. Databases include GenBank, EMBL, and DNA Database of Japan (DDBJ).

Query and individual sequences can be aligned using the methods and computer programs described above, and include BLAST 2. 0, available over the world wide web at http ://www. ncbi. nlm. nih. Qov/BLAST/. See also Altschul, et al. Nucleic Acids Res. (1997) 25 : 3389- 3402. Another alignment algorithm is Fasta, available in the Genetics Computing Group (GCG) package, Madison, Wisconsin, USA, a wholly owned subsidiary of Oxford Molecular Group, Inc.

Other techniques for alignment are described in Doolittle, supra. Preferably, an alignment program

that permits gaps in the sequence is utilized to align the sequences. The Smith-Waterman is one type of algorithm that permits gaps in sequence alignments. See Meth. Mol. Biol. (1997) 70 : 173-187.

Also, the GAP program using the Needleman and Wunsch alignment method can be utilized to align sequences. An alternative search strategy uses MPSRCH software, which runs on a MASPAR computer. MPSRCH uses a Smith-Waterman algorithm to score sequences on a massively parallel computer. This approach improves ability to identify sequences that are distantly related matches, and is especially tolerant of small gaps and nucleotide sequence errors. Amino acid sequences encoded by the provided polynucleotides can be used to search both protein and DNA databases.

Incorporated herein by reference are all sequences that have been made public as of the filing date of this application by any of the DNA or protein sequence databases, including the patent databases (e. g., GeneSeq). Also incorporated by reference are those sequences that have been submitted to these databases as of the filing date of the present application but not made public until after the filing date of the present application.

Results of individual and query sequence alignments can be divided into three categories : high similarity, weak similarity, and no similarity. Individual alignment results ranging from high similarity to weak similarity provide a basis for determining polypeptide activity and/or structure.

Parameters for categorizing individual results include : percentage of the alignment region length where the strongest alignment is found, percent sequence identity, and p value. The percentage of the alignment region length is calculated by counting the number of residues of the individual sequence found in the region of strongest alignment, e. g., contiguous region of the individual sequence that contains the greatest number of residues that are identical to the residues of the corresponding region of the aligned query sequence. This number is divided by the total residue length of the query sequence to calculate a percentage. For example, a query sequence of 20 amino acid residues might be aligned with a 20 amino acid region of an individual sequence. The individual sequence might be identical to amino acid residues 5, 9-15, and 17-19 of the query sequence. The region of strongest alignment is thus the region stretching from residue 9-19, an 11 amino acid stretch. The percentage of the alignment region length is : l l (length of the region of strongest alignment) divided by (query sequence length) 20 or 55%.

Percent sequence identity is calculated by counting the number of amino acid matches between the query and individual sequence and dividing total number of matches by the number of residues of the individual sequences found in the region of strongest alignment. Thus, the percent identity in the example above would be 10 matches divided by 11 amino acids, or approximately, 90. 9% P value is the probability that the alignment was produced by chance. For a single alignment, the p value can be calculated according to Karlin et al., Proc. Natl. Acad. Sci. (1990) 87 : 2264 and

Karlin et al., Proc. Natl. Acad. Sci. (1993) 90. The p value of multiple alignments using the same query sequence can be calculated using an heuristic approach described in Altschul et al., Nat. Genet.

(1994) 6 : 119. Alignment programs such as BLAST program can calculate the p value. See also Altschul et al., Nucleic Acids Res. (1997) 25 : 3389-3402.

Another factor to consider for determining identity or similarity is the location of the similarity or identity. Strong local alignment can indicate similarity even if the length of alignment is short. Sequence identity scattered throughout the length of the query sequence also can indicate a similarity between the query and profile sequences. The boundaries of the region where the sequences align can be determined according to Doolittle, supra ; BLAST 2. 0 (see, e. g., Altschul, et al. Nucleic Acids Res. (1997) 25 : 3389-3402) or FAST programs : or by determining the area where sequence identity is highest.

High Similaritv. In general, in alignment results considered to be of high similarity, the percent of the alignment region length is typically at least about 55% of total length query sequence ; more typically, at least about 58% ; even more typically ; at least about 60% of the total residue length of the query sequence. Usually, percent length of the alignment region can be as much as about 62% ; more usually, as much as about 64% ; even more usually, as much as about 66%. Further, for high similarity, the region of alignment, typically, exhibits at least about 75% of sequence identity ; more typically, at least about 78% ; even more typically ; at least about 80% sequence identity. Usually, percent sequence identity can be as much as about 82% ; more usually, as much as about 84% ; even more usually, as much as about 86%.

The p value is used in conjunction with these methods. If high similarity is found, the query sequence is considered to have high similarity with a profile sequence when the p value is less than or equal to about 10 ; more usually ; less than or equal to about 10 ; even more usually ; less than or equal to about 10. More typically, the p value is no more than about 10 ; more typically ; no more than or equal to about 10 ; even more typically ; no more than or equal to about 10 15 for the query sequence to be considered high similarity.

Weak Similaritv. In general, where alignment results considered to be of weak similarity, there is no minimum percent length of the alignment region nor minimum length of alignment. A better showing of weak similarity is considered when the region of alignment is, typically, at least about 15 amino acid residues in length ; more typically, at least about 20 ; even more typically ; at least about 25 amino acid residues in length. Usually, length of the alignment region can be as much as about 30 amino acid residues ; more usually, as much as about 40 ; even more usually, as much as about 60 amino acid residues. Further, for weak similarity, the region of alignment, typically,

exhibits at least about 35% of sequence identity ; more typically, at least about 40% ; even more typically ; at least about 45% sequence identity. Usually, percent sequence identity can be as much as about 50% ; more usually, as much as about 55% ; even more usually, as much as about 60%.

If low similarity is found, the query sequence is considered to have weak similarity with a profile sequence when the p value is usually less than or equal to about 10 ; more usually ; less than or equal to about 10 ; even more usually ; less than or equal to about 10. More typically, the p value is no more than about 10 ; more usually ; no more than or equal to about 10 ; even more usually ; no more than or equal to about 10 for the query sequence to be considered weak similarity.

Similaritv Determined bv Sequence Identitv Alone. Sequence identity alone can be used to determine similarity of a query sequence to an individual sequence and can indicate the activity of the sequence. Such an alignment, preferably, permits gaps to align sequences. Typically, the query sequence is related to the profile sequence if the sequence identity over the entire query sequence is at least about 15% ; more typically, at least about 20% ; even more typically, at least about 25% ; even more typically, at least about 50%. Sequence identity alone as a measure of similarity is most useful when the query sequence is usually, at least 80 residues in length ; more usually, 90 residues ; even more usually, at least 95 amino acid residues in length. More typically, similarity can be concluded based on sequence identity alone when the query sequence is preferably 100 residues in length ; more preferably, 120 residues in length ; even more preferably, 150 amino acid residues in length.

Alignments with Profile and Multiple Aligned Sequences. Translations of the provided polynucleotides can be aligned with amino acid profiles that define either protein families or common motifs. Also, translations of the provided polynucleotides can be aligned to multiple sequence alignments (MSA) comprising the polypeptide sequences of members of protein families or motifs. Similarity or identity with profile sequences or MSAs can be used to determine the activity of the gene products (e. g., polypeptides) encoded by the provided polynucleotides or corresponding cDNA or genes. For example, sequences that show an identity or similarity with a chemokine profile or MSA can exhibit chemokine activities.

Profiles can designed manually by (1) creating an MSA, which is an alignment of the amino acid sequence of members that belong to the family and (2) constructing a statistical representation of the alignment. Such methods are described, for example, in Birney et al., Nucl. Acid Res. (1996) 24 (14) : 2730-2739. MSAs of some protein families and motifs are publicly available. For example, http :// enome. wustl. edu/Pfami includes MSAs of 547 different families and motifs. These MSAs are described also in Sonnhammer et al., Proteins (1997) 28 : 405-420. Other sources over the world

wide web include the site at http ://www. embl-heidelber. de/argosiali/ali. htm I ; alternatively, a message can be sent to ALI (i. EMBL-HEIDELBERG. DE for the information. A brief description of these MSAs is reported in Pascarella et al., Prot. Eng. (1996) 9 (3) : 249-251. Techniques for building profiles from MSAs are described in Sonnhammer et al., supra ; Birney et al., supra ; and"Computer Methods for Macromolecular Sequence Analysis,"Methods in Enzymology (1996) 266, Doolittle, Academic Press, Inc., San Diego, California, USA.

Similarity between a query sequence and a protein family or motif can be determined by (a) comparing the query sequence against the profile and/or (b) aligning the query sequence with the members of the family or motif. Typically, a program such as Searchwise is used to compare the query sequence to the statistical representation of the multiple alignment, also known as a profile (see Birney et al., supra). Other techniques to compare the sequence and profile are described in Sonnhammer et al., supra and Doolittle. supra.

Next, methods described by Feng et al., J. Mol. Evol. (1987) 25 : 351 and Higgins et al., CABIOS (1989) 5 : 151 can be used align the query sequence with the members of a family or motif, also known as a MSA. Sequence alignments can be generated using any of a variety of software tools. Examples include PileUp, which creates a multiple sequence alignment, and is described in Feng et al., J. Mol. Evol. (1987) 25 : 351. Another method, GAP, uses the alignment method of Needleman et al., J. Mol. Biol. (1970) 48 : 443. GAP is best suited for global alignment of sequences.

A third method, BestFit, functions by inserting gaps to maximize the number of matches using the local homology algorithm of Smith et al., Adv. Appl. Math. (1981) 2 : 482. In general, the following factors are used to determine if a similarity between a query sequence and a profile or MSA exists : (I) number of conserved residues found in the query sequence, (2) percentage of conserved residues found in the query sequence. (3) number of frameshifts, and (4) spacing between conserved residues.

Some alignment programs that both translate and align sequences can make any number of frameshifts when translating the nucleotide sequence to produce the best alignment. The fewer frameshifts needed to produce an alignment, the stronger the similarity or identity between the query and profile or MSAs. For example, a weak similarity resulting from no frameshifts can be a better indication of activity or structure of a query sequence, than a strong similarity resulting from two frameshifts. Preferably, three or fewer frameshifts are found in an alignment ; more preferably two or fewer frameshifts ; even more preferably, one or fewer frameshifts ; even more preferably, no frameshifts are found in an alignment of query and profile or MSAs.

Conserved residues are those amino acids found at a particular position in all or some of the family or motif members. Alternatively, a position is considered conserved if only a certain class of amino acids is found in a particular position in all or some of the family members. For example, the

N-terminal position can contain a positively charged amino acid, such as lysine, arginine, or histidine.

Typically, a residue of a polypeptide is conserved when a class of amino acids or a single amino acid is found at a particular position in at least about 40% of all class members ; more typically, at least about 50% ; even more typically, at least about 60% of the members. Usually, a residue is conserved when a class or single amino acid is found in at least about 70% of the members of a family or motif ; more usually, at least about 80% ; even more usually, at least about 90% ; even more usually, at least about 95%.

A residue is considered conserved when three unrelated amino acids are found at a particular position in the some or all of the members ; more usually, two unrelated amino acids. These residues are conserved when the unrelated amino acids are found at particular positions in at least about 40% of all class member ; more typically, at least about 50% ; even more typically, at least about 60% of the members. Usually, a residue is conserved when a class or single amino acid is found in at least about 70% of the members of a family or motif ; more usually, at least about 80% ; even more usually, at least about 90% ; even more usually, at least about 95%.

A query sequence has similarity to a profile or MSA when the query sequence comprises at least about 25% of the conserved residues of the profile or MSA ; more usually, at least about 30% ; even more usually ; at least about 40%. Typically, the query sequence has a stronger similarity to a profile sequence or MSA when the query sequence comprises at least about 45% of the conserved residues of the profile or MSA ; more typically, at least about 50% ; even more typically ; at least about 55%.

Identification of Secreted & Membrane-Bound Polypeptides Both secreted and membrane-bound polypeptides of the present invention are of particular interest. For example, levels of secreted polypeptides can be assayed in body fluids that are convenient, such as blood, plasma, serum, and other body fluids such as urine, prostatic fluid and semen. Membrane-bound polypeptides are useful for constructing vaccine antigens or inducing an immune response. Such antigens would comprise all or part of the extracellular region of the membrane-bound polypeptides. Because both secreted and membrane-bound polypeptides comprise a fragment of contiguous hydrophobic amino acids, hydrophobicity predicting algorithms can be used to identify such polypeptides.

A signal sequence is usually encoded by both secreted and membrane-bound polypeptide genes to direct a polypeptide to the surface of the cell. The signal sequence usually comprises a stretch of hydrophobic residues. Such signal sequences can fold into helical structures. Membrane- bound polypeptides typically comprise at least one transmembrane region that possesses a stretch of hydrophobic amino acids that can transverse the membrane. Some transmembrane regions also

exhibit a helical structure. Hydrophobic fragments within a polypeptide can be identified by using computer algorithms. Such algorithms include Hopp & Woods, Proc. rVatl. Acad. Sci. USA (1981) 78 : 3824-3828 ; Kyte & Doolittle, J. Mol. Biol. (1982) 157 : 105-132 ; and RAOAR algorithm, Degli Esposti et al., Eur. J Biocheni. (1990) 190 : 207-219.

Another method of identifying secreted and membrane-bound polypeptides is to translate the polynucleotides of the invention in all six frames and determine if at least 8 contiguous hydrophobic amino acids are present. Those translated polypeptides with at least 8 ; more typically, 10 ; even more typically, 12 contiguous hydrophobic amino acids are considered to be either a putative secreted or membrane bound polypeptide. Hydrophobic amino acids include alanine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, threonine, tryptophan, tyrosine, and valine Identification of the Function of an Expression Product of a Full-Length Gene Ribozymes, antisense constructs, and dominant negative mutants can be used to determine function of the expression product of a gene corresponding to a polynucleotide provided herein.

These methods and compositions are particularly useful where the provided novel polynucleotide exhibits no significant or substantial homology to a sequence encoding a gene of known function.

Antisense molecules and ribozymes can be constructed from synthetic polynucleotides. Typically, the phosphoramidite method of oligonucleotide synthesis is used. See Beaucage et al., Tet. Lett.

(1981) 22 : 1859 and USPN 4, 668, 777. Automated devices for synthesis are available to create oligonucleotides using this chemistry. Examples of such devices include Biosearch 8600, Models 392 and 394 by Applied Biosystems, a division of Perkin-Elmer Corp., Foster City, California, USA ; and Expedite by Perceptive Biosystems. Framingham, Massachusetts, USA. Synthetic RNA, phosphate analog oligonucleotides, and chemically derivatized oligonucleotides can also be produced, and can be covalently attache to other molecules. RNA oligonucleotides can be synthesized, for example, using RNA phosphoramidites. This method can be performed on an automated synthesizer, such as Applied Biosystems, Models 392 and 394, Foster City, California, USA.

Phosphorothioate oligonucleotides can also be synthesized for antisense construction. A sulfurizing reagent, such as tetraethylthiruam disulfide (TETD) in acetonitrile can be used to convert the internucleotide cyanoethyl phosphite to the phosphorothioate triester within 15 minutes at room temperature. TETD replaces the iodine reagent, while all other reagents used for standard phosphoramidite chemistry remain the same. Such a synthesis method can be automated using Models 392 and 394 by Applied Biosystems, for example.

Oligonucleotides of up to 200 nt can be synthesized, more typically, 100 nt, more typically 50 nt ; even more typically 30 to 40 nt. These synthetic fragments can be annealed and ligated

together to construct larger fragments. See, for example, Sambrook et al., supra. Trans-cleaving catalytic RNAs (ribozymes) are RNA molecules possessing endoribonuclease activity. Ribozymes are specifically designed for a particular target, and the target message must contain a specific nucleotide sequence. They are engineered to cleave any RNA species site-specifically in the background of cellular RNA. The cleavage event renders the mRNA unstable and prevents protein expression. Importantly, ribozymes can be used to inhibit expression of a gene of unknown function for the purpose of determining its function in an in vitro or in vivo context, by detecting the phenotypic effect. One commonly used ribozyme motif is the hammerhead, for which the substrate sequence requirements are minimal. Design of the hammerhead ribozyme, as well as therapeutic uses of ribozymes, are disclosed in Usman et al., Current Opin. Struct. Biol. (1996) 6 : 527. Methods for production of ribozymes, including hairpin structure ribozyme fragments, methods of increasing ribozyme specificity, and the like are known in the art.

The hybridizing region of the ribozyme can be modified or can be prepared as a branche structure as described in Horn and Urdea, Nucleic Acids Res. (1989) 17 : 6959. The basic structure of the ribozymes can also be chemically altered in ways familiar to those skilled in the art, and chemically synthesized ribozymes can be administered as synthetic oligonucleotide derivatives modified by monomeric units. In a therapeutic context, liposome mediated delivery of ribozymes improves cellular uptake, as described in Birikh et al., Eur. J. Biochem. (1997) 245 : 1.

Antisense nucleic acids are designed to specifically bind to RNA, resulting in the formation of RNA-DNA or RNA-RNA hybrids, with an arrest of DNA replication, reverse transcription or messenger RNA translation. Antisense polynucleotides based on a selected polynucleotide sequence can interfere with expression of the corresponding gene. Antisense polynucleotides are typically generated within the cell by expression from antisense constructs that contain the antisense strand as the transcribed strand. Antisense polynucleotides based on the disclosed polynucleotides will bind and/or interfere with the translation of mRNA comprising a sequence complementary to the antisense polynucleotide. The expression products of control cells and cells treated with the antisense construct are compared to detect the protein product of the gene corresponding to the polynucleotide upon which the antisense construct is based. The protein is isolated and identified using routine biochemical methods.

Given the extensive background literature and clinical experience in antisense therapy, one skilled in the art can use selected polynucleotides of the invention as additional potential therapeutics. The choice of polynucleotide can be narrowed by first testing them for binding to"hot spot"regions of the genome of cancerous cells. If a polynucleotide is identified as binding to a"hot spot", testing the polynucleotide as an antisense compound in the corresponding cancer cells is warranted.

As an alternative method for identifying function of the gene corresponding to a polynucleotide disclosed herein, dominant negative mutations are readily generated for corresponding proteins that are active as homomultimers. A mutant polypeptide will interact with wild-type polypeptides (made from the other allele) and form a non-functional multimer. Thus, a mutation is in a substrate-binding domain, a catalytic domain, or a cellular localization domain.

Preferably, the mutant polypeptide will be overproduced. Point mutations are made that have such an effect. In addition, fusion of different polypeptides of various lengths to the terminus of a protein can yield dominant negative mutants. General strategies are available for making dominant negative mutants (see, e. g., Herskowitz, Nature (1987) 329 : 219). Such techniques can be used to create loss of function mutations, which are useful for determining protein function.

Polypeptides and Variants Thereof The polypeptides of the invention include those encoded by the disclosed polynucleotides, as well as nucleic acids that, by virtue of the degeneracy of the genetic code, are not identical in sequence to the disclosed polynucleotides. Thus, the invention includes within its scope a polypeptide encoded by a polynucleotide having the sequence of any one of SEQ ID NOS : I-1079 or a variant thereof.

In general, the term"polypeptide"as used herein refers to both the full length polypeptide encoded by the recited polynucleotide, the polypeptide encoded by the gene represented by the recited polynucleotide, as well as portions or fragments thereof."Polypeptides"also includes variants of the naturally occurring proteins, where such variants are homologous or substantially similar to the naturally occurring protein, and can be of an origin of the same or different species as the naturally occurring protein (e. g., human, murine, or some other species that naturally expresses the recited polypeptide, usually a mammalian species). In general. variant polypeptides have a sequence that has at least about 80%, usually at least about 90%, and more usually at least about 98% sequence identity with a differentially expressed polypeptide of the invention, as measured by BLAST 2. 0 using the parameters described above. The variant polypeptides can be naturally or non- naturally glycosylated, ie., the polypeptide has a glycosylation pattern that differs from the glycosylation pattern found in the corresponding naturally occurring protein.

The invention also encompasses homologs of the disclosed polypeptides (or fragments thereof) where the homologs are isolated from other species, i. e. other animal or plant species, where such homologs, usually mammalian species, e. g. rodents, such as mice, rats ; domestic animals, e. g., horse, cow, dog, cat ; and humans. By"homolog"is meant a polypeptide having at least about 35%, usually at least about 40% and more usually at least about 60% amino acid sequence identity to a particular differentially expressed protein as identified above, where sequence identity is determined using the BLAST 2. 0 algorithm, with the parameters described supra.

In general, the polypeptides of the subject invention are provided in a non-naturally occurring environment, e. g. are separated from their naturally occurring environment. In certain embodiments, the subject protein is present in a composition that is enriched for the protein as compared to a control. As such, purified polypeptide is provided, where by purified is meant that the protein is present in a composition that is substantially free of non-differentially expressed polypeptides, where by substantially free is meant that less than 90%, usually less than 60% and more usually less than 50% of the composition is made up of non-differentially expressed polypeptides.

Also within the scope of the invention are variants ; variants of polypeptides include mutants, fragments, and fusions. Mutants can include amino acid substitutions, additions or deletions. The amino acid substitutions can be conservative amino acid substitutions or substitutions to eliminate non-essential amino acids, such as to alter a glycosylation site, a phosphorylation site or an acetylation site, or to minimize misfolding by substitution or deletion of one or more cysteine residues that are not necessary for function. Conservative amino acid substitutions are those that preserve the general charge, hydrophobicity/hydrophilicity, and/or steric bulk of the amino acid substituted. Variants can be designed so as to retain or have enhanced biological activity of a particular region of the protein (e. g., a functional domain and/or, where the polypeptide is a member of a protein family, a region associated with a consensus sequence). Selection of amino acid alterations for production of variants can be based upon the accessibility (interior vs. exterior) of the amino acid (see, e. g., Go et al, Int. J. Peptide Protein Res. (1980) 15 : 211), the thermostability of the variant polypeptide (see, e. g., Querol et al., Prot. Eng. (1996) 9 : 265), desired glycosylation sites (see, e. g., Olsen and Thomsen, J. Gen. Microbiol. (1991) 137 : 579), desired disulfide bridges (see, e. g., Clarke et al., Biochemistry (1993) 32 : 4322 ; and Wakarchuk et al., Protein Eng. (1994) 7 : 1379), desired metal binding sites (see, e. g., Toma et al., Biochemistry (1991) 30 : 97, and Haezerbrouck et al., Protein Eng. (1993) 6 : 643), and desired substitutions with in proline loops (see, e. g., Masul et al., Appl. Env. Microbiol. (1994) 60 : 3579). Cysteine-depleted muteins can be produced as disclosed in USPN 4, 959, 314.

Variants also include fragments of the polypeptides disclosed herein, particularly biologically active fragments and/or fragments corresponding to functional domains. Fragments of interest will typically be at least about 10 aa to at least about 15 aa in length, usually at least about 50 aa in length, and can be as long as 300 aa in length or longer, but will usually not exceed about 1000 aa in length, where the fragment will have a stretch of amino acids that is identical to a polypeptide encoded by a polynucleotide having a sequence of any SEQ ID NOS : 1-1079, or a homolog thereof. The protein variants described herein are encoded by polynucleotides that are

within the scope of the invention. The genetic code can be used to select the appropriate codons to construct the corresponding variants.

Computer-Related Embodiments In general, a library of polynucleotides is a collection of sequence information, which information is provided in either biochemical form (e. g., as a collection of polynucleotide molecules), or in electronic form (e. g., as a collection of polynucleotide sequences stored in a computer-readable form, as in a computer system and/or as part of a computer program). The sequence information of the polynucleotides can be used in a variety of ways, e. g., as a resource for gene discovery, as a representation of sequences expressed in a selected cell type (e. g., cell type markers), and/or as markers of a given disease or disease state. In general, a disease marker is a representation of a gene product that is present in all cells affected by disease either at an increased or decreased level relative to a normal cell (e. g., a cell of the same or similar type that is not substantially affected by disease). For example, a polynucleotide sequence in a library can be a polynucleotide that represents an mRNA, polypeptide. or other gene product encoded by the polynucleotide, that is either overexpressed or underexpressed in a breast ductal cell affected by cancer relative to a normal (i. e., substantially disease-free) breast cell.

The nucleotide sequence information of the library can be embodied in any suitable form, e. g., electronic or biochemical forms. For example, a library of sequence information embodied in electronic form comprises an accessible computer data file (or, in biochemical form, a collection of nucleic acid molecules) that contains the representative nucleotide sequences of genes that are differentially expressed (e. g., overexpressed or underexpressed) as between, for example, i) a cancerous cell and a normal cell ; ii) a cancerous cell and a dysplastic cell ; iii) a cancerous cell and a cell affected by a disease or condition other than cancer ; iv) a metastatic cancerous cell and a normal cell and/or non-metastatic cancerous cell ; v) a malignant cancerous cell and a non-malignant cancerous cell (or a normal cell) and/or vi) a dysplastic cell relative to a normal cell. Other combinations and comparisons of cells affected by various diseases or stages of disease will be readily apparent to the ordinarily skilled artisan. Biochemical embodiments of the library include a collection of nucleic acids that have the sequences of the genes in the library, where the nucleic acids can correspond to the entire gene in the library or to a fragment thereof, as described in greater detail below.

The polynucleotide libraries of the subject invention generally comprise sequence information of a plurality of polynucleotide sequences, where at least one of the polynucleotides has a sequence of any of SEQ ID NOS : 1-1079. By plurality is meant at least 2, usually at least 3 and can include up to all of SEQ ID NOS : 1-1079. The length and number of polynucleotides in the

library will vary with the nature of the library, e. g., if the library is an oligonucleotide array, a cDNA array, a computer database of the sequence information, etc.

Where the library is an electronic library, the nucleic acid sequence information can be present in a variety of media."Media"refers to a manufacture, other than an isolated nucleic acid molecule, that contains the sequence information of the present invention. Such a manufacture provides the genome sequence or a subset thereof in a form that can be examined by means not directly applicable to the sequence as it exists in a nucleic acid. For example, the nucleotide sequence of the present invention, e. g. the nucleic acid sequences of any of the polynucleotides of SEQ ID NOS : I-1079, can be recorded on computer readable media, e. g. any medium that can be read and accessed directly by a computer. Such media include, but are not limited to : magnetic storage media, such as a floppy disc. a hard disc storage medium, and a magnetic tape ; optical storage media such as CD-ROM : electrical storage media such as RAM and ROM ; and hybrids of these categories such as magnetic/optical storage media. One of skill in the art can readily appreciate how any of the presently known computer readable mediums can be used to create a manufacture comprising a recording of the present sequence information."Recorded"refers to a process for storing information on computer readable medium, using any such methods as known in the art. Any convenient data storage structure can be chosen, based on the means used to access the stored information. A variety of data processor programs and formats can be used for storage, e. g. word processing text file, database format, etc. In addition to the sequence information, electronic versions of the libraries of the invention can be provided in conjunction or connection with other computer- readable information and/or other types of computer-readable files (e. g., searchable files, executable files, etc, including, but not limited to, for example, search program software, etc.).

By providing the nucleotide sequence in computer readable form, the information can be accessed for a variety of purposes. Computer software to access sequence information is publicly available. For example, the gapped BLAST (Altschul et al. Nucleic Acids Res. (1997) 25 : 3389-3402) and BLAZE (Brutlag et al. Coup. Chem. (1993) 17 : 203) search algorithms on a Sybase system can be used to identify open reading frames (ORFs) within the genome that contain homology to ORFs from other organisms.

As used herein,"a computer-based system"refers to the hardware means, software means, and data storage means used to analyze the nucleotide sequence information of the present invention.

The minimum hardware of the computer-based systems of the present invention comprises a central processing unit (CPU), input means, output means, and data storage means. A skilled artisan can readily appreciate that any one of the currently available computer-based system are suitable for use in the present invention. The data storage means can comprise any manufacture comprising a

recording of the present sequence information as described above, or a memory access means that can access such a manufacture.

"Search means"refers to one or more programs implemented on the computer-based system, to compare a target sequence or target structural motif, or expression levels of a polynucleotide in a sample, with the stored sequence information. Search means can be used to identify fragments or regions of the genome that match a particular target sequence or target motif. A variety of known algorithms are publicly known and commercially available, e. g. MacPattern (EMBL), BLASTN and BLASTX (NCBI). A"target sequence"can be any polynucleotide or amino acid sequence of six or more contiguous nucleotides or two or more amino acids, preferably from about 10 to 100 amino acids or from about 30 to 300 nt A variety of comparing means can be used to accomplish comparison of sequence information from a sample (e. g., to analyze target sequences, target motifs, or relative expression levels) with the data storage means. A skilled artisan can readily recognize that any one of the publicly available homology search programs can be used as the search means for the computer based systems of the present invention to accomplish comparison of target sequences and motifs. Computer programs to analyze expression levels in a sample and in controls are also known in the art.

A"target structural motif,"or"target motif,"refers to any rationally selected sequence or combination of sequences in which the sequence (s) are chosen based on a three-dimensional configuration that is formed upon the folding of the target motif, or on consensus sequences of regulatory or active sites. There are a variety of target motifs known in the art. Protein target motifs include, but arc not limited to, enzyme active sites and signal sequences. Nucleic acid target motifs include, but are not limited to, hairpin structures, promoter sequences and other expression elements such as binding sites for transcription factors.

A variety of structural formats for the input and output means can be used to input and output the information in the computer-based systems of the present invention. One format for an output means ranks the relative expression levels of different polynucleotides. Such presentation provides a skilled artisan with a ranking of relative expression levels to determine a gene expression profile..

As discussed above, the"library"of the invention also encompasses biochemical libraries of the polynucleotides of SEQ ID NOS : 1-1079, e. g., collections of nucleic acids representing the provided polynucleotides. The biochemical libraries can take a variety of forms, e. g., a solution of cDNAs, a pattern of probe nucleic acids stably associated with a surface of a solid support (i. e., an array) and the like. Of particular interest are nucleic acid arrays in which one or more of SEQ ID NOS : I-1079 is represented on the array. By array is meant a an article of manufacture that has at least a substrate with at least two distinct nucleic acid targets on one of its surfaces, where the number of distinct nucleic acids can be considerably higher, typically being at least 10 nt, usually at

least 20 nt and often at least 25 nt. A variety of different array formats have been developed and are known to those of skill in the art. The arrays of the subject invention find use in a variety of applications, including gene expression analysis, drug screening, mutation analysis and the like, as disclosed in the above-listed exemplary patent documents.

In addition to the above nucleic acid libraries, analogous libraries of polypeptides are also provided, where the where the polypeptides of the library will represent at least a portion of the polypeptides encoded by SEQ ID NOS : I-1079.

Utilities Use of Polvnucleotide Probes in Mapping, and in Tissue Profilin Polynucleotide probes, generally comprising at least 12 contiguous nt of a polynucleotide as shown in the Sequence Listing, are used for a variety of purposes, such as chromosome mapping of the polynucleotide and detection of transcription levels. Additional disclosure about preferred regions of the disclosed polynucleotide sequences is found in the Examples. A probe that hybridizes specifically to a polynucleotide disclosed herein should provide a detection signal at least 5-, 10-, or 20-fold higher than the background hybridization provided with other unrelated sequences.

Detection of Expression Levels. Nucleotide probes are used to detect expression of a gene corresponding to the provided polynucleotide. In Northern blots, mRNA is separated electrophoretically and contacted with a probe. A probe is detected as hybridizing to an mRNA species of a particular size. The amount of hybridization is quantitated to determine relative amounts of expression, for example under a particular condition. Probes are used for in situ hybridization to cells to detect expression. Probes can also be used in vivo for diagnostic detection of hybridizing sequences. Probes are typically labeled with a radioactive isotope. Other types of detectable labels can be used such as chromophores, fluors, and enzymes. Other examples of nucleotide hybridization assays are described in W092/02526 and USPN 5, 124, 246.

Alternatively, the Polymerase Chain Reaction (PCR) is another means for detecting small amounts of target nucleic acids (see, e. g., Mullis et al., Meth. Enzymol. (1987) 155 : 335 ; USPN 4, 683, 195 ; and USPN 4, 683, 202). Two primer polynucleotides nucleotides that hybridize with the target nucleic acids are used to prime the reaction. The primers can be composed of sequence within or 3'and 5'to the polynucleotides of the Sequence Listing. Alternatively, if the primers are 3'and 5' to these polynucleotides, they need not hybridize to them or the complements. After amplification of the target with a thermostable polymerase, the amplified target nucleic acids can be detected by methods known in the art, e. g., Southern blot. mRNA or cDNA can also be detected by traditional blotting techniques (e. g., Southern blot, Northern blot, etc.) described in Sambrook et al.,"Molecular Cloning : A Laboratory Manual" (New York, Cold Spring Harbor Laboratory, 1989) (e. g., without PCR amplification). In general, mRNA or cDNA generated from mRNA using a polymerase enzyme

can be purified and separated using gel electrophoresis, and transferred to a solid support, such as nitrocellulose. The solid support is exposed to a labeled probe, washed to remove any unhybridized probe, and duplexes containing the labeled probe are detected.

Mapping. Polynucleotides of the present invention can be used to identify a chromosome on which the corresponding gene resides. Such mapping can be useful in identifying the function of the polynucleotide-related gene by its proximity to other genes with known function. Function can also be assigned to the polynucleotide-related gene when particular syndromes or diseases map to the same chromosome. For example, use of polynucleotide probes in identification and quantification of nucleic acid sequence aberrations is described in USPN 5, 783, 387. An exemplary mapping method is fluorescence in situ hybridization (FISH), which facilitates comparative genomic hybridization to allow total genome assessment of changes in relative copy number of DNA sequences (see, e. g., Valdes et al., Methods in Molecular Biology (1997) 68 : 1). Polynucleotides can also be mapped to particular chromosomes using, for example, radiation hybrids or chromosome-specific hybrid panels.

See Leach et al., Avances in Genetics, (1995) 33 : 63-99 ; Walter et al., Nature Genetics (1994) 7 : 22 ; Walter and Goodfellow, Trends in Genetics (1992) 9 : 352. Panels for radiation hybrid mapping are available from Research Genetics, Inc., Huntsville, Alabama, USA. Databases for markers using various panels are available via the world wide web at http :/F/shgc-www. stanford. edu ; and http ://www-eenome. wi. mit. edu/csi-bin/contia/rhmapper. pi. The statistical program RHMAP can be used to construct a map based on the data from radiation hybridization with a measure of the relative likelihood of one order versus another. RHMAP is available via the world wide web at http ://www. sph. umich. edu/group/statgen/software. In addition, commercial programs are available for identifying regions of chromosomes commonly associated with disease, such as cancer.

Tissue Tvping or Profiling. Expression of specific mRNA corresponding to the provided polynucleotides can vary in different cell types and can be tissue-specific. This variation of mRNA levels in different cell types can be exploited with nucleic acid probe assays to determine tissue types. For example, PCR, branched DNA probe assays, or blotting techniques utilizing nucleic acid probes substantially identical or complementary to polynucleotides listed in the Sequence Listing can determine the presence or absence of the corresponding cDNA or mRNA.

Tissue typing can be used to identify the developmental organ or tissue source of a metastatic lesion by identifying the expression of a particular marker of that organ or tissue. If a polynucleotide is expressed only in a specific tissue type, and a metastatic lesion is found to express that polynucleotide, then the developmental source of the lesion has been identified. Expression of a particular polynucleotide can be assayed by detection of either the corresponding mRNA or the protein product. As would be readily apparent to any forensic scientist, the sequences disclosed herein are useful in differentiating human tissue from non-human tissue. In particular, these

sequences are useful to differentiate human tissue from bird, reptile, and amphibian tissue, for example.

Use of Polvmorphisms. A polynucleotide of the invention can be used in forensics, genetic analysis, mapping, and diagnostic applications where the corresponding region of a gene is polymorphic in the human population. Any means for detecting a polymorphism in a gene can be used, including, but not limited to electrophoresis of protein polymorphic variants, differential sensitivity to restriction enzyme cleavage, and hybridization to aliele-specific probes.

Antibodv Production Expression products of a polynucleotide of the invention, as well as the corresponding mRNA, cDNA, or complete gene, can be prepared and used for raising antibodies for experimental, diagnostic, and therapeutic purposes. For polynucleotides to which a corresponding gene has not been assigned, this provides an additional method of identifying the corresponding gene. The polynucleotide or related cDNA is expressed as described above, and antibodies are prepared. These antibodies are specific to an epitope on the polypeptide encoded by the polynucleotide, and can precipitate or bind to the corresponding native protein in a cell or tissue preparation or in a cell-free extract of an in vitro expression system.

Methods for production of antibodies that specifically bind a selected antigen are well known in the art. Immunogens for raising antibodies can be prepared by mixing a polypeptide encoded by a polynucleotide of the invention with an adjuvant, and/or by making fusion proteins with larger immunogenic proteins. Polypeptides can also be covalently linked to other larger immunogenic proteins, such as keyhole limpet hemocyanin. Immunogens are typically administered intradermally, subcutaneously, or intramuscularly to experimental animals such as rabbits, sheep, and mice, to generate antibodies. Monoclonal antibodies can be Monoclonal antibodies can be generated by isolating spleen cells and fusing myeloma cells to form hybridomas. Alternatively, the selected polynucleotide is administered directly, such as by intramuscular injection, and expressed in vivo.

The expressed protein generates a variety of protein-specific immune responses, including production of antibodies, comparable to administration of the protein.

Preparations of polyclonal and monoclonal antibodies specific for polypeptides encoded by a selected polynucleotide are made using standard methods known in the art. The antibodies specifically bind to epitopes present in the polypeptides encoded by polynucleotides disclosed in the Sequence Listing. Typically. at least 6, 8, 10, or 12 contiguous amino acids are required to form an epitope. Epitopes that involve non-contiguous amino acids may require a longer polypeptide, e. g., at least 15, 25, or 50 amino acids. Antibodies that specifically bind to human polypeptides encoded by the provided polypeptides should provide a detection signal at least 5-, 10-, or 20-fold higher than a detection signal provided with other proteins when used in Western blots or other immunochemical

assays. Preferably, antibodies that specifically polypeptides of the invention do not bind to other proteins in immunochemical assays at detectable levels and can immunoprecipitate the specific polypeptide from solution.

The invention also contemplates naturally occurring antibodies specific for a polypeptide of the invention. For example, serum antibodies to a polypeptide of the invention in a human population can be purified by methods well known in the art, e. g., by passing antiserum over a column to which the corresponding selected polypeptide or fusion protein is bound. The bound antibodies can then be eluted from the column, for example using a buffer with a high salt concentration.

In addition to the antibodies discussed above, the invention also contemplates genetically engineered antibodies, antibody derivatives (e. g., single chain antibodies, antibody fragments (e. g., Fab, etc.)), according to methods well known in the art.

Polynucleotides or Arrays for Diagnostics Polynucleotide arrays provide a high throughput technique that can assay a large number of polynucleotide sequences in a sample. This technology can be used as a diagnostic and as a tool to test for differential expression, e. g., to determine function of an encoded protein. Arrays can be created by spotting polynucleotide probes onto a substrate (e. g., glass, nitrocelllose, etc.) in a two- dimensional matrix or array having bound probes. The probes can be bound to the substrate by either covalent bonds or by non-specific interactions, such as hydrophobic interactions. Samples of polynucleotides can be detectably labeled (e. g., using radioactive or fluorescent labels) and then hybridized to the probes. Double stranded polynucleotides, comprising the labeled sample polynucleotides bound to probe polynucleotides, can be detected once the unbound portion of the sample is washed away. Techniques for constructing arrays and methods of using these arrays are described in EP 799 897 ; WO 97/29212 ; WO 97/27317 ; EP 785 280 ; WO 97/02357 ; USPN 5, 593, 839 ; USPN 5, 578, 832 ; EP 728 520 ; USPN 5, 599, 695 ; EP 721 016 ; USPN 5, 556, 752 ; WO 95/22058 ; and USPN 5, 631, 734. Arrays can be used to, for example, examine differential expression of genes and can be used to determine gene function. For example, arrays can be used to detect differential expression of a polynucleotide between a test cell and control cell (e. g., cancer cells and normal cells). For example, high expression of a particular message in a cancer cell, which is not observed in a corresponding normal cell, can indicate a cancer specific gene product. Exemplary uses of arrays are further described in, for example, Pappalarado et al., Sem. Radiation Oncol. (1998) 8 : 217 ; and Ramsay Nature Biotechnol. (1998) 16 : 40.

Differential Expression in Diagnosis The polynucleotides of the invention can also be used to detect differences in expression levels between two cells, e. g., as a method to identify abnormal or diseased tissue in a human. For

polynucleotides corresponding to profiles of protein families, the choice of tissue can be selected according to the putative biological function. In general, the expression of a gene corresponding to a specific polynucleotide is compared between a first tissue that is suspected of being diseased and a second, normal tissue of the human. The tissue suspected of being abnormal or diseased can be derived from a different tissue type of the human, but preferably it is derived from the same tissue type ; for example an intestinal polyp or other abnormal growth should be compared with normal intestinal tissue. The normal tissue can be the same tissue as that of the test sample, or any normal tissue of the patient, especially those that express the polynucleotide-related gene of interest (e. g., brain, thymus, testis, heart, prostate, placenta, spleen, small intestine, skeletal muscle, pancreas, and the mucosal lining of the colon). A difference between the polynucleotide-related gene, mRNA, or protein in the two tissues which are compared, for example in molecular weight, amino acid or nucleotide sequence, or relative abundance, indicates a change in the gene, or a gene which regulates it, in the tissue of the human that was suspected of being diseased. Examples of detection of differential expression and its use in diagnosis of cancer are described in USPNs 5, 688, 641 and 5, 677, 125.

A genetic predisposition to disease in a human can also be detected by comparing expression levels of an mRNA or protein corresponding to a polynucleotide of the invention in a fetal tissue with levels associated in normal fetal tissue. Fetal tissues that are used for this purpose include, but are not limited to, amniotic fluid, chorionic villi, blood, and the blastomere of an in vitro-fertilized embryo. The comparable normal polynucleotide-related gene is obtained from any tissue. The mRNA or protein is obtained from a normal tissue of a human in which the polynucleotide-related gene is expressed. Differences such as alterations in the nucleotide sequence or size of the same product of the fetal polynucleotide-related gene or mRNA, or alterations in the molecular weight, amino acid sequence, or relative abundance of fetal protein, can indicate a germline mutation in the polynucleotide-related gene of the fetus, which indicates a genetic predisposition to disease. In general, diagnostic, prognostic, and other methods of the invention based on differential expression involve detection of a level or amount of a gene product, particularly a differentially expressed gene product, in a test sample obtained from a patient suspected of having or being susceptible to a disease (e. g., breast cancer, lung cancer, colon cancer and/or metastatic forms thereof), and comparing the detected levels to those levels found in normal cells (e. g., cells substantially unaffected by cancer) and/or other control cells (e. g., to differentiate a cancerous cell from a cell affected by dysplasia).

Furthermore, the severity of the disease can be assessed by comparing the detected levels of a differentially expressed gene product with those levels detected in samples representing the levels of differentially gene product associated with varying degrees of severity of disease. It should be noted

that use of the term"diagnostic"herein is not necessarily meant to exclude"prognostic"or "prognosis,"but rather is used as a matter of convenience.

The term"differentially expressed gene"is generally intended to encompass a polynucleotide that can, for example, include an open reading frame encoding a gene product (e. g., a polypeptide), and/or introns of such genes and adjacent 5'and 3'non-coding nucleotide sequences involved in the regulation of expression, up to about 20 kb beyond the coding region, but possibly further in either direction. The gene can be introduced into an appropriate vector for extrachromosomal maintenance or for integration into a host genome. In general, a difference in expression level associated with a decrease in expression level of at least about 25%, usually at least about 50% to 75%, more usually at least about 90% or more is indicative of a differentially expressed gene of interest, i. e., a gene that is underexpressed or down-regulated in the test sample relative to a control sample. Furthermore, a difference in expression level associated with an increase in expression of at least about 25%, usually at least about 50% to 75%, more usually at least about 90% and can be at least about 1'/2-fold, usually at least about 2-fold to about 10-fold, and can be about 100-fold to about 1, 000-fold increase relative to a control sample is indicative of a differentially expressed gene of interest, i. e., an overexpressed or up-regulated gene.

"Differentially expressed polynucleotide"as used herein means a nucleic acid molecule (RNA or DNA) comprising a sequence that represents a differentially expressed gene, e. g., the differentially expressed polynucleotide comprises a sequence (e. g., an open reading frame encoding a gene product) that uniquely identifies a differentially expressed gene so that detection of the differentially expressed polynucleotide in a sample is correlated with the presence of a differentially expressed gene in a sample."Differentially expressed polynucleotides"is also meant to encompass fragments of the disclosed polynucleotides, e. g., fragments retaining biological activity, as well as nucleic acids homologous, substantially similar, or substantially identical (e. g., having about 90% sequence identity) to the disclosed polynucleotides.

"Diagnosis"as used herein generally includes determination of a subject's susceptibility to a disease or disorder, determination as to whether a subject is presently affected by a disease or disorder, as well as to the prognosis of a subject affected by a disease or disorder (e. g., identification of pre-metastatic or metastatic cancerous states, stages of cancer, or responsiveness of cancer to therapy). The present invention particularly encompasses diagnosis of subjects in the context of breast cancer (e. g., carcinoma in situ (e. g., ductal carcinoma in situ), estrogen receptor (ER)-positive breast cancer, ER-negative breast cancer, or other forms and/or stages of breast cancer), lung cancer (e. g., small cell carcinoma, non-small cell carcinoma, mesothelioma, and other forms and/or stages of lung cancer), and colon cancer (e. g., adenomatous polyp, colorectal carcinoma, and other forms and/or stages of colon cancer).

"Sample"or"biological sample"as used throughout here are generally meant to refer to samples of biological fluids or tissues, particularly samples obtained from tissues, especially from cells of the type associated with the disease for which the diagnostic application is designed (e. g., ductal adenocarcinoma), and the like."Samples"is also meant to encompass derivatives and fractions of such samples (e. g., cell lysats). Where the sample is solid tissue, the cells of the tissue can be dissociated or tissue sections can be analyzed.

Methods of the subject invention useful in diagnosis or prognosis typically involve comparison of the abundance of a selected differentially expressed gene product in a sample of interest with that of a control to determine any relative differences in the expression of the gene product, where the difference can be measured qualitatively and/or quantitatively. Quantitation can be accomplished, for example, by comparing the level of expression product detected in the sample with the amounts of product present in a standard curve. A comparison can be made visually ; by using a technique such as densitometry, with or without computerized assistance ; by preparing a representative library of cDNA clones of mRNA isolated from a test sample, sequencing the clones in the library to determine that number of cDNA clones corresponding to the same gene product, and analyzing the number of clones corresponding to that same gene product relative to the number of clones of the same gene product in a control sample ; or by using an array to detect relative levels of hybridization to a selected sequence or set of sequences. and comparing the hybridization pattern to that of a control. The differences in expression are then correlated with the presence or absence of an abnormal expression pattern. A variety of different methods for determining the nucleic acid abundance in a sample are known to those of skill in the art (see, e. g., WO 97/27317).

In general, diagnostic assays of the invention involve detection of a gene product of a the polynucleotide sequence (e. g., mRNA or polypeptide) that corresponds to a sequence of SEQ ID NOS : 1-1079 The patient from whom the sample is obtained can be apparently healthy, susceptible to disease (e. g., as determined by family history or exposure to certain environmental factors), or can already be identified as having a condition in which altered expression of a gene product of the invention is implicated.

Diagnosis can be determined based on detected gene product expression levels of a gene product encoded by at least one, preferably at least two or more, at least 3 or more, or at least 4 or more of the polynucleotides having a sequence set forth in SEQ ID NOS : 1-1079, and can involve detection of expression of genes corresponding to all of SEQ ID NOS : 1-1079 and/or additional sequences that can serve as additional diagnostic markers and/or reference sequences. Where the diagnostic method is designed to detect the presence or susceptibility of a patient to cancer, the assay preferably involves detection of a gene product encoded by a gene corresponding to a polynucleotide that is differentially expressed in cancer. Examples of such differentially expressed polynucleotides

are described in the Examples below. Given the provided polynucleotides and information regarding their relative expression levels provided herein, assays using such polynucleotides and detection of their expression levels in diagnosis and prognosis will be readily apparent to the ordinarily skilled artisan.

Any of a variety of detectable labels can be used in connection with the various embodiments of the diagnostic methods of the invention. Suitable detectable labels include fluorochromes, (e. g. fluorescein isothiocyanate (FITC), rhodamine, Texas Red, phycoerythrin, allophycocyanin, 6- carboxyfluorescein (6-FAM), 2', 7'-dimethoxy-4', 5'-dichloro-6-carboxyfluorescein, 6-carboxy-X- rhodamine (ROX), 6-carboxy-2', 4', 7', 4, 7-hexachlorofluorescein (HEX), 5-carboxyfluorescein (5-FAM) or N, N, N', N'-tetramethyl-6-carboxyrhodamine (TAMRA)), radioactive labels, (e. g. 32p, 35S, 3H, etc.), and the like. The detectable label can involve a two stage systems (e. g., biotin-avidin, hapten-anti-hapten antibody, etc.) Reagents specific for the polynucleotides and polypeptides of the invention, such as antibodies and nucleotide probes, can be supplied in a kit for detecting the presence of an expression product in a biological sample. The kit can also contain buffers or labeling components, as well as instructions for using the reagents to detect and quantify expression products in the biological sample. Exemplary embodiments of the diagnostic methods of the invention are described below in more detail.

Polypeptide detection in diagnosis. In one embodiment, the test sample is assayed for the level of a differentially expressed polypeptide. Diagnosis can be accomplished using any of a number of methods to determine the absence or presence or altered amounts of the differentially expressed polypeptide in the test sample. For example, detection can utilize staining of cells or histological sections with labeled antibodies, performed in accordance with conventional methods.

Cells can be permeabilized to stain cytoplasmic molecules. In general, antibodies that specifically bind a differentially expressed polypeptide of the invention are added to a sample, and incubated for a period of time sufficient to allow binding to the epitope, usually at least about 10 minutes. The antibody can be detectably labeled for direct detection (e. g., using radioisotopes, enzymes, fluorescers, chemiluminescers, and the like), or can be used in conjunction with a second stage antibody or reagent to detect binding (e. g., biotin with horseradish peroxidase-conjugated avidin, a secondary antibody conjugated to a fluorescent compound, e. g. fluorescein, rhodamine, Texas red, etc.). The absence or presence of antibody binding can be determined by various methods, including flow cytometry of dissociated cells, microscopy, radiography, scintillation counting, etc. Any suitable alternative methods can of qualitative or quantitative detection of levels or amounts of differentially expressed polypeptide can be used, for example ELISA, western blot, immunoprecipitation, radioimmunoassay, etc.

mRNA detection. The diagnostic methods of the invention can also or alternatively involve detection of mRNA encoded by a gene corresponding to a differentially expressed polynucleotides of the invention. Any suitable qualitative or quantitative methods known in the art for detecting specific mRNAs can be used. mRNA can be detected by, for example, in situ hybridization in tissue sections, by reverse transcriptase-PCR, or in Northern blots containing poly A+ mRNA. One of skill in the art can readily use these methods to determine differences in the size or amount of mRNA transcripts between two samples. mRNA expression levels in a sample can also be determined by generation of a library of expressed sequence tags (ESTs) from the sample, where the EST library is representative of sequences present in the sample (Adams, et al., (1991) Science 252 : 1651). Enumeration of the relative representation of ESTs within the library can be used to approximate the relative representation of the gene transcript within the starting sample. The results of EST analysis of a test sample can then be compared to EST analysis of a reference sample to determine the relative expression levels of a selected polynucleotide, particularly a polynucleotide corresponding to one or more of the differentially expressed genes described herein. Alternatively, gene expression in a test sample can be performed using serial analysis of gene expression (SAGE) methodology (e. g., Velculescu et al., Science (1995) 270 : 484) or differential display (DD) methodology (see, e. g., U. S.

5, 776, 683 ; and U. S. 5, 807, 680).

Alternatively, gene expression can be analyzed using hybridization analysis.

Oligonucleotides or cDNA can be used to selectively identify or capture DNA or RNA of specific sequence composition, and the amount of RNA or cDNA hybridized to a known capture sequence determined qualitatively or quantitatively, to provide information about the relative representation of a particular message within the pool of cellular messages in a sample. Hybridization analysis can be designed to allow for concurrent screening of the relative expression of hundreds to thousands of genes by using, for example, array-based technologies having high density formats, including filters, microscope slides, or microchips, or solution-based technologies that use spectroscopic analysis (e. g., mass spectrometry). One exemplary use of arrays in the diagnostic methods of the invention is described below in more detail.

Use of a single gene in diagnostic applications. The diagnostic methods of the invention can focus on the expression of a single differentially expressed gene. For example, the diagnostic method can involve detecting a differentially expressed gene, or a polymorphism of such a gene (e. g., a polymorphism in an coding region or control region), that is associated with disease. Disease- associated polymorphisms can include deletion or truncation of the gene, mutations that alter expression level and/or affect activity of the encoded protein, etc.

A number of methods are available for analyzing nucleic acids for the presence of a specific sequence, e. g. a disease associated polymorphism. Where large amounts of DNA are available,

genomic DNA is used directly. Alternatively, the region of interest is cloned into a suitable vector and grown in sufficient quantity for analysis. Cells that express a differentially expressed gene can be used as a source of mRNA, which can be assayed directly or reverse transcribed into cDNA for analysis. The nucleic acid can be amplified by conventional techniques, such as the polymerase chain reaction (PCR), to provide sufficient amounts for analysis, and a detectable label can be included in the amplification reaction (e. g., using a detectably labeled primer or detectably labeled oligonucleotides) to facilitate detection. Alternatively, various methods are also known in the art that utilize oligonucleotide ligation as a means of detecting polymorphisms, see e. g., Riley et al., Nucl.

Acids Res. (1990) 18 : 2887 ; and Delahuntyetal., Am. J. Hum. Genet. (1996) 58 : 1239.

The amplified or cloned sample nucleic acid can be analyzed by one of a number of methods known in the art. The nucleic acid can be sequenced by dideoxy or other methods, and the sequence of bases compared to a selected sequence, e. g., to a wild-type sequence. Hybridization with the polymorphic or variant sequence can also be used to determine its presence in a sample (e. g., by Southern blot, dot blot, etc.). The hybridization pattern of a polymorphic or variant sequence and a control sequence to an array of oligonucleotide probes immobilized on a solid support, as described in US 5, 445, 934, or in WO 95/35505, can also be used as a means of identifying polymorphic or variant sequences associated with disease. Single strand conformational polymorphism (SSCP) analysis, denaturing gradient gel electrophoresis (DGGE), and heteroduplex analysis in gel matrices are used to detect conformational changes created by DNA sequence variation as alterations in electrophoretic mobility. Alternatively, where a polymorphism creates or destroys a recognition site for a restriction endonuclease, the sample is digested with that endonuclease, and the products size fractionated to determine whether the fragment was digested. Fractionation is performed by gel or capillary electrophoresis, particularly acrylamide or agarose gels.

Screening for mutations in a gene can be based on the functional or antigenic characteristics of the protein. Protein truncation assays are useful in detecting deletions that can affect the biological activity of the protein. Various immunoassays designed to detect polymorphisms in proteins can be used in screening. Where many diverse genetic mutations lead to a particular disease phenotype, functional protein assays have proven to be effective screening tools. The activity of the encoded protein can be determined by comparison with the wild-type protein.

Pattern matching in diagnosis using arrays. In another embodiment, the diagnostic and/or prognostic methods of the invention involve detection of expression of a selected set of genes in a test sample to produce a test expression pattern (TEP). The TEP is compared to a reference expression pattern (REP), which is generated by detection of expression of the selected set of genes in a reference sample (e. g., a positive or negative control sample). The selected set of genes includes at least one of the genes of the invention, which genes correspond to the polynucleotide sequences of

SEQ ID NOS : I-1079. Of particular interest is a selected set of genes that includes gene differentially expressed in the disease for which the test sample is to be screened.

"Reference sequences"or"reference polynucleotides"as used herein in the context of differential gene expression analysis and diagnosis/prognosis refers to a selected set of polynucleotides, which selected set includes at least one or more of the differentially expressed polynucleotides described herein. A plurality of reference sequences, preferably comprising positive and negative control sequences, can be included as reference sequences. Additional suitable reference sequences are found in GenBank, Unigene, and other nucleotide sequence databases (including, e. g., expressed sequence tag (EST), partial, and full-length sequences).

"Reference array"means an array having reference sequences for use in hybridization with a sample, where the reference sequences include all, at least one of, or any subset of the differentially expressed polynucleotides described herein. Usually such an array will include at least 3 different reference sequences, and can include any one or all of the provided differentially expressed sequences. Arrays of interest can further comprise sequences, including polymorphisms, of other genetic sequences, particularly other sequences of interest for screening for a disease or disorder (e. g., cancer, dysplasia, or other related or unrelated diseases, disorders, or conditions). The oligonucleotide sequence on the array will usually be at least about 12 nt in length, and can be of about the length of the provided sequences, or can extend into the flanking regions to generate fragments of 100 nt to 200 nt in length or more. Reference arrays can be produced according to any suitable methods known in the art. For example, methods of producing large arrays of oligonucleotides are described in U. S. 5, 134, 854, and U. S. 5, 445, 934 using light-directed synthesis techniques. Using a computer controlled system, a heterogeneous array of monomers is converted, through simultaneous coupling at a number of reaction sites, into a heterogeneous array of polymers.

Alternatively, microarrays are generated by deposition of pre-synthesized oligonucleotides onto a solid substrate, for example as described in PCT published application no. WO 95/35505.

A"reference expression pattern"or"REP"as used herein refers to the relative levels of expression of a selected set of genes, particularly of differentially expressed genes, that is associated with a selected cell type, e. g., a normal cell, a cancerous cell, a cell exposed to an environmental stimulus, and the like. A"test expression pattern"or"TEP"refers to relative levels of expression of a selected set of genes, particularly of differentially expressed genes, in a test sample (e. g., a cell of unknown or suspected disease state, from which mRNA is isolated).

REPs can be generated in a variety of ways according to methods well known in the art. For example, REPs can be generated by hybridizing a control sample to an array having a selected set of polynucleotides (particularly a selected set of differentially expressed polynucleotides), acquiring the hybridization data from the array, and storing the data in a format that allows for ready comparison of

the REP with a TEP. Alternatively, all expressed sequences in a control sample can be isolated and sequenced, e. g., by isolating mRNA from a control sample, converting the mRNA into cDNA, and sequencing the cDNA. The resulting sequence information roughly or precisely reflects the identity and relative number of expressed sequences in the sample. The sequence information can then be stored in a format (e. g., a computer-readable format) that allows for ready comparison of the REP with a TEP. The REP can be normalized prior to or after data storage, and/or can be processed to selectively remove sequences of expressed genes that are of less interest or that might complicate analysis (e. g., some or all of the sequences associated with housekeeping genes can be eliminated from REP data).

TEPs can be generated in a manner similar to REPs, e. g., by hybridizing a test sample to an array having a selected set of polynucleotides, particularly a selected set of differentially expressed polynucleotides, acquiring the hybridization data from the array, and storing the data in a format that allows for ready comparison of the TEP with a REP. The REP and TEP to be used in a comparison can be generated simultaneously, or the TEP can be compared to previously generated and stored REPs.

In one embodiment of the invention, comparison of a TEP with a REP involves hybridizing a test sample with a reference array, where the reference array has one or more reference sequences for use in hybridization with a sample. The reference sequences include all, at least one of, or any subset of the differentially expressed polynucleotides described herein. Hybridization data for the test sample is acquired, the data normalized, and the produced TEP compared with a REP generated using an array having the same or similar selected set of differentially expressed polynucleotides.

Probes that correspond to sequences differentially expressed between the two samples will show decreased or increased hybridization efficiency for one of the samples relative to the other.

Methods for collection of data from hybridization of samples with a reference arrays are well known in the art. For example, the polynucleotides of the reference and test samples can be generated using a detectable fluorescent label, and hybridization of the polynucleotides in the samples detected by scanning the microarrays for the presence of the detectable label using, for example, a microscope and light source for directing light at a substrate. A photon counter detects fluorescence from the substrate, while an x-y translation stage varies the location of the substrate. A confocal detection device that can be used in the subject methods is described in USPN 5, 631, 734. A scanning laser microscope is described in Shalon et al., Genome Res. (1996) 6 : 639. A scan, using the appropriate excitation line, is performed for each fluorophore used. The digital images generated from the scan are then combined for subsequent analysis. For any particular array element, the ratio of the fluorescent signal from one sample (e. g., a test sample) is compared to the fluorescent signal from another sample (e. g., a reference sample), and the relative signal intensity determined.

Methods for analyzing the data collected from hybridization to arrays are well known in the art. For example, where detection of hybridization involves a fluorescent label, data analysis can include the steps of determining fluorescent intensity as a function of substrate position from the data collected, removing outliers, i. e. data deviating from a predetermined statistical distribution, and calculating the relative binding affinity of the targets from the remaining data. The resulting data can be displayed as an image with the intensity in each region varying according to the binding affinity between targets and probes.

In general, the test sample is classified as having a gene expression profile corresponding to that associated with a disease or non-disease state by comparing the TEP generated from the test sample to one or more REPs generated from reference samples (e. g., from samples associated with cancer or specific stages of cancer, dysplasia, samples affected by a disease other than cancer, normal samples, etc.). The criteria for a match or a substantial match between a TEP and a REP include expression of the same or substantially the same set of reference genes, as well as expression of these reference genes at substantially the same levels (e. g., no significant difference between the samples for a signal associated with a selected reference sequence after normalization of the samples, or at least no greater than about 25% to about 40% difference in signal strength for a given reference sequence. In general, a pattern match between a TEP and a REP includes a match in expression, preferably a match in qualitative or quantitative expression level, of at least one of, all or any subset of the differentially expressed genes of the invention.

Pattern matching can be performed manually, or can be performed using a computer program. Methods for preparation of substrate matrices (e. g., arrays), design of oligonucleotides for use with such matrices, labeling of probes, hybridization conditions, scanning of hybridized matrices, and analysis of patterns generated, including comparison analysis, are described in, for example, U. S.

5, 800, 992.

Diagnosis. Prognosis and Management of Cancer The polynucleotides of the invention and their gene products are of particular interest as genetic or biochemical markers (e. g., in blood or tissues) that will detect the earliest changes along the carcinogenesis pathway and/or to monitor the efficacy of various therapies and preventive interventions. For example, the level of expression of certain polynucleotides can be indicative of a poorer prognosis, and therefore warrant more aggressive chemo-or radio-therapy for a patient or vice versa. The correlation of novel surrogate tumor specific features with response to treatment and outcome in patients can define prognostic indicators that allow the design of tailored therapy based on the molecular profile of the tumor. These therapies include antibody targeting and gene therapy.

Determining expression of certain polynucleotides and comparison of a patients profile with known expression in normal tissue and variants of the disease allows a determination of the best possible

treatment for a patient, both in terms of specificity of treatment and in terms of comfort level of the patient. Surrogate tumor markers, such as polynucleotide expression, can also be used to better classify, and thus diagnose and treat, different forms and disease states of cancer. Two classifications widely used in oncology that can benefit from identification of the expression levels of the polynucleotides of the invention are staging of the cancerous disorder, and grading the nature of the cancerous tissue.

The polynucleotides of the invention can be useful to monitor patients having or susceptible to cancer to detect potentially malignant events at a molecular level before they are detectable at a gross morphological level. Furthermore, a polynucleotide of the invention identified as important for one type of cancer can also have implications for development or risk of development of other types of cancer, e. g., where a polynucleotide is differentially expressed across various cancer types. Thus, for example, expression of a polynucleotide that has clinical implications for metastatic colon cancer can also have clinical implications for stomach cancer or endometrial cancer.

Staging. Staging is a process used by physicians to describe how advanced the cancerous state is in a patient. Staging assists the physician in determining a prognosis, planning treatment and evaluating the results of such treatment. Staging systems vary with the types of cancer, but generally involve the following"TNM"system : the type of tumor, indicated by T ; whether the cancer has metastasized to nearby lymph nodes, indicated by N ; and whether the cancer has metastasized to more distant parts of the body, indicated by M. Generally, if a cancer is only detectable in the area of the primary lesion without having spread to any lymph nodes it is called Stage 1. If it has spread only to the closest lymph nodes, it is called Stage II. In Stage III, the cancer has generally spread to the lymph nodes in near proximity to the site of the primary lesion. Cancers that have spread to a distant part of the body, such as the liver, bone, brain or other site, are Stage IV, the most advanced stage.

The polynucleotides of the invention can facilitate fine-tuning of the staging process by identifying markers for the aggresivity of a cancer, e. g. the metastatic potential, as well as the presence in different areas of the body. Thus, a Stage II cancer with a polynucleotide signifying a high metastatic potential cancer can be used to change a borderline Stage II tumor to a Stage III tumor, justifying more aggressive therapy. Conversely, the presence of a polynucleotide signifying a lower metastatic potential allows more conservative staging of a tumor.

Grading of cancers. Grade is a term used to describe how closely a tumor resembles normal tissue of its same type. The microscopic appearance of a tumor is used to identify tumor grade based on parameters such as cell morphology, cellular organization, and other markers of differentiation.

As a general rule, the grade of a tumor corresponds to its rate of growth or aggressiveness, with undifferentiated or high-grade tumors being more aggressive than well differentiated or low-grade tumors. The following guidelines are generally used for grading tumors : 1) GX Grade cannot be

assessed ; 2) G I Well differentiated ; G2 Moderately well differentiated ; 3) G3 Poorly differentiated ; 4) G4 Undifferentiated. The polynucleotides of the invention can be especially valuable in determining the grade of the tumor, as they not only can aid in determining the differentiation status of the cells of a tumor, they can also identify factors other than differentiation that are valuable in determining the aggressiveness of a tumor, such as metastatic potential.

Detection of lung cancer. The polynucleotides of the invention can be used to detect lung cancer in a subject. Although there are more than a dozen different kinds of lung cancer, the two main types of lung cancer are small cell and nonsmall cell, which encompass about 90% of all lung cancer cases. Small cell carcinoma (also called oat cell carcinoma) usually starts in one of the larger bronchial tubes, grows fairly rapidly, and is likely to be large by the time of diagnosis. Nonsmall cell lung cancer (NSCLC) is made up of three general subtypes of lung cancer. Epidermoid carcinoma (also called squamous cell carcinoma) usually starts in one of the larger bronchial tubes and grows relatively slowly. The size of these tumors can range from very small to quite large.

Adenocarcinoma starts growing near the outside surface of the lung and can vary in both size and growth rate. Some slowly growing adenocarcinomas are described as alveolar cell cancer. Large cell carcinoma starts near the surface of the lung, grows rapidly, and the growth is usually fairly large when diagnosed. Other less common forms of lung cancer are carcinoid, cylindroma, mucoepidermoid, and malignant mesothelioma.

The polynucleotides of the invention, e. g., polynucleotides differentially expressed in normal cells versus cancerous lung cells (e. g., tumor cells of high or low metastatic potential) or between types of cancerous lung cells (e. g., high metastatic versus low metastatic), can be used to distinguish types of lung cancer as well as identifying traits specific to a certain patient's cancer and selecting an appropriate therapy. For example, if the patient's biopsy expresses a polynucleotide that is associated with a low metastatic potential, it may justify leaving a larger portion of the patient's lung in surgery to remove the lesion. Alternatively, a smaller lesion with expression of a polynucleotide that is associated with high metastatic potential may justify a more radical removal of lung tissue and/or the surrounding lymph nodes, even if no metastasis can be identified through pathological examination.

Detection of breast cancer. The majority of breast cancers are adenocarcinomas subtypes, which can be summarized as follows : 1) ductal carcinoma in situ (DCIS), including comedocarcinoma ; 2) infiltrating (or invasive) ductal carcinoma (IDC) ; 3) lobular carcinoma in situ (LCIS) ; 4) infiltrating (or invasive) lobular carcinoma (ILC) ; 5) inflammatory breast cancer ; 6) medullary carcinoma ; 7) mucinous carcinoma ; 8) Paget's disease of the nipple ; 9) Phyllodes tumor ; and 10) tubular carcinoma ;

The expression of polynucleotides of the invention can be used in the diagnosis and management of breast cancer, as well as to distinguish between types of breast cancer. Detection of breast cancer can be determined using expression levels of any of the appropriate polynucleotides of the invention, either alone or in combination. Determination of the aggressive nature and/or the metastatic potential of a breast cancer can also be determined by comparing levels of one or more polynucleotides of the invention and comparing levels of another sequence known to vary in cancerous tissue, e. g. ER expression. In addition, development of breast cancer can be detected by examining the ratio of expression of a differentially expressed polynucleotide to the levels of steroid hormones (e. g., testosterone or estrogen) or to other hormones (e. g., growth hormone, insulin). Thus expression of specific marker polynucleotides can be used to discriminate between normal and cancerous breast tissue, to discriminate between breast cancers with different cells of origin, to discriminate between breast cancers with different potential metastatic rates, etc.

Detection of colon cancer. The polynucleotides of the invention exhibiting the appropriate expression pattern can be used to detect colon cancer in a subject. Colorectal cancer is one of the most common neoplasms in humans and perhaps the most frequent form of hereditary neoplasia.

Prevention and early detection are key factors in controlling and curing colorectal cancer. Colorectal cancer begins as polyps, which are small, benign growths of cells that form on the inner lining of the colon. Over a period of several years, some of these polyps accumulate additional mutations and become cancerous. Multiple familial colorectal cancer disorders have been identified, which are summarized as follows : 1) Familial adenomatous polyposis (FAP) ; 2) Gardner's syndrome ; 3) Hereditary nonpolyposis colon cancer (HNPCC) ; and 4) Familial colorectal cancer in Ashkenazi Jews. The expression of appropriate polynucleotides of the invention can be used in the diagnosis, prognosis and management of colorectal cancer. Detection of colon cancer can be determined using expression levels of any of these sequences alone or in combination with the levels of expression.

Determination of the aggressive nature and/or the metastatic potential of a colon cancer can be determined by comparing levels of one or more polynucleotides of the invention and comparing total levels of another sequence known to vary in cancerous tissue, e. g., expression of p53, DCC ras, lor FAP (see, e. g., Fearon ER, et al., Cell (1990) 61 (5) : 759 ; Hamilton SR et al., Cancer (1993) 72 : 957 ; Bodmer W, et al., Nat Genet. (1994) 4 (3) : 217 ; Fearon ER, Ann N YAcad Sci. (1995) 768 : 101). For example, development of colon cancer can be detected by examining the ratio of any of the polynucleotides of the invention to the levels of oncogenes (e. g. ras) or tumor suppressor genes (e. g.

FAP or p53). Thus expression of specific marker polynucleotides can be used to discriminate between normal and cancerous colon tissue, to discriminate between colon cancers with different cells of origin, to discriminate between colon cancers with different potential metastatic rates, etc.

Detection of prostate cancer. The polynucleotides and their corresponding genes and gene

products exhibiting the appropriate differential expression pattern can be used to detect prostate cancer in a subject. Over 95% of primary prostate cancers are adenocarcinomas. Signs and symptoms may include : frequent urination, especially at night, inability to urinate, trouble starting or holding back urination, a weak or interrupted urine flow and frequent pain or stiffness in the lower back, hips or upper thighs.

Many of the signs and symptoms of prostate cancer can be caused by a variety of other non- cancerous conditions. For example, one common cause of many of these signs and symptoms is a condition called benign prostatic hypertrophy, or BPH. In BPH, the prostate gets bigger and may block the flow or urine or interfere with sexual function. The methods and compositions of the invention can be used to distinguish between prostate cancer and such non-cancerous conditions.

The methods of the invention can be used in conjunction with conventional methods of diagnosis, e. g., digital rectal exam and/or detection of the level of prostate specific antigen (PSA), a substance produced and secreted by the prostate.

Use of Polvnucleotides to Screen for Peptide Analogs and Antagonists Polypeptides encoded by the instant polynucleotides and corresponding full length genes can be used to screen peptide libraries to identify binding partners, such as receptors, from among the encoded polypeptides. Peptide libraries can be synthesized according to methods known in the art (see, e. g., USPN 5, 010, 175, and WO 91/17823). Agonists or antagonists of the polypeptides if the invention can be screened using any available method known in the art, such as signal transduction, antibody binding, receptor binding, mitogenic assays, chemotaxis assays, etc. The assay conditions ideally should resemble the conditions under which the native activity is exhibited in vivo, that is, under physiologic pH, temperature, and ionic strength. Suitable agonists or antagonists will exhibit strong inhibition or enhancement of the native activity at concentrations that do not cause toxic side effects in the subject. Agonists or antagonists that compete for binding to the native polypeptide can require concentrations equal to or greater than the native concentration, while inhibitors capable of binding irreversibly to the polypeptide can be added in concentrations on the order of the native concentration.

Such screening and experimentation can lead to identification of a novel polypeptide binding partner, such as a receptor, encoded by a gene or a cDNA corresponding to a polynucleotide of the invention, and at least one peptide agonist or antagonist of the novel binding partner. Such agonists and antagonists can be used to modulate, enhance, or inhibit receptor function in cells to which the receptor is native, or in cells that possess the receptor as a result of genetic engineering. Further, if the novel receptor shares biologically important characteristics with a known receptor, information about agonist/antagonist binding can facilitate development of improved agonists/antagonists of the known receptor.

Pharmaceutical Compositions and Therapeutic Uses Pharmaceutical compositions of the invention can comprise polypeptides, antibodies, or polynucleotides (including antisense nucleotides and ribozymes) of the claimed invention in a therapeutically effective amount. The term"therapeutically effective amount"as used herein refers to an amount of a therapeutic agent to treat, ameliorate, or prevent a desired disease or condition, or to exhibit a detectable therapeutic or preventative effect. The effect can be detected by, for example, chemical markers or antigen levels. Therapeutic effects also include reduction in physical symptoms, such as decreased body temperature. The precise effective amount for a subject will depend upon the subject's size and health, the nature and extent of the condition, and the therapeutics or combination of therapeutics selected for administration. Thus, it is not useful to specify an exact effective amount in advance. However, the effective amount for a given situation is determined by routine experimentation and is within the judgment of the clinician. For purposes of the present invention, an effective dose will generally be from about 0. 01 mg/kg to 50 mg/kg or 0. 05 mg/kg to about 10 mg/kg of the DNA constructs in the individual to which it is administered.

A pharmaceutical composition can also contain a pharmaceutically acceptable carrier. The term"pharmaceutically acceptable carrier"refers to a carrier for administration of a therapeutic agent, such as antibodies or a polypeptide, genes, and other therapeutic agents. The term refers to any pharmaceutical carrier that does not itself induce the production of antibodies harmful to the individual receiving the composition, and which can be administered without undue toxicity.

Suitable carriers can be large, slowly metabolized macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, and inactive virus particles. Such carriers are well known to those of ordinary skill in the art. Pharmaceutically acceptable carriers in therapeutic compositions can include liquids such as water, saline, glycerol and ethanol. Auxiliary substances, such as wetting or emulsifying agents, pH buffering substances, and the like, can also be present in such vehicles. Typically, the therapeutic compositions are prepared as injectables, either as liquid solutions or suspensions ; solid forms suitable for solution in, or suspension in, liquid vehicles prior to injection can also be prepared. Liposomes are included within the definition of a pharmaceutically acceptable carrier. Pharmaceutically acceptable salts can also be present in the pharmaceutical composition, e. g., mineral acid salts such as hydrochlorides, hydrobromides, phosphates, sulfates, and the like ; and the salts of organic acids such as acetates, propionates, malonates, benzoates, and the like. A thorough discussion of pharmaceutically acceptable excipients is available in Remington's Pharmaceutical Sciences (Mack Pub. Co., N. J.

1991).

Delivery Methods. Once formulated, the compositions of the invention can be (1) administered directly to the subject (e. g., as polynucleotide or polypeptides) ; or (2) delivered ex

vivo, to cells derived from the subject (e. g., as in ex vivo gene therapy). Direct delivery of the compositions will generally be accomplished by parenteral injection, e. g., subcutaneously, intraperitoneally, intravenously or intramuscularly, intratumoral or to the interstitial space of a tissue.

Other modes of administration include oral and pulmonary administration, suppositories, and transdermal applications, needles. and gene guns or hyposprays. Dosage treatment can be a single dose schedule or a multiple dose schedule.

Methods for the ex vivo delivery and reimplantation of transformed cells into a subject are known in the art and described in e. g., International Publication No. WO 93/14778. Examples of cells useful in ex vivo applications include, for example, stem cells, particularly hematopoetic, lymph cells, macrophages, dendritic cells, or tumor cells. Generally, delivery of nucleic acids for both ex vivo and in vitro applications can be accomplished by, for example, dextran-mediated transfection, calcium phosphate precipitation, polybrene mediated transfection, protoplast fusion, electroporation, encapsulation of the polynucleotide (s) in liposomes, and direct microinjection of the DNA into nuclei, all well known in the art.

Once a gene corresponding to a polynucleotide of the invention has been found to correlate with a proliferative disorder, such as neoplasia, dysplasia, and hyperplasia, the disorder can be amenable to treatment by administration of a therapeutic agent based on the provided polynucleotide, corresponding polypeptide or other corresponding molecule (e. g., antisense, ribozyme, etc.).

The dose and the means of administration of the inventive pharmaceutical compositions are determined based on the specific qualities of the therapeutic composition, the condition, age, and weight of the patient, the progression of the disease, and other relevant factors. For example, administration of polynucleotide therapeutic compositions agents of the invention includes local or systemic administration, including injection, oral administration, particle gun or catheterized administration, and topical administration. Preferably, the therapeutic polynucleotide composition contains an expression construct comprising a promoter operably linked to a polynucleotide of at least 12, 22, 25, 30, or 35 contiguous nt of the polynucleotide disclosed herein. Various methods can be used to administer the therapeutic composition directly to a specific site in the body. For example, a small metastatic lesion is located and the therapeutic composition injected several times in several different locations within the body of tumor. Alternatively, arteries which serve a tumor are identified, and the therapeutic composition injected into such an artery, in order to deliver the composition directly into the tumor. A tumor that has a necrotic center is aspirated and the composition injected directly into the now empty center of the tumor. The antisense composition is directly administered to the surface of the tumor, for example, by topical application of the composition. X-ray imaging is used to assist in certain of the above delivery methods.

Receptor-mediated targeted delivery of therapeutic compositions containing an antisense polynucleotide, subgenomic polynucleotides, or antibodies to specific tissues can also be used.

Receptor-mediated DNA delivery techniques are described in, for example, Findeis et al., Trends Biotechnol. (1993) 11 : 202 ; Chiou et al., Gene Therapeutics : Methods And Applications Of Direct Gene Transfer (J. A. Wolff, ed.) (1994) ; Wu et al., J. Biol. Chem. (1988) 263 : 621 ; Wu et al., J. Biol.

Chem. (1994) 269 : 542 ; Zenke et al., Proc. Natl. Acad. Sci. (USA) (1990) 87 : 3655 ; Wu et al., J. Biol.

Chem. (1991) 266 : 338. Therapeutic compositions containing a polynucleotide are administered in a range of about 100 ng to about 200 mg of DNA for local administration in a gene therapy protocol.

Concentration ranges of about 500 ng to about 50 mg, about I pg to about 2 mg, about 5 g to about 500 u. g, and about 20 ig to about 100 n. g of DNA can also be used during a gene therapy protocol.

Factors such as method of action (e. g., for enhancing or inhibiting levels of the encoded gene product) and efficacy of transformation and expression are considerations which will affect the dosage required for ultimate efficacy of the antisense subgenomic polynucleotides. Where greater expression is desired over a larger area of tissue, larger amounts of antisense subgenomic polynucleotides or the same amounts readministered in a successive protocol of administrations, or several administrations to different adjacent or close tissue portions of, for example, a tumor site, may be required to effect a positive therapeutic outcome. In all cases, routine experimentation in clinical trials will determine specific ranges for optimal therapeutic effect. For polynucleotide related genes encoding polypeptides or proteins with anti-inflammatory activity, suitable use, doses, and administration are described in USPN 5, 654, 173.

The therapeutic polynucleotides and polypeptides of the present invention can be delivered using gene delivery vehicles. The gene delivery vehicle can be of viral or non-viral origin (see generally, Jolly, Cancer Gene Therapy (1994) 1 : 51 ; Kimura. Human Gene Therapy (1994) 5 : 845 ; Connelly, Human Gene Therapy (1995) 1 : 185 ; and Kaplitt, Nature Genetics (1994) 6 : 148).

Expression of such coding sequences can be induced using endogenous mammalian or heterologous promoters. Expression of the coding sequence can be either constitutive or regulated.

Viral-based vectors for delivery of a desired polynucleotide and expression in a desired cell are well known in the art. Exemplary viral-based vehicles include, but are not limited to, recombinant retroviruses (see, e. g., WO 90/07936 ; WO 94/03622 ; WO 93/25698 ; WO 93/25234 ; USPN 5, 219, 740 ; WO 93/11230 ; WO 93/10218 ; USPN 4, 777, 127 ; GB Patent No. 2, 200, 651 ; EP 0 345 242 ; and WO 91/02805), alphavirus-based vectors (e. g., Sindbis virus vectors, Semliki forest virus (ATCC VR-67 ; ATCC VR-1247), Ross River virus (ATCC VR-373 ; ATCC VR-1246) and Venezuelan equine encephalitis virus (ATCC VR-923 ; ATCC VR-1250 ; ATCC VR 1249 ; ATCC VR-532), and adeno-associated virus (AAV) vectors (see, e. g., WO 94/12649, WO 93/03769 ; WO

93/19191 ; WO 94/28938 ; WO 95/11984 and WO 95/00655). Administration of DNA linked to killed adenovirus as described in Curiel, Hum. Gene Ther. (1992) 3 : 147 can also be employed.

Non-viral delivery vehicles and methods can also be employed, including, but not limited to, polycationic condensed DNA linked or unlinked to killed adenovirus alone (see, e. g., Curiel, Hum.

Gene Ther. (1992) 3 : 147) ; ligand-linked DNA (see, e. g., Wu, J. Biol. Chem. (1989) 264 : 16985) ; eukaryotic cell delivery vehicles cells (see, e. g., USPN 5, 814, 482 ; WO 95/07994 ; WO 96/17072 ; WO 95/30763 ; and WO 97/42338) and nucleic charge neutralization or fusion with cell membranes.

Naked DNA can also be employed. Exemplary naked DNA introduction methods are described in WO 90/11092 and USPN 5, 580, 859. Liposomes that can act as gene delivery vehicles are described in USPN 5, 422, 120 ; WO 95/13796 ; WO 94/23697 ; WO 91/14445 ; and EP 0524968. Additional approaches are described in Philip, Mol. Cell Biol. (1994) 14 : 2411, and in Woffendin, Proc. Natl.

Acad. Sci. (1994) 91 : 1581 Further non-viral delivery suitable for use includes mechanical delivery systems such as the approach described in Woffendin et al., Proc. Natl. Acad. Sci. USA (1994) 91 (24) : 11581. Moreover, the coding sequence and the product of expression of such can be delivered through deposition of photopolymerized hydrogel materials or use of ionizing radiation (see, e. g., USPN 5, 206, 152 and WO 92/11033). Other conventional methods for gene delivery that can be used for delivery of the coding sequence include, for example, use of hand-held gene transfer particle gun (see, e. g., USPN 5, 149, 655) ; use of ionizing radiation for activating transferred gene (see, e. g., USPN 5, 206, 152 and WO 92/11033).

The present invention will now be illustrated by reference to the following examples which set forth particularly advantageous embodiments. However, it should be noted that these embodiments are illustrative and are not to be construed as restricting the invention in any way.

EXAMPLES The following examples are offered primarily for purposes of illustration. It will be readily apparent to those skilled in the art that the formulations, dosages, methods of administration, and other parameters of this invention may be further modified or substituted in various ways without departing from the spirit and scope of the invention.

Example 1 : Source of Biological Materials and Overview of Novel Polvnucleotides Expressed b the Biological Materials cDNA libraries were constructed from either human colon cancer cell line Kml2L4-A (Morikawa, et al., Cancer Research (1988) 48 : 6863), KM 12C (Morikawa et al. Cancer Res. (1988) 48 : 1943-1948), or MDA-MB-231 (Brinkley et al. Cancer Res. (1980) 40 : 3118-3129) was used to

construct a cDNA library from mRNA isolated from the cells. Sequences expressed by these cell lines were isolated and analyzed ; most sequences were about 275-300 nucleotides in length. The KM12L4-A cell line is derived from the KM12C cell line. The KM12C cell line, which is poorly metastatic (low metastatic) was established in culture from a Dukes'stage B2 surgical specimen (Morikawa et al. Cancer Res. (1988) 48 : 6863). The KML4-A is a highly metastatic subline derived from KM12C (Yeatman et al. Nucl. Acids. Res. (1995) 23 : 4007 ; Bao-Ling et al. Proc. Annu. Meet.

Am. Assoc. Cancer. Res. (1995) 21 : 3269). The KM12C and KM12C-derived cell lines (e. g., KM12L4, KM12L4-A, etc.) are well-recognized in the art as a model cell line for the study of colon cancer (see, e. g., Moriakawa et al., supra ; Radinsky et al. Clin. Cancer Res. (1995) 1 : 19 ; Yeatman et al., (1995) supra ; Yeatman et al. Clin. Exp. Metastasis (1996) 14 : 246). The MDA-MB-231 cell line was originally isolated from pleural effusions (Cailleau, J. Natl. Cancer. Inst. (1974) 53 : 661), is of high metastatic potential, and forms poorly differentiated adenocarcinoma grade II in nude mice consistent with breast carcinoma.

The sequences of the isolated polynucleotides were first masked to eliminate low complexity sequences using the XBLAST masking program (Claverie"Effective Large-Scale Sequence Similarity Searches,"In : Computer Methods for Macromolecular Sequence Analysis, Doolittle, ed., Meth. Enzymol. 266 : 212-227 Academic Press, NY, NY (1996) ; see particularly Claverie, in "Automated DNA Sequencing and Analysis Techniques"Adams et al., eds., Chap. 36, p. 267 Academic Press, San Diego, 1994 and Claverie et al. Comput. Chem. (1993) 17 : 191). Generally, masking does not influence the final search results, except to eliminate sequences of relative little interest due to their low complexity, and to eliminate multiple"hits"based on similarity to repetitive regions common to multiple sequences, e. g., Alu repeats. Masking resulted in the elimination of 43 sequences. The remaining sequences were then used in a BLASTN vs. GenBank search; sequences that exhibited greater than 70% overlap, 99% identity, and a p value of less than 1 x 10-40 were discarded. Sequences from this search also were discarded if the inclusive parameters were met, but the sequence was ribosomal or vector-derived.

The resulting sequences from the previous search were classified into three groups (1, 2 and 3 below) and searched in a BLASTX vs. NRP (non-redundant proteins) database search : (1) unknown (no hits in the GenBank search), (2) weak similarity (greater than 45% identity and p value of less than 1x10), and (3) high similarity (greater than 60% overlap, greater than 80% identity, and p value less than 1 x 10-5). Sequences having greater than 70% overlap, greater than 99% identity, and p value of less than 1 x 10-40 were discarded.

The remaining sequences were classified as unknown (no hits), weak similarity, and high similarity (parameters as above). Two searches were performed on these sequences. First, a BLAST vs. EST database search was performed and sequences with greater than 99% overlap, greater than 99% similarity and a p value of less than 1 x 10-40 were discarded. Sequences with a p value of less than 1 x 10 65 when compared to a database sequence of human origin were also excluded. Second, a BLASTN vs. Patent GeneSeq database was performed and sequences having greater than 99% identity, 0p value less than 1 x 10-4, and greater than 99% overlap were discarded.

The remaining sequences were subjected to screening using other rules and redundancies in the dataset. Sequences with a p value of less than l x l0 in relation to a database sequence of human origin were specifically excluded. The final result provided the 982 sequences listed as SEQ ID NOS : 1-982 in the accompanying Sequence Listing and summarized in Table I A (inserted prior to claims). Each identified polynucleotide represents sequence from at least a partial mRNA transcript.

Table 1 A provides : 1) the SEQ ID NO assigned to each sequence for use in the present specification ; 2) the filing date of the U. S. priority application in which the sequence was first filed ; 3) the attorney docket number assigned to the priority application (for internal use) ; 4) the SEQ ID NO assigned to the sequence in the priority application ; 5) the sequence name used as an internal identifier of the sequence ; and 6) the name assigned to the clone from which the sequence was isolated. Because the provided polynucleotides represent partial mRNA transcripts, two or more polynucleotides of the invention may represent different regions of the same mRNA transcript and the same gene. Thus, if two or more SEQ ID NOS : are identified as belonging to the same clone, then either sequence can be used to obtain the full-length mRNA or gene.

In order to confirm the sequences of SEQ ID NOS : 1-982, the clones were retrieved from a library using a robotic retrieval system, and the inserts of the retrieved clones re-sequenced. These "validation"sequences are provided as SEQ ID NOS : 983-996 in the Sequence Listing, and a summary of the"validation"sequences provided in Table I B (inserted prior to claims). Table 1B provides : 1) the SEQ ID NO assigned to each sequence for use in the present specification ; 2) the sample name assigned to the"validation"sequence obtained ; and 3) the name of the clone that contains the indicated"validation"sequence."Validation"sequences can be correlated with the original sequences they validate by referring to Table I A. Because the"validation"sequences are often longer than the original polynucleotide sequences and thus provide additional sequence information. All validation sequences can be obtained either from the corresponding clone or from a cDNA library described herein (e. g., using primers designed from the sequence provided in the sequence listing).

Example 2 : Results of Public Database Search to Identify Function of Gene Products SEQ ID NOS : 1-1079 were translated in all three reading frames, and the nucleotide sequences and translated amino acid sequences used as query sequences to search for homologous sequences in either the GenBank (nucleotide sequences) or Non-Redundant Protein (amino acid sequences) databases. Query and individual sequences were aligned using the BLAST 2. 0 programs, available over the world wide web at http ://ww. ncbi. nlm. nih. gov/BLAST/. (see also Altschul, et al.

Nucleic Acids Res. (1997) 25 : 3389-3402). The sequences were masked to various extents to prevent searching of repetitive sequences or poly-A sequences, using the XBLAST program for masking low complexity as described above in Example 1.

Tables 2A and 2B (inserted before the claims) provide the alignment summaries having a p value of 1 x 10 or less indicating substantial homology between the sequences of the present invention and those of the indicated public databases. Table 2A provides the SEQ ID NO of the query sequence, the accession number of the GenBank database entry of the homologous sequence, and the p value of the alignment. Table 2A provides the SEQ ID NO of the query sequence, the accession number of the Non-Redundant Protein database entry of the homologous sequence, and the p value of the alignment. The alignments provided in Tables 2A and 2B are the best available alignment to a DNA or amino acid sequence at a time just prior to filing of the present specification.

The activity of the polypeptide encoded by the SEQ ID NOS listed in Tables 2A and 2B can be extrapolated to be substantially the same or substantially similar to the activity of the reported nearest neighbor or closely related sequence. The accession number of the nearest neighbor is reported, providing a publicly available reference to the activities and functions exhibited by the nearest neighbor. The public information regarding the activities and functions of each of the nearest neighbor sequences is incorporated by reference in this application. Also incorporated by reference is all publicly available information regarding the sequence, as well as the putative and actual activities and functions of the nearest neighbor sequences listed in Table 2 and their related sequences. The search program and database used for the alignment, as well as the calculation of the p value are also indicated.

Full length sequences or fragments of the polynucleotide sequences of the nearest neighbors can be used as probes and primers to identify and isolate the full length sequence of the corresponding polynucleotide. The nearest neighbors can indicate a tissue or cell type to be used to construct a library for the full-length sequences of the corresponding polynucleotides.

Example 3 : Identification of Contiguous Sequences Havions a Polynucleotide of the Invention The novel polynucleotides were used to screen publicly available and proprietary databases

to determine if any of the polynucleotides of SEQ ID NOS : 1-982 would facilitate identification of a contiguous sequence, e. g., the polynucleotides would provide sequence that would result in 5' extension of another DNA sequence, resulting in production of a longer contiguous sequence composed of the provided polynucleotide and the other DNA sequence (s). Contiging was performed using the Gelmerge application (default settings) of GCG from the Univ. of Wisconsin.

Using these parameters, 83 contiged sequences were generated. These contiged sequences are provided as SEQ ID NOS : 997-1079 (see Table I C). Table I C provides the SEQ ID NO of the contig sequence, the name of the sequence used to create the contig, and the accession number of the publicly available tentative human consensus (THC) sequence used with the sequence of the corresponding sequence name to provide the contig. The sequence name of Table 1C can be correlated with the SEQ ID NO : of the polynucleotide used to generate the contig by referring to Tables I A and IB.

The contiged sequences (SEQ ID NOS : 997-1079) represent longer sequences that encompass another of the polynucleotide sequence of the invention. The contiged sequences were then translated in all three reading frames to determine the best alignment with individual sequences using the BLAST programs as described above. The sequences were masked using the XBLAST program for masking low complexity as described above in Example 1. As described in more detail below, several of the contiged sequences were found to encode polypeptides having characteristics of a polypeptide belonging to a known protein families (and thus represent new members of these protein families) and/or comprising a known functional domain (see Example 4 and Table 3 below). Thus the invention encompasses fragments, fusions, and variants of such polynucleotides that retain biological activity associated with the protein family and/or functional domain identified herein.

Example 4 : Members of Protein Families SEQ ID NOS : I-1079 were used to conduct a profile search as described in the specification above. Several of the polynucleotides of the invention were found to encode polypeptides having characteristics of a polypeptide belonging to a known protein family (and thus represent nmembers of these protein families) and/or comprising a known functional domain. Table 3 (inserted before claims) provides the SEQ ID NO : of the query sequence, a brief description of the profile hit, the position of the query sequence within the individual sequence (indicated as"start"and"stop"), and the orientation (Direction,"Dir") of the query sequence with respect to the individual sequence, where forward (for) indicates that the alignment is in the same direction (left to right) as the sequence provided in the Sequence Listing and reverse (rev) indicates that the alignment is with a sequence complementary to the sequence provided in the Sequence Listing.

Some polynucleotides exhibited multiple profile hits where the query sequence contains overlapping profile regions, and/or where the sequence contains two different functional domains.

Each of the profile hits of Table 3 are described in more detail below. The acronyms for the profiles (provided in parentheses) are those used to identify the profile in the Pfam and Prosite databases.

The Pfam database can be accessed through any of the following URLS : http ://pfam. wustl. edu/index. html ; http ://wvw. sanger. ac. uk/ Software/Pfam/ ; and http ://www. cgr. ki. se/Pfam/. The Prosite database can be accessed at http ://www. expasy. ch/prosite/.

The public information available on the Pfam and Prosite databases regarding the various profiles, including but not limited to the activities, function, and consensus sequences of various proteins families and protein domains, is incorporated herein by reference.

14-3-3 Family (14 3 3 : Pfam Pfam Accession No. PF00244). SEQ ID NO : 1053 corresponds to a sequence encoding a 14-3-3 protein family member. The 14-3-3 protein family includes a group of closely related acidic homodimeric proteins of about 30 kD first identified as very abundant in mammalian brain tissues and located preferentially in neurons (Aitken et al. Trends Biochem. Sci. (1995) 20 : 95-97 ; Morrison Science (1994) 266 : 56-57 ; and Xiao et al. Nature (1995) 376 : 188-191). The 14-3-3 proteins have multiple biological activities, including a key role in signal transduction pathways and the cell cycle. 14-3-3 proteins interact with kinases (e. g., PKC or Raf-1), and can also function as protein-kinase dependent activators of tyrosine and tryptophan hydroxylases.

The 14-3-3 protein sequences are extremely well conserved, and include two highly conserved regions : the first is a peptide of I 1 residues located in the N-terminal section ; the second, a 20 amino acid region located in the C-terminal section. The consensus patterns are as follows : 1) R-N-L- [LIV]-S- [VG]- [GA]-Y- [KN]-N- [IVA] ; 2) Y-K- [DE]-S-T-L-I- [IM]-Q-L- [LF]- [RHC]-D-N- [LF]-T- [LS]-W- [TAN]- [SAD].

Ank Repeats (ANK : Pfam Accession No. PF0023). SEQ ID NO : 31 1, represents a polynucleotide encoding an Ank repeat-containing protein. The ankyrin motif is a 33 amino acid sequence named after the protein ankyrin which has 24 tandem 33-amino-acid motifs. Ank repeats were originally identified in the cell-cycle-control protein cdc 10 (Breeden et al., Nature (1987) 329 : 651). Proteins containing ankyrin repeats include ankyrin, myotropin, 1-kappaB proteins, cell cycle protein cdclO, the Notch receptor (Matsuno et al., Development (1997) 124 (21). 4265) ; G9a (or BAT8) of the class III region of the major histocompatibility complex (Biochem J. 290 : 811-818, 1993), FABP, GABP, 53BP2, Linl2, glp-l, SW14, and SW16. The functions of the ankyrin repeats are compatible with a role in protein-protein interactions (Bork, Proteins (1993) 17 (4) : 363 ; Lambert and Bennet, Eur. J. Biochein. (1993) 211 : 1 ; Kerr et al., Current Op. Cell Biol. (1992) 4 : 496 ; Bennet et al., J. Biol. Chem. (1980) 255 : 6424).

ATPases Associated with Various Cellular Activities (ATPases ; Pfam Accession No.

PF0004). SEQ ID NOS : 1035, 1058, and 1072 corresond to a sequence that encodes a member of a family of ATPases Associated with diverse cellular Activities (AAA). The AAA protein family is composed of a large number of ATPases that share a conserved region of about 220 amino acids containing an ATP-binding site (Froehlich et al., J. Cell Biol. (1991) 114 : 443 ; Erdmann et al. Cell (1991) 64 : 499 ; Peters etal., EMBO J. (1990) 9 : 1757 ; Kunau et al., Biochimie (1993) 75 : 209-224 ; Confalonieri et al., BioEssays (1995) 17 : 639 ; http ://yeamob. pci. chemie. uni- tuebingen. de/AAA/Description. html). The AAA domain, which can be present in one or two copies, acts as an ATP-dependent protein clamp (Confalonieri et al. (1995) BioEssays 17 : 639) and contains a highly conserved region located in the central part of the domain. The consensus pattern is : [LIVMT]-x- [LIVMT]- [LIVMF]-x- [GATMC]- [ST]- [NS]-x (4)- [LIVM]- D-x-A- [LIFA]-x-R.

Basic Region Plus Leucine Zipper Transcription Factors (BZIP : Pfam Accession No. PF00170). SEQ ID NO : 918 represents a polynucleotide encoding a novel member of the family of basic region plus leucine zipper transcription factors. The bZIP superfamily (Hurst, Protein Prof.

(1995) 2 : 105 ; and Ellenberger, Curr. Opin. Struct. Biol. (1994) 4 : 12) of eukaryotic DNA-binding transcription factors encompasses proteins that contain a basic region mediating sequence-specific DNA-binding followed by a leucine zipper required for dimerization. The consensus pattern for this protein family is : [KR]-x (1, 3)- [RKSAQ]-N-x (2)- [SAQ] (2)-x- [RKTAENQ]-x-R-x- [RK].

EF Hand (Efhandt Pfam Accession No. PF00036). SEQ ID NO : 242 corresponds to a polynucleotide encoding a member of the EF-hand protein family, a calcium binding domain shared by many calcium-binding proteins belonging to the same evolutionary family (Kawasaki et al., Protein. Prof. (1995) 2 : 305-490). The domain is a twelve residue loop flanked on both sides by a twelve residue alpha-helical domain, with a calcium ion coordinated in a pentagonal bipyramidal configuration. The six residues involved in the binding are in positions 1, 3, 5, 7, 9 and 12 ; these residues are denoted by X, Y, Z,-Y,-X and-Z. The invariant Glu or Asp at position 12 provides two oxygens for liganding Ca (bidentate ligand). The consensus pattern includes the complete EF-hand loop as well as the first residue which follows the loop and which seem to always be hydrophobic : D-x- [DNS]- {ILVFYW}- [DENSTG]- [DNQGHRK]- {GP}- [LIVMC]- [DENQSTAGC]-x (2)- [DE]- [LIVMFYW].

Ets Domain (Ets Nterm : Pfam Accession No. PF 110178). SEQ ID NO : 547, and thus the sequence it validates, represents a polynucleotide encoding a polypeptide with N-terminal homology in ETS domain. Proteins of this family contain a conserved domain, the"ETS-domain,"that is involved in DNA binding. The domain appears to recognize purine-rich sequences ; it is about 85 to 90 amino acids in length, and is rich in aromatic and positively charged residues (Wasylyk, et al., Eur. J. Biochem. (1993) 211 : 718). The ets gene family encodes a novel class of DNA-binding

proteins, each of which binds a specific DNA sequence and comprises an ets domain that specifically interacts with sequences containing the common core tri-nucleotide sequence GGA. In addition to an ets domain, native ets proteins comprise other sequences which can modulate the biological specificity of the protein. Ets genes and proteins are involved in a variety of essential biological processes including cell growth, differentiation and development, and three members are implicated in oncogenic process.

(FKH ; Pfam Accession No. PF00250). SEQ ID NO : 925 corresponds to a gene encoding a polypeptide comprising a forkhead domain. The forkhead domain (also known as a"winged helix") is present in a family of eukaryotic transcription factors, and is a conserved domain of about 100 amino acid residues that is involved in DNA-binding (Weigel et al. Cell (1990) 63 : 455-456 ; Clark et al. Nature (1993) 364 : 412-420). Mammalian genes that comprise a forkhead domain include those encoding : 1) transcriptional activators (e. g., HNF-3-alpha,-beta, and-gamma proteins, which interact with the cis-acting regulatory regions of a number of fiver genes) ; 2) interleukin- enhancer binding factor (ILF), which binds to purine-rich NFAT-1 ike motifs in the HIV-1 LTR and the interleukin-2 promoter and is involved in both positive and negative regulation of important viral and cellular promoter elements ; 3) transcription factor BF-1, which plays an important role in the establishment of the regional subdivision of the developing brain and in the development of the telencephalon ; 4) human HTLF, which binds to the purine-rich region in human T-cell leukemia virus long terminal repeat (HTLV-I LTR) ; 5) transcription factors FREAC-I (FKHL5, HFH-8), FREAC-2 (FKHL6), FREAC-3 (FKHL7, FKH-1), FREAC-4 (FKHL8), FREAC-5 (FKHL9, FKH-2, HFH-6), FREAC-6 (FKHL 10, HFH-5), FREAC-7 (FKHL I), FREAC-8 (FKHL12, HFH-7), FKH-3, FKH-4, FKH-5, HFH-1 and HFH-4 ; 6) human AFXI which is involved in a chromosomal translocation that causes acute leukemia ; and 7) human FKHR which is involved in a chromosomal translocation that causes rhabdomyosarcoma. The fork domain is highly conserved, and is detected by two consensus patterns : the first corresponding to the N-terminal section of the domain ; the second corresponding to a heptapeptide located in the central section of the domain. The consensus patterns are as follows : 1) [KR]-P- [PTQ]- [FYLVQH]-S- [FY]-x (2)- [LIVM]-x (3, 4)- [AC]- [LIM] ; and 2) W- [QKR]- [NS]-S- [LIV]-R-H.

Helicases conserved C-terminal domain (helicase C ; Pfam Accession No. PF00271). SEQ ID NOS : 227 and 1058 represent polynucleotides encoding novel members of the DEAD/H helicase family. The DEAD box family comprises a number of eukaryotic and prokaryotic proteins involved in ATP-dependent, nucleic-acid unwinding. All DEAD box family members of the above proteins share a number of conserved sequence motifs, some of which are specific to the DEAD family while others are shared by other ATP-binding proteins or by proteins belonging to the helicases 'superfamily' (Hodgman, Nature (1988) 333 : 22 and Nature (1988) 333 : 578 ;

http ://www. expasy. ch/www/iinder/HELICASES_TEXT. html). One of these motifs, called the'D-E- A-D-box', represents a special version of the B motif of ATP-binding proteins. Some other proteins belong to a subfamily which have His instead of the second Asp and are thus said to be'D-E-A-H- box'proteins (Wassarman D. A., et al., Nature (1991) 349 : 463 ; Harosh I., et al., Nucleic Acids Res.

(1991) 19 : 6331 ; Koonin E. V., et al., J Gen. Virol. (1992) 73 : 989 ; http ://www. expasy. ch/www/linder/ HELICASESTEXT. html). The following signature patterns are used to identify member for both subfamilies : 1) [LIVMF] (2)-D-E-A-D- [RKEN]-x- [LIVMFYGSTN] ; and 2) [GSAH]-x- [LIVMF] (3)- D-E- [ALIV]-H- [NECR].

Kazal serine protease inhibitors family signature (Kazal ; Pfam Accession No. PF00050).

SEQ ID NO : 97 corresponds to a polynucleotide of a gene encoding a serine protease inhibitor of the Kazal inhibitor family (Laskowski et al. Annu. Rev. Biochem. (1980) 49 : 593-626). The basic structure of Kazal serine protease inhibitors such a type of inhibitor is described at Pfam Accession No. PF00050. Exemplary proteins known to belong to this family include : pancreatic secretory trypsin inhibitor (PSTI), whose physiological function is to prevent the trypsin-catalyzed premature activation of zymogens within the pancreas ; mammalian seminal acrosin inhibitors ; canidae and felidae submandibular gland double-headed protease inhibitors, which contain two Kazal-type domains, the first one inhibits trypsin and the second one elastase ; a mouse prostatic secretory glycoprotein, induced by androgens, and which exhibits anti-trypsin activity ; avian ovomucoids ; chicken ovoinhibitor ; and the leech trypsin inhibitor Bdellin B-3. The consensus pattern is as follows : C-x (7)-C-x (6)-Y-x (3)-C-x (2, 3)-C, where the four C's are involved in disulfide bonds.

MAP kinase kinase (mkk). SEQ ID NOS : 635 and 992 represent members of the MAP kinase kinase (mkk) family. MAP kinases (MAPK) are involved in signal transduction, and are important in cell cycle and cell growth controls. The MAP kinase kinases (MAPKK) are dual-specificity protein kinases which phosphorylate and activate MAP kinases. MAPKK homologues have been found in yeast, invertebrates, amphibians, and mammals. Moreover, the MAPKK/MAPK phosphorylation switch constitutes a basic module activated in distinct pathways in yeast and in vertebrates.

MAPKKs are essential transducers through which signals must pass before reaching the nucleus. For review, see, e. g., Biologique Biol Cell (1993) 79 : 193-207 ; Nishida et al., Trends Biochem Sci (1993) 18 : 128-31 ; Ruderman Curr Opin Cell Biol (1993) 5 : 207-13 ; Dhanasekaran et al., Oncogene (1998) 17 : 1447-55 ; Kiefer et al., Biochem Soc Trans (1997) 25 : 491-8 ; and Hill, Cell Signal (1996) 8 : 533-44.

Neurotransmitter-Gated Ion-Channel (neur chan : Pfam Accession No. PF00065). SEQ ID NO : 1078 corresponds to a sequence encoding a neurotransmitter-gated ion channel.

Neurotransmitter-gated ion-channels, which provide the molecular basis for rapid signal transmission at chemical synapses, are post-synaptic oligomeric transmembrane complexes that transiently form a ionic channel upon the binding of a specific neurotransmitter. Five types of neurotransmitter-gated

receptors are known : 1) nicotinic acetylcholine receptor (AchR) ; 2) glycine receptor ; 3) gamma- aminobutyric-acid (GABA) receptor ; 4) serotonin 5HT3 receptor ; and 5) glutamate receptor. All known sequences of subunits from neurotransmitter-gated ion-channels are structurally related, and are composed of a large extracellular glycosylated N-terminal ligand-binding domain, followed by three hydrophobic transmembrane regions that form the ionic channel, followed by an intracellular region of variable length. A fourth hydrophobic region is found at the C-terminal of the sequence.

The consensus pattern is : C-x- [LIVMFQ]-x- [LIVMF]-x (2)- [FY]-P-x-D-x (3)-C, where the two C's are linked by a disulfide bond.

PDZ Domain (PDZ : Pfam Accession No. PF00595.) SEQ ID NOS : 523 and 980 correspond to a gene comprising a PDZ domain (also known as DHR or GLGF domain). PDZ domains comprise 80-100 residue repeats, several of which interact with the C-terminal tetrapeptide motifs X-Ser/Thr- X-Val-COO-of ion channels and/or receptors, and are found in mammalian proteins as well as in bacteria, yeast. and plants (Pontig et al. Protein Sci (1997) 6 (2) : 464-8). Proteins comprising one or more PDZ domains are found in diverse membrane-associated proteins, including members of the MAGUK family of guanylate kinase homologues, several protein phosphatases and kinases, neuronal nitric oxide synthase, and several dystrophin-associated proteins, collectively known as syntrophins (Ponting et al. Bioessays (1997) 19 (6) : 469-79). Many PDZ domain-containing proteins are localised to highly specialised submembranous sites, suggesting their participation in cellular junction formation, receptor or channel clustering, and intracellular signalling events. For example, PDZ domains of several MAGUKs interact with the C-terminal polypeptides of a subset of NMDA receptor subunits and/or with Shaker-type K+ channels. Other PDZ domains have been shown to bind similar ligands of other transmembrane receptors. In cell junction-associated proteins, the PDZ mediates the clustering of membrane ion channels by binding to their C-terminus. The X-ray crystallographic structure of some proteins comrpising PDZ domains have been solved (see, e. g., Doyle et al. Cell (1996) 85 (7) : 1067-76).

Protein phosphatase 2A regulatorv subunit PR55 signatures (PR55 : Pfam Accession No.

PF01240). SEQ ID NO : 1028 corresponds to a gene encoding a protine phosphatase 2A reguatory subunit. Protein phosphatase 2A (PP2A) is a serine/threonine phosphatase involved in many aspects of cellular function including the regulation of metabolic enzymes and proteins involved in signal transduction. PP2A is a trimeric enzyme that consists of a core composed of a catalytic subunit associated with a 65 Kd regulatory subunit (PR65), also called subunit A ; this complex then associates with a third variable subunit (subunit B), which confers distinct properties to the holoenzyme (Mayer et al. Trends Cell Biol. (1994) 4 : 287-291). One of the forms of the variable subunit is a 55 Kd protein (PR55) which is highly conserved in mammals (where three isoforms are known to exist). This subunit may perform a substrate recognition function or be responsible for

targeting the enzyme complex to the appropriate subcellular compartment. Two perfectly conserved sequences of 15 residues, one located the N-terminal region, the other in the center of the protein, serve as the basis for the consensus patterns : 1) E-F-D-Y-L-K-S-L-E-I-E-E-K-I-N ; 2) N- [AG]-H- [TA]-Y-H-I-N-S-I-S- [LIVM]-N-S-D Protein Kinase (protkinase : Pfam Accession No. PF00069). SEQ ID NOS : 635, 992, and 1078 represent polynucleotides encoding protein kinases, which catalyze phosphorylation of proteins in a variety of pathways, and are implicated in cancer. Eukaryotic protein kinases (Hanks, et al., FASEB J. (1995) 9 : 576 ; Hunter, Meth. Enzymol. (1991) 200 : 3 ; Hanks, et al., Meth. Enzymol. (1991) 200 : 38 ; Hanks, Curr. Opin. Struct. Biol. (1991) 1 : 369 ; Hanks et al., Science (1988) 241 : 42) belong to a very extensive family of proteins that share a conserved catalytic core common to both serine/threonine and tyrosine protein kinases. There are a number of conserved regions in the catalytic domain of protein kinases. The first region, located in the N-terminal extremity of the catalytic domain, is a glycine-rich stretch of residues in the vicinity of a lysine residue, which has been shown to be involved in ATP binding. The second region, located in the central part of the catalytic domain, contains a conserved an aspartic acid residue that is important for the catalytic activity of the enzyme (Knighton, et al., Science (1991) 253 : 407).

The protein kinase profile includes two signature patterns for this second region : one specific for serine/threonine kinases and the other for tyrosine kinases. A third profile is based on the alignment in (Hanks, et al., FASEB J. (1995) 9 : 576) and covers the entire catalytic domain. The consensus patterns are as follows : I) [LIV]-G-{P}-G-{P}-[FYWMGSTNH]-[SGA]-{PW}- [LIVCAT]- {PD}-x- [GSTACLIVMFY]-x (5, 18)- [LIVMFYWCSTAR]- [AIVP]- [LIVMFAGCKR]-K, where K binds ATP ; 2) [LIVMFYC]-x- [HY]-x-D- [LIVMFY]-K-x (2)-N- [LIVMFYCT] (3), where D is an active site residue ; and 3) [LIVMFYC]-x-[HY]-x-D-[LIVMFY]-[RSTAC]-x (2)-N-[LIVMFYC], where D is an active site residue.

Ras familv proteins (ras ; Pfam Accession No. PF00071). SEQ ID NO : 527 represents polynucleotides encoding the ras family of small GTP/GDP-binding proteins (Valencia et al., 1991, Biochemistry 30 : 4637-4648). Ras family members generally require a specific guanine nucleotide exchange factor (GEF) and a specific GTPase activating protein (GAP) as stimulators of overall GTPase activity. Among ras-related proteins, the highest degree of sequence conservation is found in four regions that are directly involved in guanine nucleotide binding. The first two constitute most of the phosphate and Mg2+ binding site (PM site) and are located in the first half of the G-domain.

The other two regions are involved in guanosine binding and are located in the C-terminal half of the molecule. Motifs and conserved structural features of the ras-related proteins are described in Valencia et al., 1991, Biochemistry 30 : 4637-4648. A major consensus pattern of ras proteins is : D- T-A-G-Q-E-K- [LF]-G-G-L-R- [DE]-G-Y-Y.

Src homology domain 3 (SH3 ; Pfam Accession No. PF00018). SEQ IDNO : 450 corresponds to a gene comprising a Src homology domain. The Src homology 3 (SH3) domain is a small protein domain of about 60 amino acid residues first identified as a conserved sequence in the non-catalytic part of several cytoplasmic protein tyrosine kinases (e. g. Src, Abl, Lck) ( Mayer et al. Nature (1988) 332 : 272-275). Since then, it has been found in a great variety of other intracellular or membrane-associated proteins (Musacchio et al. FEBSLett. (1992) 307 : 55-61 ; Pawson et al. Curr. Biol. (1993) 3 : 434-442 ; Mayer et al. Trends Cell Biol. (1993) 3 : 8-13 ; Pawson Nature (1995) 373 : 573-580). The SH3 domain has a characteristic fold which consists of five or six beta-strands arranged as two tightly packed anti-parallel beta sheets. The linker regions may contain short helices (Kuriyan et aL Curr. Opin. Struct. Biol. (1993) 3 : 828-837). The SH3 domain is thought to mediate assembly of specific protein complexes via binding to proline-rich peptides (Morton et al.

Curr. Biol. (1994) 4 : 615-617). In general SH3 domains are found as single copies in a given protein, but there a significant number of proteins comprise two SH3 domains and a few comprise 3 or 4 copies. The profile to detect SH3 domains is based on a structural alignment consisting of 5 gap-free blocks and 4 linker regions totaling 62 match positions.

Trvpsin (trypsin : Pfam Accession No. PF00089). SEQ ID NOS : 635, 995, and 984 correspond to novel serine proteases of the trypsin family. The catalytic activity of the serine proteases from the trypsin family is provided by a charge relay system involving an aspartic acid residue hydrogen- bonded to a histidine, which itself is hydrogen-bonded to a serine. The sequences in the vicinity of the active site serine and histidine residues are well conserved (Brenner Nature (1988) 334 : 528). The consensus patterns for the trypsin protein family are : I) [LIVM]- [ST]-A- [STAG]-H-C, where H is the active site residue ; and 2) [DNSTAGC]- [GSTAPIMVQH]-x (2)-G- [DE]-S-G- [GS]- [SAPHV]- [LIVMFYWH]- [LIVMFYSTANQH], where S is the active site residue. All sequences known to belong to this family are detected by the above consensus sequences, except for 18 different proteases which have lost the first conserved glycine. If a protein includes both the serine and the histidine active site signatures, the probability of it being a trypsin family serine protease is 100%.

WD Domain, G-Beta Repeats (WD domain ; Pfam Accession No. PF00400). SEQ ID NOS : 505, 721, and 1018 represent a members of the WD domain/G-beta repeat family. Beta- transducin (G-beta) is one of the three subunits (alpha, beta, and gamma) of the guanine nucleotide- binding proteins (G proteins) which act as intermediaries in the transduction of signals generated by transmembrane receptors (Gilman, Annu. Rev. Biochem. (1987) 56 : 615). The alpha subunit binds to and hydrolyzes GTP ; the beta and gamma subunits are required for the replacement of GDP by GTP as well as for membrane anchoring and receptor recognition. In higher eukaryotes, G-beta exists as a small multigene family of highly conserved proteins of about 340 amino acid residues. Structurally, G-beta has eight tandem repeats of about 40 residues, each containing a central Trp-Asp motif (this

type of repeat is sometimes called a WD-40 repeat). The consensus pattern for the WD domain/G- Beta repeat family is : [LIVMSTAC]- [LIVMFYWSTAGC]- [LIMSTAG]- [LIVMSTAGC]-x (2)- [DN]-x (2)- [LIVMWSTAC]-x- [LIVMFSTAG]-W- [DEN]- [LIVMFSTAGCN].

WW/rsp5/WWP domain signature and profile (WW domain ; Pfam Accession No. PF00397).

SEQ ID NO : 606 corresponds to a gene encoding a protein comprising a WW domain. The WW domain (Bork et al. Trends Biochem. Sci. (1994) 19 : 531-533 ; Andre et al. Biochem. Biophys. Res.

Commun. (1994) 205 : 1201-1205 ; Hofmann etal. FEBSLett. (1995) 358 : 153-157 ; Sudol etal. FEBS Lett. (1995) 369 : 67-71 ; http ://www. bork. embl-heidelberg. de/Modules/ww-gif. html) (also known as rsp5 or WWP) was discovered as a short conserved region in a number of unrelated proteins, among them dystrophin, the gene responsible for Duchenne muscular dystrophy. The domain, which spans about 35 residues, is repeated up to 4 times in some proteins. It has been shown (Chen et al. Proc.

Natl. Acad. Sci. US. A. (1995) 92 : 7819-7823) to bind proteins with particular proline-motifs, [AP]-P- P- [AP]-Y, and thus resembles somewhat SH3 domains. The WW domain conatins beta-strands grouped around four conserved aromatic positions, generally tryptophan. The name WW or WWP derives from the presence of two tryptophane as well as a conserved proline. The WW domain is frequently associated with other domains typical for proteins in signal transduction processes. The consensus pattern for WW domains is : W-x (9, 11)- [VFY]- [FYW]-x (6, 7)- [GSTNE]- [GSTQCR]- [FYW]-x (2)-P.

Zinc Finger, C2H2 Type (ZincHmg_C2H2 : Pfam Accession No. PF00096). Several sequences corresponded to polynucleotides encoding members of the C2H2 type zinc finger protein family, which contain zinc finger domains that facilitate nucleic acid binding (Klug et al., Trends Biochem. Sci. (1987) 12 : 464 ; Evansetal., Cell (1988) 52 : 1 ; Payre et al., FEBS Lett. (1988) 234 : 245 ; Miller et al., EMBO J. (1985) d : 1609 ; and Berg, Proc. Natl. Acad. Sci. USA (1988) 85 : 99). In addition to the conserved zinc ligand residues, a number of other positions are also important for the structural integrity of the C2H2 zinc fingers. (Rosenfeld et al., J. Biomol. Struct. Dyn. (1993) 11 : 557) The best conserved position, which is generally an aromatic or aliphatic residue, is located four residues after the second cysteine. The consensus pattern for C2H2 zinc fingers is : C-x (2, 4)-C-x (3)- [LIVMFYWC]-x (8)-H-x (3, 5)-H. The two C's and two H's are zinc ligands.

Zinc finger, C3HC4 type (RING finger), signature (Zincfing C3H4 ; Pfam Accession No. PF00097). SEQ ID NOS : 805 and 1078 represent polynucleotides encoding a polypeptide having a C3HC4 type zinc finger signature. A number of eukaryotic and viral proteins contain this signature, which is primarily a conserved cysteine-rich domain of 40 to 60 residues (Borden K. L. B., et al., Curr. Opin. Struct. Biol. (1996) 6 : 395) that binds two atoms of zinc, and is probably involved in mediating protein-protein interactions. The 3D structure of the zinc ligation system is uniqueto the RING domain and is refered to as the"cross-brace"motif. The spacing of the cysteines

in such a domain is C-x (2)-C-x (9 to 39)-C-x (l to 3)-H-x (2 to 3)-C-x (2)-C-x (4 to 48)-C-x (2)-C. The signature pattern for the C3HC4 finger is based on the central region of the domain : C-x-H-x- [LIVMFY]-C-x (2)-C- [LIVMYA].

Zinc finger. CCHC type (Zincfing CCHC ; Pfam Accession No. PF00098). SEQ ID NOS : 693, 973, and 1078 correspond to genes encoding a member of the family of CCHC zinc fingers.

Because the prototype CCHC type zinc finger structure is from an HIV protein, this domain is also referred to as a retrovrial-type zinc finger domain. The family also contains proteins involved in eukaryotic gene regulation, such as C. elegans GLH-1. The structure is an 18-residue zinc finger ; no examples of indels in the alignment. The motif that defines a CCHC type zinc finger domain is : C- X2-C-X4-H-X4-C (Summers J Cell Biochem 1991 Jan ; 45 ( 1) : 41-8). The domain is found in, for example, HIV-I nucleocapsid protein, Moloney murine leukemia virus nucleocapsid protine NCplO (De Rocquigny et al. Nucleic Acids Res. (1993) 21 : 823-9), and myelin transcription factor 1 (Mytl) (Kim et al. J Neurosci. Res. (1997) 50 : 272-90).

Example 5 : Differential Expression of Polvnucleotides of the Invention : Description of Libraries and Detection of Differential Expression The relative expression levels of the polynucleotides of the invention was assessed in several libraries prepared from various sources, including cell lines and patient tissue samples. Table 4 provides a summary of these libraries, including the shortened library name (used hereafter), the mRNA source used to prepared the cDNA library, the"nickname"of the library that is used in the tables below (in quotes), and the approximate number of clones in the library.

Table 4. Description of cDNA Libraries Library Description Number of (lib Clones in Library 1 Human Colon Cell Line Kml2 L4 : High Metastatic 308731 Potential (derived from Kml2C) 2 Human Colon Cell Line Kml2C : Low Metastatic 284771 Potential 3 Human Breast Cancer Cell Line MDA-MB-231 : High 326937 Metastatic Potential ; micro-mets in lung 4 Human Breast Cancer Cell Line MCF7 : Non Metastatic 318979 8 Human Lung Cancer Cell Line MV-522 : High Metastatic 223620 Potential 9 Human Lung Cancer Cell Line UCP-3 : Low Metastatic 312503 Potential 12 Human microvascular endothelial cells (HMVEC)-41938 UNTREATED (PCR (OligodT) cDNA library) 13 Human microvascular endothelial cells (HMVEC)-bFGF 42100 TREATED (PCR (OligodT) cDNA library) 14 Human microvascular endothelial cells (HMVEC)-42825 VEGF TREATED (PCR (OligodT) cDNA library) 15 Normal Colon-UC#2 Patient (MICRODISSECTED PCR 282722 (OligodT) cDNA library) 16 Colon Tumor-UC#2 Patient (MICRODISSECTED PCR 298831 (OligodT) cDNA library) 17 Liver Metastasis from Colon Tumor of UC#2 Patient 303467 (MICRODISSECTED PCR (OligodT) cDNA library) 18 Normal Colon-UC#3 Patient (MICRODISSECTED PCR 36216 (OligodT) cDNA library) 19 Colon Tumor-UC#3 Patient (MICRODISSECTED PCR 41388 (OligodT) cDNA library) 20 Liver Metastasis from Colon Tumor of UC#3 Patient 30956 (MICRODISSECTED PCR (OligodT) cDNA library) 21 GRRpz Cells derived from normal prostate epithelium 164801 22 WOca Cells derived from Gleason Grade 4 prostate 162088 cancer epithelium 23 Normal Lung Epithelium of Patient #1006 306198 (MICRODISSECTED PCR (OligodT) cDNA library) 24 Primary tumor, Large Cell Carcinoma of Patient #1006 309349 (MICRODISSECTED PCR (OligodT) cDNA library)

The KM12L4, KM12C, and MDA-MB-231 cell lines are described in Example 1 above. The MCF7 cell line was derived from a pleural effusion of a breast adenocarcinoma and is non- metastatic. The MV-522 cell line is derived from a human lung carcinoma and is of high metastatic potential. The UCP-3 cell line is a low metastatic human lung carcinoma cell line ; the MV-522 is a high metastatic variant of UCP-3. These cell lines are well-recognized in the art as models for the study of human breast and lung cancer (see, e. g., Chandrasekaran et al., Cancer Res. (1979) 39 : 870

(MDA-MB-231 and MCF-7) ; Gastpar etal., JMed Chem (1998) 41 : 4965 (MDA-MB-231 and MCF- 7) ; Ranson et al., Br J Cancer (1998) 77 : 1586 (MDA-MB-231 and MCF-7) ; Kuang et al., Nucleic Acids Res (1998) 26 : 1116 (MDA-MB-231 and MCF-7) ; Varki et al., Int J Cancer (1987) 40 : 46 (UCP-3) ; Varki et al., Tumour Biol. (1990) 11 : 327 ; (MV-522 and UCP-3) ; Varki et al., Anticancer Res. (1990) 10 : 637 ; (MV-522) ; Kelner etal., AnticancerRes (1995) 15 : 867 (MV-522) ; and Zhang et al., Anticancer Drugs (1997) 8 : 696 (MV522)). The samples of libraries 15-20 are derived from two different patients (UC#2, and UC#3). The bFGF-treated HMVEC were prepared by incubation with bFGF at 10ng/ml for 2 hrs ; the VEGF-treated HMVEC were prepared by incubation with 20ng/ml VEGF for 2 hrs. Following incubation with the respective growth factor, the cells were washed and lysis buffer added for RNA preparation. The GRRpz and WOca cell lines were provided by Dr.

Donna M. Peehl, Department of Medicine, Stanford University School of Medicine. GRRpz was derived from normal prostate epithelium. The WOca cell line is a Gleason Grade 4 cell line.

Each of the libraries is composed of a collection of cDNA clones that in turn are representative of the mRNAs expressed in the indicated mRNA source. In order to facilitate the analysis of the millions of sequences in each library, the sequences were assigned to clusters. The concept of"cluster of clones"is derived from a sorting/grouping of cDNA clones based on their hybridization pattern to a panel of roughly 300 7bp oligonucleotide probes (see Drmanac et al., Genomics (1996) 37 (1) : 29). Random cDNA clones from atissue library are hybridized at moderate stringency to 300 7bp oligonucleotides. Each oligonucleotide has some measure of specific hybridization to that specific clone. The combination of 300 of these measures of hybridization for 300 probes equals the"hybridization signature"for a specific clone. Clones with similar sequence will have similar hybridization signatures. By developing a sorting/grouping algorithm to analyze these signatures, groups of clones in a library can be identified and brought together computationally.

These groups of clones are termed"clusters". Depending on the stringency of the selection in the algorithm (similar to the stringency of hybridization in a classic library cDNA screening protocol), the"purity"of each cluster can be controlled. For example, artifacts of clustering may occur in computational clustering just as artifacts can occur in"wet-lab"screening of a cDNA library with 400 bp cDNA fragments, at even the highest stringency. The stringency used in the implementation of cluster herein provides groups of clones that are in general from the same cDNA or closely related cDNAs. Closely related clones can be a result of different length clones of the same cDNA, closely related clones from highly related gene families, or splice variants of the same cDNA.

Differential expression for a selected cluster was assessed by first determining the number of cDNA clones corresponding to the selected cluster in the first library (Clones in 1 St), and the determining the number of cDNA clones corresponding to the selected cluster in the second library (Clones in 2nd). Differential expression of the selected cluster in the first library relative to the

second library is expressed as a"ratio"of percent expression between the two libraries. In general, the"ratio"is calculated by : 1) calculating the percent expression of the selected cluster in the first library by dividing the number of clones corresponding to a selected cluster in the first library by the total number of clones analyzed from the first library ; 2) calculating the percent expression of the selected cluster in the second library by dividing the number of clones corresponding to a selected cluster in a second library by the total number of clones analyzed from the second library ; 3) dividing the calculated percent expression from the first library by the calculated percent expression from the second library. If the"number of clones"corresponding to a selected cluster in a library is zero, the value is set at I to aid in calculation. The formula used in calculating the ratio takes into account the "depth"of each of the libraries being compared, i. e., the total number of clones analyzed in each library.

In general, a polynucleotide is said to be significantly differentially expressed between two samples when the ratio value is greater than at least about 2, preferably greater than at least about 3, more preferably greater than at least about 5, where the ratio value is calculated using the method described above. The significance of differential expression is determined using a z score test (Zar, Biostatistical Analvsis, Prentice Hall, Inc., USA,"Differences between Proportions,"pp 296-298 (1974).

Examples 6-11 : Differential Expression of Polvnucleotides of the Invention A number of polynucleotide sequences have been identified that are differentially expressed between, for example, cells derived from high metastatic potential cancer tissue and low metastatic cancer cells, and between cells derived from metastatic cancer tissue and normal tissue. Evaluation of the levels of expression of the genes corresponding to these sequences can be valuable in diagnosis, prognosis, and/or treatment (e. g., to facilitate rationale design of therapy, monitoring during and after therapy, etc.). Moreover, the genes corresponding to differentially expressed sequences described herein can be therapeutic targets due to their involvement in regulation (e. g., inhibition or promotion) of development of, for example, the metastatic phenotype. For example, sequences that correspond to genes that are increased in expression in high metastatic potential cells relative to normal or non-metastatic tumor cells may encode genes or regulatory sequences involved in processes such as angiogenesis, differentiation, cell replication, and metastasis.

Detection of the relative expression levels of differentially expressed polynucleotides described herein can provide valuable information to guide the clinician in the choice of therapy. For example, a patient sample exhibiting an expression level of one or more of these polynucleotides that corresponds to a gene that is increased in expression in metastatic or high metastatic potential cells may warrant more aggressive treatment for the patient. In contrast, detection of expression levels of

a polynucleotide sequence that corresponds to expression levels associated with that of low metastatic potential cells may warrant a more positive prognosis than the gross pathology would suggest.

A number of polynucleotide sequences of the present invention are differentially expressed between human microvascular endothelial cells (HMVEC) that have been treated with growth factors relative to untreated HMVEC. Sequences that are differentially expressed between growth factor- treated HMVEC and untreated HMVEC can represent sequences encoding gene products involved in angiogenesis, metastasis (cell migration), and other development and oncogenic processes. For example, sequences that are more highly expressed in HMVEC treated with growth factors (such as bFGF or VEGF) relative to untreated HMVEC can serve as drug targets for chemotherapeutics, e. g., decreasing expression of such up-regulated genes or inhibitin gthe activity of the encoded gene product would serve to inhibit tumor cell angiogenesis. Detection of expression of these sequences in colon cancer tissue can be valuable in determining diagnostic, prognostic and/or treatment information associated with the prevention of achieving the malignant state in these tissues, and can be important in risk assessment for a patient. A patient sample displaying an increased level of one or more of these polynucleotides may thus warrant closer attention or more frequent screening procedures to catch the malignant state as early as possible.

The differential expression of the polynucleotides described herein can thus be used as, for example, diagnostic markers, prognostic markers, for risk assessment, patient treatment and the like.

These polynucleotide sequences can also be used in combination with other known molecular and/or biochemical markers. The following examples provide relative expression levels of polynucleotides from specified cell lines and patient tissue samples.

Example 6 : High Metastatic Potential Breast Cancer Versus Low Metastatic Breast Cancer Cells The tables bellow summarize the data for polynucleotides that represent genes differentially expressed between high metastatic potential and low metastatic potential breast cancer cells.

Table 5. High metastatic potential breast (lib3) > low metastatic potential breast cancer cells (lib4) JSEQIDNO : Ub 3 Clones Lib4 Clones Ub3/Lib4 a781 13 0 12. 68 :...... _. ; . . .......... 779 7 0 6.83 691 7 0 6.83 686 7 0 6.83 916 6 0 5. 85 Table 6. Low metastatic potential breast (lib4) > high metastatic potential breast cancer cells (lib3) Table 6 SEQ ID NO: Lib 3 Clones Lib4 Clones Lib4/Lib3 558 0 340 348. 48 656 0 64 65.6 661 0 57 58.42 ! 647 0 43 44. 07 547 0 41 42.02 648 0 40 41 592 4 115 29.47 654 0 28 28.7 646 0 21 21.52 636 3 61 20.84 533 1 17 17.42 549 0 17 17.42 650 3 50 17.08 . 657 0 16 16.4 624 0 16 16.4 637 0 13 13.32 ! 653 1 11 : 11.27 562 1 11 11.27 587 1 11 11.27 609 1 11 11.27 590 0 10 10.25 641 0 10 10.25 532 1 10 10.25 ; 10. 2. 623 0 9 9.22 591 0 8 8.2 .................... o @21 0 8 8.2 214 0 7 7.17 607 0 7 7.17 554 0 7 7.17 584 0 555 0 7 7.17 582 0 7 7.17 584 0 7 7.17 599 0 0 7.17 5 0 6 6. 15 561 0 6 6.15 572 0 6 6.15 359 0 6 6.15 635 0 6 6.15 113 0 6 6.15 603 0 6 6.15

Example 7 : High Metastatic Potential Lung Cancer Versus Low Metastatic Lung Cancer Cells The following summarizes polynucleotides that represent genes differentially expressed between high metastatic potential lung cancer cells and low metastatic potential lung cancer cells : Table 7. High metastatic potential lung (lib8) > low metastatic potential lung cancer cells (lib9) SEQ ID NO : Lib 8 Clones Lib 9 Clones Lib8/Lib9 1571 z35 48. 91 969 8 0 11.18 350 5 0 6.99 Example 8 : High Metastatic Potential Colon Cancer Versus Low Metastatic Colon Cancer Cells Table 8 summarizes polynucleotides that represent genes differentially expressed between high metastatic potential and low metastatic potential colon cancer cells : Table 8. Low metastatic potential colon (lib2) > high metastatic potential colon cancer cells (libl) SEQ ID Nô : bibi Clones Lib2 Clones Lib2/Libl 5 7 8 i 8. 67 189 0 6 6.5 Example 9 : High Tumor Potential Colon Tissue Vs. Metastasized Colon Cancer Tissue The following table summarizes polynucleotides that represent genes differentially expressed between high tumor potential colon cancer cels and cells derived from high metastatic potential colon cancer cells of a patient.

Table 9. High tumor potential colon tissue (lit 16) vs. high metastatic colon tissue (lib 17) SEQ ID NO : Lib 16 Clones Lib 17 Clones Libl7/Libl6 100 0 7 6.89 3 12 i Example 10 : Differential Expression Across Multiple Libraries A number of polynucleotide sequences have been identified that represent genes that are differentially expressed across multiple libraries. Expression of these sequences in a tissue or any origin can be valuable in determining diagnostic, prognostic and/or treatment information associated with the prevention of achieving the malignant state in these tissues, and can be important in risk assessment for a patient. These polynucleotides can also serve as non-tissue specific markers of, for example, risk of metastasis of a tumor. The differential expression data for these sequences is provided inTable 10 below.

Table 10. Genes Differentially Expressed Across Multiple Library Comparisons SEQ ID Cell or Tissue Sample and Cancer State Compared RATIO NO : 34 ! Low Met Colon (lib2) > High Met Colon (libl) 8. 67 34 High Met Breast (lib3)>Low Met Breast(Lib4) 5.85 i209 Low Met Lung (lib9) > High Met Lung(lib8) 17.44 ! Colon Tumor Tissue (lib 16) > Normal Colon Tissue(lib15) 3.42 209 Colon Tumor Tissue (libl9) > Normal Colon Tissue (lib18) 66.5 209 Colon Met Colon Tissue (tib20) > Normal Colon Tissue (lib18) 14.04 209 Colon Tumor Tissue (libl9) > High Met Colon Tissue (lib20) 4. 74 1316 High Met Colon (libl) > Low Met Colon (lib2) 5. 76 ì6316 Low Met Breast (lib4) > High Met Breast (Lib3) 17. 28 Low Met Breast (lib4) > High Met Breast (Lib3) l645 High Met Lung (lib8) > Low Met Lung (lib9) 9. 56 854 High Met Breast (lib3)> Low Met Breast (Lib4) 9.76 854 HMVEC-bFGF (libl3) > HMVEC (libl2)'4. 98 long 1854 Key for Table 10 : High Met = high metastatic potential ; Low Met = low metastatic potential ; met =

metastasized ; tumor = non-metastasized tumor ; HMVEC = human microvascular endothelial cell ; bFGF = bFGF treated.

Detection of expression of genes that correspond to the above polynucleotides may be of particular interest in diagnosis, prognosis, risk assesment, and monitoring of treatment. Furthermore, differential expression of a specific gene across multiple libraries can also be indicative of a gene whose expression is associated with, for example, suppression of the metastatic phenotype or with development of the cell toward a metastatic phenotype. For example, SEQ ID NO : 209 corresponds to a gene that is expressed at relatively higher levels in colon tumor tissue than in high metastatic potential colon tumor tissue, and at relatively higher levels in high metastatic potential colon tumor tissue than in normal colon tissue. Thus a relatively increased level of expression of the gene corresponding to SEQ ID NO : 209 may be used as marker of a pre-metastatic colon cells either alone or in combination with other markers.

Some polynucleotides exhibited opposite differential expression trends in libraries of different origin (see, e. g.., SEQ ID NO : 316). These data suggest that the differential expressio

patterns of some gene associated with development of metastases indicate a unique role for those genes specific for the tissue of origin.

Those skilled in the art will recognize, or be able to ascertain, using not more than routine experimentation, many equivalents to the specific embodiments of the invention described herein.

Such specific embodiments and equivalents are intended to be encompassed by the following claims.

All publications and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference. The citation of any publication is for its disclosure prior to the filing date and should not be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention.

Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it is readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.

Deposit Information. The following materials were deposited with the American Type Culture Collection (CMCC = Chiron Master Culture Collection).

Table 11. Cell Lines Deposited with ATCC Cell Line Deposit Date ATCC Accession No. CMCC Accession No. KM12L4-A March 19, 1998 CRL-12496 11606 Kml2C May 15, 1998 CRL-12533 11611 MDA-MB-231 May 15, 1998 CRL-12532 10583 MCF-7 October 9, 1998 CRL-12584 10377 In addition, pools of selected clones, as well as libraries containing specific clones, were assigned an"ES"number (internal reference) and deposited with the ATCC. Table 21 below provides the ATCC Accession Nos. of the ES deposits, all of which were deposited on or before May 13, 1999. The names of the clones contained within each of these deposits are provided in the tables numbered 22 and greater (inserted before the claims).

Table 12 : Pools of Clones and Libraries Deposited with ATCC on or before September 23, 1999 Library No. CMCC No. ATCC Deposit No. Library No. CMCC No. ATCC Deposit No. | ES55 5058 ES65 5068 ES56 5059 ES66 5069 ES57 5060 ES67 5070 ES58 5061 ES68 5071 ES59 5062 ES69 5072 ES60 5063 ES70 5073 ES61 5064 ES71 5074 ES62 5065 ES72 5075 ES63 5066 ES73 5076 ES64 5067 ES74 5077

The deposits described herein are provided merely as convenience to those of skill in the art, and is not an admission that a deposit is required under 35 U. S. C. § 112. The sequence of the polynucleotides contained within the deposited material, as well as the amino acid sequence of the polypeptides encoded thereby, are incorporated herein by reference and are controlling in the event of any conflict with the written description of sequences herein. A license may be required to make, use, or sell the deposited material, and no such license is granted hereby.

Retrieval of Individual Clones from Deposit of Pooled Clones. Where the ATCC deposit is composed of a pool of cDNA clones or a library of cDNA clones, the deposit was prepared by first transfecting each of the clones into separate bacterial cells. The clones in the pool or library were then deposited as a pool of equal mixtures in the composite deposit. Particular clones can be obtained from the composite deposit using methods well known in the art. For example, a bacterial cell containing a particular clone can be identified by isolating single colonies, and identifying colonies containing the specific clone through standard colony hybridization techniques, using an oligonucleotide probe or probes designed to specifically hybridize to a sequence of the clone insert (e. g., a probe based upon unmasked sequence of the encoded polynucleotide having the indicated SEQ ID NO). The probe should be designed to have a Tm of approximately 80°C (assuming 2°C for each A or T and 4°C for each G or C). Positive colonies can then be picked, grown in culture, and the recombinant clone isolated. Alternatively, probes designed in this manner can be used to PCR to isolate a nucleic acid molecule from the pooled clones according to methods well known in the art, e. g., by purifying the cDNA from the deposited culture pool, and using the probes in PCR reactions to produce an amplified product having the corresponding desired polynucleotide sequence.

Table IA Priority Appln Information SEQ Filed Dkt No. SEQ Sequence Name Clone Name ID ID NO : NO : 1 9/28/98 1492.001 1 RTA00000617F.o. 18. 2 M00005513A : H01 2 9/28/98 1492. 001 2 RTA00001075F. h. 12. 1 M00005434A : F11 3 9/28/98 1492. 001 3 RTA00001076F. m. 09. 1 M00006946B : C08 4 9/28/98 1492. 001 4 RTA00001075F. o. 08. 1 M00005628D : A10 5 9/29/98 1492.001 5 RTA00001064F. f. 14. 1 M00005465A : A07 6 9/28/98 1492. 001 6 RTA00001075F. n. l 9. 1 M00005614A : B07 7 9/28/98 1492. 001 7 RTA00001075F. i. 24. 1 M00005453B : B06 8 9/28/98 1492. 001 8 RTA00001075F. p. 24. 1 M00005721D : B03 9 9/28/98 1492.001 9 RTA00001075F. o. 04. 1 M00005621B : C09 10 9/28/98 1492. 001 10 RTA00000616F. j. 04. 1 M00005412D : G07 11 9/28/98 1492.001 11 RTA00001064F. k. 01. 1 M00005708C : D11 12 9/28/98 1492.001 12 RTA00001064F.j.19.1 M00005657B : Fl 1 13 9/28/98 1492. 001 13 RTA00001065F. a. 22. 1 M00006920B : H07 14 9/28/98 1492. 001 14 RTA00001076F. d. 11.1 M00006623C : G07 15 9/28/98 1492. 001 15 RTA00000615F. e. 08. 2 M00004872A : D07 16 9/28/98 1492. 001 16 RTA00000617F. p. 05. A M00005515D : G02 17 9/28/98 1492. 001 17 RTA00001076F. f. 03. 1 M00006668D : B10 18 9/28/98 1492. 001 18 RTA00001064F. 1. 17. 2 M00006582A : F12 19 9/28/98 1492. 001 19 RTA00001076F. h. 13. 1 M00006745B : C05 20 9/28/98 1492. 001 20 RTA00001075F. k. 12. 1 M00005482A : D08 21 9/28/98 1492.001 21 RTA00001076F.c. 09. 1 M00006594B : D05 22 9/28/98 1492. 001 22 RTA00001076F. 1. 16. 1 M00006919A : H12 23 9/28/98 1492.001 23 RTA00001076F. b. 13. 1 M00005825A : A10 24 9/28/98 1492.001 24 RTA00001065F. d. 06. 2 M00007078B : H04 25 9/28/98 1492. 001 25 RTA00001075F. p. 23. 1 M00005721C : A12 26 9/28/98 1492. 001 26 RTA00001075F. n. 22. 1 M00005616B : E11 27 9/28/98 1492.001 27 RTA00001075F. o. 21. 1 M00005648C : E10 28 9/28/98 1492.001 28 RTA00001065F. b. 22. 1 M00006968A : H05 29 9/28/98 1492.001 29 RTA00001075F. p. 06. 1 M00005698A : H12 30 9/28/98 1492.001 30 RTA00001076F. d. 19. 1 M00006630A : E05 31 9/28/98 1492. 001 31 RTA00001075F. e. 14. 1 M00005375B : H03 32 9/28/98 1492. 001 32 RTA00001065F. f. 02. 1 M00007186A : A 12 33 9/28/98 1492. 001 33 RTA00001064F. p. 03. 1 M00006814D : D09 34 9/28/98 1492. 001 34 RTA00001076F. i. l9. 1 M00006813B : E04 35 9/28/98 1492. 001 35 RTA00001077F. c. 06. 1 M00007157B : B04 36 9/28/98 1492. 001 36 RTA00001064F. c. 21. 1 M00005366D : E12 37 9/28/98 1492. 001 37 RTA00001065F. e. 21. 1 M00007177A : G07 38 9/28/98 1492. 001 38 RTA00001076F. o. 14. 1 M00007038D : D01 39 9/28/98 1492. 001 39 RTA00001064F. c. 01. 1 M00005327C : G08 40 9/28/98 1492. 001 40 RTA00001064F. d. 16. 1 M00005397A : G08 41 9/28/98 1492. 001 41 RTA00000615F. e. 05. 2 M00004870D : E05 42 9/28/98 1492. 001 42 RTA00000616Fj. 12. 1 M00005413D : G12 43 9/28/98 1492. 001 43 RTA00001075F. a. 17. 1 M00004852B : H08 44 9/28/98 1492. 001 44 RTA00001076F. n. 10. 1 M00006989C : B01 45 9/28/98 1492. 001 45 RTA00001075F. 1. 04. 1 M00005505D : H08 46 9/28/98 1492. 001 46 RTA00001075F. I. 10. 1 M00005509B : E10 47 9/28/98 1492. 001 47 RTA00001075F. i. 09. 1 M00005444D : D01 48 9/28/98 1492. 001 48 RTA00001075Fj. 13. 1 M00005464B : B08 49 9/28/98 1492. 001 49 RTA00001076F. e. 03. 1 M00006635A : C01 50 9/28/98 1492. 001 50 RTA00001076Fj. 14. 1 M00006837B : H12 51 9/28/98 1492.001 51 RTA00001075F. g. l9. 1 M00005418C : B09 52 9/28/98 1492. 001 52 RTA00001075F. m. 05. 1 M00005538C : H11 53 9/28/98 1492. 001 53 RTA00001076F. p. 03. 1 M00007046D : E10 54 9/28/98 1492. 001 54 RTA00001075F. h. l9. 1 M00005435B : F01 55 9/28/98 1492.001 55 RTA00001075F. h. 14. 1 M00005434C : E02 56 9/28/98 1492.001 56 RTA00001076F.1. 14. 1 M00006917B : C05 57 9/28/98 1492. 001 57 RTA00001075F. h. 17. 1 M00005434D : H02 58 9/28/98 1492. 001 58 RTA00001075F. f. 18. 1 M00005396C : H04 59 9/28/98 1492. 001 59 RTA00001076F. 1. 03. 1 M00006894D : A07 60 9/28/98 1492. 001 60 RTA00001065F. d. 07. 2 M00007079D : H01 61 9/28/98 1492. 001 61 RTA00001075F. e. 18. 1 M00005377C : F07 62 9/28/98 1492. 001 62 RTA00001065F. d. 03. 2 M00007065D : A03 63 9/28/98 1492. 001 63 RTA00001076F. b. 18. 1 M00006577A : B01 64 9/28/98 1492. 001 64 RTA00001075F. m. 16. 1 M00005569B : E04 65 9/28/98 1492. 001 65 RTA00001076F. d. 13. 1 M00006627C : C02 66 9/28/98 1492.001 66 RTA00001076F.i.16.1 M00006805D : H12 67 9/28/98 1492. 001 67 RTA00001076F. p. 10. 1 M00007064B : E09 68 9/28/98 1492.001 68 RTA00001064F. p. 14. 1 M00006835D : C08 69 9/28/98 1492.001 69 RTA00001077F. b. 04. 1 M00007126D : H01 70 9/28/98 1492.001 70 RTA00001076F. d. 04. 1 M00006619A : G11 71 9/28/98 1492. 001 71 RTA00001077F. a. 22. 1 M00007121D : All 72 9/28/98 1492.001 72 RTA00001077F.c.19.1 M00007178D : A10 73 9/28/98 1492. 001 73 RTA00001065F. f. 06. 1 M00007197D : D12 74 9/28/98 1492. 001 74 RTA00000616F. f. 11. 3 M00005395D : D11 75 9/28/98 1492.001 75 RTA00001064F.1. 13. 2 M00006577B : F01 76 9/28/98 1492. 001 76 RTA00001064F. o. 08. 1 M00006757D : H04 77 9/28/98 1492.001 77 RTA00001075F.o. 03. 1 M00005621A : B05 78 9/28/98 1492. 001 78 RTA00001064F. 1. 23. 2 M00006596D : H02 79 9/28/98 1492.001 79 RTA00001076F. e. 01. 1 M00006631D : G09 80 9/28/98 1492. 001 80 RTA00001075F.j. 22. 1 M00005473C : F02 81 9/28/98 1492. 001 81 RTA00001076F. h. 16. 1 M00006757A : C09 82 9/28/98 1492.001 82 RTA00001075F.j.08.1 M00005459B : A01 83 9/28/98 1492. 001 83 RTA00001064F. o. 19. 1 M00006795C : B12 84 9/28/98 1492. 001 84 RTA00001064F. o. 07. 1 M00006756D : G07 85 9/28/98 1492. 001 85 RTA00001076F. i. 09. 1 M00006790D : F10 86 9/28/98 1492. 001 86 RTA00001076F. i. 22. 1 M00006815D : D11 87 9/28/98 1492. 001 87 RTA00001076F. c. 21. 1 M00006613C : C02 88 9/28/98 1492. 001 88 RTA00001076F. j. 19. 1 M00006846A : B03 89 9/28/98 1492. 001 89 RTA00001064F. o. 13. 1 M00006779D : F03 90 9/28/98 1492. 001 90 RTA00001077F. a. 06. 1 M00007101C : H01 91 9/28/98 1492. 001 91 RTA00001064F. n. 01. 1 M00006664A : C05 92 9/28/98 1492. 001 92 RTA00001064F. c. 12. 1 M00005358A : H03 93 9/28/98 1492. 001 93 RTA00001077F. d. 07. 1 M00007196D : D02 94 9/28/98 1492. 001 94 RTA00001077F. c. 18. 1 M00007177B : C02 95 9/28/98 1492. 001 95 RTA00001064F. g. 12. 1 M00005490B : B02 96 9/28/98 1492. 001 96 RTA00001075F. b. 07. 1 M00004866C : H08 97 9/28/98 1492.001 97 RTA00000617F. p. 03. 2 M00005515B : B08 98 9/28/98 1492. 001 98 RTA00000616F. f. 10. M00005395D : B12 99 9/28/98 1492. 001 99 RTA00001064F. p. 15. 1 M00006840A : AI2 100 9/28/98 1492. 001 100 RTA00000617F. p. 10. 2 M00005516D : F12 101 9/28/98 1492. 001 101 RTA00001076F. m. 01. 1 M00006925B : B02 102 9/28/98 1492. 001 102 RTA00001075F. f. 15. 1 M00005395C : Cl 1 103 9/28/98 1492. 001 103 RTA00001075F. e. 23. 1 M00005385B : A10 104 9/28/98 1492. 001 104 RTA00001076F. f. 12. 1 M00006688C : C12 105 9/28/98 1492. 001 105 RTA00001075F. g. 21. 1 M00005420C : E03 106 9/28/98 1492. 001 106 RTA00001076F. g. 18. 1 M00006727A : H12 107 9/28/98 1492. 001 107 RTA00001075F. d. 24. 1 M00005363D : C05 108 9/28/98 1492. 001 108 RTA00001075F. e. 02. 1 M00005364C : A02 109 9/28/98 1492. 001 109 RTA00001075F. m. 14. 1 M00005563C : D05 110 9/28/98 1492. 001 110 RTA00001064F. h. 07. 1 M00005520A : H11 111 9/28/98 1492. 001 111 RTA00001065F. b. 07. 1 M00006936C : G11 112 9/28/98 1492. 001 112 RTA00001065F. b. 23. 1 M00006968D : H02 113 9/28/98 1492. 001 113 RTA00001064F. g. 15. 1 M00005497C : G08 114 9/28/98 1492. 001 114 RTA00001064F. d. 14. 1 M00005390C : E05 115 9/28/98 1492.001 115 RTA00001064F.1. 22. 2 M00006595C : B08 116 9/28/98 1492. 001 116 RTA00001064F. p. 04. 1 M00006816D : D08 117 9/28/98 1492. 001 117 RTA00001076F. g.04.1 M00006712A : F01 118 9/28/98 1492. 001 118 RTA00001075F. p17. 1 M00005709D : H05 119 9/28/98 1492.001 119 RTA00001075F.1. 03. 1 M00005505B : D10 120 9/28/98 1492.001 120 RTA00001076F.1. 23. 1 M00006925A : B09 121 9/28/98 1492. 001 121 RTA00001076F. k. 11. 1 M00006874D : E01 122 9/28/98 1492.001 122 RTA00001076F. n. 15. 1 M00006994A : C12 123 9/28/98 1492. 001 123 RTA00001075F. o. 10. 1 M00005629B : G06 124 9/28/98 1492. 001 124 RTA00001075F. n. 04. 1 M00005589B : H12 125 9/28/98 1492. 001 125 RTA00001075F. f. 06. 1 M00005388B : B02 126 9/28/98 1492. 001 126 RTA00001076F.j.05.1 M00006823A : H06 127 9/28/98 1492. 001 127 RTA00001076F. o. 18. 1 M00007041C : C05 128 9/28/98 1492. 001 128 RTA00001064Fj. 14. 1 M00005648C : C 11 129 9/28/98 1492. 001 129 RTA00001064F. d. 06. 1 M00005376B : E08 130 9/28/98 1492. 001 130 RTA00001077F. d. 10. 1 M00007200A : B12 131 9/28/98 1492. 001 131 RTA00001065F. d. l9. 1 M00007109D : G01 132 9/28/98 1492. 001 132 RTA00001064F. f. 13. 1 M00005464D : D07 133 9/28/98 1492. 001 133 RTA00001075F. k. 20. 1 M00005493D : H12 134 9/28/98 1492. 001 134 RTA00001075F.k.07.1 M00005479C : A05 135 9/28/98 1492. 001 135 RTA00001075F. a. 14. 1 M00004847D : G01 136 9/28/98 1492. 001 136 RTA00001076F. f. 22. 1 M00006704A : C11 137 9/28/98 1492.001 137 RTA00001076F. m. ll. l M00006949B : C07 138 9/28/98 1492. 001 138 RTA00001064F. i. 13. 2 M00005618C : Hl 1 139 9/28/98 1492. 001 139 RTA00001076F. f. 19. 3 M00006694D : G06 140 9/28/98 1492. 001 140 RTA00001076F. c. 23. 1 M00006617A : A06 141 9/28/98 1492. 001 141 RTA00001077F. a. 09. 1 M00007107C : D02 142 9/28/98 1492. 001 142 RTA00001064F. b. 14. 1 M00005020B:D10 143 9/28/98 1492. 001 143 RTA00001075F. e. 21. 1 M00005382A:G09 144 9/28/98 1492. 001 144 RTA00001075F. p. 15. 1 M00005705D : G09 145 9/28/98 1492. 001 145 RTA00001076F. n. 11. 1 M00006991B : E05 146 9/28/98 1492. 001 146 RTA00001065F. e. 18. 1 M00007161C : D12 147 9/28/98 1492. 001 147 RTA00000615F. e. 06. 2 M00004871C : C04 148 9/28/98 1492. 001 148 RTA0000064F. a. 04. 2 M00004821D : C03 149 9/28/98 1492. 001 149 RTA00001075F.j. 18. 1 M00005469A : D10 150 9/28/98 1492. 001 150 RTA00001077F. c. 05. 1 M00007156D : E11 151 9/28/98 1492. 001 151 RTA00001075F. g. 22. 1 M00005420C : E10 152 9/28/98 1492. 001 152 RTA00001077F. a. 08. 1 M00007104D : D10 153 9/28/98 1492. 001 153 RTA00001077F.c. 15. 1 M00007172D : H03 154 9/28/98 1492. 001 154 RTA00001077F.c. 16. 1 M00007175B : B11 155 9/28/98 1492. 001 I5. IM00007I41A b. G08 156 9/28/98 1492. 001 156 RTA00001077F. c. 17. 1 M00007175D : G02 157 9/28/98 1492. 001 157 RTA00001077F. a. 14. 1 M00007116A : C08 158 9/28/98 1492. 001 158 RTA00001075F. i. 02. 1 M00005438D : A08 157 9/28/98 1492.001 159 RTA00001075F.1.11.1 M00005509D : G05 160 9/28/98 1492. 001 160 RTA00001064F. d. 20. 1 M00005403A : D12 161 9/28/98 1492. 001 161 RTA00001076F. h. 10. 1 M00006740A : A06 162 9/28/98 1492.001 162 RTA00001075F. k. 21. 1 M00005494C : F08 163 9/28/98 1492. 001 163 RTA00001075F. i. 21. 1 M00005450C : G09 164 9/28/98 1492.001 164 RTA00001076F. p. 24. 1 M00007093C : C11 165 9/28/98 1492. 001 165 RTA00001075F. f. 03. 1 M00005385D : B08 166 9/28/98 1492. 001 166 RTA00001065F. d. 18. 2 M00007107A : H08 167 9/28/98 1492.001 167 RTA00001076F.o. 05. 1 M00007026A : A03 168 9/28/98 1492. 001 168 RTA00001075F. d. 10. 1 M00005353C : H01 169 9/28/98 1492. 001 169 RTA00001064F. d. 07. 1 M00005378B : B04 170 9/28/98 1492.001 170 RTA00001064F. b. 11. 1 M00006945D : A07 171 9/28/98 1492. 001 171 RTA00001076F. g. 17. 1 M00006726D : H10 172 9/28/98 1492. 001 172 RTA00001065F. a. 21.1 M00006918D : G08 173 9/28/98 1492. 001 173 RTA00001077F. d. l2. 1 M00007203C : E06 174 9/28/98 1492. 001 174 RTA00001064F. g. 08. 1 M00005481C : H05 175 9/28/98 1492. 001 175 RTA00001064F. f. 02. 1 M00005449D : D04 176 9/28/98 1492. 001 176 RTA00001075F. a. 02. 1 M00004825A : G12 177 9/28/98 1492. 001 177 RTA00001064F. b. 16. 1 M00005296B : H07 178 9/28/98 1492. 001 178 RTA00001077F. c. 02. 1 M00007152A : A10 179 9/28/98 1492.001 179 RTA00001064F. g. 04. 1 M00005480C : A04 180 9/28/98 1492. 001 180 RTA00001075F. c. 12. 1 M00005305A : H01 181 9/28/98 1492.001 181 RTA00001064F.o. 04. 1 M00006752C : D04 182 9/28/98 1492. 001 182 RTA00001077F. a. 21. 1 M00007121A : G04 183 9/28/98 1492. 001 183 RTA00001074F. f. 1l. 1 M00005392C : B03 184 9/28/98 1492.001 184 RTA00001064F. k. 24. 2 M00005820A : Hl 1 185 9/28/98 1492. 001 185 RTA00001075F. d. 02. 1 M00005342D : E04 186 9/28/98 1492. 001 186 RTA00001076F. c. 13. 1 M00006600D : G07 187 9/28/98 1492.001 187 RTA00001075F. b. 15. 1 M00004872C : G03 188 9/28/98 1492. 001 188 RTA00001064F. f. 09.1 M00005461C : D 11 189 9/28/99 1492. 001 189 RTA00001075F. g. 14. 1 M00005416B : AOI 190 9/28/98 1492.001 190 RTA00001075F. f. 17. 1 M00005396A : COI 191 9/28/98 1492.001 191 RTA00001076F.1. 05. 1 M00006895D : A02 192 9/28/98 1492. OO1 192 RTA00001076F. o. 02. 1 M00007019B : G01 193 9/28/98 1492. 001 193 RTA00001064F. b. 07. 1 M00005000A : HO5 194 9/28/98 1492.001 194 RTA00001075F. d. 17. 1 M00005358B : D10 195 9/28/98 1492.001 195 RTA00000624F.f.12.2 M00005607A : C08 196 9/28/98 1492. 001 196 RTA00001075F. c. 22. 1 M00005342B : GOI 197 9/28/98 1492. 001 197 RTA00001065F. a. 17. 1 M00006914C : D07 198 9/28/98 1492.001 198 RTA00001075F. b. 02. 1 M00004859D : D01 199 9/28/98 1492. 001 199 RTA00001077F. c. 12. 1 M00007167C : B10 200 9/28/98 1492.001 200 RTA00001077F.c. 20. 1 M00007179B : H04 201 9/28/98 1492. 001 201 RTA00001076F. m. 04. 1 M00006934B : B 11 202 9/28/98 1492. 001 202 RTA00001076FJ. 22. 1 M00006859D : E11 203 9/28/98 1492.001 203 RTA00001076F. 001 13.1 M00006882C:D03 204 9/28/98 1492.001 204 RTA00001074F. k. 14. 1 M00005485C : F09 205 9/28/98 1492. 001 205 RTA00001076F. f. 10. 1 M00006680D : A01 206 9/28/98 1492. 001 206 RTA00001064F. o. 05. 1 M00006755C : C03 207 9/28/98 1492. 001 207 RTA00001064F.1.05.2 M00005826B : F10 208 9/28/98 1492.001 208 RTA00001076F. p. 04. 1 M00007047D : C02 209 9/28/98 1492. 001 209 RTA00001064F. 1. 04. 1 M00005822D : C05 210 9/28/98 1492. 001 210 RTA00001076F. c. 03. 1 M00006584D : D01 211 9/28/98 1492. 001 211 RTA00001064F. m. 06. 1 M00006621B : B06 212 9/28/98 1492. 001 212 RTA00001075F. k. 15. 1 M00005486A : F07 213 9/28/98 1492.001 213 RTA00001064F.d.08.1 M00005378C : B12 214 9/28/98 1492. 001 214 RTA00001077F. d. 11. 1 M00007202A : A09 215 9/28/98 1492. 001 215 RTA00001077F. b. 14. 1 M00007140C : G12 216 9/28/98 1492. 001 216 RTA00001075F. k. 04. 1 M00005476D : A11 217 9/28/98 1492. 001 217 RTA00001064F. n. 03. 1 M00006678C : B07 218 9/28/98 1492. 001 218 RTA00001075F. i. 12. 1 M00005446B : D10 219 9/28/98 1492. 001 219 RTA00001075F. f. 04. 1 M00005386C : G01 220 9/28/98 1492. 001 220 RTA00001076F. n. 14. 1 M00006993B : F02 221 9/28/98 1492. 001 221 RTA00001064F. k. 19. 2 M0000581OB : C07 222 9/28/98 1492. 001 222 RTA00001076F. d. 20. 1 M00006630A : E09 223 9/28/98 1492. 001 223 RTA00001077F. b. 20. 1 M00007145C : B05 224 9/28/98 1492. 001 224 RTA00001076F. f. 11. 1 M00006688A : F09 225 9/28/98 1492. 001 225 RTA00001065F. d. 01. 1 M00007047C : H04 226 9/28/98 1492. 001 226 RTA00001075F. g. 12. 1 M00005413B : B02 227 9/28/98 1492. 001 227 RTA00001064F. a. 09. 2 M00004841 C : H03 228 9/28/98 1492. 001 228 RTA00001064F. k. 20. 2 M00005810B : G02 229 9/28/98 1492. 001 229 RTA00001064F. b. 17. 1 M00005296D : G03 230 9/28/98 1493. 001 RTA00001073F. f. 17. 1 M00004087A : H06 231 9/28/98 1493.00 2 RTA00001073F.1. 02. 1 M00004168D : F05 232 9/28/98 1493. 001 3 RTA00001072F. i. 07. 3 M00003845B : A04 233 9/28/98 1493. 001 4 RTA00001071F. i. 23. 3 M00001477A : G02 234 9/28/98 1493. 001 5 RTA00000611F. e. 04. 2 M00004170C : H06 235 9/28/98 1493. 001 6 RTA00001062F. f. 19. 1 M00003888C : G08 236 9/28/98 1493.001 7 RTA00001073F.1. 22. 1 M00004176B : H09 237 9/28/98 1493.001 8 RTA00001063F.1. 10. 1 M000044 ! OA : F06 238 9/28/98 1493. 001 9 RTA00001062F. 1. 13. 1 M00004034A : A05 239 9/28/98 1493. 001 10 RTA00001074F. I. 10. 1 M00004495D : A05 240 9/28/98 1493. 001 11 RTA00001061F. d. 01. 1 M00001389C : E01 241 9/28/98 1493.001 12 RTA00001072F.j. 04. 2 M00003861D : G10 242 9/28/98 1493. 001 13 RTA00001073F. d. 04. 1 M00004048C : C02 243 9/28/98 1493.001 14 RTA00001061F.j. 09. 1 M00001507A : H06 244 9/28/98 1493.001 15 RTA00001071A. h. 16. 1 M00001450D : H12 245 9/28/98 1493.001 16 RTA00001062F.o. 17. 1 M00004108B : D04 246 9/28/98 1493. 001 17 RTA00001073F. c. 20. 1 M00004046C : A04 247 9/28/98 1493. 001 18 RTA00001063F. k. 14. 1 M00004381A : E10 248 9/28/98 1493. 001 19 RTA00000611F. e. 18. 2 M00004171D : H10 249 9/28/98 1493.001 20 RTA00001072F. a. 18. 2 M00001655C : F07 250 9/28/98 1493. 001 21 RTA00001072F. b. 04. 2 M00001660A : B10 251 9/28/98 1493.001 22 RTA00001074F. g. 19. 1 M00004372A : A08 252 9/28/98 1493. 001 231 RTA00001072F. 09.3 M00003845C : F08 253 9/28/98 1493. 001 24 RTA00001072F. a. 21. 2 M00001657D : D07 254 9/28/98 1493. 001 25 RTA00001072F. m. 18. M00003916D : A10 255 9/28/98 1493. 001 26 RTA00001061 F. b. 04. 1 M00001360B : F09 256 9/28/98 1493. 001 27 RTA00001072F. o. 06. S M00003935A:C04 257 9/28/98 1493.001 28 RTA00001072F. n. 19. 3 M00003931A:G01 258 9/28/98 1493.001 29 RTA00001073F. e. 08. 1 M00004068A : A03 259 9/28/98 1493.001 30 RTA00001074F. g. 22. 1 M00004373D : G10 260 9/28/98 1493. 001 31 RTA00001073F. c. OI. 1 M00004030C : E05 261 9/28/98 1493.001 32 RTA00001074F.f.15 M00004360B : B08 262 9/28/98 1493. 001 33 RTA00001074F. f. 01. 1 M00004350A : C04 263 9/28/98 1493. 001 34RTA00001074F. d. 08. 1 M00004318D : D07 264 9/28/98 1493.001 35 RTA00001072F. f. 11. 2 M00003788D : E06 265 9/28/98 1493.001 36 RTA00001074F. e. 05. 1 M00004337A : A07 266 9/28/98 1493.001 37 RTA00001072F. g. 05. 2 M00003803B : G12 267 9/28/98 1493. 001 38 RTA00001071Fj. 04. 3 M00001479D : B10 268 9/28/98 1493. 001 39 RTA00001074Fj. 05. 1 M00004415A : A01 269 9/28/98 1493. 001 40 RTA00001074Fj. 04. 1 M00004414D : C11 270 9/28/98 1493. 001 41 RTA00001073F. e. 06. 1 M00004067C : C10 271 9/28/98 1493.001 42 RTA00001071F. d. 14. 1 M00001389A : F03 272 9/28/98 1493. 001 43 RTA00001071 F. f. 12. 1 M00001418C : F06 273 9/28/98 1493. 001 44 RTA00001061F. m. 13. 1 M00001601D : A03 274 9/28/98 1493.001 45 RTA00001061F.e.171. M00001418A : A02 2784 9/28/98 1493.001 46 RTA00001071F.m. 09. 3 M00001563A : F04 276 9/28/98 1493.001 47 RTA00001062F.1. 05. 1 M00004029D : H03 277 9/28/98 1493. 001 48 RTA00001073F. i. 02. 2 M00004125B : A02 278 9/28/98 1493. 001 49 RTA00001063F. 1. 04. 1 M00004404C : B03 279 9/28/98 1493. 001 50 RTA00001063F. 1. 14. 1 M00004412A : G05 280 9/28/98 1493. 001 51 RTA00001063F. e. 05. 1 M00004232D : G 11 281 9/28/98 1493. 001 52 RTA00001062F. f. 06. 1 M00003880A : G10 282 9/28/98 1493.001 53 RTA00001072F. b. 23. 2 M00001683B : F12 283 9/28/98 1493. 001 54 RTA00001073F. a. 13. 1 M00003989D : A02 284 9/28/98 1493. 001 55 RTA00001074F. h. 16. 1 M00004386C : C03 285 9/28/98 1493. 001 56 RTA00001073F. a. 15. 1 M00003991A : D05 286 9/28/98 1493.001 57 RTA00001073F. k. 01. 1 M00004152A : F03 287 9/28/98 1493.001 58 RTA00001072F.1.19.2 M00003901B : C02 288 9/28/98 1493. 001 59 RTA00001072F. i. 15. 3 M00003848A : E08 289 9/28/98 1493.001 60 RTA00001072F. i. 05. 3 M00003844D : B02 290 9/28/98 1493. 001 61 RTA00001074F. m. 06. 1 M00004603D : D09 291 9/28/98 1493.001 62 RTA00001062F.m.15.1 M00004063B : B12 292 9/28/98 1493.001 63 RTA00001074F. d. l9. 1 M00004326D : D06 293 9/28/98 1493.001 64 RTA00001073F.j. 02. 1 M00004140B : C02 294 9/28/98 1493. 001 65 RTA00001071F. I. 11. 1 M00001545D : F12 295 9/28/98 1493. 001 66 RTA00001074F. f. 12. 1 M00004356C : D02 296 9/28/98 1493. 001 67 RTA00001073F.h.03.1 M00004110A : G03 297 9/28/98 1493.001 68 RTA00001074F. a. 19. 1 M00004275A : H07 298 9/28/98 1493.001 69 RTA00001063F. g. 15. 1 M00004292A : C08 299 9/28/98 1493.001 70 RTA00001061F. a. 09. 1 M00001345C : B10 300 9/28/98 1493. 001 71 RTA00001063F. f. 23. 1 M00004284A : C09 301 9/28/98 1493. 001 72 RTA00001073F. e. 10. 1 M00004069A : E04 302 9/28/98 1493. 001 73 RTA00001073F. g. 15. 1 M00004103A : E06 303 9/28/98 1493. 001 74 RTA00001073F. n. 20. 1 M00004209B : GOI 304 9/28/98 1493. 001 75 RTA00001073F. g. 11. 1 M00004099C : F04 305 9/28/98 1493.001 76 RTA00001071F. p. 05. 1 M00001630A : E08 306 9/28/98 1493. 001 77 RTA00001073F. I. I9. 1 M00004175D : D05 307 9/28/98 1493. 001 78 RTA00001074Fj. 17. 1 M00004426B : H06 308 9/28/98 1493. 001 79 RTA00001074F. b. 22. 1 M00004292A : F03 309 9/28/98 1493. 001 80 RTA00001071F. d. l9. 1 M00001391C:B05 310 9/28/98 1493.001 81 RTA00001062F.j. 02. 1 M00003960D : E09 311 9/28/98 1493. 001 82 RTA00001072F. b. 09. 2 M00001664D : E02 312 9/28/98 1493.001 83 RTA00001073F. 001 08. 1 M00003998C b. D04 313 9/28/98 1493. 001 84 RTA00001062Fj. 19. 1 M00003977D : H04 314 9/28/98 1493. 001 85 RTA00001062F. m. 18. 1 M00004066D : C02 315 9/28/98 1493.001 86 RTA00001062F. b. 02. 1 M00003775C : COI 316 9/28/98 1493. 001 87 RTA00001061F. d. 20. 1 M00001401B : A02 317 9/28/98 1493. 001 88 RTA00001071F. n. 05. 3 M00001579C : E07 318 9/28/98 1493. 001 89 RTA00001073F. 1. 04. 1 M00004170B : G04 319 9/28/98 1493. 001 90 RTA00001071F. h. 04. 1 M00001442D : D09 320 9/28/98 1493. 001 91 RTA00001062F. o. 1l. l M00004104C : F06 321 9/28/98 1493. 001 92 RTA00001062F. i. 10. 1 M00003939B : C02 322 9/28/98 1493.001 93RTA00001071F. g. 16. 1 M00001431A : F03 323 9/28/98 1493. 001 94 RTA00001061F. d. 06. 1 M00001392A : F02 324 9/28/98 1493. 001 95 RTA00001071F. m. 01. 3 M00001561A : G10 325 9/28/98 1493. 001 96 RTA00001062F. n. 06. 1 M00004081A : E11 326 9/28/98 1493. 001 97 RTA00001061F.d. 14. 1 M00001397D : G04 327 9/28/98 1493. 001 98 RTA00001061f.j.10.1 M00001507D : F09 328 9/28/98 1493. 001 99 RTA00001063F. c. 07. 1 M00004185B : H03 329 9/28/98 1493. 001 100 RTA00001061F.j. 12. 1 M00001513B : F05 330 9/28/98 1493. 001 101 RTA00001061F. o. 22. 1 M00001678A : B10 331 9/28/98 1493. 001 102 RTA00001071F. e. 03. 1 M00001395D : B04 332 9/28/98 1493. 001 103 RTA00001072F. e. 13. 2 M00003772C : F12 333 9/28/98 1493. 001 104 RTA00001062F. i. 03. 1 M00003928D : A04 334 9/28/98 1493. 001 105 RTA00001072F. d. 20. 2 M00003761C : C05 335 9/28/98 1493. 001 106 RTA00001074F. g. 16. 1 M00004371B : A05 336 9/28/98 1493. 001 107 RTA00001074F.f.09.1 M00004353D : C06 337 9/28/98 1493. 001 108 RTA00001071F. k. 12. 1 M00001505C : C10 338 9/28/98 1493. 001 109 RTA00001074F. f. 13. 1 M00004357A : B10 339 9/28/98 1493. 001 110 RTA00001071F. e. 08. 1 M00001397C : FOI 340 9/28/98 1493. 001 111 RTA00001073F. h. 11. 1 M00004117D : F06 341 9/28/98 1493. 001 112 RTA00001072F.o.14.2 M00003937D : F09 342 9/28/98 1493. 001 113 RTA00001074F. c. 11. 1 M00004298A : H09 343 9/28/98 1493. 001 114 RTA00001074F. g. 08. 1 M00004368A : G 11 344 9/28/98 1493. 001 115 RTA00001073F. a. 18. 1 M00003993C : G I I 345 9/28/98 1493. 001 116 RTA00001073F. f. 19. 1 M00004090A : B 11 346 9/28/98 1493.001 117 RTA00001072F.1 20. 2 M00003902C : D02 347 9/28/98 1493. 001 118 RTA00001073F. b. 06. 1 M00003997D : G03 348 9/28/98 1493.001 119 RTA00001062F.o. 14. 1 M00004105C:C05 349 9/28/98 1493. 001 120 RTA00001071F.i.04.3 M00001457D:E08 350 9/28/98 1493.001 121 RTA00001074F. a. 23. 1 M00004278C : Hl 1 351 9/28/98 1493. 001 122 RTA00001073F. c. 04. 1 M00004034A : G03 352 9/28/98 1493.001 123 RTA00001072F. h. 18. 2 M00003833D : F11 353 9/28/98 1493. 001 124 RTA00001074F. i. 06. 1 M00004403A : A02 354 9/28/98 1493. 001 125 RTA00001063F. e. 09. 1 M00004240A : D03 355 9/28/98 1493. 001 126 RTA00001061F. d. 03. 1 M00001390C:H05 356 9/28/98 1493. 001 127 RTA00001063F. 23. 1 M00004225A : E03 357 9/28/98 1493. 001 128 RTA00001063F. k. 08. 1 M00004378A : H10 358 9/28/98 1493.001 129 RTA00001062F.b.04.1 M00003776B : F08 359 9/28/98 1493. 001 130 RTA00001063F. b. 18. 1 M00004178B : F07 360 9/28/98 1493. 001 131 RTA00001062F. b. 11. 1 M00003788B : C08 361 9/28/98 1493.001 132 RTA00001074F.1.23.1 M00004504C : G07 362 9/28/98 1493. 001 133 RTA00001063F. m. 08. 1 M00004444C : H11 363 9/28/98 1493.001 134 RTA00001071F.1.13.2 M00001549C : F10 364 9/28/98 1493. 001 135 RTA00001072F. p. 19. 2 M00003973A : D09 365 9/28/98 1493.001 136 RTA00001071F.k. 17. 1 M00001517C : A10 366 9/28/98 1493. 001 137 RTA00001072F.o.24.2 M00003943B : C12 367 9/28/98 1493. 001 138 RTA00001074F. a. 20. 1 M00004276A : C06 368 9/28/98 1493. 001 139 RTA00001073F. c. 16. 1 M00004043C : A06 369 9/28/98 1493.001 40 RTA00001074F.j.10.1 M00004422C : A01 370 9/28/98 1493. 001 141 RTA00001063F. n. 16. 1 M00004498D : F02 371 9/28/98 1493. 001 142 RTA00001071 F. o. 16. 1 M00001615A : D01 372 9/28/98 1493. 001 143 RTA00001073F. k. 16. 1 M00004165D : H12 373 9/28/98 1493. 001 144 RTA00001062F. e. 14. 1 M00003856A : H10 374 9/28/98 1493. 001 145 RTA00001071F. h. 22. 1 M00001454D : H09 375 9/28/98 1493. 001 146 RTA00001071F. o. 18. 1 M00001618C : E01 376 9/28/98 1493. 001 147 RTA00001062F. p. 19. 1 M00004140D : E03 377 9/28/98 1493. 001 148 RTA00001062F. d. 04. 1 M00003818C : D02 378 9/28/98 1493. 001 149 RTA00001072F. n. 22. 3 M00003933A : B04 379 9/28/98 1493. 001 150 RTA00001063F. c. 11. 1 M00004187A : B05 380 9/28/98 1493. 001 151 RTA00001061F. j. 22. 1 M00001531B : A03 381 9/28/98 1493. 001 152 RTA00001062F. d. 08. 1 M00003820C : E08 382 9/28/98 1493. 001 153 RTA00001062F. f. 02. 1 M00003877C : G01 383 9/28/98 1493.001 154 RTA00001062F. d. 24. 1 M00003839D : C03 384 9/28/98 1493.001 155 RTA00001074F. h. 24. 1 M00004391C : FI2 385 9/28/98 1493. 001 156 RTA00001071F. a. 10. 1 M00001341A : H10 386 9/28/98 1493. 001 157 RTAOOOOi074F. k. 13. 1 M00004449B : B05 387 9/28/98 1493. 001 158 RTA00001072F. k. 16. 2 M00003884C : G09 388 9/28/98 1493. 001 159 RTA00001073F. k. 09. 1 M00004158C : B01 389 9/28/98 1493. 001 160 RTA00001074F. b. 14. 1 M00004288D:E07 390 9/28/98 1493. 001 161 RTA00001073F. k. 08. 1 M00004157C : E06 391 9/28/98 1493. 001 162 RTA00001074F. i. 17. 1 M00004406D : E11 392 9/28/98 1493. 001 163 RTA00001074F. k. 10. 1 M00004447A : A10 393 9/28/98 1493. 001 164 RTA00001062F. p. 14. 1 M00004135D : DO1 394 9/28/98 1493. 001 165 RTA00001071F. m. 153 M00001569A : H01 395 9/28/98 1493.001 166 RTA00001074F. h. 15. 1 M00004385D : D06 396 9/28/98 1493. 001 167 RTA00001062F. i. 09. 1 M00003935D : E04 397 9/28/98 1493.001 168 RTA00000611F. e. 06. 2 M00004170D : C06 398 9/28/98 1493. 001 169 RTA00001062F. d. 19. 1 M00003835B : C05 399 9/28/98 1493. 001 170 RTA00001062F. o. 15. 1 M00004107A : E02 400 9/28/98 1493. 001 171 RTA00001071F. a. 07. 1 M00001340C : A08 401 9/28/98 1493. 001 172 RTA00001062F. d. 07. 1 M00003820B : G04 402 9/28/98 1493. 001 173 RTA00001074F.j.11.1 M00004423A : B05 403 9/28/98 1493. 001 174 RTA00001071F. m. 11. 3 M00001565C : F06 404 9/28/98 1493. 001 175 RTA00001062F. i. 01. 1 M00003926A : D01 405 9/28/98 1493.001 176 RTA00001072F. g. 08. 2 M00003804D:F12 406 9/28/98 1493. 001 177 RTA00001071F. n. 16. 1 M00001594A : H01 407 9/28/98 1493. 001 178 RTA00001062F. a. 09. 1 M00003756D : B09 408 9/28/98 1493. 001 179 RTA00001073F. h. 08. 1 M00004114C : B09 409 9/28/98 1493. 001 180 RTA00001073F. e. 03. 1 M00004064B : G03 410 9/28/98 1493. 001 181 RTA00001073F.c. 23. 1 M00004048A : E10 411 9/28/98 1493.001 182 RTA00001074F.1.15.1 M00004498D : All 412 9/28/98 1493. 001 183 RTA00001073F. 1. 21. 1 M00004176A : H05 413 9/28/98 1493.001 184 RTA00001071F.d.15.1 M00001398B : B12 414 9/28/98 1493. 001 185 RTA00001073F. i. 08. 1 M00004127C : C08 415 9/28/98 1493. 001 186 RTA00001073F. k. 21. 1 M00004167A : H04 416 9/28/98 1493. 001 187 RTA00001072F.j. 05. 2 M00003865B : D10 417 9/28/98 1493. 001 188 RTA00001063F. i. 15. 1 M00004335A : G05 418 9/28/98 1493. 001 189 RTA00001062F.g.21.1 M00003907C : D02 419 9/28/98 1493. 001 190 RTA00001073F. b. 16. 1 M00004027C : E06 420 9/28/98 1493. 001 191 RTA00001062F. g. 06. 1 M00003895C : F05 421 9/28/98 1493. 001 192 RTA00001071F. b. 17. 1 M00001360B : B01 422 9/28/98 1493. 001 193 RTA00001073F. f. 18. 1 M00004087B : D05 423 9/28/98 1493.001 194 RTA00001074F. b. 04. 1 M00004280D : D10 424 9/28/98 1493. 001 195 RTA00001072F. d. 23. 2 M00003762D : C02 425 9/28/98 1493. 001 196 RTA00001073F. 1. 14. 1 M00004173A : D03 426 9/28/98 1493. 001 197 RTA00001061F. p. 21. 1 M00003747C : G12 427 9/28/98 1493. 001 198 RTA00001071F. n. 22. 1 M00001598C : F02 428 9/28/98 1493. 001 199 RTA00001073F. d. 22. 1 M00004059D : A09 429 9/28/98 1493. 001 200 RTA00001072Fj. 14. 2 M00003876C : Gl 1 430 9/28/98 1493. 001 201 RTA00001071F. k. 21. 2 M00001528D : B12 431 9/28/98 1493. 001 202 RTA00001074F. a. 09. 1 M00004269C : B10 432 9/28/98 1493. 001 203 RTA00001073F. p. l9. 1 M00004253A : E02 433 9/28/98 1493. 001 204 RTA00001061F. b. 02. 1 M00001358B : F12 434 9/28/98 1493. 001 205 RTA00001063F. e. 10. 1 M00004240C : A06 435 9/28/98 1493. 001 206 RTA00001074Fj. 18. 1 M00004427D : H04 436 9/28/98 1493. 001 207 RTA00001073F.f.09.1 M00004084C : F05 437 9/28/98 1493. 001 208 RTA00001071F. 1. 19. 1 M00001558D : E02 438 9/28/98 1493. 001 209 RTA00001073F. c. 09. 1 M00004036B : C11 439 9/28/98 1493. 001 210 RTA00001074F. a. 14. 1 M00004270C : H05 440 9/28/98 1493. 001 211 RTA00001074F. 1. 03. 1 M00004466A : E04 441 9/28/98 1493. 001 212 RTA00000611F. f. 13. 2 M00004175D : G10 442 9/28/98 1493. 001 213 RTA00001074F. e. 16. 1 M00004343A : G07 443 9/28/98 1493. 001 214 RTA00001073F. 1. 05. 1 M00004170C : A12 444 9/28/98 1493. 001 215 RTA00001074F. e. l9. 1 M00004347A : F10 445 9/28/98 1493. 001 216 RTA00001073F. e. 07. 1 M00004067C : E05 446 9/28/98 1493. 001 217 RTA00001062F. p. 22. 1 M00004142C : A06 447 9/28/98 1493. 001 218 RTA00001061F. c. 11. 1 M00001382D : F03 448 1493.001 9/28/98 219 RTA00001062F.f.01.1 M00003877C : A08 449 9/28/98 1493. 001 220 RTA00001072F. 1. 09. 2 M00003893A : D03 450 9/28/98 1493. 001 221 RTA00001072F. i. 14. 2 M00003847B : H01 451 9/28/98 1493. 001 222 RTA00001063F. g. 18. 1 M00004295A : C02 452 9/28/98 1493.001 223 RTA00001062F.j.18.1 M00003977C : DOI 453 9/28/98 1493. 001 224 RTA00001061F. b. 05. 1 M00001360D : C12 454 9/28/98 1493. 001 225 RTA00001074F. e. 18. 1 M00004344B : C06 455 9/28/98 1493. 001 226 RTA00001061F.o. 20. 1 M00001677B : G01 456 9/28/98 1493. 001 227 RTA00001062F. d. 10. 1 M00003822A : D02 457 9/28/98 1493. 001 228 RTA00001062F. h. 16. 1 M00003919D : FOI 458 9/28/98 1493. 001 229 RTA00001063F. e. l9. 1 M00004251B : H12 459 9/28/98 1493. 001 230 RTA00001061F. o. 18. 1 M00001675C : F05 460 9/28/98 1493. 001 231 RTA00001072Fj. 20. 2 M00003879D : A09 461 9/28/98 1493. 001 232 RTA00001071F.j. 15. 3 M00001485A : C04 462 9/28/98 1493. 001 233 RTA00001071F. a. 09. 1 M00001340C : D09 463 9/28/98 1493. 001 234 RTA00001074F.j.13.1 M00004423C : F03 464 9/28/98 1493. 001 235 RTA00001071F. i. 15. 3 M00001466C : Hl 1 465 9/28/98 1493. 001 236 RTA00001071F. b. 13. 1 M00001358C : D09 466 9/28/98 1493. 001 237 RTA00001061F. g. 05. 1 M00001441D : G02 467 9/28/98 1493. 001 238 RTA00001063F. e. 16. 1 M00004249A : C09 468 9/28/98 1493. 001 239 RTA00001072Fj. 22. 2 M00003880B : B08 469 9/28/98 1493. 001 240 RTA00001063F. i. 16. 1 M00004335D : D03 470 9/28/98 1493. 001 241 RTA00000611F. f. 05. 2 M00004174B : B12 471 9/28/98 1493. 001 242 RTA00001071F. p. 07. 1 M00001631D : G08 472 9/28/98 1493. 001 243 RTA00001071F. c. 12. 1 M00001375C : C11 473 9/28/98 1493. 001 244 RTA00001074F. k. 15. 1 M00004450A : G07 474 9/28/98 1493. 001 245 RTA00001061F. e. 19. 1 M00001419A : E01 475 9/28/98 1493. 001 246 RTA00001073F. g. 22. 1 M00004108C : D07 476 9/28/98 1493. 001 247 RTA00001061F. g. 01. 1 M00001437D : A12 477 9/28/98 1493. 001 248 RTA00001072F. n. 08. 2 M00003923D : A03 478 9/28/98 1493. 001 249 RTA00001074F. b. 12. 1 M00004286D : D02 479 9/28/98 1493. 001 250 RTA00001061F. 1. 18. 1 M00001576C : E03 480 9/28/98 1493. 001 251 RTA00001074Fj. 03. 1 M00004414D : AO 1 481 9/28/98 1493.001 252 RTA00001072F. h. 07. 2 M00003824A : B 11 482 9/28/98 1493. 001 253 RTA00001072F. j. 18. 2 M00003877C : C11 483 9/28/98 1493. 001 254 RTA00001063F. c. 21. 1 M00004198B : G08 484 9/28/98 1493. 001 255 RTA00001073F. m. 1l. l M00004181A : B05 485 9/28/98 1493. 001 256 RTA00001061F.h.16.1 M00001463C : E12 486 9/28/98 1493. 001 257 RTA00001073F. i. 11. 1 M00004128B : H11 487 9/28/98 1493.001 258 RTA00001062F. k. 20. 1 M00003997A : C08 488 9/28/98 1493. 001 259 RTA00001062F. o. 05. 1 M00004101A : C12 489 9/28/98 1493.001 260 RTA00001073F.p.01.1 M00004237B : GOI 490 9/28/98 1493. 001 261 RTA00001072F. a. 04. 2 M00001647D : A02 491 9/28/98 1493. 001 262 RTA00001073F. e. 12. 1 M00004071C : B06 492 9/28/98 1493.001 263 RTA00001073F. p. 22. 1 M00004253D : D04 492 9/28/98 1493.001 264 RTA00001072F. i. 19.3 3 M00003853C : A09 494 9/28/98 1493.001 265 RTA00001071F. d. 06. 1 M00001386B : E01 495 9/28/98 1493. 001 266 RTA00001073F.j. 20. 1 M00004149C : D 11 496 9/28/98 1493. 001 267 RTA00001074F.1.20.1 M00004502B : G05 497 9/28/98 1493. 001 268 RTA00001072F. h. 14. 2 M00003829C : G07 498 9/28/98 1493. 001 269 RTA00001062F. b. 13. 1 M00003788C : C05 499 9/28/98 1493. 001 270 RTA00001061F. j. 14. 1 M00001514B : C02 500 9/28/98 1493. 001 271 RTA00001072Fj. 11. 2 M00003870C : H03 501 9/28/98 1493. 001 272 RTA00001074F. m. 01. 1 M00004507A : F11 502 9/28/98 1493. 001 273 RTA00001063F. f. 03. 1 M00004264B : F03 503 9/28/98 1493. 001 274 RTA00001071F. I. 21. 1 M00001559D : E02 504 9/28/98 1493. 001 275 RTA00001072F. b. 11. 2 M00001669B : H04 505 9/28/98 1493. 001 276 RTA00001074F. i. 16. 1 M00004406A : H12 506 9/28/98 1493. 001 277 RTA00001061Fj. 03. 1MOOOOI500A : A02 507 9/28/98 1493. 001 278 RTA00001062F. n. 16. 1 M00004085B : D12 508 9/28/98 1493. 001 279 RTA00001073Fj. 03. 1 M00004140C : D04 509 9/28/98 1493. 001 280 RTA00001072F. k. 01. 2 M00003880C : D06 510 9/28/98 1493. 001 281 RTA00001074F. k. 08. 1 M00004445D : A04 511 9/28/98 1493. 001 282 RTA00001062F. k. 05. 1 M00003985B : F06 512 9/28/98 1493. 001 283 RTA00001073F. h. 01. 1 M00004109A : B07 513 9/28/98 1493. 001 284 RTA000006I1F. f.5. 2 M00004176A : E07 514 9/28/98 1493. 001 285 RTA00001073F. b. 01. 1 M00003995B : C06 515 9/28/98 1493. 001 286 RTA00001072F. c. 16. 2 M00001694B : H12 516 9/28/98 1493. 001 287 RTA00001073F. c. 10. 1 M00004036C : E10 517 9/28/98 1493. 001 288 RTA00001062F. g. 22. 1 M00003908C : C04 518 9/28/98 1493. 001 289 RTA00001074F. d. 15. 1 M00004323B : G12 519 9/28/98 1493. 001 290 RTA00001061F. c. 12. 1 M00001383C : C04 520 9/28/98 1493. 001 291 RTA00001073F. k. 15. 1 M00004165B : E03 521 9/28/98 1493. 001 292 RTA00001072Fj. 23. 2 M00003880B : D03 522 9/28/98 1493.001 293 RTA00001073F.j. 21. 1 M00004150A : B09 5234 9/28/98 1493.001 294 RTA00001074F. h. 20. 1 M00004123B : G05 524 9/28/98 1493. 001 295 RTA00001063F. g. 05. 1 M00004285C : B06 525 9/28/98 1493. 001 296 RTA00001061F. a. 21. 1 M00001352D : A09 526 9/28/98 1493. 001 297 RTA00001061F. d. 17. 1 M00001399B : C04 527 9/28/98 1493.001 298 RTA00001072F. h. 04. 2 M00003819D : B02 528 9/29/98 1494. 001 RTA00001082Fj. ll. l M00027137D : F05 529 9/28/98 1493.001 2 RTA00001082F. h. 08. 1 M00027042D : E02 530 9/29/98 1494.001 3 RTA00001082F. e. 15. 1 M00026936D : D01 531 9/29/98 1494.001 4 RTA00001082F.1 21. 1 M00027204B : A08 532 9/29/98 1494. 001 5 RTA00001082F. e. 05. 1 M00026910C : C05 533 9/28/98 1493.001 6 RTA00001082F.. 07. 1 M00027085C : H12 534 9/29/98 1494. 001 7 RTA00001082F. i. 12. 1 M00027096B : A01 535 9/29/98 1494. 001 8 RTA00001082F. m. 12. 1 M00027218C : D06 536 9/29/98 1494. 001 9 RTA00001082F. p. 16. 1 M00027364D : E08 537 9/29/98 1494. 001 10 RTA00001082F. g. 22. 1 M00027028B : C12 538 9/29/98 1494.001 11 RTA00001069F.e. 20. 1 M00026857A : F02 539 9/29/98 1494. 001 12 RTA00001082F. c. 05. 3 M00026811A : H01 540 9/29/98 1494.001 13 RTA00001083F.c. 15. 1 M00027529B : B 11 541 9/29/98 1494. 001 14 RTA00001082F. f. 08. 1 M00026964C : H02 542 9/29/98 1494.001 15 RTA00001082F.o.01.1 M00027280D : H01 543 9/29/98 1494. 001 16 RTA00001082F. 1. 05. 1 M00027190B : F06 544 9/29/98 1494.001 17 RTA00001082F.1. 10. 1 M00027196A : A10 545 9/29/98 1494.001 18 RTA00001069F. i. 06. 1 M00026972A : F04 546 9/29/98 1494. 001 19 RTA00001082F. o. 21. 1 M00027339D : E10 547 9/29/98 1494.001 20 RTA00001069F.c.13.1 M00023390A : C04 548 9/29/98 1494. 001 21 RTA00001069F. g. 11. 1 M00026914C : H10 549 9/29/98 1494. 001 22 RTA00001082F. e. 21. 1 M00026945B : C10 550 9/29/98 1494. 001 23 RTA00001083F. a. 18. 1 M00027396C : B06 551 9/29/98 1494. 001 24 RTA00001069F. a. 21. 1 M00023298B : G07 552 9/29/98 1494. 001 25 RTA00001083F. a. 17. 1 M00027393D : FOI 553 9/29/98 1494. 001 26 RTA00001083F. a. 23. 1 M00027439B : A09 554 9/29/98 1494.001 27 RTA00001083F. e. 18. 1 M00027642C : D11 555 9/29/98 1494.001 28 RTA00001083F. e. 04. 1 M00027618A : B08 556 9/29/98 1494. 001 29 RTA00001069Fj. 21. 1 M00027067A : B02 557 9/29/98 1494. 001 30 RTA00001082F. h. 20. 1 M00027069D : F02 558 9/29/98 1494. 001 31 RTA00001069F. o. 03. 1 M00027386D : C02 559 9/29/98 1494. 001 32 RTA00001082F. 1. 04. 1 M00027189C : D04 560 9/29/98 1494. 001 33 RTA00001082F. o. 05. 1 M00027282D : G01 561 9/29/98 1494.001 34 RTA00001069F. a. 11. 1 M00023284B : G06 562 9/29/98 1494. 001 35 RTA00001069F. n. 05. 1 M00027283C : H12 563 9/29/98 1494.001 36 RTA00001069F. a. 22. 1 M00023299B : A01 564 9/29/98 1494. 001 37 RTA00001069F. h. 10. 1 M00026942C : A06 565 9/29/98 1494. 001 38 RTA00001082F. h. 19. 1 M00027067B : E09 566 9/29/98 1494. 001 39 RTA00001082F. b. 05. 1 M00023343B : C08 567 9/29/98 1494.001 40 RTA00001082F.j. 05. 1 M00027131C : E07 568 9/29/98 1494.001 41 RTA00001083F. b. 09. 1 M00027459A : G12 569 9/29/98 1494. 001 42 RTA00001082F. d. 07. M00026871C : F12 570 9/29/98 1494. 001 43 RTA00001083F. c. 03. 1 M00027499B : G02 571 9/29/98 1494.001 44 RTA00001082F.f.01.1 M00026949A : F04 572 9/29/98 1494. 001 45 RTA00001082F. h. 12. 1 M00027053C : B06 573 9/29/98 1494. 001 46 RTA00001082F. a. 03. 1 M00023282B : H09 574 9/29/98 1494.001 47 RTA00001082F.1. 03. 1 M00027188A : D12 575 9/29/98 1494.001 48 RTA00001082F. k. 04. 1 M00027154B : D05 576 9/29/98 1494. 001 49 RTA00001069F. b. 18. 1 M00023340A : A10 577 9/29/98 1494.001 50 RTA00001069F. o. 21. 1 M00027546B : AI1 578 9/29/98 1494. 001 51 RTA00001082F. k. 01. 1 M00027152D : H06 579 9/29/98 1494. 001 52 RTA00001083F. a. l4. 1 M00027388A : G05 580 9/29/98 1494. 001 53 RTA00001069F. k. 0l. 1 M00027085A : G10 581 9/29/98 1494. 001 54 RTA00001069F. h. 09. 1 M00026941C : E11 582 9/29/98 1494.001 55 RTA00001069F.o.11.1 M00027462D : A12 583 9/29/98 1494. 001 56 RTA00001083F. a. 22. 1 M00027438D : A03 584 9/29/98 1494.001 57 RTA00001082F.m. 21. 1 M00027231C : D08 585 9/29/98 1494. 001 58 RTA00001083F.f.18.1 M00027752B : E05 586 9/29/98 1494. 001 59 RTA00001082F. i. 03. 1 M00027083C : F06 587 9/29/98 1494.001 60 RTA00001082F. n. 01. 1 M00027234C : B05 588 9/29/98 1494.001 61 RTA00001082F.1. 02. 1 M00027184D : H02 589 9/29/98 1494. 001 62 RTA00001082F. k. 18. 1 M00027178B : E04 590 9/29/98 1494. 001 63 RTA00001069F. d. 09. 1 M00023413D : F04 591 9/29/98 1494. 001 64 RTA00001069F. p. 05. 1 M00027607A:A09 592 9/29/98 1494. 001 65 RTA00001069F. m. 14. 1 M00027231A : D01 593 9/29/98 1494. 001 66 RTA00001083F. c. 21. 1 M00027557D : B06 594 9/29/98 1494.001 67 RTA00001069F.i. 23. 1 M00027023B : H12 595 9/29/98 1494.001 68 RTA00001082F.1.07.1 M00027193A:F07 596 9/29/98 1494. 001 69 RTA00001082F. c. 15. 3 M00026850B : F07 597 9/29/98 1494. 001 70 RTA00001082F. f. l8. 1 M00026982C : D08 598 9/29/98 1494. 001 71 RTA00001082F. h. 17. 1 M00027062C : C04 599 9/29/98 1494. 001 72 RTA00001082F. p. 14. 1 M00027363D : A08 600 9/29/98 1494.001 73 RTA00001069F.j.04.1 M00027028A : B06 601 9/29/98 1494. 001 74 RTA00001069F. p. 21. 1 M00027740C : C05 602 9/29/98 1494.001 75 RTA00001082F. e. 07. 1 M00026913D : G11 603 9/29/98 1494. 001 76 RTA00001082F. d. 23. 3 M00026905A : G11 604 9/29/98 1494. 001 77 RTA00001083F. b. 18. 1 M00027484A : G03 605 9/29/98 1494. 001 78 RTA00001069F. o. 06. 1 M00027396A : F07 606 9/29/98 1494. 001 79 RTA00001082F. p. 01. 1 M00027343B : H05 607 9/29/98 1494.001 80 RTA00001082F.p.11.1 M00027356A : H02 608 9/29/98 1494. 001 81 RTA00001083F. f. l9. 1 M00027759B : B11 609 9/29/98 1494. 001 82 RTA00001082F. i. 04. 1 M00027083D : F06 610 9/29/98 1494. 001 83 RTA00001082F. pl2. 1 M00027357D : A02 611 9/29/98 1494.001 84 RTA00001082F. d. 15. 3 M00026882A : E07 612 9/29/98 1494. 001 85 RTA00001082F. i. 20. 1 M00027115B : G04 613 9/29/98 1494.001 86 RTA00001069F. d. 03. 1 M00023401C : D12 614 9/29/98 1494.001 87 RTA00001082F. e. 10. 1 M00026928A : B06 615 9/29/98 1494.001 88 RTA00001082F. a. 07. 1 M00023295B : C03 616 9/29/98 1494. 001 89 RTA00001069F. n. 15. 1 M00027329A : H04 617 9/29/98 1494.001 90 RTA00001082F.d.08.3 M00026872A : C10 618 9/29/98 1494. 001 RTA00001083F. f. 13. 1 M00027728A. B03 619 9/29/98 1494. 001 92 RTA00001082F. b. 03. 1 M00023340B:H12 620 9/29/98 1494. 001 93 RTA00001069F. b. 09. 1 M00023321B : F06 621 9/29/98 1494. 001 94 RTA00001082F. 1. 20. 1 M00027202B : B09 622 9/29/98 1494. 001 95 RTA00001083F. c. 14. 1 M00027528A : G03 623 9/29/98 1494.001 96 RTA00001069F.c. 07. 1 M00023369D : C05 624 9/29/98 1494. 001 97 RTA00001083F. d. 16. 1 M00027598C : D06 625 9/29/98 1494. 001 98 RTA00001069F. e. 22. 1 M00026858C : H05 626 9/29/98 1494. 001 99 RTA00001082Fj. 10. 1 M00027137C : A03 627 9/29/98 1494. 001 100 RTA00001069F. b. 01. 1 M0002330IB : COI 628 9/29/98 1494. 001 101 RTA00001069F. J. 20. 1 M00027066A : A04 629 9/29/98 1494. 001 102 RTA00001069F. e. 24. 1 M00026861A : B05 630 9729/98 1494. 001 103 RTA00001069F. b. 08. 1 M00023321A : F07 631 9/29/98 1494. 001 104 RTA00001069F. k. 16. 1 M00027131A : H02 632 9/29/98 1494. 001 105 RTA00001069F.j.22.1 M00027072C : Al 1 633 9/29/98 1494. 001 106 RTA00001069Fj. 07. 1 M00027036B : D07 634 9/29/98 1494. 001 107 RTA00001083F. c. 20. 1 M00027551C : B07 635 9/29/98 1494. 001 108 RTA00001069F. 1. 11. 1 M00027169D : H06 636 9/29/98 1494. 001 109 RTA00001069F. c. 03. 1 M00023363C : A04 637 9/29/98 1494. 001 110 RTA00001069F. 1. 14. 1 M00027175D : A05 638 9/29/98 1494. 001 _ RTA00001083F. c. 10. 1 M00027518B : B07 639 9/29/98 1494. 001 112 RTA00001082F. a. 04. 1 M00023287A : D08 640 9/29/98 1494. 001 113 RTA00001069F. m. 13. 1 M00027225B : D03 641 9/29/98 1494. 001 114 RTA00001082F. n. 08. 1 M00027250A : C04 642 9/29/98 1494.001 115 RTA00001069F. e. 09. 1 M00026819B : E02 643 9/29/98 1494.001 116 RTA00001082F. p. 18. 1 M00027369A : B03 644 9/29/98 1494. 001 117 RTA00001082F. d. 24. M00026906B : G03 645 9/29/98 1494. 001 118 RTA00001069F. c. 23. 1 M00023398D : F10 646 9/29/98 1494. 001 119 RTA00001069F. b. l9. 1 M00023340B : B07 647 9/29/98 1494. 001 120 RTA00001082F. n. 03. 1 M00027237C : D04 648 9/29/98 1494. 001 121 RTA00001069F. a. 13. 1 M00023289D : E06 649 9/29/98 1494.001 122 RTA00001069F. e. 16. 1 M00026846C : B01 650 9/29/98 1494. 001 123 RTA00001069F. p. 04. 1 M00027603C : E02 651 9/29/98 1494. 001 124 RTA00001069F. m. 21. 1 M00027248D : D01 652 9/29/98 1494.001 125 RTA00001082F. h. 14. 1 M00027056B : H07 653 9/29/98 1494.001 126 RTA00001069F.p.03.1 M00027592D : C05 654 9/29/98 1494. 001 127 RTA00001069F. n. 02. 1 M00027266C : G12 655 9/29/98 1494.001 128 RTA00001082F.m.01.1 M00027209D : B09 656 9/29/98 1494. 001 129 RTA00001083F. e. 09. 1 M00027628D : D08 657 9/29/98 1494. 001 130 RTA00001069F. d. 18. 1 M00023432D : F09 658 9/29/98 1494. 001 131 RTA00001069F. e. 06. 1 M00026810A : H04 659 9/29/98 1494.001 132 RTA00001069F. e. 05. 1 M00026809C : D10 660 9/29/98 1494. 001 133 RTA00001083F. c. 05. 1 M00027502C : H02 661 9/29/98 1494. 001 134 RTA00001069F. c. 10. 1 M00023373A : D01 662 9/29/98 1494. 001 135 RTA00001082F. k. 10. 1 M00027164A : A09 663 9/29/98 1494. 001 136 RTA00001083F. c. 07. 1 M00027507C : C06 664 9/29/98 1494. 001 137 RTA00001082Fj. 15. 1 M00027142A : COI 665 10/8/98 1495. 001 RTA00001079Fj. 08. 1 M00022217B : E03 666 10/8/98 1495.001 2 RTA00001081F. h. 04. 1 M00022854D : C04 667 10/8/98 1495. 001 3 RTA00001078F. h. 08. 1 M00021624B : D03 668 10/8/98 1495.001 4 RTA00001079F. b. 12. 1 M00022056C : D12 669 10/8/98 1495.001 5 RTA00001066F.o 03. 1 M00022074A : F05 670 10/8/98 1495.001 6 RTA00001067F. p. 05. 1 M00022640B : G10 671 10/8/98 1495.001 7 RTA00001079F.1. 05. 1 M00022260C : H07 672 10/8/98 1495. 001 8 RTA00001078F. f. 17. 1 M00008083A : H11 673 10/8/98 1495.001 9 RTA00001079F.1. 04. 1 M00022259A : D04 674 10/8/98 1495. 001 10 RTA00001079F. m. l9. 1 M00022368C : C11 675 10/8/98 1495. 001 11 RTA00001081F. f. 08. 1 M00022831C : F11 676 10/8/98 1495.001 12 RTA00001079F. e. 13. 1 M00022113B : A12 677 10/8/98 1495.001 13 RTA00001081F.f.21.1 M00022838B : E05 678 10/8/98 1495.001 14 RTA00001079F. g. 11. 1 M00022152A : G05 679 10/8/98 1495. 001 15 RTA00001067F. i. 05. 1 M00022392C : H06 680 10/8/98 1495. 001 16 RTA00001067F. n. 01. 1 M00022561B : B09 681 10/8/98 1495. 001 17 RTA00001080F. i. 20. 1 M00022569D : H03 682 10/8/98 1495. 001 18 RTA00001081F. p. 04. 1 M00023096A : F03 683 10/8/98 1495.001 19 RTA00001078F. d. 04. 1 M00008023A : B03 684 10/8/98 1495. 001 20 RTA00001080F. h. 09. 1 M00022546B : F12 685 10/8/98 1495. 001 21 RTA00000631F. a. 10. 3 M00022362D : G11 686 10/8/98 1495. 001 22 RTA00001078F. f. 15. 1 M00008082B : H10 687 10/8/98 1495. 001 23 RTA00001078F. a. 11. 1 M0007948D : F08 688 10/8/98 1495. 001 24 RTA00001078F. e. 08. 1 M00008052C : G 11 689 10/8/98 1495.001 25 RTA00001078F.c. 08. 1 M00008012D : E07 690 10/8/98 1495.001 26 RTA00001078F. b. 18. 1 M00008001B : E11 691 10/8/98 1495. 001 27 RTA00001078F. d. 08. 1 M00008023C : A06 692 10/8/98 1495. 001 28 RTA00001080F. p. 19. 1 M00022711B : A05 693 10/8/98 1495. 001 29 RTA00001078F. a. 17. 1 M00007965C : B02 694 10/8/98 1495. 001 30 RTA00001078F. n. 22. 2 M00021958A : A04 695 10/8/98 1495.001 31 RTA00001079F. d. l2. 1 M00022090D : B03 696 10/8/98 1495. 001 32 RTA00001078Fj. 16. 1 M00021696C : E02 697 10/8/98 1495. 001 33 RTA00001080F. n. 06. 1 M00022655A : F09 698 10/8/98 1495. 001 34 RTA00001067F. d. 16. 1 M00022214A : D01 699 10/8/98 1495. 001 35 RTA00001078F. 1. 03. 2 M00021865B : F06 700 10/8/98 1495. 001 36 RTA00001080F. o. 02. 1 M00022684B : F 11 701 10/8/98 1495.001 37 RTA00001067F. p. 15. 1 M00022652B : G06 702 10/8/98 1495. 001 38 RTA00001079F. d. 16. 1 M00022094A : A09 703 10/8/98 1495. 001 39 RTA00001068F. c. 17. 1 M00022826A : C08 704 10/8/98 1495.001 40 RTA00001080F. g. 05. 1 M00022527D : A09 705 10/8/98 1495. 001 41 RTA00001081F. e. 07. 1 M00022813C : B09 706 10/8/98 1495. 001 42 RTA00001066F. g. 16. 1 M00021653C : B06 707 10/8/98 1495.001 43 RTA00001066F.1. 05. 1 M00021972A : C10 708 10/8/98 1495. 001 44 RTA00001066F. h. l6. 1 M00021691B : E04 709 10/8/98 1495.001 45 RTA00001081F. g. 13. 1 M00022844C : A01 710 10/8/98 1495.001 46 RTA00001067F. p. 07. 1 M00022641C : H03 711 10/8/98 1495. 001 47 RTA00001080F. g. 02. 1 M00022525C : E09 712 10/8/98 1495. 001 48 RTA00001080F. i. 02. 1 M00022559D : F10 713 10/8/98 1495. 001 49 RTA00001080F. g. 22. 1 M00022541D : G06 714 10/8/98 1495. 001 50 RTA00001067F. d. 20. 1 M00022216C : H02 715 10/8/98 1495. 001 51 RTA00001079F. k. 17. 1 M00022252A : C01 716 10/8/98 1495. 001 52 RTA00001068F. d. 04. 1 M00022838A H05 717 10/8/98 1495.001 53 RTA00001079F. n. 11. 1 M00022377A : E02 718 10/8/98 1495. 001 54 RTA00001066F. d. 22. 1 M00008053D : E09 719 10/8/98 1495. 001 55 RTA00001068F. f. 08. 1 M00023002A : C02 720 10/8/98 1495. 001 56 RTA00001081F. o. 16. 1 M00023038D : D04 721 10/8/98 1495.001 57 RTA00001080F.f. 18. 1 M00022518C : C04 722 10/8/98 1495. 001 58 RTA00001080F. a. 16. 1 M00022434D : B06 723 10/8/98 1495.001 59 RTA00001080F.j.18.1 M00022590D : E08 724 10/8/98 1495. 001 60 RTA00001080F. n. 1l. l M00022659B : COI 725 10/8/98 1495.001 61 RTA00001078F, e. 01. 1 M0008048C : A08 726 10/8/98 1495. 001 62 RTA00001078F. b. 07. 1 M00007992A : G04 727 10/8/98 1495. 001 63 RTA00001078F. b. 0l. 1 M00007985C : G07 728 10/8/98 1495.001 64 RTA00001080F. n. 14. 1 M00022664A : E04 729 10/8/98 1495. 001 65 RTA00001078F. o. 21. 2 M00021980A : F03 730 10/8/98 1495. 001 66 RTA00001078F. c. 06. 1 M00008012B : C05 731 10/8/98 1495. 001 67 RTA00001080F. o. 15. 1 M00022695D : B02 732 10/8/98 1495. 001 68 RTA00001080F. o. 16. 1 M00022696A : H03 733 10/8/98 1495. 001 69 RTA00001081F. a. 07. 2M00022720A : COI 734 10/8/98 1495.001 70 RTA00001078F. f. 22. 1 M00008089C:B08 735 10/8/98 1495.001 71 RTA00001078F.g.02.1 M0008093C:G08 736 10/8/98 1495.001 72 RTA00001078F.j.13.2 M00021689A:G05 737 10/8/98 1495. 001 73 RTA00001078F. 1. 02. 2 M00021864C : C07 738 10/8/98 1495. 001 74 RTA00001078F. i. 14. 2 M00021667C : G10 739 10/8/98 1495. 001 75 RTA00001079F. d. 04. 1 M00022087A : D01 740 10/8/98 1495. 001 76 RTA00001079F. I. 09. 1 M00022263A : COI 741 10/8/98 1495. 001 77 RTA00001067F. o. 19. 1 M00022627B : D01 742 10/8/98 1495. 001 78 RTA00001068F. b. 0I. 1 M00022714B : D04 743 10/8/98 1495.001 79 RTA00001079F. f. 07. 1 M00022128A : C05 744 10/8/98 1495. 001 80 RTA00001068F. a. 03. 1 M00022669D : G07 745 10/8/98 1495. 001 81 RTA00001066F. f. 03. 1 M00008088D : B01 746 10/8/98 1495. 001 82 RTA00001067F. o. 18. 1 M00022627A : A02 747 10/8/98 1495. 001 83 RTA00001079F. k. 12. 1 M00022249C : G09 748 10/8/98 1495. 001 84 RTA00001081F. g. 07. 1 M00022843A : D02 749 10/8/98 1495.001 85 RTA00001079F.j.01.1 M00022214A : H05 750 10/8/98 1495. 001 86 RTA00001067F. p. 10. 1 M00022648D : G11 751 10/8/98 1495. 001 87 RTA0000108IF. f. 16. 1 M00022836C : A07 752 10/8/98 1495. 001 88 RTA00001080F. i. 05. 1 M00022561D : E06 753 10/8/98 1495.001 89 RTA00001067F.1. 02. 1 M00022490B : G12 754 10/8/98 1495. 001 90 RTA00001068F. a. 23. 1 M00022709A : G02 755 10/8/98 1495. 001 91 RTA00001067F. d. 18. 1 M00022214C : E09 756 10/8/98 1495. 001 92 RTA00001066F. o. 05. 1 M00022077D : A12 757 10/8/98 1495. 001 93 RTA00001066F. m. 08. 1 M00022015D : C11 758 10/8/98 1495.001 94 RTA00001066F. b. 12. 1 M00007978B : C04 759 10/8/98 1495. 001 95 RTA00001066F. c. 08. 1 M00008002B : F09 760 10/8/98 1495. 001 96 RTA00001081F. p. 05. 1 M00023096C : A03 761 10/8/98 1495.001 97 RTA00001081F.c.01.1 M00022746D : D05 762 10/8/98 1495. 001 98 RTA00001079F. m. 23. 1 M00022370A : G07 763 10/8/98 1495.001 99 RTA00001079F.m.09.1 M00022300A:A05 764 10/8/98 1495. 001 100 RTA00001081F. c. 21. 1 M00022785C : B10 765 10/8/98 1495. 001 101 RTA00001079F. o. 04. 1 M00022383C : F05 766 10/8/98 1495. 001 102 RTA00001080F.b.10.1 M000224491D : B05 767 10/8/98 1495.001 103 RTA00001078F.c.09.1 M0008012D : H04 768 10/8/98 1495. 001 104 RTA00001078F. d. 19. 1 M00008044C : A05 769 10/8/98 1495. 001 105 RTA00001081F. a. 11. 2 M00022722D : C07 770 10/8/98 1495. 001 106 RTA00001080F. n. 15. 1 M00022664C : G10 771 10/8/98 1495. 001 107 RTA00001078F. a. 09. 1 M00007941D : D07 772 10/8/98 1495.001 108 RTA00001078F. g. 20. 1 M00021614A : C09 773 10/8/98 1495.001 109 RTA00001066F. h. 23. 1 M00021841A : E11 774 10/8/98 1495. 001 110 RTA00001081F.1. 11. 2 M00022922D : G06 775 10/8/98 1495. 001 111 RTA00001079F. d. 18. 1 M00022096B : D10 776 10/8/98 1495. 001 112 RTA00001066F.f.21.1 M0008100D : C08 777 10/8/98 1495. 001 113 RTÅ00001078Fj. 06. 1 M00021680D : H08 778 10/8/98 1495. 001 114 RTA00001067F. d. 08. 1 M00022205A : C02 779 10/8/98 1495.001 115 RTA00001068F. b. 05. 1 M00022717C : F05 780 10/8/98 1495. 001 116 RTA00001079F. c. 05. 1 M00022071D : C08 781 10/8/98 1495. 001 117 RTA00001078F. k. 10. 2 M00021852C : D12 782 10/8/98 1495. 001 118 RTA00001081F. i. 18. 2 M00022884D : A07 783 10/8/98 1495. 001 119 RTA00001066F. b. 21. 1 M00007996C : B 11 784 10/8/98 1495. 001 120 RTA00001066F. i. 08. 1 M00021851D : H06 785 10/8/98 1495. 001 121 RTA00001068F. e. 08. 1 M00022915C : C09 786 10/8/98 1495. 001 122 RTA00001079Fj. 15. 1 M00022220B : B06 787 10/8/98 1495. 001 123 RTA00001078Fj. 18. 2 M00021698A : H03 788 10/8/98 1495. 001 124 RTA00001066F. b. 09. 1 M0007977B : C 11 789 10/8/98 1495. 001 125 RTA00001079F. i. 20. 1 M00022207C : COI 790 10/8/98 1495.001 126 RTA00001080F. e. 15. 1 M00022506D : B03 791 10/8/98 1495. 001 127 RTA00001080F. 1. 03. 1 M00022617B : A01 792 10/8/98 1495. 001 128 RTA00001080F. e. 10. 1 M00022501D : A09 793 10/8/98 1495. 001 129 RTA00001067F. c. 22. 1 M00022184D : F07 794 10/8/98 1495. 001 130 RTA00001081 F. p. 11. 1 M00023097A : C03 795 10/8/98 1495.001 131 RTA00001081F.p.08.1 M00023096D : B 11 796 10/8/98 1495.001 132 RTA00001080F.c. 19. 1 M00022471 D : A05 797 10/8/98 1495. 001 133 RTA00001081F. b. 06. 1 M00022736B : B03 798 10/8/98 1495. 001 134 RTA00001081F. m. 22. 1 M00022983A : H04 799 10/8/98 1495. 001 135 RTA00001081F. d. 11. 1 M00022801A : G04 800 10/8/98 1495. 001 136 RTA00001081F. n. 13. 1 M00023002D : CI2 801 10/8/98 1495. 001 137 RTA00001067F. d. 17. 1 M00022214C : C11 802 10/8/98 1495. 001 138 RTA00001081F. c. 13. 1 M00022772A : A06 803 10/8/98 1495. 001 139 RTA00001078F. b. l9. 1 M00008001D : F11 804 10/8/98 1495. 001 140 RTA00001078F. a. 04. 1 M00007931A : B07 805 10/8/98 1495.001 141 RTA00001078F. b. 16. 1 M00008000D : G11 806 10/8/98 1495. 001 142 RTA00001078F. b. 04. 1 M00007987A : D10 807 10/8/98 1495. 001 143 RTA00001078F. d. 18. 1 M00008044B : F07 808 10/8/98 1495.001144 RTA00001068F. e. 05. 1 M00022904D : D04 809 10/8/98 1495. 001 145 RTA00001078F. i. 18. 1 M00021674A : B07 810 10/8/98 1495. 001 146 RTA00001066F.e.01.1 M0008054C : C03 811 10/8/98 1495. 001 147 RTA00001078F. n. 14. 2 M00021949D : A05 812 10/8/98 1495. 001 148 RTA00001067F. i. 17. 1 M00022413B : D07 813 10/8/98 1495. 001 149 RTA00001079F.1.19.1 M00022278C : E04 814 10/8/98 1495. 001 150 RTA00001081F.1.12.2 M00022923A : A09 815 10/8/98 1495. 001 151 RTA00001067F.j.03.1 M00022420B : C08 816 10/8/98 1495. 001 152 RTA00001068F. d. 19. 1 M00022898C : H07 817 10/8/98 1495. 001 153 RTA00001081F. g. 23. 1 M00022853D : C05 81 10/8/98 1495.001 154 RTA00001081F.h. 16. 1 M00022860A : A07 819 10/8/98 1495. 001 155 RTA00001079F. i. 05. 1 M00022192B : H07 820 10/8/98 1495. 001 156 RTA00001068F. f. 12. 1 M00023012A : C06 821 10/8/98 1495. 001 157 RTA00001067F. e. 09. 1 M00022235D : F07 822 10/8/98 1495. 001 158 RTA00001066F. m. 10. 1 M00022018B : E09 823 10/8/98 1495. 001 159 RTA00001080Fj. 19. 1 M00022591C : F03 824 10/8/98 1495. 001 160 RTA00001080F. f. 07. 1 M00022513C : G04 825 10/8/98 1495. 001 161 RTA00001080F. e. 09. 1 M00022500B : D01 826 10/8/98 1495. 001 162 RTA00001080F. e. 19. 1 M00022509D : AI2 827 10/8/98 1495. 001 163 RTA00001066F. a. 13. 1 M00007948B : B07 828 10/8/98 1495. 001 164 RTA00001079F. p. 14. 1 M00022407D : G07 829 10/8/98 1495. 001 165 RTA00001079F. p. 03. 1 M00022399C : B02 830 10/8/98 1495. 001 166 RTA00001079F. n. 22. 1 M00022381B : C12 831 10/8/98 1495. 001 167 RTA00001078F. a. 06. 1 M00007937C : E08 832 10/8/98 1495. 001 168 RTA00001078F. a. 19. 1 M00007973D : B03 833 10/8/98 1495.001 169 RTA00001078F. b. 15. 1 M00008000D : B06 834 10/8/98 1495.001 170 RTA00001079F.c. 15. 1 M00022078B : B04 835 10/8/98 1495. 001 171 RTA00001079F. d. 06. 1 M00022088B : E05 836 10/8/98 1495. 001 172 RTA00001067F. a. 05. 1 M00022118A : D08 837 10/8/98 1495. 001 173 RTA00001078F. i. 15. 2 M00021668D : G09 838 10/8/98 1495. 001 174 RTA00001066F. a. ll. l M00007947B : F07 839 10/8/98 1495. 001 175 RTA00001078F. k. 02. 2 M00021846B : F05 840 10/8/98 1495. 001 176 RTA00001066F. h. 04. 1 M00021669B : G02 841 10/8/98 1495. 001 177 RTA00001066F. c. 21. 1 M00008015B : D08 842 10/8/98 1495. 001 178 RTA00001080F. h. 06. 1 M00022544C : D08 843 10/8/98 1495. 001 179 RTA00001067F. c. 16. 1 M00022177D : G02 844 10/8/98 1495.001 180 RTA00001080F. f. 21. 1 M00022522B : A05 845 10/8/98 1495. 001 181 RTA00001080F.a.10.1 M00022425A : F11 846 10/8/98 1495. 001 182 RTA00001081F. o. 10. 1 M00023034B : B10 847 10/8/98 1495. 001 183 RTA00001078F. b. 17. 1 M0008001A : G11 848 10/8/98 1495. 001 184 RTA00001078F. g. 04. 1 M00008094D : C02 849 10/8/98 1495. 001 185 RTA00001080F. p. 05. 1 M00022704A : H08 850 10/8/98 1495. 001 186 RTA00001067F.f.04.1 M00022256D : G11 851 10/8/98 1495. 001 187 RTA00001066F. c. 11. 1 M00008003B : F09 852 10/8/98 1495. 001 188 RTA00001081F. b. 19. 1 M00022743C : G05 853 10/8/98 1495. 001 189 RTA00001081F. p. 14. 1 M00023097C : D10 854 10/8/98 1495. 001 190 RTA00001067F. k. l6. 1 M00022467C : H07 855 10/8/98 1495. 001 191 RTA00001081F. b. 11. 1 M00022737D:B02 856 10/8/98 1495. 001 192 RTA00001080F. k. 12. 1 M00022601A : A09 857 10/8/98 1495. 001 193 RTA00001066F. a. 08. 1 M00007943C : B02 858 10/8/98 1495. 001 194 RTA00001081F. b. 10. 1 M00022737B : F12 859 10/8/98 1495. 001 195 RTA00001080F. d. 15. 1 M00022488C : H02 860 10/8/98 1495. 001 196 RTA00001079F. p. 04. 1 M00022399D:A07 861 10/8/98 1495.001 197 RTA00001067F. e. 23. 1 M00022251A:F07 862 10/8/98 1495.001 198 RTA00001068F. a. 08. 1 M00022684C : C 12 863 10/8/98 1495. 001 199 RTA00001078F. h. 16. 1 M00021628C : B09 864 10/8/98 1495. 001 200 RTA00001081F. g. 18. 1 M00022848D : H09 865 10/8/98 1495.001 201 RTA00001081F.m.15.1 M00022968D : G06 866 10/8/98 1495.001 202 RTA00001067F. k. 09. 1 M00022459C : G05 867 10/8/98 1495. 001 203 RTA00001080F. g. 04. 1 M00022527B : H05 868 10/8/98 1495. 001 204 RTA00001081F.j. 19. 2M00022902C : F1I 869 10/8/98 1495. 001 205 RTA00001081F. o. 03. 1 M00023023B : A05 870 10/8/98 1495.001 206 RTA00001079F. b. 23. 1 M00022067A:B03 871 10/8/98 1495. 001 207 RTA00001078F. n. 16. 2 M00021951B : A01 872 10/8/98 1495.001 208 RTA00001067F. b. 01.1 M00022134D:D12 873 10/8/98 1495.001 209 RTA00001080F.a.17.1 M00022435C : C05 874 10/8/98 1495.001 210 RTA00001080F.c.17.1 M00022469A:A05 875 10/8/98 1495. 001 211 RTA00001068F. f. 10. 1 M00023003C : C10 876 10/8/98 1495.001 212 RTA00001081F..18. M00022861C : B04 877 10/8/98 1495.001 213 RTA00001066F.p.19.1 M00022106D : B06 878 10/8/98 1495.001 214 RTA00001080F. 001 09. tM00022464D c. F12 879 10/8/98 1495. 001 215 RTA00001078F. c. 12. 1 M00008014C : H01 880 10/8/98 1495. 001 216 RTA00001080F. I. 10. 1 M00022622A : E08 881 10/8/98 1495. 001 217 RTA00001078F. g. 11. 1 M00008099A : C12 882 10/8/98 1495. 001 218 RTA00001068F. f. 09. 1 M00023003A : H01 883 10/8/98 1495.001 219 RTA00001067F. f. 10. 1 M00022261C : D06 884 10/8/98 1495.001 220 RTA00001080F.o. 05. 1 M00022687C : C11 885 10/8/98 1495. 001 221 RTA00001078F.h.04.1 M00021620D : B06 886 10/8/98 1495.001 22 RTA00001078F. p. 03. 2 M00021981D : A11 887 10/8/98 1495. 001 223 RTA00001080F. e. 20. 1 M00022510A : B09 888 10/8/98 1495.001 224 RTA00001078F. k. 19. 2 M00021861C : B08 889 10/8/98 1495.001 225 RTA00001078F. d. 20. 1 M00008045A : B05 890 10/8/98 1495. 001 226 RTA00001078F. b. 22. 1 M0008006A:H02 891 10/8/98 1495. 001 227 RTA00001068F. a. 13. 1 M00022701C : A05 892 10/8/98 1495. 001 228 RTA00001080F. m. 16. 1 M00022641D : F08 893 10/8/98 1495. 001 229 RTA00001080F. o. 22. 1 M00022702A : D10 894 10/8/98 1495.001 230 RTA00001080F. k. 16. 1 M00022604A : F06 895 10/8/98 1495. 001 231 RTA00001067F. d. 04. 1 M00022199A : F09 896 10/8/98 1495. 001 232 RTA00001067F. k. 10. 1 M00022460C : E12 897 10/8/98 1495. 001 233 RTA00001078F. n. 04. 2 M00021931B : F04 898 10/8/98 1495. 001 234 RTA00001078F. n. 07. 2 M00021945A : B04 899 10/8/98 1495. 001 235 RTA00001081F. a. 16. 1 M00022725D : G05 900 10/8/98 1495. 001 236 RTA00001078F. 1. 13. 2 M00021879B : C11 901 10/8/98 1495. 001 237 RTA00001078F. f. 13. 1 M00008082B : C05 902 10/8/98 1495. 001 238 RTA00001079F. d. 05. 1 M00022087D : F12 903 10/8/98 1495. 001 239 RTA00001067F. i. 13. 1 M00022406C : G03 904 10/8/98 1495. 001 240 RTA00001068F. d. 23. 1 M00022902B : F10 905 10/8/98 1495. 001 241 RTA00001078F. c. 13. 1 M00008014D : A 11 906 10/8/98 1495. 001 242 RTA00001078F. a. 18. 1 M00007969B : E10 907 10/8/98 1495. 001 243 RTA00001068F. b. 23. 1 M00022765B:E03 908 10/8/98 1495. 001 244 RTA00001078F. f. 21. 1 M00008085B : G01 909 10/8/98 1495. 001 245 RTA00001067F. b. 15. 1 M00022144D : D09 910 10/8/98 1495. 001 246 RTA00001078F. o. 04. 2 M00021963C : H04 911 10/8/98 1495. 001 247 RTA00001081 F. e. 14. 1 M00022817D : B09 912 10/8/98 1495. 001 248 RTA00001078F. k. 04. 2 M00021847B : A09 913 10/8/98 1495. 001 249 RTA00001079F. g. 15. 2 M00022158C : C08 914 10/8/98 1495. 001 250 RTA00001067F. k. 23. 1 M00022477C : C07 915 10/8/98 1495. 001 251 RTA00001079F. h. 08. 2 M00022176A:F02 916 10/8/98 1495. 001 252 RTA00001078F. d. l7. 1 M00008028D : BOI 917 10/8/98 1495. 001 253 RTA00001067F. d. 07. 1 M00022203B : A05 918 10/8/98 1495. 001 254 RTA00001068F. e. 04. 1 M00022903D : H02 919 10/8/98 1495. 001 255 RTA00001068F. a. 06. 1 M00022682A : F10 920 10/8/98 1495.001 256 RTA00001078F.e.10.1 M0008054C : E07 921 10/8/98 1495.001 257 RTA00001079F. b. 11. 1 M00022056B : G12 922 10/8/98 1495. 001 258 RTA00001066F. h. 1l. l M00021676B : B12 923 10/8/98 1495.001 259 RTA00001079F.d.01.1 M00022084B : C03 924 10/8/98 1495.001 260 RTA00001067F. g. 14. 1 M00022363C : D03 925 10/8/98 1495. 001 261 RTA00001066F. g. 06. 1 M00021625B : G07 926 10/8/98 1495. 001 262 RTA00001081F.j. 09. 2 M00022893D : C06 927 10/8/98 1495.001 263 RTA00001068F.e.19.1 M00022963A : E07 928 10/8/98 1495. 001 264 RTA00001079F. 1. 21. 1 M00022282A : A11 929 10/8/98 1495. 001 265 RTA00001078F. h. 09. 1 M00021624B : E11 930 10/8/98 1495.001 266 RTA00001078F. d. 16. 1 M00008027D : H09 931 10/8/98 1495.001 267 RTA00001079F.g.22.2 M00022167B : H02 932 10/8/98 1495.001 268 RTA00001066F. e. 15. 1 M00008075D : B01 933 10/8/98 1495.001 269 RTA00001080F. g. 16. 1 M00022538D : B02 934 10/8/98 1495.001 270 RTA00001080F. b. 07. 1 M00022447A : H06 935 10/8/98 1495. 001 271 RTA00001078F. n. 21. 2 M00021958A : A03 936 10/8/98 1495. 001 272 RTA00001078F. b. l2. 1 M0007998C : B04 937 10/8/98 1495. 001 273 RTA00001066F. p. 01. 2 M00022099C : A10 938 10/8/98 1495. 001 274 RTA00001066F. o. 22. 1 M00022095C : F03 939 10/8/98 1495.001 275 RTA00001080F. i. 19. 1 M00022568B : D03 940 10/8/98 1495. 001 276 RTA00001079F. g. 01. 1 M00022138C : B07 941 10/8/98 1495. 001 277 RTA00001079F. e. 02. 1 M00022102D : A10 942 10/8/98 1495. 001 278 RTA00001079F. k. 01. 1 M00022233C : D11 943 10/8/98 1495. 001 279 RTA00001079F. o. 11. 1 M00022386D : C04 944 10/8/98 1495. 001 280 RTA00001068F. d. 02. 1 M00022834A : H02 945 10/8/98 1495. 001 281 RTA00001078F. a. 07. 1 M00007939A : F06 946 10/8/98 1495. 001 282 RTA00001081F. b. 20. 1 M00022743C : G06 947 10/8/98 1495. 001 283 RTA00001067F. f. 20. 1 M00022273A : B03 948 10/8/98 1495. 001 284 RTA00001079F. c. 06. 1 M00022072D : E12 949 10/8/98 1495. 001 285 RTA00001068F. b. 24. 1 M00022768A : A10 950 10/8/98 1495. 001 286 RTA00001080F. o. 08. 1 M00022691A : G01 951 10/8/98 1495. 001 287 RTA00001078F j. 10. 2 M00021687C : A04 952 10/8/98 1495. 001 288 RTA00001080F. b. 03. 1 M00022444B : C04 953 10/8/98 1495. 001 289 RTA00001067F. e. 13. 1 M00022240C : B03 954 10/8/98 1495. 001 290 RTA00001081F. h. 05. 1 M00022856A : B09 955 10/8/98 1495. 001 291 RTA00001067F. f. OI. 1 M00022252C : A04 956 10/8/98 1495. 001 292 RTA00001080F. g. 23. 1 M00022542A : B06 957 10/8/98 1495. 001 293 RTA00001080F. h. 16. 1 M00022548A : F02 958 10/8/98 1495. 001 294 RTA00001080F. f. 15. 1 M00022517C : BOI 959 10/8/98 1495. 001 295 RTA00001080F. f. 06. 1 M00022513C : E10 960 10/8/98 1495. 001 296 RTA00001081F. a. 04. 2 M00022716A : COI 961 10/8/98 1495. 001 297 RTA00001078F. p. 16. 2 M00022001B : H10 962 10/8/98 1495.001 298 RTA00001081F. b. 03. 1 M00022734C : A03 963 10/8/98 1495.001 299 RTA00001080F. a. 21. 1 M00022441B : A06 964 10/8/98 1495. 001 300 RTA00001079F. f. 05. 1 M00022127C : EOI 965 10/8/98 1495. 001 301 RTA00001080F. n. 23. 1 M00022681D : H10 966 10/8/98 1495. 001 302 RTA00001078F. c. 18. 1 M00008016C : E06 967 10/8/98 1495. 001 303 RTA00001068F. a. 11. 1 M00022697A:C08 968 10/8/98 1495. 001 304 RTA00001068F. g. 09. 1 M00023095C : A09 969 10/8/98 1495. 001 305 RTA00001068F. a. 22. 1 M00022709A : COI 970 10/8/98 1495. 001 306 RTA00001079F. h. 09. 2 M00022176D : F05 971 10/8/98 1495. 001 307 RTA00001079F. h. 01. 2 M00022169A : E11 972 10/8/98 1495. 001 308 RTA00001078F. g. 07. 1 M00008097C : E04 973 10/8/98 1495. 001 309 RTA00001078F. m. 08. 2 M00021908B : F03 974 10/8/98 1495. 001 310 RTA00001080F. a. 03. 1 M00022417B : COI 975 10/8/98 1495. 001 311 RTA00001079F. o. 06. 1 M00022384B : E06 976 10/8/98 1495. 001 312 RTA00001079F. p. 06. 1 M00022401C : G07 977 10/8/98 1495.001 313 RTA00001078F. p. 18. 2 M00022001D : E06 978 10/8/98 1495. 001 314 RTA00001068F. a. 17. 1 M00022705B : F08 979 10/8/98 1495. 001 315 RTA00001078F. a. 10. 1 M0007948C:G01 980 10/8/98 1495. 001 316 RTA00001079F. h. 20. 2 M00022184D : H07 981 10/8/98 1495. 001 317 RTA00001081F. n. 03. 1 M00022986B : C02 982 10/8/98 1495. 001 318 RTA00001080F. c. 04. 1 M00022460D : C07 Table 1B SEQ ID NO : Sample Nme Clone ID 983 270. F5. sp6 : 145120 M0001401B:A02 984 344. C4. sp6 : 146251 M00023363C:A04 985 628. D9. sp6 : 157832 M00008028D : B01 986 628. F7. sp6 : 157854 M00008023C : A06 987 636.G12. sp6 : 158255 M00022077D : A12 988 653. F3. sp6 : 159004 M00023284B : G06 989 654. H6. sp6 : 159223 M00023369D : C05 990 655. B2. sp6 : 156468 M00023413D : F04 991 656.B11. sp6 : 159348 M00026905A : G11 992 661.C10. sp6 : 159743 M00027169D : H06 993 953.B04. sp6 : 185140 M00005434D : H02 994 270. F5. sp6 : 145120 M0001401B : A02 995 344. C4. sp6 : 146251 M00023363C : A04 996 655. B2. sp6 : 156468 M00023413D : F04 Table 1C SEQ ID NO : Sequence Name THC Accession No. | 997 RTA00001071F. i. 23. AA173046 998 RTA00001079F.m.19.1 THC220786 999 RTA00001067F. i. 05. 1 THC233199 1000 RTA00001082F. o. 01. 1 THC 178783 1001 RTA00001067F. n. 01. 1 AA173079 1002 RTA00001076F. b. 13. 1 AA554659 1003 RTA00001064F.p. 03. 1 AA432284 1004 RTA00001072F. g. 05. 2 H20612 1005 RTA00001064F. c. 01. 1 EST55879 1006 RTA00001083F. b. 09. 1 W30744 1007 RTA00001083F. c. 03. 1 THC205070 1008 RTA00001066F.h.16.1 EST14169 1009 RTA00001076F. n. 10. 11 TEC144372 1010 RTA00001061F. e. l7. 1 N48670 1011 RTA00001071F. m. 09. R56510 1012 RTA00001080F. g. 02. 1 THC77700 1013 RTA00001073F. i. 02. 2 Z46186 1014 RTA00001076F j. 14. 1 THC 144372 1015 RTA00001068F. d. 04. 1 AA011604 1016 RTA00001069F. o. 11. 1 AA576259 1017 RTA00001073F. k. 01. 1 R52934 1018 RTA00001080F. f. 18. 1 THC 126698 1019 RTA00001075F. e. 18. 1 THC209874 1020 RTA00001076F. d. 13. 1AA158197 1021 RTA00001065F. f. 06. 1 THC219476 1022 RTA00001068F. b. 01. 1 THC151511 1023 RTA00001068F. a. 03. 1 THC220020 1024 RTA00001072F. b. 09. 2 AA554360 1025 RTA00001076F. i. 09. 1 EST20991 1026 RTA00001073F. 1. 04. 1 AA527712 1027 RTA00001067F. d. 18. 1 THC198501 1028 RTA00001082F. b. 03. 1 THC218291 1029 RTA00001082F.1. 20. 1 THC204015 1030 RTA00001081F. c. 21. 1 THC203534 1031 RTA00001069F. b. 08. 1 THC234347 1032 RTA00001074F. f. 09. 1 N53623 1033 RTA00001066F. h. 23. 1 THC129284 1034 RTA00001064F. h. 07. 1 THC 161794 1035 RTA00001066F. f. 21.1 T92493 1036 RTA00001069F. m. 13. 1 AA148143 1037 RTA00001064F. d. 14. 1 THC138642 1038 RTA00001068F. e. 08. 1 AA633643 1039 RTA00001065F. d. l9. 1 THC227618 1040 RTA00001069F. e. 06. 1 T19066 1041 RTA00001069F. e. 05. 1 T19066 1042 RTA00001082F.j.15.1 THC226714 1043 RTA00001067F. i. 17. 1 EST83778 1044 RTA00001081F.1.12.2 AA121009 1045 RTA00001080F. e. l9. 1 T99190 1046 RTA00001065F. d. 18. 2 H59526 1047 RTA00001078F. a. 06. 1 AA453802 1048 RTA00001065F. a. 21. 1 THC86626 1049 RTA00001075F. a. 02. 1 AA632565 1050 RTA00001066F. c. 21. 1 AA465322 1051 RTA00001080F. h. 06. 1 THC232157 1052 RTA00001067F. b. 01.1 EST79811 1053 RTA00001071F.1.19.1 THC208816 1054 RTA00001062F.f.01.1 THC105335 1055 RTA00001063F. g. 18. 1 THC205088 1056 RTA00001062F. j. 18. 1 THC220715 1057 RTA00001078F. b. 22. 1 THC232576 1058 RTA00001064F. a. 09. 2 THC171312 1059 RTA00001064F. k. 20. 2 THC200994 1060 RTA00001080F. m. 16. 1 EST62430 1061 RTA00001078F. n. 04. 2 THC231131 1062 RTA00001071F. p. 07. 1 AA524115 1063 RTA00001074F. k. 15. 1 AA053768 1064 RTA00001073F. g. 22. 1 THC146930 1065 RTA00001067F. k. 23. 1 THC211481 1066 RTA00001068F. a. 06. 1 THC232664 1067 RTA00001067F. g. 14. 1 THCl10314 1068 RTA00001072F.i.19.3 EST84170 1069 RTA00001079F. g. 22. 2 THC146930 1070 RTA00001061F.. 03. 1 THC195525 1071 RTA00001072F.c. 16. 2 AA159011 1072 RTA00001061F.c. 12. 1THC196151 1073 RTA00001072FJ. 23. 2 N99474 1074 RTA00001080F.f.06.1 R06925 1075 RTA00001080F. a. 21.11 THC173393 1076 RTA00001068F. a. ll. l THC202663 1077 RTA00001078F.g. 07. 1 EST89489 1078 RTA00001078F. m. 08. 2 THC233725 1079 RTA00001068F. a. l7. 1 N86176 Table 2A : Nearest Neighbor (BlastN vs. Genbank) SEQ ID ACC'N DESCRIP. P VALUE Homo sapiens C3H-type zinc finger protein; similar to D. melanogaster muscleblind B protein (MBLL) mRNA NM_005757|>gi|3779239|gb|AF061261|AF061261 Homo sapiens zinc finger 1. 1 protein (MBLL) mRNA, complete cds 7. 00E-99 5 M86697 Peptostreptococcus magnus protein L gene, complete cds. 1. 90E+00 6 AF080255. 1 Homo sapiens lodestar protein mRNA, complete cds I. OOE-37 Caenorhabditis elegans cosmid H40L08, complete sequence 7 Z95310 [Caenorhabditis elegans] 2. 00E+00 9 AF124981. 1 Bombyx mori nuclear receptor GRF (GRF) mRNA, complete cds 1. 90E+00 Xenopus laevis transposon TXr. l l transposase pseudogene, 10 U43663 complete cds 4. 20E+00 Helicobacter pylori, strain J99 section 56 of 132 of the complete 11 AE001495 genome 2. 00E+00 Mus musculus mLhx6. 1a mRNA for LIM-homeodomain (LHX) 12 AB031040. 1 protein 6. 1a, complete cds 1. 00E-79 13 AF132973. 1 Homo sapiens CGI-39 protein mRNA, complete cds 2. OOE-30 14 L81907 Homo sapiens (subclone 1 c 12 from PI H69) DNA sequence 2. 00E+00 Helicobacter pylori, strain J99 section 104 of 132 of the 15 AE001543 complete genome 8. 00E-03 16 L42167 Mus musculus (clone R24) rds gene, partial cds 4. 70E-01 17 U58870 Bos taurus carbonic anhydrase IV mRNA, complete cds 6. 80E-01 Oryza sativa mRNA for cytochrome c oxidase subunit 6b-1, 18 AB025187. 1 complete cds 2. 30E-01 19 AE000723 Aquifex aeolicus section 55 of 109 of the complete genome 6. 80E-01 Mus musculus chloride channel regulator (Icln) gene, exon 2 and 20 U72058 partial cds 6. 80E-01 Aspergillus parasiticus norsolorinic acid reductase (nor) gene, 21 U24698 complete cds 6.50E-01 22 AB014528 Homo sapiens mRNA for KIAA0628 protein, complete cds O. 00E+00 M. morganii DNA for orf3, orf4, orf5, orf6, orf7, orf8, orf9, and 23 X90691 rumA & rumB genes 2. 00E+00 Macaca fascicularis eosinophil cationic protein gene, complete 25 U24098 cds 6. 60E-01 27 U19355 Rattus norvegicus satellite sequence dOMco3. 6. 60E-01 28 U39655 Caenorhabditis elegans cosmid C46F4 1. 90E+00 Rat S-adenosylmethionine decarboxylase (AMDP I) pseudogene, 29 M34463 complete cds. 1. 90E+00 Table 2A : Nearest Neighbor (BlastN vs. Genbank) SEQACC'N ID ACC'N DESCRIP. P VALUE 30 AU028891/Mus musculus mRNA for U8, complete cds 7. 00E-43 D. melanogaster (strain Af-S) alcohol dehydrogenase gene (allele 31 M19547 Adh-S), complete cds. 2. 00E+00 32 AB029001. 1 Homo sapiens mRNA for KIAA1078 protein, partial cds e-158 33 AF063668. 1 Mus musculus type XIII collagen (coll3al) gene, exon 3 2. 10E+00 34 X07356 Chicken nicotinic acetylcholine receptor non-alpha gene exon 5 6. 60E-01 35 U69609 Human transcriptional repressor (GCF2) mRNA, complete cds 1. 80E+00 36 AF041861 Mus musculus synaptojanin 2 isoform zeta mRNA, partial cds 1. 90E+00 37 AB028975. 1 Homo sapiens mRNA for KIAA1052 protein, complete cds 1. 90E+00 Mus musculus rod cGMP phosphodiesterase delta subunit 38 AF046000 (Pde6d) gene, complete cds 5. 50E-01 39 L09705 Human DNA sequence. 6. 10E-01 41 AF052692 Homo sapiens connexin 31 (GJB3) mRNA, complete cds e-132 Caenorhabditis elegans cosmid C27D8, complete sequence 42 Z80214 [Caenorhabditis elegans] 4. 70E-01 Streptococcus canis (group G) albumin-binding protein gene, 43 M95520 partial cds. 2. 30E-01 Plasmodium falciparum chromosome 2, section 29 of 73 of the 44 AE001392 complete sequence 7. 70E-02 Mus musculus epithelial sodium channel gamma subunit mRNA, 45 AF112187 complete cds 2. 10E+00 46 M31616 O. sativa ADPglucose pyrophosphorylase gene complete cds. 2. 30E-01 Human transcription factor junB (junB) gene, 5'region and 47 U20734 complete cds. 2. 30E-01 Anopheles bwambae 12S ribosomal RNA, D-loop, and tRNA-Ile 48 U35782 mitochondrial genes, partial sequence. 2. 30E-01 49 AF138280. 1 Gallus gallus chondromodulin-I mRNA, complete cds 3. OOE-03 Plasmodium falciparum chromosome 2, section 29 of 73 of the 50 AE001392 complete sequence 7. 60E-02 52 D45385 Pokeweed mRNA for polyphenol oxidase, complete cds 2. 20E-01 53 J04804 C. elegans vinculin (deb-1) gene, complete cds. 2. 20E-01 54 M34431 Human PVT-IGLC fusion protein mRNA, 5'end. 6. 70E-01 Bacillus subtilis ORF1, 3'end ; wall-associated protein (walA) 55 L05634 gene, complete cds ; complete ORF3. 6. 50E-01 Table 2A : Nearest Neighbor (BlastN vs. Genbank) SEQ ID ACC'N DESCRIP. P VALUE 56 X82430 E. coli transposable element IS1294 2. 20E-01 57 AJ224356 Solanum lycopersicon tDETI gene 6. 70E-01 Human tyrosine kinase (TXK) gene, exon 8, partial cds. >gil1161352lgblU34371lHSTECTXT05 Human tyrosine kinase 58 U07792 TXK (txk) gene, exon 5. 6. 60E-01 Bos taurus mRNA for platelet-activating factor acetylhydrolase 59 D87559 2, complete cds 2. 20E-01 Borrelia burgdorferi 2. 9-7 locus, ORF-A-D, REV, and 60 U45427 lipoprotein (LPA and LPB) genes, complete cds 6. 60E-01 61 AB018343. 1 Homo sapiens mRNA for KIAA0800 protein, complete cds e-177 62 X92186 M. musculus llbeta-hydroxysteroiddehydrogenasetype 1 gene 0. 66 63 U51899 Human kappa-casein gene, complete cds 0. 65 cathepsin B {5'region} [human, Genomic, 886 nt, segment 1 of 64 S62069 2] 0. 22 Bovine ASS mRNA encoding argininosuccinate synthetase, 65 M26198 complete cds. 0. 22 Chlamydia pneumoniae section 44 of 103 of the complete 66 AE001628 genome 2. 20E-01 Rana catesbeiana myosin heavy chain (MHC-3) mRNA, partial 67 AF097906 cds 6. 40E-01 Archaeoglobus fulgidus section 84 of 172 of the complete 68 AE001023 genome 2. 30E-01 Trypanoplasma borelli mitochondrion cytochrome oxidase subunit 1 (coxl), cytochrome oxidase subunit 2 and complete 9S 69 U11682 rRNA gene and partial 12S rRNA gene. 6. 40E-01 70 J03267 Rat atrial natriuretic factor (ANF) gene, 5'end. 6. 40E-01 Human DNA sequence from clone 898I4 on chromosome 22q13.33. Contains a GSS and a putative CpG island, complete 71 AL034546. 5 sequence [Homo sapiens] 6. 20E-01 72 U78730 Homo sapiens mad protein homolog Smad2 gene, exon 7 1. 90E-01 73 D87686. 1 Homo sapiens mRNA for KIAA0017 protein, complete cds e-175 74 AF085361. 1 Homo sapiens HSPC032 mRNA, complete cds 2. OOE-55 75 AF168786. 1 Sorghum bicolor soluble starch synthase mRNA, partial cds 2. 50E-02 Caenorhabditis elegans cosmid B0331, complete sequence 76 Z99102 [Caenorhabditis elegans] 7. 40E-02 77 AE001247 Treponema pallidum section 63 of 87 of the complete genome 2. 30E-01 Table 2A : Nearest Neighbor (BlastN vs. Genbank) SEQ ID ACC'N DESCRIP. P VALUE Human transcription factor junB (junB) gene, 5'region and 78 U20734 complete cds. 5. 00E-08 79 X92112 G. gallus mRNA for guanylate-binding protein 7. 50E-02 80 AF043692 Caenorhabditis elegans cosmid C17F3 2. 00E+00 Pisum sativum PsCHS4 gene for chalcone synthase, complete 81 D88260 cds 6. 70E-01 82 D87433 Human mRNA for KIAA0246 gene, partial cds 2. 30E-01 83 X70301 S. lemnae internal telomeric sequence maa81 2. 30E-01 84 AB018249 Homo sapiens gene for CC chemokine LEC, complete cds 7. 50E-02 85 D32072 Mouse mRNA for an isoform of TGF-b type II receptor 7. 40E-02 86 AB018317. 1 Homo sapiens mRNA for KIAA0774 protein. partial cds 1. 90E+00 87 Z46372 R. norvegicus RNA for DNA topoisomerase II 7. 20E-02 NM_003958 Homo sapiens C3HC4-type zinc finger protein sapiens mRNA 88. 1 for KIAA0646 protein, complete cds 6. 50E-01 Eschscholzia californica berberine bridge enzyme (bbel) gene, 89 AF005655 complete cds 7. 70E-02 90 AF042192 Xenopus laevis paraxial protocadherin mRNA. complete cds 6. 20E-01 91 Y12002 N. crassa DNA for protein kinase C homologue 2. 20E-01 HIV-I isolate DW. s. 0 from Switzerland pol protein (pol) gene, 92 AF077697 partial cds 2. OOE-01 93 L31848 Homo sapiens serine/threonine kinase receptor 2 6. 00E-I ! Rattus norvegicus UDP-glucose : ceramide glycosyltransferase 94 AF047707 mRNA, complete cds 6. 00E-01 95 X92112 G. gallus mRNA for guanylate-binding protein 7. 10E-02 96 X82333 H. sapiens IRLB gene (exonl-3) 5. 30E-02 97 AJ228139. 2 Homo sapiens mRNA for LETKI precursor 2. OOE-97 98 M13075 Human albumin gene, exon 1 and 5'flank. 1. 40E+00 99 AF025430 Papaver somniferum berberine bridge enzyme 2. 90E-01 100 X92346 M. musculus mRNA for CART1 protein 1. 70E-02 Plasmodium falciparum chromosome 2, section 4 of 73 of the 102 AE001367 complete sequence 2. 50E-02 103 AB014524 Homo sapiens mRNA for KIAA0624 protein, partial cds O. OOE+00 104 AB007546 Homo sapiens gene for LECT2, complete cds 2. 20E-01 Buchnera aphidicola succinyl-diaminopimelate aminotransferase (dapD) gene, partial cds ; periplasmic serine protease (htrA), hypothetical protein, acetohydroxy acid synthase large subunit 105 AF060492 (ilvl), acetohydroxy acid synthas... 7. 50E-02 106 D16360 Human DNA for plasma glutathione peroxidase, exon 1 2. 50E-02 Table 2A : Nearest Neighbor (BlastN vs. Genbank) SEQ ID ACC'N DESCRIP. P VALUE Wolbachia sp. DNA for GroES protein homolog, GroEL protein 107 AB002287 homolog, partial cds 6. 60E-01 108 X16349 Human gene for sex hormone-binding globulin (SHBG) 2. 40E-02 Plasmodium falciparum DNA *** SEQUENCING IN 109 Z97349 PROGRESS *** from contig 3-06 complete sequence 6. 50E-01 110 L06898 Actinomyces viscosus sialidase (nanH) gene, complete cds. 2. 20E-01 Rhesus monkey psi-eta-globin gene intergenic region, with Alu 111 J03818 repeats. 2. 1 OE-01 Vibrio parahaemolyticus ClpX-like protein (clpX) gene, partial 112 U66708 cds, and ton protease (lonS) gene, complete cds 1. 90E+00 113 AF078164. 2 Homo sapiens Ku70-binding protein (KUB3) mRNA, partial cds e-174 Drosophila melanogaster mRNA for Dof protein, transcript I, 114 AJ010642 partial 1. 90E+00 Diadasia martialis cytochrome oxidase I (COl) gene, 115 AF039096 mitochondrial gene encoding mitochondrial protein, partial cds 8. 10E-01 Bacteriophage BK5-T ORF'410, 3'end pf cds, 20 ORFs, repressor protein, and Cro repressor protein genes, complete cds, 116 L44593 ORF70'gene, 5'end of cds. 2. 30E-01 Drosophila virilis cecropin I (Cec 1), cecropin 2 complete cds 117 U71249 and cecropin, pseudogene, exon 1 0. 22 Homo sapiens mRNA ; cDNA DKFZp564L1916 (from clone 118 AL049223. I DKFZp564L 1916) e-161 Bacillus sp. gene for thermostable alkaline protease, complete 119 D13158. 2 cds 0. 69 S. cerevisiae alpha-aminoadipate reductase (LYS2) gene, 120 M36287 complete cds. 6. 70E-01 121 AF083457. 1 Equus caballus microsatellite COR014 sequence 8. 00E-03 122 X66015 T. aestivum mRNA 3 for cathepsin B (2557) 8. 00E-03 Drosophila melanogaster leucine-rich repeat/Ig transmembrane 123 U42767 protein KEKI precursor (kekl) mRNA, complete cds 1. 90E+00 124 X06670 Yeast NUC 1 gene for mitochondrial nuclease 7. 10E-02 125 Z49613 S. cerevisiae chromosome X reading frame ORF YJR113c 6. 50E-01 126 U00038 Caenorhabditis elegans cosmid T21DI I 220E-01 127 M60177 Escherichia coli enterobactin (entF) gene, complete cds. 6. 50E-01 H. sapiens flow-sorted chromosome 6 HindIII fragment, 128 Z84506 SC6pA28B 10 2. 10E-01 Monkey (rhesus) delta-globin pseudogene ; 5'flank and exons 1 129 J00334 & 2. 2. 10E-01 Table 2A : Nearest Neighbor (BlastN vs. Genbank) SEQ _-.-_ ID ACC'N DESCRIP. P VALUE NM_002844 Homo sapiens protein tyrosine phosphatase, receptor type, K 130. 1 (PTPRK) mRNA phosphatase mRNA, complete cds 7. OOE-03 Human nucleolar fibrillar center protein (ASE-1) mRNA, 131 U86751 complete cds 8. 00E-03 132 D63735 Distolasterias nipon DNA for 16S rRNA. partial sequence 3. 00E-03 133 D13469 M. hyopneumoniae genome, repeated DNA sequence 7. 60E-02 H. sapiens gene for ventricular myosin light chain 2 >gil340286lgblL01652lHUMVMLC Human ventricular myosin 134 Z15030 light chain 2 gene, seven exons. 7. 60E-02 Human DNA sequence from clone 370N13 on chromosome Xq25-26. 3. Contains an exon of the GRIA3 gene for glutamate receptor, ionotrophic, AMPA 3. Contains ESTs, complete 135 AL035426. 2 sequence [Homo sapiens] 2. 20E-01 Human myosin VIla (MY07A) gene, exons 5, 6, 7, 8, 9, 10, 11, 136 U61420 12, 13 and 14 3. OOE-03 137 AF155117. 1 Homo sapiens NY-REN-62 antigen mRNA, partial cds e-142 138 AE001129 Borrelia burgdorferi (section 15 of 70) of the complete genome 8. 80E-02 139 AB014528 Homo sapiens mRNA for KIAA0628 protein, complete cds 2. 00E-39 140 X85980 H. sapiens serine hydroxymethyltransferase pseudogene 2. 40E-02 141 D16474 Human mRNA, Xq terminal portion 9. 00E-04 NM_005180 Homo sapiens murine leukemia viral (bmi-1) oncogene homolog 142. 1 (BMI1) mRNA 8. 00E-04 Borrelia burgdorferi tuf-s10 operon : elongation factor (tuf), ribosomal proteins S 10 (rpsJ), L3 (rplC), L4 (rplD), L23 (rplW), 143 U78193 L2 (rplB), S 19 (rpsS), and L22 cds 1. 00E-03 144 AF052168 Homo sapiens clone 24762 mRNA sequence 6. 60E-01 NM_001863 Homo sapiens cytochrome c oxidase subunit VIb mRNA, 145. 1 complete sequence 9. 00E-05 146 AB010273. 1 Homo sapiens pshsp47 gene, complete cds 1. 9 Homo sapiens mRNA full length insert cDNA clone 147 AL 109729. 1 EUROIMAGE 123453 1 E-81 Human cholesteryl ester transfer protein (CETP) gene, partial 148 U71187. 1 cds and promoter region 0. 023 149 X90761 Homo sapiens hHa2 gene 0. 0003 150 AF045742 Xenopus laevis Smad7 mRNA, complete cds 0. 028 Homo sapiens mRNA ; cDNA DKFZp564P063 (from clone 151 AL049300. 1 DKFZp564P063) 0. 00001 Table 2A : Nearest Neighbor (BlastN vs. Genbank) SEQ ID ACC'N DESCRIP. P VALUE Homo sapiens genomic DNA, chromosome 21q22. 1, D21S226- 152 AP000273. 1 AML region, clone : f80G10, complete sequence 0. 003 Nom001277 153. 1 Homo sapiens choline kinase (CHK) mRNA kinase 0. 00003 154 AC001036 Homo sapiens (subclone 2 f7 from PI H48) DNA sequence 0. 002 155 U45432 Human ETV6 gene, promoter region and partial cds 0. 008 156 AF045742 Xenopus laevis Smad7 mRNA, complete cds 0. 25 D. silvestris clone U28T2 non-LTR retrotransposon DNA (3778 157 X60175 bp) 0. 66 158 X93334 H. sapiens mitochondrial DNA, complete genome 0. 00001 159 J04838 Human apolipoprotein B (APOB) gene, exons 21, 22 and 23. 0. 000001 Hylobates lar (clone LambdaGialphaGI) 3'alphalAlul D, 160 M94631 3'alpha I Alu I E and 3'alpha1Alu1 F Alu repeat regions. 0. 000003 Caenorhabditis elegans cosmid F32H5, complete sequence 161 Z81524 [Caenorhabditis elegans] 0. 71 Sus scrofa centromere-specific repeat, T32M clone, Mc2 satellite 162 U42364 DNA amplified from S0048 primer set. 0. 23 Homo sapiens RPC62 gene for RNA polymerase III subunit, 163 AJ238233. 1 exon 13 1E-35 165 AF030697 Homo sapiens semaphorin L (SEMAL) gene, partial cds 0. 00000002 166 Y08639 H. sapiens mRNA for nuclear orphan receptor ROR-beta 0. 092 167 X71934 H. sapiens XB gene for tenascin-X, repeat XIII 0. 0001 168 M17374 X. laevis beta-globin mRNA, 5'UTR. 0. 03 169 M65243 Synthetic mRNA leader sequence UTK. 0. 083 Homo sapiens ribosomal protein L38 (RPL38) mRNA NM_000999 >gil407422lemblZ26876lHSRPL38 H. sapiens gene for ribosomal 170. 1 protein L38 2E-09 171 X73501 H. sapiens gene for cytokeratin 20 3E-13 172 M17374 X. laevis beta-globin mRNA, 5'UTR. 9. 00E-03 173 Z24233 H. sapiens (D12S352) DNA segment containing 2E-11 Homo sapiens sialyltransferase 4A mRNA >gil410225lgblLl3972lHUMSIAT Homo sapiens beta- NM_003033 galactoside alpha-23-sialyltransferase (SIAT4A) mRNA, 174. 1 complete cds 7. 00E-13 175 AF039652 Homo sapiens ribonuclease H type II mRNA, complete cds 9E-88 H. sapiens (D1S414) DNA segment containing (CA) repeat ; 176 Z23435 clone AFM179xg5 ; single read 0. 001 177 M17374 X. laevis beta-globin mRNA, 5'UTR. 0. 009 Mus musculus cytoplasmic phosphoprotein PACSIN2 mRNA, 178 AF128535. 1 complete cds 2E-20 179 U19358 Saccharomyces cerevisiae dnaJ homolog Hljlp 3. 00E-14 Table 2A : Nearest Neighbor (BlastN vs. Genbank) SEQ ID ACC'N DESCRIP. 180 AB011139 Homo sapiens mRNA for KIAA0567 protein, partial cds 4. 00E-16 181 AF154851. 1 Salvelinus alpinus mitochondrion complete genome 2. 20E-01 182 AB028980. 1 Homo sapiens mRNA for KIAA1057 protein, partial cds 4. 00E-38 183 U39178 Human phosphodiesterase (PDEA) gene, intron 16, 3'end 1E-16 184 U02455 Cloning vector rpDR2, complete sequence. 6. 00E-19 Homo sapiens clone 686 protein (KIAA0684) mRNA NM_006048 >gil4104975lgblAF043117lAF043117 Homo sapiens ubiquitin- 85. 1 fusion degradation protein 2 (UFD2) mRNA, complete cds 2. 00E-64 Limulus polyphemus cytochrome oxidase II complete sequence, ATP synthase 8 (ATPase 8) gene, complete cds, and ATP 186 AF002644 synthase 6 (ATPase 6) gene, partial cds, mitochond... 2. 40E-02 H. sapiens CpG island DNA genomic Msel fragment, clone 504, 187 Z58806 forward read cpg50f4. ftla 6. 00E-20 188 U58736 Caenorhabditis elegans cosmid EGAP7. 8. 00E-03 189 V01270 R. norvegicus genes for 18S, 5. 8St and 28S ribosomal RNAs 6. 00E-21 190 L42098 Homo sapiens (subclone 5 c7 from P I H22) DNA sequence. 9. 00E-14 H. sapiens CpG island DNA genomic Msel fragment, clone 7f5, 191 Z63236 forward read cpg7f5. ft1d 2.00E-21 192 AF145957. 2 Mus musculus groucho-related gene product 1. OOE-57 NM_003193 Homo sapiens tubulin-specific chaperone e tubulin-folding 193. 1 cofactor E mRNA, complete cds 2. OOE-23 194 U65980 Borrelia hermsii 38 kDa lipoprotein Gpd gene, complete cds 2. 00E+00 Human mariner2 transposable element, complete consensus 195 U49974 sequence 4. OOE-28 196 Z47053 Human microsatellite DNA sequence 5E-29 197 X80424 M. musculus tex23 mRNA (5'region) 1. OOE-27 198 U75467 Drosophila melanogaster Rga and Atu genes. complete cds 4. 00E-28 199 U43077 Human CDC37 homolog mRNA, complete cds I. OOE-28 Homo sapiens 3-oxoacid CoA transferase mRNA >gi|1519051|gb|U62961|HSU62961 Human succinyl CoA : 3- NM_000436 oxoacid CoA transferase precursor (OXCT) mRNA, complete 200. 1 cds 2. 00E-29 Homo sapiens retinoic acid induced 3 (RAI3) mRNA NM_003979 >gil4063889lgblAF095448iAF095448 Homo sapiens putative G 201. 1 protein-coupled receptor (RAIGI) mRNA, complete cds e-158 202 Z22466 H. sapiens DNA sequence 5E-30 Table 2A : Nearest Neighbor (BlastN vs. Genbank) SEQ _ __-_-_ _ _ ID ACC'N DESCRIP. P VALUE Human mRNA for collagen VI alpha-1 C-terminal globular 203 X15880 domain 7. 00E-33 204 U47322 Cloning vector DNA, complete sequence. 8E-34 H. sapiens CpG island DNA genomic Msel fragment, clone 32a6, 205 Z55306 forward read cpg32a6. ftla 2E-20 Homo sapiens PAC clone DJ1152D16 from Xq23, complete 206 AC005190 sequence [Homo sapiens] I. OOE-26 H. sapiens CpG island DNA genomic Msel fragment, clone 14e3, 207 Z56833 reverse read cpg ! 4e3. rtlb7. 00E-tl Rat rCACN4A mRNA for L-type voltage-dependent calcium 208 D38101 channel alpha 1 subunit, complete cds 2. 40E-02 H. sapiens CpG island DNA genomic Msel fragment, clone 14e3, 209 Z56833 reverse read cpgl 4e3. rtl b 6. 00E-11 Homo sapiens farnesyl diphosphate synthase NM_002004 dimethylal Iyltranstransferase, geranyltranstransferase) for 212. 1 KIAA0003 gene. complete cds 2. 00E-43 213 AB023234. 1 Homo sapiens mRNA for KIAA1017 protein, complete cds e-172 NM003492 214. I Homo sapiens ITBA1 gene (ITBA 1) mRNA protein 1. OOE-49 215 X52994 Sheep mRNA for CD3 gamma subunit (partial) 5. 00E-08 Homo sapiens histone deacetylase 3 (HDAC3) gene, complete 216 AF059650 cds 6. 80E-01 217 U49046 Mus musculus zinc finger protein (Zfp64) mRNA. complete cds 3. 00E-55 NM_003488 Homo sapiens A kinase anchor protein. 149kD mRNA for kinase 218. 1 A anchor protein 3. OOE-21 219 J03764 Human, plasminogen activator inhibitor-l gene, exons 2 to 9. 3. 00E-26 220 Y16675 Homo sapiens mRNA for afíatoxin Bl-aldehyde reductase 8. 00E-03 221 AF085715 Mus musculus homeobox protein SPXI mRNA, complete cds 2. 10E-01 Loligo forbesi mRNA for phosphatidylinositol-specific 222 X76968 phospholipase C 1. 9 223 X55741 H. sapiens FKBP cDNA 2.00E-65 224 X85060 B. taurus cosmid-derived microsatellite DNA 3. 003-76 225 AJ001119 Bos taurus mRNA for Rab5 GDP/GTP exchange factor, Rabex5 3E-79 Mus musculus mRNA for hepatoma-derived growth factor, 226 D63850 complete cds, strain : BALB/c e-102 227 AB018344. 1 Homo sapiens mRNA for KIAA0801 protein, complete cds e-169 228 X81058 M. musculus tex261 mRNA e-112 Table 2A : Nearest Neighbor (BlastN vs. Genbank) SEQ ID ACC'N DESCRIP. P VALUE Homo sapiens kinesin family member protein KIF3A mRNA, 229 AF041853 complete cds e-162 Taenia taeniaeformis mitochondrial DNA for large subunit 234 AB020395 ribosomal RNA, partial sequence 1. 90E+00 235 AF120325. 1 Cricetulus griseus class I beta tubulin gene, complete cds 1. 80E+00 Mus musculus bromodomain-containing protein BP75 mRNA, 237 AF084259 complete cds 0. 64 239 M77820 Xenopus laevis fibronectin mRNA, complete cds. 2 241 AB007930 Homo sapiens mRNA for KIAA0461 perotein, partial cds e-178 242 D87463 Human mRNA for KIAA0273 gene, complete cds 2 Mus musculus diaphanous-related formin (Dia2) mRNA, 244 AF094519 complete cds e-143 Human DNA sequence from cosmid L241 B9, Huntington's Disease Region, chromosome 4p163 contains polymorphic 246 Z69708 VNTR pYNZ32 2 Homo sapiens ELL complex EAP30 subunit mRNA, complete 247 AF156102. 1 cds e-169 Homo sapiens kidney epithelial sodium channel gamma subunit 248 L36592 (gamma hENaC) mRNA, complete cds. 0. 63 250 AF039945 Homo sapiens synaptojanin 2B mRNA, partial cds 2. 1 252 U29487 Caenorhabditis elegans cosmid C09C7 0. 71 NM003794 Homo sapiens sorting nexin 4 (SNX4) mRNA nexin 4 mRNA, 253. 1 complete cds e-151 255 AE001267 Treponema pallidum section 83 of 87 of the complete genome 6. 70E-01 Homo sapiens SRY (sex determining region Y)-box 13(SOX13) NM_005686 mRNA >gil4323170lgblAF098915lAF098915 Homo sapiens type 256. 1 I diabetes autoantigen ICA12 mRNA, complete cds 0. 23 257 Z49373 S. cerevisiae chromosome X reading frame ORF YJL098w 2 258 AF125392. 1 Homo sapiens insulin induced protein 2 mRNA, complete cds 8. 003-96 260 X07618 Human mRNA for cytochrome P450 dbl variant a 6. 90E-01 Mus musculus Cctq gene for chaperonin containing TCP-1 theta 261 AB022161. 1 subunit, complete cds 0. 7 262 AF001794 Mus musculus Treacher Collins Syndrome protein 0. 69 Mus musculus strain 129/SvJ mast cell protease 8 (Mcpt8) gene, 263 AF119362. 1 complete cds 0. 22 Plasmodium falciparum chromosome 2, section 32 of 73 of the 264 AE001395 complete sequence 6. 80E-01 265 U19775 Human MAP kinase Mxi2 (MXI2) mRNA. complete cds 2. 10E+00 Table 2A : Nearest Neighbor (BlastN vs. Genbank) SEQ ID ACC'N DESCRIP. PVALUE 266 AJ131389 Homo sapiens mRNA for PEX 3 protein, partial e-171 267 M25779 S.cerevisiae SEC59 gene, complete cds. 1.90E+00 268 AF009953 Glycine max 35 kDa seed maturation protein 0.66 269 Z35284 H. sapiens mRNA for MDR3 P-glycoprotein 2. 40E-02 Pleurocera prasinatum strain 12B-1 16S ribosomal RNA gene, 270 AF050052 mitochondrial gene for mitochondrial RNA, partial sequence 6.60E-01 271 AF043494 Pinus strobus microsatellite RPS3 repeat region 6.60E-01 NM 001388 Homo sapiens developmentally regulated GTP-binding protein 2 272. I (DRG2) mRNA GTP-binding protein 0. 65 Nom 000242 Homo sapiens mannose-binding lectin, soluble mannose-binding 273 .1 protein C 6.90E-01 274 S82740 NPM/ALK=fusion gene {translocation breakpoint} 7.10E-01 275 AB006621 Homo sapiens mRNA for KIAA0283 gene. partial cds 1. 90E+00 276 AB023162. 1 Homo sapiens mRNA for KIAA0945 protein, complete cds e-169 Homo sapiens ARF GTPase-activating protein GITI mRNA, 277 AF124490. 1 complete cds e-173 278 L29454 Mouse fibrillin (Fbn-I) mRNA, complete cds. 0. 64 279 ABC 18264. 1 Homo sapiens mRNA for KIAA0721 protein. partial cds e-148 Mus musculus rod cGMP phosphodiesterase delta subunit 280 AF046000 (Pde6d) gene, complete cds 0. 52 281 X86791 S. scrofa beta-globin gene 0. 37 282 AL050368. 1 Homo sapiens mRNA : cDNA DKFZp566A1124 2. 1 Acholeplasma laidlawii DNA topoisomerase IV ParE subunit (parE) and DNA topoisomerase IV ParC subunit (parC) genes, 283 AF 174426. 1 partial cds 2. 1 284 AJ009770 Homo sapiens mRNA for putative transcription factor, partial e-165 Mus musculus lymphocyte-specific adaptor protein Lnk (Lnk) 285 U89992 mRNA, complete cds 0. 23 287 AF132479 Mus musculus Ese2L protein mRNA. complete cds 0. 7 288 X76753. 2 Homo sapiens HG 5-HTT gene for serotonin transporter, exon I 2. 1 289 D64033 Oryzias latipes DNA for transferrin, complete cds 0. 23 Bacillus subtilis wapA and orf genes for wall-associated protein 290 D29985 and hypothetical proteins 0. 68 Homo sapiens mRNA; cDNA DKFZp586N1720 (from clone 291 AL049442. 1 DKFZp586N1720) e-166 Table 2A : Nearest Neighbor (BlastN vs. Genbank) SEQ ID ACC'N DESCRIP. P VALUE cgs2+=cyclic AMP dependent protein kinase regulatory subunit homolog [Schizosaccharomyces pombe=fission yeast, Genomic, 292 S64907 3596 nt] 0. 68 Bos taurus rod outer segment guanylate cyclase precursor (ROS- 293 AF027202 GC 1) gene, exons 9 through 11 2 294 ABO11540 Homo sapiens mRNA for MEGF7, partial cds 0. 076 Homo sapiens mRNA ; cDNA DKFZp586D1519 (from clone 295 AL096842. 1 DKFZp586D 1519) e-177 296 D78503. 1 Mus musculus seizure-related mRNA, partial sequence 0. 68 297 AF079557 Mus musculus poly (ADP-ribose) glycohydrolase 2 H. sapiens CpG island DNA genomic Msel fragment, clone 8a6, 298 Z66316 forward read cpg8a6. ft1f 0. 22 Human phosphatidylinositol 3-kinase catalytic subunit pl l Odelta 299 U86453 mRNA. complete cds 2. 1 Crocidura russula partial mitochondrial cytb gene >gil3319900lemblAJ000468. I lCRAJ468 Crocidura russula 300 AJ000467. 1 partial mitochondrial cytb gene 0. 22 301 X63721 S. cerevisiae HEMI9 gene for uroporphvrinogen decarboxylase 0. 67 302 AJ005390 1 Homo sapiens SCNN I B gene, exons 9 and 10 0. 23 303 X06150 Rat mRNA for glycine methyltransferase (EC 2. 1. 1. 20) 0. 22 304 X63771. 1 Soybean Mosaic Virus gene for coat protein 2 Homo sapiens FHI/FH2 domain-containing protein FHOS 305 AF113615. 1 (FHOS) mRNA. complete cds e-176 306 AF052193 Gallus gallus translation repressor mRNA, partial cds 0. 66 307 D13903 Mouse mRNA for MPTPdelta (type A) 0. 22 Human type 11 3-beta hydroxysteroid dehydrogenase/5-delta-4- 308 M77144 delta isomerase gene, complete cds. 0. 22 Homo sapiens chromosome 22 CpG island DNA, genomic Msel 309 AJ236656 fragment, clone 22CGIB49B8, complete read 0. 66 310 M84732 Plasmodium yoelii sporozoite surface protein 2 gene 0. 22 311 X83433 O. sativa mRNA for lipid transfer protein, b21 0. 66 Homo sapiens genomic DNA, chromosome 21q21. 2, LL56-APP region, clone B2291 C 14-R44F3, segment 10/10, complete 312 AP000145. 1 sequence 0. 0000004 313 AB025570. 1 Equus caballus CgA mRNA for chromogranin A, complete cds 0. 22 314 AF006482 Mus musculus nucleoside triphosphatase 0. 69 315 AF141308. 1 Homo sapiens polyamine modulated factor-I 0. 65 Table 2A : Nearest Neighbor (BlastN vs. Genbank) SEQ ID ACC'N DESCRIP. P VALUE 316 AF092945 Charybdis feriatus molt-inhibiting hormone 0. 22 317 D90773 E. coli genomic DNA, Kohara clone #262 (30. 3-30. 5 min.) 1. 9 318 D26077 Mouse mRNA for KIF3B protein, complete cds 0. 21 Streptomyces coelicolor bldKA, bldKB, bldKC, and bldkD 319 U68036 genes. complete cds, and bldkE gene, partial cds 0. 64 S. oleracea mRNA (omp24) for chloroplast outer envelope 24 kD 321 X75563 protein 0. 68 322 AB006628 Homo sapiens mRNA for KIAA0290 gene. partial cds 0. 21 323 AJ238878. 1 Haloferax volcanii ORF1, strain WR340 0. 21 Mycoplasma genitalium section 18 of 51 of the complete 324 U39696 genome 0. 21 Human DNA sequence from clone 232D4 on chromosome 326 AL031590 22q 13. 1 Contains GSS, complete sequence [Homo sapiens] 0. 67 Homo sapiens putative glycolipid transfer protein mRNA, 327 AF103731. 1 complete cds e-168 328 U88984 Mus musculus NIK mRNA, complete cds 0. 22 329 AJ006031 Mus musculus IHABP gene, promoter 2E-40 330 AL049953. 1 Homo sapiens mRNA : cDNA DKFZp564P0622 6E-52 331 L49144 Homo sapiens neuroendocrine-specific protein 0. 81 332 U25810 Bos taurus lysozyme (LZ) gene. complete cds 0. 000004 Exema neglecta haplotype 188 cytochrome oxidase I (COI) gene, 333 AF092681 mitochondrial gene encoding mitochondrial protein, partial cds 0. 77 Archaeoglobus fulgidus section 141 of 172 of the complete 334 AE000966 genome 2. 1 335 AF091234 Mus musculus putative transcription factor mRNA, complete cds 4E-90 336 M25702 Human thyroid peroxidase (TPO) gene, exon 2. 0. 078 337 Z70029 B. vulgaris mitochondrial DNA, RAPD fragment 0. 075 338 AF072432 Dictyostelium discoideum gp63 homolog mRNA, complete cds 0. 69 339 M13241 Human N-myc gene, exons 2 and 3. 0. 074 340 X07703 Chironomus tentans Balbiani ring gene BR6 3'-end 0. 076 341 X57564 A. rusticana mRNA for neutral peroxidase 0. 077 342 Z74084 S. cerevisiae chromosome IV reading frame ORF YDL036c 2 Caenorhabditis elegans transcription factor E12/47 homolog 343 U30248 gene, complete cds 2. 1 344 Y09396 C. annuum mRNA for CDC48p-like protein 2 Caenorhabditis elegans cosmid H19N07, complete sequence 345 Z92835 [Caenorhabditis elegans] 0. 68 Table 2A : Nearest Neighbor (BlastN vs. Genbank) SEQ ID ACC'N DESCRIP. P VALUE | Homo sapiens zinc finger transcriptional regulator (GOS24) 346 M92844 gene, complete cds 2 Treponema pallidum GroEL gene and gene encoding putative 347 X54111 enol-pyruvyltransferase 0. 22 348 Z71419 S. cerevisiae chromosome XIV reading frame ORF YNL143c 0. 64 349 AL034486 S. pombe chromosome I cosmid c2H10 1. 9 NM000127 350. 1 Homo sapiens exostoses (multiple) 1 (EXTI) mRNA 2 351 U61997 Zea mays B chromosome centromere repeat K ! 1 sequence 0. 074 352 AB018255. 1 Homo sapiens mRNA for KIAA0712 protein, complete cds 7E-43 353 S60289 LeB4=legumin {5'region} [Vicia faba, Genomic, 1222 nt] 0. 072 Plasmodium falciparum chromosome 2. section 28 of 73 of the 354 AE001391 complete sequence 0. 24 Methanococcus jannaschii section 20 of 150 of the complete 357 U67478 genome 0. 068 358 AE001146 Borrelia burgdorferi (section 32 of 70) of the complete genome 1. 9 Streptococcus crista HmpA gene, partial cds, putative 359 U46542 adhesin/ABC transport system protein (scbA) gene, complete cds 0. 073 360 Z36067 S. cerevisiae chromosome 11 reading frame ORF YBR198c 1. 3 Teucridium parvifolium NADH dehydrogenase (ndhF) gene, 361 U78684 chloroplast gene encoding chloroplast protein. partial cds 0. 29 Homo sapiens Eph-like receptor tyrosine kinase hEphBlb 362 AF037332 (EphB 1) mRNA, complete cds 0. 26 Drosophila melanogaster eukaryotic initiation factors 4E-I and 363 U54469 4E-II (eIF4E) gene, complete cds. 0. 24 Mus musculus thioredoxin-dependent peroxide reductase (tpx) 364 U20611 mRNA, complete cds. 0. 027 365 L34542 Rattus norvegicus non-receptor protein kinase 0. 7 366 Y14993 Schizosaccharomyces pombe gut2 gene 0. 23 Plasmodium falciparum DNA *** SEQUENCING IN 367 AL008983 PROGRESS *** from contig 3-54, complete sequence 0. 025 Homo sapiens mRNA ; cDNA DKFZp434D193 (from clone 368 AL080129. 1 DKFZp434D193) e-100 369 AF100304 Caenorhabditis elegans cosmid W07B3 0. 65 Bacillus stearothermophilus limonene hydroxylase (pOT435) 370 AF039527 gene, complete cds 0. 22 Homo sapiens genomic DNA, chromosome 21q22. 1, D21S226- 371 AP000258. 1 AML region, clone : Q89A6, complete sequence 0. 00001 Table 2A : Nearest Neighbor (BlastN vs. Genbank) SEQ ID ACC'N DESCRIP. P VALUE Entamoeba histolytica 70 kDa heat shock protein Hsp70-Bip 372 AF082519 precursor (BiP) gene, complete cds 0. 0009 373 M38224 T. brucei procyclic acidic repetitive protein 1. 9 374 Z70720 S. pombe chromosome I cosmid clB9 0. 65 375 AF069532 Homo sapiens CDP-diacylglycerol synthase 2 SE-20 376 X97570 Z. mays dek34 gene 0. 22 Homo sapiens ubiquitin specific protease 9, X chromosome NM_004652 (Drosophila fat facets related) (USP9X) mRNA ubiquitin 377. l hydrolase 0. 023 Branchiostoma lanceolatum mRNA for intermediate filament 378 AJ223578 protein C2 0. 024 Dictyostelium discoideum mitochondrial genes for ribosomal 379 D63523. 1 proteins, complete and partial cds 0. 22 380 L35528 Mus musculus manganese superoxide dismutase 0. 074 Homo sapiens carbohydrate (chondroitin 6/keratan) sulfotransferase 2 (CHST2) mRNA mRNA for N- acetylglucosamine-6-O-sulfotransferas e mRNA for long form of NM 004267 N-acetylglucosamine-6-O-sulfotransferase (GIcNAc6ST), 381 1 complete cds 0. 003 Caenorhabditis elegans cosmid F18A11, complete sequence 382 Z81507 [Caenorhabditis elegans] 1. 9 Homo sapiens endogenous retrovirus W envelope protein 383 AF072506. 2 precursor mRNA. complete cds 0. 75 Mycoplasma genitalium cdsA, frr, hsdS. smbA, tsf genes from bases 539564 to 546816 (section 52 of 56) of the complete 384 U39730 genome 0. 009 Saccharomyces cerevisiae (chromosome II) AR04-homologue (YBR1701), YBR1702, YBR1703, 30S ribosomal protein- 385 L20296 homologue (YBR1704) and pseudoprotease-homologue 2 386 D50500 Mouse mRNA for Rab 11, partial sequence 0. 22 387 X52263 C. tentans balbiani ring 3 (BR3) gene 2 388 M68998 Human alpha-l type XIII collagen (COL 13A 1) gene, exon 1. 0. 008 Plasmodium falciparum (strain Dd2) variant-specific surface 389 L40608 protein (var-l) gene, complete cds. 2 390 D12688 Mouse P-cadherin gene, exon 1 and 2 2 391 AE001150 Borrelia burgdorferi (section 36 of 70) of the complete genome 0. 008 392 X80852 M. musculus gene for liver type phosphofructokinase 0. 073 Trichomonas vaginalis pre-mRNA processing 8 protein homolog 393 AF115849. 1 PRP8 (PRP8) gene, complete cds 2 Table 2A : Nearest Neighbor (BlastN vs. Genbank) SEQ ID ACC'N DESCRIP. P VALUE 394 L31848 Homo sapiens serine/threonine kinase receptor 2 0. 069 Borrelia burgdorferi flgK, flbF, thdF, gidA, gidB, moxR, orfl, 395 AJ003222 orf2, orf3, orf4 and orf5 genes 0. 006 396 AB02895S I Homo sapiens mRNA for KIAA1035 protein, partial cds 0. 055 397 AF155110. 1 Homo sapiens NY-REN-45 antigen mRNA, complete cds 0. 07 398 M24842 Human keratin 18 (K18) gene, complete cds. e-142 399 AL050074. 1 Homo sapiens mRNA ; cDNA DKFZp566F1946 e-171 401 D13469 M. hyopneumoniae genome, repeated DNA sequence 0. 003 Methanococcus jannaschii section 52 of 150 of the complete 402 U67510 genome 0. 074 Homo sapiens HCR (a-helix coiled-coil rod homologue) gene, 403 AB029343. 1 complete cds 0. 21 404 L43391 Homo sapiens (subclone 5_g12 from PI H16) DNA sequence. 0. 7 Orpinomyces sp. PC-2 beta-glucosidase (bgll) mRNA, complete 405 AF016864. 1 cds 0. 22 406 L31848 Homo sapiens serine/threonine kinase receptor 2 0. 072 407 X65521 K. lactis centromere 2 (KICEN2) DNA 0. 024 HIV-I clone 13Pb9-4 from Seattle, envelope glycoprotein, V3- 408 U56221 V5 region (env) gene, partial cds 0. 22 Homo sapiens cAMP specific phosphodiesterase products, 409 AF157816. 1 complete cds 2E-I 1 Homo sapiens clone 25191 GTP-specific succinyl-CoA 410 AF131748 synthetase beta subunit (SCS) mRNA sequence, partial cds 0. 23 411 AF034783 Synthetic helper virus genomic sequence fragment 2 Homo sapiens calcium binding protein (ALG-2) mRNA, 412 AF035606 complete cds 0. 000004 Plasmodium falciparum secreted polymorphic antigen gene, 413 L07944 complete cds 0. 001 Plasmodium falciparum chromosome 2, section 55 of 73 of the 414 AE001418 complete sequence 0. 026 Human DNA sequence from cosmid L21F12, Huntington's 415 Z68886 Disease Region, chromosome 4pal6. 3 7E-12 416 X82192 H. sapiens EST mRNA (G5) 0. 23 NM004998 417. 1 Homo sapiens myosin IC (MYOIC) mRNA complete cds. 0. 0001 418 U55042 Bos taurus myosin X, complete cds 0. 2 Table 2A : Nearest Neighbor (BlastN vs. Genbank) SEQ ID ACC'N DESCRIP. P VALUE 419 AF026069. 1 Homo sapiens phosphomevalonate kinase 0. 66 Homo sapiens mRNA ; cDNA DKFZp434C153 (from clone 420 AL080128. 1 DKFZp434C153) 0. 62 PGKI=phosphoglycerate kinase 1 {3'nuclease-sensitive region} 421 S75476 [human, Genomic, 3571 nt] 0. 00003 422 M57682 Rat brain calcium channel alpha-1 subunit mRNA, complete cds. 0. 0001 Homo sapiens genomic DNA, chromosome 6p21. 3, HLA class I 423 AB023053. 1 region, clone : 53L9, complete sequence 0. 074 Human DNA polymerase gamma (polg) gene, promoter region 424 U74651 and partial cds 7E-11 426 X86336 H. sapiens C7 gene, exon 9 0. 026 427 AB000931. 2 Homo sapiens FUT2 gene, intron I. complete sequence 0. 0003 428 U20365 Mus musculus smooth muscle gamma-actin gene, complete cds 0. 0003 Homo sapiens diacylglycerol kinase epsilon gene, promoter and 429 AF136745. 1 partial cds 0. 0000001 Human gene for small cytoplasmic 7SL RNA (7L30. 1) 430 X04249 pseudogene 0. 000001 431 AB029016. 1 Homo sapiens mRNA for KIAA1093 protein, partial cds 0. 00000005 Plasmodium falciparum chromosome 2, section 58 of 73 of the 432 AE001421 complete sequence 0. 001 433 AB023189. 1 Homo sapiens mRNA for KIAA0972 protein, complete cds 0. 003 434 U68061 Human MUC2 gene, promoter region 0. 000001 NM_005971 Homo sapiens phospholemman-like, expressed in breast tumors, 435. 1 8kD (PLML) mRNA protein 5E-09 436 AC001050 Homo sapiens (subclone 3 e9 from Ft H55) DNA sequence 5E-09 437 AF151843. 1 Homo sapiens CGI-85 protein mRNA, complete cds IE-35 Human natural resistance-associated macrophage protein 438 U26447 (NRAMP1) gene, 3'region 6E-10 Caenorhabditis elegans cosmid H36L18, complete sequence 439 Z95309 [Caenorhabditis elegans] 2 440 AF144622. 1 Homo sapiens beta-catenin gene, intron 2 and partial cds 2 441 J04990 Human cathepsin G gene, complete cds. 0. 0000001 442 U22657 Mus musculus genomic locus related to cellular morphology. 0. 076 Table 2A : Nearest Neighbor (BlastN vs. Genbank) SEQ | l l ID ACC'N DESCRIP. P VALUE Homo sapiens genomic DNA, chromosome 21q22. 1, D21S226- 443 AP000262. 1 AML region, clone : S680, complete sequence 2E-12 Homo sapiens Wiskott-Aldrich Syndrome protein flanking 444 AFH 5549. 2 region 6E-21 Homo sapiens pancreatic tumor-related protein mRNA, partial 445 M55409 cds 8E-13 Nom 006530 Homo sapiens Glioma-amplified sequence-41 GAS41 protein 446. 1 mRNA, complete cds e-154 Schistosoma mansoni G protein beta subunit-like protein trans- 447 U30261 spliced mRNA, complete cds 3E-14 448 AF132966. 1 Homo sapiens CGI-32 protein mRNA, complete cds e-169 Human thymidine kinase gene, complete cds, with clustered Alu 449 M15205 repeats in the introns. lE-14 450 X92565 C. elegans mRNA for LIN-2B protein 0. 0000001 NM006466 Homo sapiens polymerase (RNA) III (DNA directed) (39kD) 451. I (RPC39) mRNA subunit (RPC39) mRNA, complete cds 3E-15 452 AF086460 Homo sapiens full length insert cDNA clone ZD85A02 e-117 Homo sapiens (subclone H8 8_f5 from PI 35 H5 C8) DNA 453 L35664 sequence. 2E-10 454 X69951 H. sapiens gene for casein kinase II alpha subunit 2E-20 455 AB007930 Homo sapiens mRNA for KIAA0461 perotein, partial cds e-177 456 L81840 Homo sapiens (subclone lf8 from PI H43) DNA sequence IE-27 457 X94354 H. sapiens DNA for Cone cGMP-PDE gene 4E-17 458 AB024291. 1 Zea mays ZmRR2 mRNA, complete cds 0. 025 459 Y 16790 Homo sapiens hHa4 gene, complete CDS 0. 66 460 U67209 Human clone HS2. 10 Alu-Ya5 sequence 2E-19 461 M30951 Gorilla 28S ribosomal RNA gene fragment. 5E-20 462 AF029062 Homo sapiens DEAD-box protein (BAT1) gene, partial cds lue-18 463 ABC14601 Homo sapiens mRNA for K1AA0701 protein, partial cds 1E-14 464 M30950 Chimpanzee 28S ribosomal RNA gene fragment. 6E-21 465 AB005619 Gallus gallus mRNA for chromobox protein 3E-26 Homo sapiens glutathione S-transferase subunit 13 homolog 466 AF070657 mRNA, complete cds 2E-54 467 M58775 Polaribacter glomeratus 16S ribosomal RNA 2. 1 468 AJ000992. 1 Dictyostelium discoideum gdtl gene 0. 67 469 AB014589 Homo sapiens mRNA for KIAA0689 protein, partial cds e-158 H. sapiens CpG island DNA genomic Msel fragment, clone 470 Z63830 90h2, reverse read cpg90h2. rtla 3E-26 Table 2A: Nearest neighbor (BlastN vs. Genbank) SEQ ID ACC'N DESCRIP. P VALUE NM002273 471. 1 Homo sapiens keratin 8 (KRT8) mRNA keratin 8 e-120 Homo sapiens clone HAW 100 putative ribonuclease III mRNA, 472 AF116910. 1 complete cds e-173 473 AF131739 Homo sapiens clone 25189 mRNA sequence, complete cds e-124 474 AF 100615. 1 Homo sapiens chromosome 15 MRG 15 protein 7E-74 475 AB019490. 1 Homo sapiens IDN4-GGTR7 mRNA, partial cds e-156 476 L20941 Human ferritin heavy chain mRNA. complete cds. 1 E-27 477 AF088022 Homo sapiens full length insert cDNA clone ZC18H06 SE-30 478 L06845 Human cysteinyl-tRNA synthetase mRNA, partial cds. 1E-39 479 AB014542 Homo sapiens mRNA for KIAA0642 protein. partial cds 2E-54 Homo sapiens excision repair protein ERCC4 mRNA, complete 480 L77890 cds, clone cer4-40 2E-30 481 L32838 Mouse germline interleukin 1 receptor antagonist 0. 076 Homo sapiens nucleosome assembly protein 1-like 1 (NAP1L1) NM_004537 mRNA >gil 189066lgblM86667lHUMNAP H. sapiens NAP 482. 1 (nucleosome assembly protein) mRNA, complete cds e-123 483 U85258 Human estrogen related receptor alpha (ESTRRA) pseudogene 8E-34 484 U79656 Human Treacher Collins syndrome (TCOF1) gene, exon 21 8E-34 485 AF067864. 1 Homo sapiens transferrin receptor 2 alpha 4E-91 486 X03100 Human HLA-SB (DP) alpha gene IE-16 487 AF013277 Bombyx mori topoisomerase II (TOPOII) mRNA, complete cds 0. 23 Mus musculus von Ebner minor salivary gland protein mRNA, 488 U46068 complete cds. IE-35 Methanococcus jannaschii section 105 of 150 of the complete 489 U67563 genome IE-35 490 AB016492. 1 Homo sapiens hJTB gene, complete cds e-118 491 X98176 H. sapiens mRNA for MACH-beta-I protein IE-36 Homo sapiens huntingtin interacting protein HYPK mRNA, 492 AF049613 partial cds 7E-22 493 AF039690. 1 Homo sapiens antigen NY-CO-8 (NY-CO-8) mRNA, partial cds 1E-37 NM_001003|Homo sapiens ribosomal protein, large, PI ribosomal 494. 1 phosphoprotein Pl mRNA, complete cds. 4E-38 Table 2A : Nearest Neighbor (BlastN vs. Genbank) SEQ ID ACC'N DESCRIP. P VALUE Shigella sonnei form I operon ORF protein genes, complete cds, 495 U34305 insertion sequence IS630 protein gene, complete cds. 0. 074 496 U61538 Human calcium-binding protein chp mRNA, complete cds 4E-38 497 AJ243512. 1 Homo sapiens mRNA for Barx2 protein (Barx2 gene) lE-46 498 AF077043. 1 Homo sapiens 60S ribosomal protein L36 mRNA, complete cds 4E-59 499 Y 14223 Homo sapiens BPI gene, exon 9 0. 00001 500 X07425 Human gene for U 6 RNA IE-35 Mus musculus RORgamma orphan nuclear receptor mRNA, 501 U43508 complete cds 0. 23 Human DNA sequence from PAC 179115, BRCA2 gene region chromosome 13ql2-13 contains lactase-phlorizin hydrolase 502 Z92541 (LCT) 0. 078 503 X57435 H. sapiens mRNA for transcription factor AP-4 0. 26 Z. mays mRNA for b-32 protein, putative regulatory factor of 504 X70154 zein expression (clone b-32. 152) 2. 1 505 AF069737 Xenopus laevis notchless (nle) mRNA, complete cds 2E-94 Mus musculus mRNA for hepatoma-derived growth factor, 506 D63850 complete cds, strain : BALB/c SE-50 NM006295 507. 1 Homo sapiens valyl-tRNA synthetase I (VARS 1) mRNA 2E-50 Homo sapiens mRNA for protein encoded by cxorf5 (71-7A) 508 Y16355 gene, alternatively spliced form e-157 509 U67317 Cuphea wrightii beta-ketoacyl-ACP synthase II 0. 68 NM006571 Homo sapiens novel RGD-containing protein mRNA, complete 510. 1 cds 1 E-56 Homo sapiens VAMP (vesicle-associated membrane protein)- associated protein A (33kD) (VAPA) mRNA, and translated NM003574 products VAMP-associated protein of 33 kDa (VAP-33) mRNA, 511. 1 complete cds e-129 Homo sapiens zinc finger protein 124 (HZF-16) HZF- NM 003431 16=Kruppel-related zinc finger gene homolog HEP-G2, mRNA, 512. 1 2080 nt] 2E-60 Human autoantigen small nuclear ribonucleoprotein Sm-D 513 J03798 mRNA, complete cds. 2E-72 514 AL049670. 1 Human gene from PAC 69E11, chromosome I e-174 515 AB014603 Homo sapiens mRNA for KIAA0703 protein, complete cds e-167 NM000977 Homo sapiens ribosomal protein L13 (RPL13) mRNA 516. 1 >gil29382lemblX64707lHSBBC1 H. sapiens BBC1 mRNA 2E-63 Table 2A : Nearest Neighbor (BlastN vs. Genbank) SEQ _--_- ID ACC'N DESCRIP. P VALUE H. sapiens CpG island DNA genomic Msel fragment. clone 26c2, 517 Z55204 reverse read cpg26c2. rt1a 1E-28 518 AC002181 Homo sapiens (subclone 2 a l2 from BAC Hl l l) DNA sequence 0. 001 NM_006371 Homo sapiens cartilage-associated protein sapiens mRNA for 519. l cartilage-associated protein (CASP) e-171 520 AF102507. 1 Homo sapiens fizzy-related protein mRNA, partial cds e-153 Rattus norvegicus pyridoxine 5'-phosphate oxidase mRNA, 521 U91561 complete cds e-100 522 X56974 M. musculus mRNA for external transcribed spacer e-163 Mus musculus channel interacting PDZ domain protein mRNA, 523 AF060539 complete cds e-138 Homo sapiens kinesin superfamily motor KIF4 mRNA, complete 524 AF071592 cds 0 525 X68199 R. norvegicus MYR1 mRNA for myosin I heavy chain e-128 Homo sapiens no arches-like (zebrafish) zinc finger protein NM006693 (NAR) mRNA >gi|4098571|gb|U79569|HSU79569 Human no 526. 1 arches (nar) mRNA. complete cds e-160 527 Z22818 Canis familiaris mRNA for Rabl2 protein e-159 Mus musculus NEDD8-conjugating enzyme (Uba3) mRNA, 529 AF077330 complete cds 0. 62 532 AF118268. 1 Coprinus cinereus laccase 2 precursor (lcc2) gene, complete cds 2 533 AF118268. 1 Coprinus cinereus laccase 2 precursor (lcc2) gene, complete cds 1. 9 Coccidioides immitis complement fixation/chitinase antigen 534 U33265 mRNA, complete cds 1. 8 538 AF079867. 1 Acomys cahirinus clone pAcah3 satellite sequence 1. 8 Homo sapiens cleavage stimulation factor, 3'pre-RNA, subunit NM_001324 1, 50kD (CSTF1) mRNA pZ50-19) cleavage stimulation factor 539. 1 50kDa subunit, complete cds. 0. 69 540 AB012265 Mus musculus mRNA for wizL, complete cds 0. 64 541 Y18504. 1 Homo sapiens X5L gene e-151 Gracilaria chilensis 18S ribosomal RNA gene, partial sequence ; internal transcribed spacer 1, 5. 8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence ; and 25S 542 AF034265 ribosomal RNA gene, partial sequence 0. 62 Mus musculus prolyl 4-hydroxylase alpha (ll)-subunit mRNA, 543 U16163 complete cds 0. 62 Table 2A : Nearest Neighbor (BlastN vs. Genbank) SEQ ID ACC'N DESCRIP. P VALUE 544 U53004 Human GT335 gene, exons 1, 2, 3, and 4 0. 61 Homo sapiens mRNA containing (CAG) 6 repeat, clone CZ-CAG 545 Y13870. 1 12 0. 22 Homo sapiens DNA polymerase epsilon catalytic subunit protein 546 AF 127950. 1 (POLE 1) gene, exons 17, 18 and 19 0. 21 547 AF071538 Homo sapiens Ets transcription factor PDEF e-166 548 D63876 Human mRNA for KIAA0154 gene, partial cds 0. 61 549 AE001326 Chlamydia trachomatis section 53 of 87 of the complete genome 2. 3 H. sapiens CpG island DNA genomic Msel fragment, clone 550 Z58704 49b2, reverse read cpg49b2. rtlb 2. 3 551 X78576 R. oryzae fumR gene 0. 22 Oryza sativa gypsy-type retrotransposon RIRE8A DNA, internal 552 AB014740. 1 region, complete sequence 0. 64 553 X78562 O. limosus hypoglycemic hormone mRNA CHAA, 2409bp 0. 21 554 X99719 S. enterica hsdM, hsdS & hsdR genes 1. 9 Mus musculus Rho-associated, coiled-coil forming protein 555 U58513 kinase p 160 ROCK-2 mRNA, complete cds 1. 9 556 Z83002 B. pagrosomi partial 28S rRNA gene 0. 66 557 AL080223. 1 Homo sapiens mRNA ; cDNA DKFZp566H2446 e-150 Homo sapiens mRNA ; cDNA DKFZp564J142 (from clone 558 AL080066. 1 DKFZp564J142) 0. 00003 Nicotiana tabacum glutamate decarboxylase isozyme 2 559 AF020424 (NtGAD2) mRNA. complete cds 1. 8 Haemophilus influenzae Rd section 83 of 163 of the complete 560 U32768 genome 0. 21 Plasmid pJDI from Neisseria gonorrheae DNA, complete 561 M 10316 genome. 2 Bos taurus mRNA for placenta growth factor precursor, 562 AB004272. 1 complete cds 1. 9 563 X05427 Drosophila ultrabithorax (Ubx) gene promoter region 1. 9 S. pneumoniae mismatch repair protein (hexA) gene, complete 564 M 18729 cds. 0. 21 565 M87060 Rattus rattus cardiac AE3 gene, exons 1-23. 0. 086 566 M36662 Chicken alpha-1 collagen type III gene, 3'end. 0. 083 567 AF135450 1 Sus scrofa SMCY (SMCY) gene, partial cds 0. 081 568 Z34293 A. thaliana (CDNA4) myosin heavy chain mRNA 2. 2 Rattus norvegicus glycerol-3-phosphate dehydrate 569 U83880 dehydrogenase (mtGPDH) mRNA, 3'UTR IE-59 Table 2A : Nearest Neighbor (BlastN vs. Genbank) SEQ ID ACC'N DESCRIP. P VALUE 570 AF133913. 1 Mus musculus ARL-6 interacting protein-6 4E-79 571 AF077543. 1 Caenorhabditis elegans cosmid H07I21 1. 9 572 X77829 A. niger (N400) gsdA gene 0. 07 573 X74765 H. sapiens CSK gene for protein tyrosine kinase 0. 069 574 X63510 M. musculus CAMLI gene (exons 5-9) 0. 62 Rattus norvegicus type I hexokinase (HKI) gene, promoter 575 U27319 region and partial cds 0. 61 576 L23863 Rat Sknli mRNA. 0. 068 H. sapiens isoform I gene for L-type calcium channel, exon 47 577 Z26284. 1 and 48 0. 069 578 S66283 Spnb-l=beta-spectrin [mice. reticulocyte ? mRNA, 8126 ntl 0. 069 579 M36305 Galago crassicaudatus gamma globin gene, complete cds. 0. 07 580 AB018337. 1 Homo sapiens mRNA for KIAA0794 protein, partial cds 0. 22 H. sapiens CpG island DNA genomic Msel fragment, clone 581 Z60182 193a12 reverse read cpgl93al2. rtla 0. 21 582 AF121948. 1 Homo sapiens telomerase reverse transcriptase 0. 003 584 Y10019 R. norvegicus mRNA for DRM protein 0. 21 Drosophila melanogaster clone GH08860 BcDNA. GH08860 _ 585 AF145653. 1 (BcDNA. GH08860) mRNA, complete cds 0. 64 Gossypium hirsutum group 4 late embryogenesis-abundant 586 M88321 protein (Leal4-A) gene, complete cds. 0. 024 GSTA5=glutathione S-transferase Yc2 subunit {5'region, intron 1} [rats, Morris hepatoma cell line, Genomic, 2212 nt, segment 1 587 S82821 of 3] 1. 9 5 Homo sapiens retinal pigment epithelium-specific protein 588 AF039857 (RPE65) gene, exon 3 0. 023 589 X05034 Rat C2A gene for prostatic binding protein (PBP) 0. 2 Rattus norvegicus clone ubc4a ubiquitin conjugating enzyme 590 U 13177 (E217kB) mRNA, complete cds. 0. 071 591 AF081530 Homo sapiens neuralized binding protein mRNA, complete cds e-143 592 Z73328 H. sapiens DNA (chromosome 13q, clone 117A11, 856 bp) 0. 023 Mouse lamin A/C and C2 genes, exon 6, 7, 8, 9, 10, 11 and 12, 593 D49733 complete cds 2.3 594 L04603 Trypanosoma cruzi R27-2 protein gene, complete cds. 2. 3 595 AF045742 Xenopus laevis Smad7 mRNA, complete cds 0. 72 596 D83993 Fission yeast DNA for chromosome II cosmid 1228 sequence 0. 7 Table 2A : Nearest Neighbor (BlastN vs. Genbank) SEQ ID ACC'N DESCRIP. P VALUE 597 L77036 Homo sapiens (subclone 5 d9 from PI HI 9) DNA sequence. 0. 008 Plasmodium falciparum chromosome 2, section 51 of 73 of the 598 AE001414 complete sequence 0. 008 599 AF001893 Human MEN1 region clone epsilon/beta mRNA, 3'fragment 0. 2 Human DNA sequence from cosmid L75B9, Huntington's 601 Z69652 Disease Region, chromosome 4p 16. 3 0. 023 602 Z16517 H. sapiens (D13S155) DNA segment containing 0. 041 603 X14448 Human GLA gene for alpha-D-galactosidase A (EC 3. 2. 1. 22) 0. 71 604 AF055481 Homo sapiens normal epithelial cell-specific 1 0. 029 605 AJ002550 Homo sapiens MMP-1 gene, promoter region 6E-11 Mus musculus ubiquitin protein ligase (Itch) mRNA, complete 606 AF037454 cds 0. 0009 Staphylococcus carnosus (3R)-hydroxymyristoyl acyl carrier protein dehydrase homolog (fabZ) gene, partial cds, YwpF 607 U96108 homolog, single-strand binding protein homolog Sce... 0. 8 608 X53334 Chicken mRNA for annexin II 0. 029 609 AF045742 Xenopus laevis Smad7 mRNA, complete cds 0. 028 610 AF045742 Xenopus laevis Smad7 mRNA, complete cds 0. 085 611 AF045742 Xenopus laevis Smad7 mRNA, complete cds 0. 089 612 D16474 Human mRNA. Xq terminal portion 0. 00003 Homo sapiens equilibrative nucleoside transporter 1 (ENT1) NM_004955|mRNA>gi|1845344|gb|U81375|HSU81375 Human placental 613. 1 equilibrative nucleoside transporter 1 0. 00003 614 ABC 19944. 1 Arabidopsis thaliana gene for sigma factor SigC, complete cds 1. 9 615 AB012181 Homo sapiens DNA, anonymous heat-stable fragment RP8-6A IE-34 Medicago truncatula putative cell wall protein (AMI) mRNA, 616 AF106929. 1 complete cds 0. 2 Homo sapiens glucos phosphate isomerase mRNA, intron with a 617 L09105 conserved tandem repeat. 0. 00003 618 X06292 Human c-fes/fps proto-oncogene 0. 028 Homo sapiens solute carrier family 25 member 14 (SLC25A14), nuclear gene encoding mitochondrial product, mRNA NM003951 mitochondrial carrier protein-1 (BMCP1) mRNA, nuclear gene 619. 1 encoding mitochondrial protein, complete cds e-173 Homo sapiens mRNA ; cDNA DKFZp586E0518 (from clone 620 AL050089. 1 DKFZp586E0518) e-166 621 AF045742 Xenopus laevis Smad7 mRNA, complete cds 0. 25 622 AF045742 Xenopus laevis Smad7 mRNA, complete cds 0. 26 623 M17374 X. laevis beta-globin mRNA, 5'UTR. 0. 009 Table 2A : Nearest Neighbor (BlastN vs. Genbank) SEQ ID ACC'N DESCRIP. P VALUE 624 D32056 Human gene for 2-oxoglutarate dehydrogenase. exon 1 sequence 0. 003 625 M17374 X. laevis beta-globin mRNA, 5'UTR. 0. 027 626 M17374 X. laevis beta-globin mRNA, 5'UTR. 0. 028 627 M17374 X. laevis beta-globin mRNA, 5'UTR. 0. 028 628 M17374 X. laevis beta-globin mRNA. 5'UTR. 0. 029 629 M17374 X. laevis beta-globin mRNA, 5'UTR. 0. 028 630 M17374 X. laevis beta-globin mRNA, 5'UTR. 0. 028 631 M17374 X. laevis beta-globin mRNA, 5'UTR. 0. 029 Human DNA sequence from cosmid L96F8, Huntington's Disease Region, chromosome 4put6. 3 contains EST and cDNA >gil1182000lemblZ69365lHSL96F8A Human DNA sequence from cosmid L96F8, Huntington's Disease Region, chromosome 632 Z69364 4p16.3 contains EST and cDNA 8E-13 NM_004435 Homo sapiens endonuclease G (ENDOG), nuclear gene encoding 633. 1 mitochondrial protein, mRNA G (ENDOG) mRNA 9E-13 Human RNA polymerase II holoenzyme component SRB7 634 U46837 (SRB7) mRNA, complete cds. 0. 21 635 M13973 Bovine protein kinase C mRNA. complete cds. 3E-14 636 AB012917 Homo sapiens mRNA for serine protease (TLSP), complete cds e-143 637 M57750 S. pombe cut2+ gene, complete cds. 0. 22 638 V00584 Human gene hY1 encoding a cytoplasmic Ro RNA 7E-21 639 L81854 Homo sapiens (subclone 2 b8 from P I H48) DNA sequence 2E-11 640 X73897 H. sapiens zinc finger domain ZF21. 3 DNA 2E-31 Insertion sequence IS1141 (from Mycobacterium intracellulare 641 L10239 strain Val4), transposase gene, complete cds, clone pVT365. 1. 8 642 AF097025 Homo sapiens cysteine desulfurase (nifS) mRNA, complete cds e-170 Borrelia afzelii R-IP3 chromosome right end, arcA and arcB 644 AF008219 genes, complete cds 0. 092 Homo sapiens Transformation/transcription domain-associated protein (TRRAP) mRNA, and translated products NM_003496 >gil4165076lgblAF076974lAF076974 Homo sapiens TRRAP 645. 1 protein (TRRAP) mRNA, complete cds 6E-43 646 AF000305. 1 Brassica napus steroid sulfotransferase 1 gene, complete cds 0. 76 Homo sapiens thyroid hormone receptor activator molecule 647 AF016031 (TRAM-1) mRNA, complete cds 8E-34 648 M97168 Homo sapiens X (inactive)-specific transcript 0. 22 Table 2A : Nearest Neighbor (BlastN vs. Genbank) SEQ ID ACC'N DESCRIP. P VALUE NM_003011 Homo sapiens SET translocation (myeloid leukemia-associated) 649. 1 (SET) mRNA cds. 9E-36 Homo sapiens chloride intracellular channel 3 (CLIC3) mRNA NM_004669 >gil4323621 lgblAF 102166lAF 102166 Homo sapiens intracellular 650. 1 chloride channel CLIC3 (CLIC3) mRNA, complete cds 4E-50 651 AJ010479. 1 Homo sapiens mRNA for kinesin-like protein 2 e-171 Human AMP deaminase (AMPD3) gene, intron 2, partial 652 U29932 sequence. lue-37 Homo sapiens distal-less homeobox protein (DLX3) gene, 653 AF028233 complete cds 3E-47 654 AF151978. 1 Homo sapiens amino acid transporter B0+ e-165 H. sapiens CpG island DNA genomic Msel fragment, clone 655 Z64037 95g8, forward read cpg95g8. ftla 2E-50 656 M32140 T. brucei heat shock protein (Hsp70) gene, upstream region. 1.9 NM_003164 Homo sapiens syntaxin SA (STX5A) mRNA mRNA, complete 657. 1 cds 7E-54 Homo sapiens heat shock transcription factor 4 (HSF4) mRNA NM_001538|>gi|1813425|dbj|D87673|D87673 Homo sapiens mRNA for heat 658. 1 shock transcription factor 4, complete cds 1E-57 Homo sapiens heat shock transcription factor 4 (HSF4) mRNA NM_001538 >gil1813425ldbjlD87673lD87673 Homo sapiens mRNA for heat 659. 1 shock transcription factor 4, complete cds lue-57 Homo sapiens (clones cYG3, B5P6C4) fragile X E mental 660 L76569 retardation syndrome protein (FMR2) mRNA, complete cds. 0. 21 661 X55110 Human mRNA for neurite outgrowth-promoting protein 2E-59 662 L20468 Rattus norvegicus cerebroglycan mRNA, complete cds. 3E-86 NM005324 663. 1 Homo sapiens H3 histone, family 3B (H3. 3B) e-127 Homo sapiens clathrin-associated/assembly/adaptor protein, NM_001283 small 1 Homo sapiens mRNA for sigmalA subunit of AP-1 664. 1 clathrin adaptor complex, complete cds e-171 665 AF007867 Lymantria dispar pheromone binding protein 1 1. 8 Riftia pachyptila endosymbiont bacterioferritin comigratory 669 U93704 protein homolog (bcp), sensor protein RssA complete cds 1. 9 670 AB002315 Human mRNA for KIAA0317 gene, complete cds 1. 8 673 X96585 M. musculus mRNA for NOV protein 1. 8 Homo sapiens mRNA for mitochondrial DNA polymerase 674 D84103 gamma complete cds 1. 7 Table 2A : Nearest Neighbor (BlastN vs. Genbank) SEQ ID ACC'N DESCRIP. P VALUE Nicotiana tabacum gene for thaumatin-like protein SE39b, 675 AB000834. 2 complete cds 1. 8 Gymnascella hyalinospora strain VAMH 7366 18S ribosomal RNA gene, partial sequence ; internal transcribed spacer 1, 5. 8S ribosomal RNA gene and internal transcribed spacer 2, complete 676 AF129853. 1 sequence ; and 28S ribosomal RNA gen... 0. 2 678 AB029007. 1 Homo sapiens mRNA for KIAA1084 protein, complete cds e-168 Homo sapiens mRNA, chromosome 1 specific transcript 679 AB007957 KIAA0488 e-145 Homo sapiens mRNA ; cDNA DKFZp434C 151 (from clone 680 AL080168. 1 DKFZp434C 151) 0 Poplar mRNA for cellulase (endo-1, 4-beta-glucanase), complete 681 D32166. 1 cds 1. 6 683 M17374 X. laevis beta-globin mRNA, 5'UTR. 0. 03 Haemophilus influenzae Rd section 107 of 163 of the complete 684 U32792 genome 2. 1 685 X74969 R. norvegicus gene for prostatic acid phosphatase 0. 02 Phanerochaete chrysosporium manganese peroxidase isozyme 3 686 U70998 (mnp3) gene, complete cds 0. 73 Homo sapiens nucleosome assembly protein l-like 4 (NAP1L4) NM_005969 mRNA >gil 1679778lgblU77456lHSU77456 Human nucleosome 687. 1 assembly protein 2 mRNA, complete cds 2. 1 688 AJ132369. 1 Sorites orbiculus SSU rRNA. isolate 206 0. 67 Drosophila melanogaster GLI-Kr zinc finger pair-rue protein 690 U04435 mRNA, complete cds. embryo, mRNA, 2959 nt] 0. 67 691 X69511 G. gallus Acra-2 gene alpha-2 subunit 0. 67 Homo sapiens neuronal acetylcholine receptor beta-3 subunit 692 AF 140762. 1 precursor (CHRNB3) gene, exon 3 2 695 Z74734 C. porcellus mRNA for guanylyl cyclase C 1. 9 Clostridium difficile ADP-ribosyltransferase enzymatic and 696 L76081 binding component (cdtA and cdtB) genes, complete cds's 0. 63 697 X82657 H. sapiens IRLB gene (exon 4) 0. 66 698 AB020649. 1 Homo sapiens mRNA for KIAA0842 protein, partial cds e-143 Homo sapiens SUMO-I activating enzyme subunit 2 (UBA2) NM_005499 mRNA >gil4096671 lgblU35832. 1 lHSU35832 Human 699. 1 anthracycline-associated resistance ARX mRNA, complete cds 1E-47 Table 2A : Nearest Neighbor (BlastN vs. Genbank) SEQ ID ACC'N DESCRIP. P VALUE 700 AB018255. 1 Homo sapiens mRNA for KIAA0712 protein, complete cds 0. 008 Human DNA sequence from clone 437022 on chromosome 22q12. 2-13. 1. Contains the 5'part of a novel VHS domain containing protein similar to predicted worm and human 701 AL035496. 6 proteins. Contains ESTs, GSSs and a putative CpG islan... 0. 0000001 702 AB020664. 1 Homo sapiens mRNA for KIAA0857 protein, partial cds e-162 Homo sapiens mRNA ; cDNA DKFZp564C103 (from clone 703 AL050269. 1 DKFZp564C103) e-173 704 M62324 Human modulator recognition factor I (MRF-1) mRNA, 3'end. 1. 8 Human DNA sequence from cosmid L60G9B, Huntington's 705 Z69363 Disease Region. chromosome 4pop16. 3 contains ESTs 0. 61 707 AF068890 Bos taurus PIMI protein (PIM1) gene, exon 5 and partial cds 0. 64 NM000211 Homo sapiens integrin beta chain, beta 2 leukocyte adhesion 708. 1 protein (LFA-I/Mac-1/pl50, 95 family) beta subunit mRNA. 0. 65 Arabidopsis thaliana pre zeta-carotene desaturase precursor (zds) 709 U38550 mRNA, complete cds. 1. 9 Homo sapiens hepatocyte nuclear factor-3 beta gene, complete 710 AF 147787. 1 cds 0. 22 711 AF140549. 1 Enterococcus faecium unknown gene 0. 19 712 AF031630 Danio rerio homeobox protein LIM-3 (lim3) gene, exons 2 and 3 0. 19 Homo sapiens MHC class II HLA-DRBI (HLA-DRBI*10) 713 AF007883 intron I sequence 0. 021 714 X71844 C. perfringens uapC, cpe, and nadC genes 0. 63 715 M87359 Yeast Eco RI fragment. 0. 56 Oryctolagus cuniculus interleukin-10 precursor, mRNA, 716 AF088887 complete cds 0. 62 717 AF151897. 1 Homo sapiens CGI-139 protein mRNA, complete cds 3E-38 Zea mays starch branching enzyme IIa (Sbe2a) mRNA, partial 718 U65948 cds 0. 61 719 AF086443 Homo sapiens full length insert cDNA clone ZD81CI I IE-68 Sus scrofa mRNA for neuron-derived orphan receptor-1 alfa 720 AJ011767 transcription factor 0. 18 721 U78547 Chlamydomonas reinhardtii PF20 mRNA, complete cds 0. 00009 Drosophila melanogaster ecdysone-regulated (E93) mRNA, 722 U25686 complete cds. 0. 54 Table 2A : Nearest Neighbor (BIastN vs. Genbank) SEQ ID ACC'N DESCRIP. P VALUE 723 AB029017. 1 Homo sapiens mRNA for KIAA1094 protein, complete cds e-102 Methanococcus jannaschii section 75 of 150 of the complete 724 U67533 genome 0. 4 725 L81892 Homo sapiens (subclone 2 h6 from P I H62) DNA sequence 2. 2 726 U83650 Mus caroli SplOO gene, exon 13 2. 1 727 X14710 B. taurus beta-lactoglobulin gene 0. 23 728 AF034920 Homo sapiens tubby like protein 1 (TULPI) gene, exons 9-11 2 Mus musculus mRNA for the third largest RNA polymerase 1I 729 D83999 subunit, complete cds 0. 22 Macropus rufogriseus MHC class II DR alpha protein precursor 730 U18109 (Maru-DRA) mRNA. complete cds. 0. 66 Trichophyton rubrum mitochondrial cytb gene and NADH1 to 731 Y18476 NADH5 genes 0. 67 Trichophyton rubrum mitochondrial cytb gene and NADH1 to 732 Y18476 NADH5 genes 0. 65 733 AF148461. 1 Homo sapiens CLNS I A gene, intron I sequence e-160 Equine adenovirus 2 385/75 hexon and endopeptidase genes, 734 L80007 complete cds 1. 9 735 X76128 T. thermophila MSE 2. 9 (left) gene germline limited sequence 0. 22 737 AF141658. 1 Ictalurus punctatus EB1 mRNA, complete cds 0. 62 Methanococcus jannaschii section 118 of 150 of the complete 738 U67576 genome 0. 21 Homo sapiens mRNA : cDNA DKFZp564C103 (from clone 739 AL050269. 1 DKFZp564C103) e-159 740 AF065389 Homo sapiens tetraspan NET-4 mRNA, complete cds 0. 21 741 AB007455. 1 Homo sapiens mRNA for P53TG1-A, complete cds 0. 22 742 U67399 Mus musculus K-cadherin/cadherin-6 mRNA, partial cds 2 743 ABC18315. 1 Homo sapiens mRNA for KIAA0772 protein, complete cds 9E-78 Homo sapiens mRNA ; cDNA DKFZp564C1940 (from clone 745 AL080164. 1 DKFZp564C 1940) 5E-20 746 X00007 Bacillus subtilis 5'end of ribosomal RNA operon rrnB 0. 22 Scutellastra longicosta 16S ribosomal RNA gene, mitochondrial 747 AF058234. 1 gene for mitochondrial RNA, partial sequence 0. 022 748 M99362 Rhesus macaque polyoma virus large T antigen gene, 3'end. 0. 2 749 U80458 Human microtubule associated protein IA mRNA, partial cds 0. 067 Table 2A : Nearest Neighbor (BlastN vs. Genbank) SEQ ID ACC'N DESCRIP. P VALUE Oryza sativa mRNA for Nad-dependent formate dehydrogenase, 750 AB019533. 1 complete cds 0. 22 Human DNA sequence from cosmid U238E5, between markers 751 Z69723 DXS6791 and DXS8038 on chromosome X 0. 2 Plasmodium falciparum mature parasite-infected erythrocyte 752 AF056936 surface antigen gene, complete cds 1. 8 753 AJO 10396. 1 Homo sapiens DKC1 gene, exons 12 to 15 0. 63 Xenopus laevis/gilli complement component C3 mRNA, partial 754 U 19253 cds. 1. 9 755 M82872 S. cerevisiae protein-tyrosine phosphatase complete cds. 0. 21 756 AF045188 Salmo salar ribosomal protein Ll8a mRNA, complete cds 0. 21 757 AJ001118 Mus musculus mRNA for monoglyceride lipase 0. 62 758 Y10377 C. albicans TOP2 gene 1. 8 759 AB014573 Homo sapiens mRNA for KIAA0673 protein, partial cds e-168 760 L24113 Saccharomyces cerevisiae Ca2+ regulatory protein 0. 19 761 M96739 Human NSCL-1 mRNA sequence. 1. 7 Human respiratory syncytial virus, recombinant mutant rA2cp, 762 AF035006 complete genome 0. 56 763 AF065389 Homo sapiens tetraspan NET-4 mRNA, complete cds 0. 19 Homo sapiens transcriptional adaptor 2 complex) (TADA3L) NM 006354 mRNA >gil3335554gblAF069733AF069733 Homo sapiens 764. 1 ADA3-like protein mRNA, complete cds e-154 765 M73752 Gossypium hirsutum Lea4-A gene, complete CDS. 0. 06 766 X79192 F. brownii pdk gene 0. 54 H. sapiens gene for transforming growth factor-beta 3 (TGF-beta 767 X14891 3) exon 7 0. 076 H. sapiens flow-sorted chromosome 6 HindIII fragment, 768 Z78708 SC6pA14H12 0. 076 Streptococcus pneumoniae D-glutamic acid adding enzyme MurD (murD), undecaprenyl-PP-MurNAc-pentapeptide- UDPGicNAc GlcNAc transferase (murG), cell division protein 769 AF068902 DivIB (divIB), orotidine-5'-decarboxylase PyrF (pyrF), an... 0. 23 Cricetulus griseus beta-1, 6-N-acetylglucosaminyltransferase 770 U62588 Lec4 cell line insertion mutant mRNA, complete cds 2 Timarcha coarcticollis mitochondrial partial tRNA-Leu gene and 771 AJ236354. 1 COII gene, isolate Los Barrios, Cadiz, Spain 0. 026 Methanococcus jannaschii section 146 of 150 of the complete 772 U67604 genome 0. 22 Table 2A : Nearest Neighbor (BlastN vs. Genbank) SEQ ID ACC'N DESCRIP. P VALUE 773 AB018257. 1 Homo sapiens mRNA for KIAA0714 protein, partial cds e-178 774 AF169299. 1 Equus caballus microsatellite HTG15 sequence 0. 21 Homo sapiens Ig heavy chain VH3 region (VH3-30. 3) mRNA, 775 U96289 partial cds 0. 64 Mouse neuroblastoma-Rat glioma hybrid cell line mRNA for a 776 Y07521 potassium channel protein NGK2 0. 076 Homo sapiens sema domain, seven thrombospondin repeats (type NM 003966 I and type 1-like), transmembrane domain semaphorin F 777. 1 homolog mRNA, complete cds 0. 071 778 U66524 Dictyostelium discoideum ORFvegl58 mRNA, partial cds 0. 071 Chilo iridescent virus DNA-directed RNA polymerase and helicase genes, complete cds's. DNA-depenent RNA polymerase largest subunit homolog iridescent virus type 6, Genomic, 3 779 M81388 genes, 7990 nt] 0. 073 780 AF132944. 1 Homo sapiens CGI-10 protein mRNA, complete cds e-170 781 AJ001700 Mus musculus mRNA for neuroserpin 0. 069 Human Down Syndrome region of chromosome 21, clone A4B8- 782 U50421 1 D8. 0. 61 783 X74159 K. lactis MBPI gene 1. 9 784 D87682 Human mRNA for KIAA0241 gene, partial cds 0. 071 Homo sapiens mRNA for type II membrane protein, complete 785 AB015633. 1 cds, clone : HP10481 7E-23 Trichomonas vaginalis glyceraldehyde-3-phosphate 786 AF022414 dehydrogenase (gap2) gene, partial cds 0. 2 787 M36996 Mouse L1M1 and L1M2 sequence DNA. 0. 21 Aedes aegypti LINE retrotransposon Juan-A including DNA binding protein and reverse transcriptase-like protein mRNA, 788 M95171 complete coding regions. 0. 069 Lupinus luteus proline-rich protein PRP2 precursor (LIPRP2) 789 U47661 gene, complete cds 0. 59 790 X55581 H. sapiens immunoglobulin heavy chain gene, diversity region 0. 59 Farfantepenaeus duorarum isolate FD6 mitochondrial control 791 AF 104500 region 0. 065 Mus musculus diaphanous-related formin (Dia2) mRNA, 792 AF094519 complete cds 3E-79 793 X95267 G. gallus mRNA for ryanodine receptor type 3 0. 63 Bacteriophage Cp-1 (Streptococcus pneumoniae), 3'inverted 794 K01872 terminal repeat. 0. 063 Table 2A : Nearest Neighbor (BlastN vs. Genbank) SET ID ACC'N DESCRIP. | 795 AF094573 Rice tungro bacilliform virus isolate T10 P194 gene, partial cds 1. 7 796 X15061 Glycine max Ibc3 gene for leghemoglobin C3 0. 062 797 Y17267 Mus musculus mRNA for ubiquitin conjugating enzyme 3E-89 Rickettsia australis strain PHS outer membrane protein B 798 AF149109. 1 (ompB) gene, partial cds 0. 061 Thermoanaerobacterium thermosaccharolyticum ptaA and ackA 799 AJ004870 genes, orfl, orf2, orf3, orf4 0. 19 800 S77555 corticotropin receptor/ACTH receptor {5'region} 0. 19 801 AJ130796 Mus musculus APC2 gene, exon 14 1. 6 802 AE001229 Treponema pallidum section 45 of 87 of the complete genome 1. 7 Suillus sinuspaulianus mitochondrial large subunit ribosomal 803 X16137 RNA gene, part 0. 69 804 AF048839. 1 Arabidopsis thaliana Atmyb 103 (MYB 103) gene, complete cds 0. 68 805 Z86109 S. carlsbergensis 12 kb region of chromosome III 0. 025 806 X67053 S. tuberosum ppc mRNA for phosphoenolpyruvate carboxylase 0. 67 807 X13423 Phaseolus vulgaris tRNA-Pro (UGG3) gene 2 H. sapiens (D9S 179) DNA segment containing (CA) repeat ; 808 Z17118 clone AFM248wfl ; single read 0. 65 809 Z23386 H. sapiens (D5S467) DNA segment containing 0. 072 Mouse T-cell surface antigen T3 delta-chain gene, exons 2, 3, 4 and 5, from B8C3 (anti-porcine insulin T-T) hybridoma, clone 810 M 12729 pMT-2. 0. 23 811 AF012551 Plasmodium falciparum ornithine decarboxylase 0. 21 Human skeletal muscle chloride channel (HUMCLC) gene, exon 812 L08265 7. 0. 075 813 X00616 Tobacco chloroplast gene P32 for thylakoid membrane protein 0. 07 Plasmodium berghei extrachromosomal plastid PB-1, ORF470 gene, partial cds, tRNA-Thr, large subunit ribosomal RNA, tRNA-Met, tRNA-Arg, tRNA-Val, tRNA-Arg, tRNA-Leu, tRNA 814 U79731 Asn, tRNA-Ala, and small subunit ribosomal RNA genes... 0. 023 II beta-globin=II beta-globin {5'region} [rats, mRNA Partial, 815 S82293 1428 nt] 2 816 AJ007398. 1 Homo sapiens mRNA for PBKI protein 0 817 AL109849. 1 Streptomyces coelicolor cosmid 3A3 0. 023 Table 2A : Nearest Neighbor (BlastN vs. Genbank) SEQ ID ACC'N DESCRIP. P VALUE Canine herpesvirus cIR6, cUS2, cUS3, cUS4, cUS6, cUS7, cUS8 819 U84223 and cUS9 genes, complete cds 0. 067 Homo sapiens cdc25B phosphatase (CDC25B) gene, 820 AF036233 alternatively spliced, partial cds 0. 024 Homo sapiens ELK1 pseudogene (ELK2) and immunoglobulin 821 AB016195. 1 heavy chain gamma pseudogene (IGHGP) 1 E-16 Human N-formyl peptide receptor (FPR1) gene, complete cds 822 L10820 and Alu repeats. 0. 023 823 AF039423 Cebus olivaceus blue opsin gene, exons 2 and 3 0. 58 824 Z97214 Xenopus laevis mRNA for MILZ protein 1. 8 825 Y17038 Mus musculus bassoon gene, exon 6 to 11 1. 7 826 X92518 H. sapiens mRNA for HMGI-C protein 0. 065 827 X06414 Mycoplasma capricolum ribosomal protein gene cluster 0. 62 828 AJ002019 Saccharomyces uvarum mitochondrial coxll gene, partial 0. 061 829 D84395 Bombyx mori DNA for cecropin A, complete cds 0. 18 830 D86077 Homo sapiens DNA for cyclin G, partial cds 0. 18 Mesocricetus auratus Mx-interacting protein kinase PKM 831 AF144573. 1 mRNA, complete cds 2E-18 832 AF123653. 1 Homo sapiens FEZ1 (FEZ1) gene, complete cds 0. 009 833 X71018 N. tabacum NPG-G27Y mRNA for polygalacturonase 0. 025 Anthocidaris crassispina mRNA for intermediate chain 1, 834 D63884 complete cds 0. 072 Plasmodium falciparum chromosome 2, section 30 of 73 of the 835 AE001393 complete sequence 0. 008 Plasmodium falciparum chromosome 2, section 32 of 73 of the 836 AE001395 complete sequence 0. 0003 837 AF007164 Drosophila melanogaster mRNA sequence 0. 21 838 AB005744 Perilla frutescens DNA for 1-limonene synthase, complete cds 0. 21 839 AF067143 Homo sapiens myosin heavy chain (MYH8) gene, partial cds 0. 21 840 X04130 Watermelon mitochondrial URF1 gene 0. 008 841 X95439 S. xylosus aroA, ccpA, acuC and acuA genes 0. 008 842 AB007404. 1 Oryza sativa gene for alanine aminotransferase, complete cds 0. 063 Human chromosome 8 flanking hypervariable simple repeat 843 X59823 DNA (clone HZREP32) 0. 21 844 AF122981. 1 Arabidopsis lyrata cultivar NC4 RPM I gene, 5'sequence 0. 002 845 AF016667. 2 Caenorhabditis elegans cosmid T20H12 4 9 Table 2A : Nearest Neighbor (BlastN vs. Genbank) SEQ ID ACC'S DESCRIP. P VALUE Slime mold (D. discoideum) gene for actin 2 sub1 actin 2 (sub 1) 846 V00184 gene 5'end. 0. 061 847 AB020656. 1 Homo sapiens mRNA for KIAA0849 protein, partial cds 0. 23 848 X82107 H. sapiens gene for tryptophanyl-tRNA synthetase 1. 9 Mouse liver receptor homologous protein (LRH-1) mRNA, 849 M81385 complete cds. 0. 025 Nom 006401 Homo sapiens acidic protein rich in leucines silver-stainable 850. 1 protein SSP29 mRNA, complete cds 0. 008 Plasmodium falciparum DNA *** SEQUENCING IN 851 AL010149 PROGRESS *** from contig 3-82, complete sequence 0. 21 852 AF151826. 1 Homo sapiens CGI-68 protein mRNA, complete cds e-153 Plasmodium falciparum chromosome 2, section 39 of 73 of the 853 AE001402 complete sequence 0. 021 854 U96976 Homo sapiens MET proto-oncogene, intron 6, 3'end 0. 068 855 D85545 Yeast chkl and ucbP4 DNA, partial and complete cds 1. 7 Homo sapiens ribonuclease P protein subunit pl4 (Rppl4) 856 AF001175 mRNA, complete cds 7E-45 Anticarsia gemmatalis nuclear polyhedrosis virus genomic repeat 857 U 14724. 1 region 0. 0008 Human DNA sequence from cosmid N I OOB 10 on chromosome 858 AL008641 22ql2. 3 0. 06 859 Y00326 Human sis proto-oncogene upstream region 0. 19 860 AF003483 Habrabracon hebetor 16S ribosomal RNA gene, partial sequence 0. 0007 Homo sapiens mRNA ; cDNA DKFZp564F053 (from clone 861 AL049265. 1 DKFZp564F053) e-122 862 Z69351 B. vulgaris repetitive DNA (clone pDRV1) 0. 0009 863 L28998 Theileria parva 28S ribosomal RNA (28S rRNA) gene. 0. 024 864 X06000 G. gallus carbonic anhydrase 11 gene exons 1-2 0. 067 865 AB000565 Homo sapiens DNA for repeat sequence Alu IE-26 866 AE000761 Aquifex aeolicus section 93 of 109 of the complete genome 0. 22 867 AF017145 Homo sapiens multidrug resistance protein 0. 0008 868 J05451 Human gastric (H+ + K+)-ATPase gene, complete cds. 0. 003 869 AB018258. 1 Homo sapiens mRNA for KIAA0715 protein, partial cds 0. 007 Mus musculus mRNA for membrane glycoprotein, complete cds zgil3251779ldbjlEl2950lEl2950 cDNA GA3-43 encoding novel polypeptide which appear when differentiate from embryo-tumor 870 D78572 cell P19 to nerve cell 0. 0001 Table 2A : Nearest Neighbor (BlastN vs. Genbank) SEQ ID ACC'N DESCRIP. P VALUE 871 AC001017 Homo sapiens (subclone 2_g8 from PI H43) DNA sequence 0. 003 872 AB018284. 1 Homo sapiens mRNA for KIAA0741 protein, complete cds 0. 0009 Human DNA sequence from cosmid L129H7, Huntington's 873 Z54147 Disease Region, chromosome 4pu6. 3 contains CpG island 0. 002 Human DNA sequence from cosmid L129H7, Huntington's 874 Z54147 Disease Region, chromosome 4p 163 contains CpG island 0. 002 NM006392 Homo sapiens nucleolar protein (KKE/D repeat) mRNA for 875. 1 nucleolar protein hNop56 e-157 876 L43392 Homo sapiens (subclone 6 a8 from PI H ! 6) DNA sequence. 0. 00001 877 X75670 O. sativa mRNA for cytochrome b5 0. 00001 878 Z23808 H. sapiens (DXS1199) DNA segment containing 0. 000009 879 L48473 Homo sapiens (subclone 7 e I I from P I H 16) DNA sequence. 0. 003 Homo sapiens neuronal and epithelial glutamate transporter 880 AF074908. I (SLCIAI) gene, exon 75E-1I Human preproenkephalin B gene 5'region and exon 1 >gil182100licllX00174 Human enkephalin B (enkB) gene, 5' 881 X02536 flank and exon 1. 0. 000001 Homo sapiens mRNA full length insert cDNA clone 882 AL109681. 1 EUROIMAGE 112333 0. 000003 Entamoeba histolytica P-glycoprotein-1 (pgpl) gene, complete 883 M88599 cds. 0. 07 Human unknown protein from clone pHGR74 mRNA, complete 884 M38188 cds. 6E-10 885 U50531 Human BRCA2 region, mRNA sequence CG030 0. 000001 H. sapiens CpG island DNA genomic Msel fragment, clone 886 Z64533 134d9, forward read cpgl34d9. ftla 0. 0000004 NM_004422 Homo sapiens dishevelled 2 (homologous to Drosophila dsh) 887. 1 (DVL2) mRNA dishevelled 2 (DVL2) mRNA, complete cds e-116 sterol regulatory element I binding protein cells, mRNA Partial, 888 S66168 547 nt, segment 2 of 2] 5527690 0. 008 889 L29556 Human (clone hSTX) sialyltransferase mRNA, 3'end. 0. 008 890 AF036703 Caenorhabditis elegans cosmid T11F80. 53 Human DNA sequence from cosmid L2F10, Huntington's Disease Region, chromosome 4pl6. 3 contains Human G protein 891 Z68281 coupled receptor kinase-like, and an RFLP 0. 000004 Human DNA sequence from clone 321120 on chromosome 892 AL035046. 5 1q32. 1-41 Contains GSSs, complete sequence 0. 0001 893 Y15083 Homo sapiens pl4. 5-like gene and Alu repeat 3E-13 Table 2A : Nearest Neighbor (BlastN vs. Genbank) SEQ ID ACC'N DESCRIP. P VALUE Homo sapiens clone SUPTH48 sequence flanking the HIV-1 894 AF044123 provirus integration site 0. 19 895 J00139 Human dihydrofolate reductase gene, exon 6 and 3'flank. 7E-44 896 Y16790 Homo sapiens hHa4 gene, complete CDS 3E-14 897 U50105 Human ankyrin (ANK1) gene, exon 15 0. 00000004 Schizosaccharomyces pombe mRNA for snoRNP protein GAR 898 AB000537 1, complete cds 0. 00000005 899 D79990 Human mRNA for KIAA0168 gene, complete cds 0. 000001 * 900 AC002183 Homo sapiens (subclone 2_h8 from BAC H111) DNA sequence 0. 00000004 901 AF045742 Xenopus laevis Smad7 mRNAt complete cds 0. 11 902 AF072468 Homo sapiens (JH8) mRNA, partial cds 2E-19 903 M 11167 Human 28S ribosomal RNA gene. 2E-09 904 D87117 Mus musculus mRNA for SAP102, complete cds 2E-09 905 AB023189. 1 Homo sapiens mRNA for KIAA0972 protein, complete cds 0 906 Y07554 Psychrobacter sp. pim gene 0. 68 Homo sapiens PAC clone DJ1152D16 from Xq23, complete 907 AC005190 sequence [Homo sapiens] 2E-29 908 AF045742 Xenopus laevis Smad7 mRNA, complete cds 0. 28 Homo sapiens Recq helicase 5 (RECQ5) gene, alternative splice 909 AF135183. 1 products, complete cds e-146 Mus musculus SH3-containing protein SH3P7 mRNA, complete 910 U58884 cds. similar to Human Drebrin 2E-13 Human leiomyoma cell line LM-30. 1/SV40 ectopic sequence 911 U29113 from HMGI-C fusion mRNA. 3'sequence, clone pCH 110. 2E-13 912 AC002252 Homo sapiens (subclone l_g7 from BAC H76) DNA sequence 3E-24 913 U95097 Xenopus laevis mitotic phosphoprotein 43 mRNA, partial cds 0. 09 Homo sapiens zinc finger protein 136 (clone pHZ-20) (ZNF136) NM_003437 mRNA >gil487784lgb {U09367lHSU09367 Human zinc finger 914. 1 protein ZNF136 2E-19 915 M17374 X. laevis beta-globin mRNA, 5'UTR. 0. 029 916 M12523 Human serum albumin (ALB) gene, complete cds. IE-15 917 AF043324 Homo sapiens N-myristoyltransferase I mRNA, complete cds 2E-51 Homo sapiens scaffold attachment factor B (SAF-B) mRNA, 918 L43631 partial cds 0. 008 Tribolium castaneum zinc finger protein (Kruppel domain 919 L01616 region) gene, partial cds. 4E-18 920 D12688 Mouse P-cadherin gene, exon 1 and 2 2 921 X94770 H. sapiens mRNA for epithelial membrane protein-2 2E-19 Table 2A : Nearest Neighbor (BlastN vs. Genbank) SEQ _ __ _-__ ID ACC'N DESCRIP. P VALUE NM_000946 Homo sapiens primase, polypeptide 1 (49kD) for DNA primase 922. 1 (subunit p48) 2E-20 Methanobacterium thermoautotrophicum from bases 264585 to 923 AE000818 276866 (section 24 of 148) of the complete genome 1. 9 Human DNA sequence from clone 141I3 on chromosome 22ql3. 1-13. 33 Contains an STS and a GSS, complete sequence 924 AL035418. 6 [Homo sapiens] 0. 0009 925 AF086040 Homo sapiens full length insert cDNA clone YX52E07 6E-73 Homo sapiens mRNA ; cDNA DKFZp564B206 (from clone 926 AL049310. 1 DKFZp564B206) 2E-09 927 J01415 Human mitochondrion, complete genome 3E-24 Homo sapiens clone SUPTH47 sequence flanking the HIV-1 928 AF044122 provirus integration site 9E-25 929 Z22640 H. magnipapillata homeobox containing exon 0. 076 Homo sapiens clathrin, heavy polypeptide-like 2 (CLTCL2) NM_004859 mRNA >gil434760ldbjlD21260lHUMORFEA Human mRNA for 930. 1 KIAA0034 gene, complete cds 4E-27 931 AL049701. 1 Human gene from PAC 433G19. chromosome I e-162 Homo sapiens U4/U6-associated RNA splicing factor (HPRP3P) mRNA >gil2708306lgblAF016370lAF016370 Homo sapiens NM_004698 U4/U6 small nuclear ribonucleoprotein hPrp3 mRNA, complete 932. 1 cds 4E-28 NM_003983 Homo sapiens solute carrier family 7 for KIAA0245 gene, 933. 1 complete cds lE-30 Homo sapiens zinc finger protein 140 (clone pHZ-39) (ZNF140) NM_003440 mRNA >gil487786lgblU09368lHSU09368 Human zinc finger 934. 1 protein ZNF140 IE-30 Homo sapiens mRNA ; cDNA DKFZp5861031 (from clone 935 AL050392. 1 DKFZp586I031) 7E-33 NM_002714 Homo sapiens protein phosphatase 1, regulatory subunit 10 936. 1 (PPPIR10) mRNA e-121 937 M27830 Human 28S ribosomal RNA gene, complete cds. 2E-33 938 M27830 Human 28S ribosomal RNA gene, complete cds. 2E-33 Human DNA sequence from cosmid N29F4 on chromosome 939 Z72521 22q11. 2-qter contains STS 0. 000001 Homo sapiens neuroblastoma-amplified protein mRNA, 940 AF056195 complete cds 2E-72 941 Z35989 S. cerevisiae chromosome II reading frame ORF YBR120c 0. 19 Rattus norvegicus O-GIcNAc transferase, pi 10 subunit (OGT) 942 U76557 mRNA, complete cds 9E-36 Table 2A: Nearest neighbor (BlastN vs. enbank) SEQ ID ACC'N DESCRIP. P VALUE H. sapiens CpG island DNA genomic Msel fragment, clone 8g7, 943 Z56141 forward read cpg8g7. ftla 3E-37 944 AF132951. 1 Homo sapiens CGI-17 protein mRNA, complete cds e-165 Homo sapiens IGF-11 mRNA-binding protein 2 sapiens NM 006548 hepatocellular carcinoma autoantigen (p62) mRNA, complete 945. 1 cds e-140 946 AF010317 Homo sapiens Pig3 (PIG3) gene, partial cds 3E-38 947 AB023151. Homo sapiens mRNA for KIAA0934 protein, partial cds 2E-54 Human DNA sequence from cosmid L69F7B, Huntington's Disease Region, chromosome 4p 163 contains Huntington 948 Z69649 Disease (HD) gene 1E-25 949 AC001159 Homo sapiens (subclone 1 h9 from PAC H92) DNA sequence 4E-17 Homo sapiens mRNA ; cDNA DKFZp564H 172 (from clone 950 AL080060. 1 DKFZp564H172) 5E-29 951 L07758 Human IEF SSP 9502 mRNA, complete cds. 4E-48 952 M29037 Human 17 beta-hydroxysteroid dehydrogenase 0. 56 953 M36704 C. perfringens perfringolysin O (pfo) gene, complete cds. 0. 22 Human endogenous retrovirus clone cl8. 4, HERV-H/HERV-E hybrid multiply spliced protease/integrase mRNA, complete cds, 954 U34991 and envelope protein mRNA, partial cds 2E-61 955 AB002369 Human mRNA for KIAA0371 gene, complete cds 0. 0009 956 AF098668 Homo sapiens acyl-protein thioesterase mRNA, complete cds e-156 Actinidia deliciosa var delicisoa polygalacturonase gene, 957 L.12019 complete cds 0. 19 958 Z12622 A. sativum mRNA encoding precursor alliinase 0. 065 Homo sapiens zinc finger protein 85 (HPF4, HTF1) (ZNF85) NM_003429 mRNA >gil 1017721 lgblU35376lHSU35376 Human repressor 959. 1 transcriptional factor (ZNF85) mRNA, complete cds. 2E-51 Homo sapiens genomic DNA, chromosome 21q22. 1, D21S226- 960 AP000249. 1 AML region, clone : B762015, complete sequence 0. 0003 961 U 16120 Human placental taurine transporter mRNA, complete cds. 2E-52 NM002286 Homo sapiens lymphocyte-activation gene 3 mRNA for CD4- 962. 1 related protein involved in lymphocyte activation 2E-53 963 D63876 Human mRNA for KIAA0154 gene, partial cds 6E-54 Homo sapiens general transcription factor IIF, polypeptide 2 NM004128 (30kD subunit) (GTF2F2) mRNA subunit of transcription 964. l initiation factor RAP30/74 7E-55 Table 2A : Nearest Neighbor (BlastN vs. Genbank) SEQ ID ACC'N DESCRIP. P VALUE Scutellospora heterogama 18S ribosomal RNA gene, partial sequence, 5. 8S ribosomal RNA gene, complete sequence, and 965 AF004691 26S ribosomal RNA gene, partial sequence 0. 22 Methanococcus jannaschii section 51 of 150 of the complete 966 U67509 genome 0. 074 967 AB010059 Homo sapiens RBP56/hTAFII68 gene exon 3, 4, 5 4E-80 968 AB007891 Homo sapiens KIAA0431 mRNA, partial cds 9E-60 Homo sapiens G alpha interacting protein (GAIP) mRNA NM_005873 >gil 1107697lemblX91809lHSPAIP H. sapiens mRNA for GAIP 969. 1 protein 4E-60 Human neuronal DHP-sensitive, voltage-dependent, calcium 970 M76558 channel alpha-ID subunit mRNA, complete cds. 0. 27 Homo sapiens zinc finger protein 124 (HZF-16) HZF- NM_003431 16=Kruppel-related zinc finger gene homolog HEP-G2, mRNA, 971. 1 2080 nt] 2E-60 Rattus norvegicus mRNA for beta-alanine-pyruvate 972 AB002584 aminotransferase, complete cds 0. 00000002 973 X85133 H. sapiens RBQ-1 mRNA 2E-64 Porphyromonas gingivalis W50 receptor antigen (rag) locus 974 AJ130872.1 encoding a major immunodominant 55kDa antigen 1.7 Mus musculus ACF7 neural isoform 1 (mACF7) mRNA, partial 975 U67203 cds 2E-66 Mus musculus ACF7 neural isoform I (mACF7) mRNA, partial 976 U67203 cds 3E-69 977 U55941 Expression vector pVP-HA2, complete sequence. 2E-79 Homo sapiens PAPS synthetase-2 (PAPSS2) mRNA, complete 978 AF074331. 1 cds e-173 M. musculus mRNA for B-cell receptor associated protein (BAP) 979 X78684 29 e-100 Mus musculus channel interacting PDZ domain protein mRNA, 980 AF060539 complete cds e-138 981 U55042 Bos taurus myosin X, complete cds e-119 982 AB000172 Porcine mRNA for endopeptidase 24. 16, complete cds e-131 H. sapiens CpG island DNA genomic Msel fragment, clone 983 Z57139 165d10, forward read epg165d10.ft1a 0. 4 984 AB012917 Homo sapiens mRNA for serine protease (TLSP), complete cds 0 985 L39064 Homo sapiens interleukin 9 receptor precursor 6E-15 986 M17374 X. laevis beta-globin mRNA, 5'UTR. 0. 36 987 AF045188 Salmo salar ribosomal protein L 8a mRNA, complete cds 0. 38 988 AF045742 Xenopus laevis Smad7 mRNA, complete cds 0. 43 Table 2A : Nearest Neighbor (BIastN vs. Genbank) SEQ _ __ ID ACC'N DESCRIP. P VALUE Emericella nidulans molybdenum cofactor biosynthetic protein 989 AF055287 (cnxF) gene, complete cds 4. 4 990 AF045742 Xenopus laevis Smad7 mRNA, complete cds 0. 38 991 X03991 Human glucagon gene 0. 42 992 AJ131021. 1 Mus musculus mRNA for pp90 ribosomal protein S6 kinase 3 2E-17 993 U18168 Human HLA class I genomic survey sequence, contains Alu. 4E-11 H. sapiens CpG island DNA genomic Msel fragment, clone 994 Z57139 165d 10, forward read cpgl65dl O. ftla 0. 4 995 AB012917 Homo sapiens mRNA for serine protease (TLSP), complete cds 0 996 AF045742 Xenopus laevis Smad7 mRNA, complete cds 0. 38 Human MHC class 11 HAL-DQA1 gene (DR4, DR4), flanking 997 M72411 region and alu repeat. 4E-21 998 J03612 P. yoelii merozoite surface antigen gene, 3'end. 0. 13 Homo sapiens mRNA, chromosome 1 specific transcript 999 AB007957 KIAA0488 0 Gracilaria chilensis 18S ribosomal RNA gene, partial sequence ; internal transcribed spacer 1, 5. 8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence ; and 25S 1000 AF034265 ribosomal RNA gene, partial sequence 0. 62 Homo sapiens mRNA ; cDNA DKFZp434C 151 (from clone 1001 AL080168. 1 DKFZp434CI51) 0 1002 AF121948. 1 Homo sapiens telomerase reverse transcriptase 0. 001 1003 AF063668. 1 Mus musculus type XIII collagen (coll3al) gene, exon 3 2. 1 NM003630 Homo sapiens peroxisomal biogenesis factor 3 mRNA for Pex3 1004. 1 protein 0 1005 M35543 Human GTP-binding protein (G25K) mRNA, complete cds. 0. 077 1006 U68216 Carica papaya ACC synthase mRNA. complete cds 4 1007 AF133913. 1 Mus musculus ARL-6 interacting protein-6 6E-82 NM_000211 Homo sapiens integrin beta chain, beta 2 leukocyte adhesion 1008. l protein (LFA-1/Mac-1/p150, 95 family) beta subunit mRNA. 0. 65 1009 D10044 Tomato aspermy virus (V-TAV) RNA ! 0. 02 1010 S82740 NPM/ALK=fusion gene {translocation breakpoint} 0. 71 Treponema denticola gufa gene, partial cds, putative flagellar operon flgB, flgC, fliE, fliF, fliG, fliH, fliI and flij genes, 1011 U78776 complete cds, and fdgA gene, partial cds 0. 14 Table 2A : Nearest Neighbor (BlastN vs. Genbank) SEQ ID ACC'N DESCRIP. P VALUE 1012 AF140549. 1 Enterococcus faecium unknown gene 0. 51 Homo sapiens ARF GTPase-activating protein GIT1 mRNA, 1013 AF 124490. 1 complete cds e-176 1014 D10044 Tomato aspermy virus (V-TAV) RNAI 0. 02 Oryctolagus cuniculus interleukin-10 precursor, mRNA, 1015 AF088887 complete cds 0. 62 1016 AF 121948. 1 Homo sapiens telomerase reverse transcriptase 0. 29 1018 U78547 Chlamydomonas reinhardtii PF20 mRNA. complete cds 0. 0001 Homo sapiens mRNA ; cDNA DKFZp434P113 (from clone 1019 AL080145. 1 DKFZp434P113) 0 Bovine ASS mRNA encoding argininosuccinate synthetase, 1020 M26198 complete cds. 0. 24 1021 D87686. 1 Homo sapiens mRNA for KIAA0017 protein, complete cds e-175 1022 X56668 Human DNA for calretinin exon I 0. 16 1023 AB007158 Homo sapiens gene for ribosomal protein S23. partial cds e-114 1024 X83433 O. sativa mRNA for lipid transfer protein, b21 0. 66 1025 D32072 Mouse MRNA isoform of TGF-b type II receptor 0. receptor 1026 D26077 Mouse mRNA for KIF3B protein, complete cds 0. 3 1027 X80111 D. melanogaster sap47-1 mRNA 2E-09 Homo sapiens solute carrier family 25 member 14 (SLC25A14), nuclear gene encoding mitochondrial product. mRNA >gil3851539lgblAFO78544lAFO78544 Homo sapiens brain NM_003951 mitochondrial carrier protein-1 (BMCP1) mRNA, nuclear gene 1028. 1 encoding mitochondrial protein. complete cds 0 1029 AF016422 Caenorhabditis elegans cosmid R09E12 0. 0007 Homo sapiens transcriptional adaptor 2 (ADA2, yeast homolog)- NM006354 3 like (PCAF histone acetylase complex) sapiens ADA3-like 1030. 1 protein mRNA, complete cds 0 1031 M17374 X. laevis beta-globin mRNA, 5'UTR. 0. 063 1032 M25702 Human thyroid peroxidase (TPO) gene, exon 2. 0. 091 1033 AB018257. 1 Homo sapiens mRNA for KIAA0714 protein, partial cds 0 1034 L06898 Actinomyces viscosus sialidase (nanH) gene, complete cds. 0. 49 Mouse neuroblastoma-Rat glioma hybrid cell line mRNA for a 1035 Y07521 potassium channel protein NGK2 0. 12 1036 AF153201. 1 Homo sapiens zinc finger protein dp mRNA, complete cds 3E-39 Drosophila melanogaster mRNA for Dof protein, transcript I, 1037 AJ010642 partial 1. 9 Table 2A : Nearest Neighbor (BlastN vs. Genbank) SEQ ID ACC'N DESCRIP. P VALUE Homo sapiens mRNA for type II membrane protein, complete 1038 AB015633. 1 cds, clone : HP10481 7E-23 Human nucleolar fibrillar center protein (ASE-1) mRNA, 1039 U86751 complete cds 0. 019 Homo sapiens heat shock transcription factor 4 (HSF4) mRNA NM_00153 |>gil 1813425ldbjlD87673lD87673 Homo sapiens mRNA for heat 1040 1 shock transcription factor 4, complete cds 1E-57 Homo sapiens heat shock transcription factor 4 (HSF4) mRNA NM-001538|>gi|1813425|dbj|D87673|D87673 Homo sapiens mRNA for heat 1041 1 shock transcription factor 4, complete cds I E-57 Homo sapiens clathrin-associated/assembly/adaptor protein, NM 001283 small 1 Homo sapiens mRNA for sigmalA subunit of AP-1 1042. 1 clathrin adaptor complex, complete cds 0 Human skeletal muscle chloride channel (HUMCLC) gene, exon 1043 L08265 7. 0. 075 Plasmodium berghei extrachromosomal plastid PB-1, ORF470 gene, partial cds, tRNA-Thr, large subunit ribosomal RNA, tRNA-Met, tRNA-Arg, tRNA-Val, tRNA-Arg, tRNA-Leu, tRNA 1044 U79731 Asn, tRNA-Ala, and small subunit ribosomal RNA genes... 0. 037 1045 X64467 H. sapiens ALAD gene for porphobilinogen synthase 0. 019 1046 M17374 X. laevis beta-globin mRNA, 5'UTR. 0. 37 Mesocricetus auratus Mx-interacting protein kinase PKM 1047 AF144573. 1 mRNA, complete cds 2E-18 1048 U79260 Human clone 23745 mRNA, complete cds 7E-26 H. sapiens (D1S414) DNA segment containing (CA) repeat ; 1049 Z23435 clone AFM179xg5 ; single read 0. 0007 1050 X95439 S. xylosus aroA, ccpA, acuC and acuA genes 0. 014 1051 M32676 Human platelet glycoprotein IIIa, intron 10, fragment A. 0.01 1052 AB018284.1 Homo sapiens mRNA for KIAA0741 protein, complete cds 0.0009 1053 AF151843. 1 Homo sapiens CGI-85 protein mRNA. complete cds 3E-33 1054 AF132966. 1 Homo sapiens CGI-32 protein mRNA, complete cds 0 NM_006466 Homo sapiens polymerase (RNA) III (DNA directed) (39kD) 1055. 1 (RPC39) mRNA subunit (RPC39) mRNA, complete cds 4E-15 1056 AF086460 Homo sapiens full length insert cDNA clone ZD85A02 e-119 1057 AF036703 Caenorhabditis elegans cosmid Tl lF8 0. 7 1058 AB018344. I Homo sapiens mRNA for KIAA0801 protein, complete cds 0 Table 2A : Nearest Neighbor (BlastN vs. Genbank) SEQ ID ACC'N DESCRIP. P VALUE 1059 X81058 M. musculus tex261 mRNA e-119 Human DNA sequence from clone 321I20 on chromosome 1060 AL035046. 5 Iq32. 1-41 Contains GSSs. complete sequence 0. 0001 1061 AF157814. 1 Homo sapiens cAMP specific phosphodiesterase 0. 00000002 NM002273 1062. 1 Homo sapiens keratin 8 (KRT8) mRNA keratin 8 e-120 1063 AF131739 Homo sapiens clone 25189 mRNA sequence, complete cds 0 1064 AL049702. 1 Human gene from PAC 433G19, chromosome 1 0 Homo sapiens mRNA ; cDNA DKFZp572P0920 (from clone 1065 AL080125. 1 DKFZp572P0920) 3E-19 NM003422 1066. 1 Homo sapiens zinc finger protein 42 2E-15 Caenorhabditis elegans cosmid KOIF9, complete sequence 1067 Z22175 [Caenorhabditis elegans] 2 1068 AF039690. 1 Homo sapiens antigen NY-CO-8 (NY-CO-8) mRNA, partial cds 1E-37 1069 AL049702. 1 Human gene from PAC 433GI9. chromosome 1 0 Mus musculus mRNA for hepatoma-derived growth factor, 1070 D63850 complete cds, strain : BALB/c 5E-50 1071 ABC 14603 Homo sapiens mRNA for KIAA0703 protein, complete cds e-167 NM006371 Homo sapiens cartilage-associated protein sapiens mRNA for 1072. 1 cartilage-associated protein (CASP) 0 Rattus norvegicus pyridoxine 5'-phosphate oxidase mRNA, 1073 U91561 complete cds e-136 Homo sapiens zinc finger protein 85 (HPF4, HTF1) (ZNF85) NM_003429 mRNA >gil 1017721 lgblU35376lHSU35376 Human repressor 1074. 1 transcriptional factor (ZNF85) mRNA, complete cds. 2E-51 1075 D63876 Human mRNA for KIAA0154 gene, partial cds 6E-54 1076 AB010059 Homo sapiens RBP56/hTAF1168 gene, exon 3, 4, 5 4E-80 Rattus norvegicus mRNA for beta-alanine-pyruvate 1077 AB002584 aminotransferase, complete cds 0. 00000002 1078 X85133 H. sapiens RBQ-I mRNA 0 Homo sapiens PAPS synthetase-2 (PAPSS2) mRNA, complete 1079 AF074331. 1 cds e-173 Table 2B Nearest Neighbor (BlastX vs. Non-Redundant Proteins) SEQ ID ACC'N DESCRIP. P VALUE 7 808943 (X82686) orf4 [bovine adenovirus type 2] 8. 30E+00 (Z81067) similar to Zinc finger, C3HC4 type (RING finger) 8 3876268 [Caenorhabditis elegans] 8. 10E+00 9 2132973 probable membrane protein YPL058c - yeast 4.50E+00 11 2746799 (AF040643) No definition line found [Caenorhabditis elegans] 2.40E-01 12 1086865 (U41272) Similar to human leukocvte surface protein 1. 80E-01 13 4680717 (AF132973) CGI-39 protein [Homo sapiens] 1. OOE-07 14 5052588 (AF145649) BcDNA. GH08388 4. OOE-09 15 2293303 (AF008220) YttA [Bacillus subtilis] 5. 90E-02 (AF071502) brahma associated protein 155 kDa [Drosophila 16 3378132 melanogaster] 4. 20E-01 17 2224605 (AB002330) KIAA0332 [Homo sapiens] 7. 30E-01 18 1439625 (U64598) weakly similar to S : cervisiae PTMI precursor 1. 30E+00 mitotic kinesin-like protein 1 PROTEIN-I >gil284312lpirllS28262 kinesin-related protein MKLP-1 - human >gi|34672|emb|CAA47628|(X67155) mitotic kinase- 19 4758718 like protein-1 [Homo sapiens] 5. 60E-01 20 399112 BETA-GALACTOSIDASE (LACTASE) 1. 40E-01 26 3785995 (AC005499) unknown protein [Arabidopsis thaliana] 5. 90E+00 27 5042442 (AC007789) putative CREB-binding protein [Oryza sativa] 3. 50E+00 PUTATIVE ABC TRANSPORTER PERMEASE PROTEIN MJ0087 >gi|2127961|pir||G64310 hemin permease homolog- Methanococcus jannaschii >gil 1590869 (U67466) hemin 28 2501404 permease (hemU) [Methanococcus jannaschii] 7. 60E+00 5-EXO-ALCOHOL DEHYDROGENASE (FDEH) 29 1706771 dehydrogenase [Pseudomonas putida] 6. 00E+00 30 5102774 (AJ238893) acyl-CoA thioesterase [Mus musculus] 6. 00E-11 HISTONE HI. 03 >gil86287lpirllD28456 histone H1. 03- 31 121896 chicken>gi|211832 (M17021)03H1 protein [Callus gallus] 4. 80E-01 32 5689493 (AB029001) KIAA1078 protein [Homo sapiens] 1.00E-53 33 4063766 (D87895) chitinase [Emericella nidulans] 1. 60E-02 34 4140029 (ABO 1543 8) alpha 1 type I collagen [Cynops pyrrhogaster] 2. 70E-02 37 1182003 (X87904) putative [Homo sapiens] 2. 70E+00 (U40941) coded for by C. elegans cDNA CEESB82F ; coded 38 1072187 for by C. elegans cDNA CEESE93F [Caenorhabditis elegans] 8. 10E+00 39 2832671 (AL021712) hypothetical protein 1. 40E+00 40 481043 bat2 protein-human >gi|29375|emb|CAA78744| 1.30E-01 41 1203952 (U49831) similar to D. melanogaster doublesex protein 4. 80E+00 Table 2B Nearest Neighbor (BlastX vs. Non-Redundant Proteins) SEQ ID ACC'N DESCRIP. P VALUE 42 2708329 (AF038564) atrophin-1 interacting protein 4 [Homo sapiens] 8. 20E+00 TRANSCRIPTION INITIATION FACTOR IIF, ALPHA SUBUNIT (TFIIF-ALPHA) (TRANSCRIPTION INITIATION FACTOR RAP74) >gil479869lpirllS35551 transcription factor IIF chain RAP74-African clawed frog IIF 43 464522 subunit lXenopus laevis] 3. 30E-01 44 2384956 (AF022985) No definition line found [Caenorhabditis elegans] 2. 00E-28 NADH dehydrogenase (ubiquinone) (EC 1. 6. 5. 3) chain 4- Crithidia oncopelti mitochondrion (SGC6) subunit 4 [Crithidia 46 418745 oncopelti] 8. 40E+00 47 289825 (M81391) thrombin [Gallus gallus] 6. 30E+00 HYPOTHETICAL 95. 4 KD PROTEIN IN MAD2-RNR2 INTERGENIC REGION >gil10778041pirllS56801 hypothetical protein YJL029c-yeast (Saccharomyces cerevisiae) >gll 1008148lembICAA893201 (Z49304) ORF 48 1352968 YJL029c [Saccharomyces cerevisiae] 2. 80E+00 (Z93385) predicted using Genefinder ; cDNA EST EMBL : D72583 comes from this gene ; cDNA EST EMBL : D75500 comes from this gene [Caenorhabditis 49 3878628 elegans] 6. OOE-03 50 2384956 (AF022985) No definition line found [Caenorhabditis elegans] 3. 00E-25 54 5262605 (AL080150) hypothetical protein [Homo sapiens] 2. 10E+00 59 4680695 (AF132962) CGI-28 protein [Homo sapiens] 2. 40E-01 60 961446 (D63877) KIAA0157 gene product is novel. 1. 20E+00 61 3882321 (AB018343) KIAA0800 protein [Homo sapiens] 1. 00E-69 62 2864624 (AL021811) putative protein [Arabidopsis thaliana] 1. 40E-01 (U65891) protein tyrosine phosphatase CRYP-2 [Gallus 65 1655907 gallus] 2. 00E+00 66 3983370 (AF102521) olfactory receptor B12 [Mus musculus] 1. 80E-01 collagen alpha 2 chain-sea urchin 2-alpha collagen precursor 67 103624 (COLL 2-alpha) [Paracentrotus lividus] 1. 50E+00 (Z68302) predicted using Genefinder ; similar to Pumilio- family RNA binding domains (aka PUM-HD, Pumilio homology domain) (3 domains) ; cDNA EST EMBL : M89238 comes from this gene ; cDNA EST EMBL : D73612 comes 68 3881789 from this gene ; cDNA ES 2. 50E-01 70 1326281 (U58732) F48D6. 2 gene product [Caenorhabditis elegans] 3. 40E+00 73 3540219 (D87686) KIAA0017 protein [Homo sapiens] 8. 00E-70 Table 2B Nearest Neighbor (BlastX vs. Non-Redundant Proteins) SEQ ID ACC'N DESCRIP. P VALUE (AF016681) contains similarity to a sperm coat polysaccaride 74 2315742 domain [Caenorhabditis elegans] 1. 60E+00 protein phosphatase 1, regulatory subunit 6 >gi|3805797|emb|CAA77081|(Y18206) serine-threonine 78 5453948 specific protein phosphatase [Homo sapiens] 6. 50E+00 80 1161051 (L39922) efflux protein [Mycobacterium tuberculosis] 8. 20E+00 5-methyltetrahydrofolate-homocysteine methyltransferase reductase >gil2981303 (AF025794) methionine synthase 81 4505279 reductase [Homo sapiens] 2. 80E+00 82 1722711 MAJOR CAPSID PROTEIN L I >gll 1020201 type 24] 1. 20E+00 (AF155124) bacterial-induced peroxidase precursor 84 5453379 [Gossypiumhirsutum] 6. 30E+00 (AE001339) ABC Transporter Membrane Protein [Chlamydia 85 3329139 trachomatis] 1. 20E+00 86 222416 (D10453) coat protein [Pea seed-borne mosaic virus] 4. 50E+00 87 1778160 (U67304) 70 kDa S6 kinase [Drosophila melanogaster3 2. 60E+00 88 1943947 (U90126) ABC transporter [Bos taurus] 2. 60E+00 (AF092564) chromosome-associated protein-C [Homo 89 3851586 sapiens] 2. 00E-03 EXTENSIN PRECURSOR carota] >gil224686lprfl1111211A 91 119711 extensin [Daucus carota] 2. 00E-03 93 728838 ! ! ! ! ALU SUBFAMILY SX WARNING ENTRY 6. 10E-01 95 4406632 (AF 131801) Unknown [Homo sapiens] 2. OOE-04 97 4585699 (AJ228139) LEKTI precursor [Homo sapiens] 9. 00E-52 99 3249026 (AF070067) unknown [Escherichia coli] 7. 70E-01 (AL031073) dJ142F18. 1 (similarto melanoma-associated 100 4210358 antigen) [Homo sapiens] 1. 70E-02 101 2137074 ribosomal transcription factor UBF2-Chinese hamster 7. 00E-06 103 3327062 (AB014524) KIAA0624 protein [Homo sapiens] 1. OOE-37 106 3328339 (AF075241) prepro-orexin [Sus scrofa] 4. 80E+00 (U40029) Contains similarity to Pfam domain : PF01060 (Worm_family_2), Score=203. 8, E-value=8. 6e-58, N=1 108 1055163 [Caenorhabditis elegans] 7. 90E+00 Table 2B Nearest Neighbor (BlastX vs. Non-Redundant Proteins) SEQ ID ACC'N DESCRIP. P VALUE METHYLPHOSPHOTRIESTER-DNA ALKYLTRANSFERASE >gi|279475|pir||XUBSMM methylphosphotriester-DNA methyltransferase (EC 2. 1. 1.-) adaA [Bacillus subtilis] >gi|2632448|emb|CAB11957| transcriptional regulator (AraC/XylS family) [Bacillus subtilis] >gi|2632466|emb|CAB11974| (Z99105) methylphosphotriester-DNA alkyltransferase and transcriptional regulator (AraC/XylS family) [Bacillus subtilis] >gi|3599599|dbj|BAA33074| (AB006424) METHYLPHOSPHOTRIESTER-DNA 109 113333 ALKYLTRANSFERASE [Bacillus subtilis] 7. 80E+00 glycoprotein-rat >gil986943 (L08134) glycoprotein [Rattus 110 2143767 norvegicus] norvegicus] 2. 00E-02 112 2905979 (AF015678) virulence determinant [African swine fever virus] 2. 00E+00 113 4867999 (AF078164) Ku70-binding protein 4.00E-60 114 3820909 (AJ010642) Dof protein [Drosophila melanogaster] 1. 90E+00 115 2291155 (AF016418) No definition line found [Caenorhabditis elegans] 8. 10E+00 (U17394) polyadenylation factor 64 kDa subunit [Xenopus 120 632500 laevis] 3. 60E+00 Ig gamma-3 chain C region (allotype G3m (b))-human >gil577056lemblCAA27268l (X03604) C gamma 3 [Homo 121 87792 sapiens] 1. 60E+00 122 3043572 (AB011096) KIAA0524 protein [Homo sapiens] 5. 00E-04 TUBULIN GAMMA CHAIN gamma tubulin-like protein 125 1729859 [Saccharomyces cerevisiae] 3. 50E+00 126 2340169 (AF015783) telomerase reverse transcriptase 1 2. 70E+00 127 2131446 hypothetical protein YDR362c-yeast 7. 90E-02 130 1616770 (U70731) putative poly (A)-binding protein FabM 1. 10E+00 (AC003979) Contains similarity to ycf37 gene product gbll001425 from Synechocystis sp. genome gblD63999. ESTs gblT43026, gblR64902, gblZ18169 and IN37374 come from 131 3287688 this gene. [Arabidopsisthaiiana] 8. OOE-03 134 1131444 (U42580) PBCV-1 glucosamine synthetase 1. 70E+00 STREPTOTHRICIN ACETYLTRANSFERASE streptothricin acetyl-transferase (AA 1-174) streptothricin-acetyl-transferase (AA 1-174) acetyltransferase [Transposon Tn7] >gil2708491 (U84739) streptothricin resistance protein [synthetic 135 134952 construct] acetyltransferase 3' [Cloning vector pSB 11] 5. 40E-01 Table 2B Nearest Neighbor (BlastX vs. Non-Redundant Proteins) SEQ ID ACC'N DESCRIP. P VALUE (D87054) 2-heptaprenyl-1, 4-naphthoquinone 136 3452684 methyltransferase [Bacillus stearothermophilus] 4. 00E-3 137 5360129 (AF155117) NY-REN-62 antigen 8. 00E-53 collagen alpha 1 (XVIII) chain precursor long form-mouse (fragment) >gil618430 (U11637) alpha-1 type XVIII collagen 143 1363109 precursor [Mus musculus] 3. 70E+00 145 113671 ! ! ! ! ALU CLASS F WARNING ENTRY ! ! ! ! 1. 40E+00 146 3874135 (Z54342) similarto acid phosphatase elegans] 7. 00E-22 148 1279390 (X97329) HER-1 protein [Danio rerio] 7. 50E+00 149 4557639 orexin receptor 2 >gil2897128 receptor [Homo sapiens] 6. 20E+00 150 4262630 (AF125963) No definition line found 3. 20E+00 H+-transporting ATP synthase (EC 3. 6. 1. 34) protein 6- 152 102129 Trypanosoma brucei mitochondrion (SGC6) 2. 80E+00 156 996018 (X91637) BRG1 protein [Gallus gallus] 5. 70E+00 (AF067622) Contains similarity to Pfam domain : PF00628 157 3158498 (PHD), Score=36. 7, E-value=1. 7e-07, N=2 2. 70E-02 158 1117913 (U40223) uridine nucleotide receptor [Homo sapiens] 2. 70E+00 162 5430752 (AC007504) Hypothetical Protein 3. 80E-02 167 226120 vicilin gene B [Saguinus oedipus] 8. 30E+00 aspartoacylase (aminoacylase 2) aspartoacylase-human >gil455834lbbsl140585 (S67156) aspartoacylase, ASP 169 4557335 [human, kidnay, Peptide, 313 aa] 7. 30E+00 170 5031129 (AF082859) lungkine [Mus musculus] 8. 60E+00 (AL049707) putative large glycine/alanine rich protein 173 4678899 [Streptomyces coelicolor] 2. 10E-01 174 728831 ! ! ! ! ALU SUBFAMILY J WARNING ENTRY 2. OOE-02 175 3004981 (AF039652) ribonuclease Htype II [Homo sapiens] 2. OOE-27 177 2911366 (AF041047) NADPH HC toxin reductase [Zea mays] 9. 60E-02 178 2217964 (Z50798) p52 [Gallus gallus] 1. OOE-12 (Z73102) Similarity to B. subtilis DNAJ protein (SW : DNAJ_BACSU) ; cDNA EST yk437al. 5 comes from this 179 3873707 gene [Caenorhabditis elegans] 3. 00E-19 180 3043658 (ABO11139) KIAA0567 protein [Homo sapiens] 2. OOE-03 182 5689451 (AB028980) KIAA1057 protein [Homo sapiens] 7. 00E-10 183 728831 ! ! ! ! ALU SUBFAMILY J WARNING ENTRY5. 00E-03 (AC003083) mitochondrial carrier protein-like ; similar to 186 2588623 Q09461 (PID : g2497990) [Homo sapiens] 3. 00E-69 187 1669601 (D88747) AR401 [Arabidopsis thaliana] 2. 00E-20 LINE-1 REVERSE TRANSCRIPTASE HOMOLOG protein 190 126296 [Nycticebus coucang] 3. 20E-01 Table 2B Nearest neighbor (BlastX vs. Non-Redundant Proteins) SEQ ID ACC'N DESCRIP. P VALUE (Z99129) dJ425C14. 2 (Placental protein DIFF33 LIKE) 191 3294180 [Homo sapiens] 4. 00E-20 192 5030439 (AC007766) R26610_1 [Homo sapiens] 7. 00E-56 193 4507375 tubulin-specific chaperone e 7. 00E-05 195 1698455 (U49974) mariner transposase [Homo sapiens] 2. 00E-05 PUTATIVE PYRUVATE-FLAVODOXIN OXIDOREDUCTASE >gil 1006618ldbjlBAA10774l (D64005) 196 1709285 pyruvate oxidoreductase [Synechocystis sp.] 8. 00E+00 (Z77667) cDNA EST EMBL : C08125 comes from this gene ; 197 3878584 cDNA EST EMBL : C09753 comes from this gene 2. 00E-04 198 1658503 (U75467) Atu [Drosophila melanogaster] 2. 00E-44 199 2655422 (AF035530) CDC37 [Gallus gallus] 2. 00E-09 3-oxoacid CoA transferase precursor : succinyl-CoA : 3- ketoacid-CoA transferase precursor >gil2492998lsplP55809lSCOT_HUMAN SUCCINYL-COA : 3- KETOACID-COENZYME A TRANSFERASE PRECURSOR 200 4557817 transferase precursor [Homo sapiens] 3. 20E+00 UNKNOWN >gi4063890 (AF095448) putative G protein- 201 4506403 coupled receptor [Homo sapiens] 4. 00E-35 (Z68319) Similarity to Human hnRNP F protein (PIR Ace. No. S43484) ; cDNA EST EMBL : D34218 comes from this gene ; cDNA EST EMBL : D37248 comes from this gene ; cDNA EST EMBL : D71817 comes from this gene ; cDNA EST EMBL : D74531 comes fro... hnRNP F protein (PIR Ace. No. S43484) ; cDNA EST EMBL : D34218 comes from this gene ; cDNA EST EMBL : D37248 comes from this gene ; cDNA EST EMBL : D71817 comes from this gene ; cDNA EST 202 3880146 EMBL : D74531 comes fro... l. OOE-01 (Z69903) predicted using Genefinder ; Similarity to Rat casein kinase I (SW : KCIDRAT) ; cDNA EST EMBL : D65322 comes from this gene ; cDNA EST EMBL : D68704 comes from this gene ; cDNA EST yk475f2. 5 comes from this gene 203 3877198 [Caenorhabditis... 1. 20E+00 (X65335) lacZ [Cloning vector pSV-beta-Galactosidase 204 987050 Control] 4. 00E-06 205 1438677 (U62376) envelope protein [Simian immunodeficiency virus] 3. 60E+00 206 2193870 (D84391) reverse transcriptase [Mus musculus] 6. 00E-06 spliceosome-associated protein ASSOCIATED PROTEIN 49 (SAP 49) (SF3B53) SAP-49-human >gil556217 (L35013) 207 5032069 spliceosomal protein 2.

Table 2B Nearest Neighbor (BlastX vs. Non-Redundant Proteins) SEQ ID ACC'N DESCRIP. P VALUE spliceosome-associated protein ASSOCIATED PROTEIN 49 (SAP 49) (SF3B53) SAP-49-human >gil556217 (L35013) 209 5032069 spliceosomal protein 2. 10E+00 CYTOCHROME B >gil625356lpirllS43269 ubiquinol-- cytochrome-c reductase (EC 1. 10. 2. 2) cytochrome b- 210 729264 humpback whale mitochondrion (SGCI) 4. 60E+00 (AF003139) Similar to cuticular collagen [Caenorhabditis 211 2088713 elegans] 4. 20E-01 212 2276366 (Z97992) putative glucan synthase 8. 40E+00 213 4589684 (AB023234) KIAA1017 protein [Homo sapiens] 2. 0E-65 214 4504739 ITBAI protein 1. 00E-10 TRANSCRIPTIONAL REGULATORY PROTEIN ARAB 217 1703364 >gil995682lemb4CAA62739l (X91393) abaB 7. SOE-01 218 2769595 (Y16135) SHT2B receptor [Canis familiaris] 8. 20E+00 (AF010144) neuronal thread protein AD7c-NTP [Homo 219 3002527 sapiens] 5. 00E-05 (U08794) envelope glycoprotein [Human immunodeficiency 221 1463014 virus type 1] 7. 70E+00 NBL4 PROTEIN >gil543191lpirllJU0188 band 4. 1 222 1709230 superfamily member protein-mouse 3. 00E-23 FK506-BINDING PROTEIN (FKBP-12) FK506-binding 223 120223 protein-mouse >gil50971 lemblCAA42762l musculus] I. OOE-19 (X65335) lacZ [Cloning vector pSV-beta-Galactosidase 224 987050 Control] 2. 00E-15 (AJ001119) RabS GDP/GTP exchange factor, Rabex5 [Bos 225 2558516 taurus] 2. 00E-36 226 2558501 (D63850) hepatoma-derived growth factor 7. OOE-30 227 5410326 (AF106680) RNA helicase [Homo sapiens] 2. OOE-45 228 631772 TEG-261 protein-mouse 5. OOE-48 (AF041853) kinesin family member protein KIF3A [Homo 229 3851492 sapiens] 3. 00E-56 lectin, galactoside-binding, soluble, 3 (galectin 3) (NOTE : redefinition of symbol) BINDING PROTEIN 35) (CBP 35) (LAMININ-BINDING PROTEIN) galactoside-binding- human >gill79531 (M57710) IgE-binding protein [Homo sapiens] >gil 186922 (M36682) laminin-binding protein 231 4504983 [Homo sapiens] 6. 00E+00 240 3873717 (Z81453) predicted using Genefinder 3. 70E+00 241 3413884 (AB007930) KIAA0461 perotein [Homo sapiens] 3E-48 242 1834503 (Z72496) mucin MUC5B [Homo sapiens] 4. 50E-01 Table 2B Nearest Neighbor (BlastX vs. Non-Redundant Proteins) SEQ ID ACCN DESCRIP. P VALUE PRESTALK PROTEIN PRECURSOR mold (Dictyostelium 243 131442 discoideum) 1. 2 (AF094519) diaphanous-related formin ; p 134 mDia2 [Mus 244 3834629 musculus] 5E-54 245 2996650 (AC004493) KIAA0324 [Homo sapiens] 0. 05 HYPOTHETICAL 130. 0 KD PROTEIN IN SNF6-SPOI I INTERGENIC REGION >gil626572lpirllS46837 hypothetical protein YHL023c-yeast (Saccharomyces cerevisiae) >gil2289893 (U 11582) No definition line found 246 731604 Saccharomyces cerevisiae] 0. 036 247 5670007 (AF156102) ELL complex EAP30 subunit 5. 00E-66 248 1 12243 1 (X92968) protein SIC [Streptococcus pyogenes] 0. 001 ER LUMEN PROTEIN RETAINING RECEPTOR falciparum 249 462022 >gi|398385|emb|CAA81128| (Z26043) ERD2 8. 80E+00 250 3850153 (AL033396) cytochrome P450 [Candida albicans] 8. 8 251 2315228 (Z98260) hypothetical protein Rvl227c 1. OOE+00 (AF100657) Contains similarity to Pfam domain : PF00614 252 3800952 (PLDc), Score=13.8, E-value=0.2, N=1 5.00E-24 UNKNOWN >gi) 3873216 (AF06S485) sorting nexin 4 [Homo 253 4507145 sapiens] 3. 00E-51 258 5410355 (AF125392) insulin induced protein 2 [Homo sapiens] 2. 10E+00 261 2905647 (AF045245) D-arabinitol kinase [Klebsiella pneumoniae) 6. 5 262 4928673 (AF136343) Cul-1 (Drosophila melanogaster] 6.50E+00 (Z81526) predicted using Genefinder ; cDNA EST EMBL : D36935 comes from this gene ; cDNA EST EMBL : D33960 comes from this gene; cDNA EST EMBL : C12255 comes from this gene ; cDNA EST EMBL : C10859 comes from this gene ; cDNA EST 263 3876644 EMBL : C1... 6. 20E+00 264 1808621 (X94355) D18L [Cowpox virus] 3. 70E+00 plasmid copy number control protein-Escherichia coli 265 628784 >gil473802ldbjlBAA055911 (D26562) coli] 2. 90E+00 peroxisomal biogenesis factor 3 PROTEIN PEX3 (PEROXIN- 3) >gil3336882lemblCAA04879l sapiens] 266 4505727 >gil42 1 8426lemblCAA08904l (AJ009866) Pex3p 4. 00E-59 268 4322053 (AF071242) homeobox protein [Danio rerio] 3. 50E+00 (AP000063) 194aa long hypothetical protein [Aeropyrum 273 5105878 pernix] 6. 50E+00 Table 2B Nearest Neighbor (BlastX vs. Non-Redundant Proteins) SEQ ID ACC'N DESCRIP. P VALUE (Z48583) cDNA EST EMBL : T00483 comes from this gene ; cDNA EST EMBL : D64526 comes from this gene ; cDNA EST EMBL : D65147 comes from this gene ; cDNA EST EMBL : D68484 comes from this gene ; cDNA EST EMBL : D67548 comes from this gene ; c... >gil3879229lemblCAA88749l EST EMBL : D64526 comes from this gene ; cDNA EST EMBL : D65147 comes from this gene ; cDNA EST EMBL : D68484 comes from this gene ; 274 3877495 cDNA EST EMBL : D67548 comes from this gene ; cDN... 6. 7 275 3322592 (AE001211) T. pallidum predicted coding region TP0311 1. 90E+00 HYPOTHETICAL 79. 4 KD PROTEIN IN PRP16-SRP40 276 1176495 INTERGENIC REGION >gil486577lemblCAA82 1 691 2. 1 (AF124490) ARF GTPase-activating protein GITI [Homo 277 4691726 sapiens] 3E-68 278 3702844 (AF06905 1) pituitary tumor transforming gene protein 5. 80E+00 279 3882163 (AB018264) KIAA0721 protein [Homo sapiens] 6. 00E-59 (U4094 1) coded for by C. elegans cDNA CEESB82F ; coded 280 1072187 for bv C. elegans cDNA CEESE93F [Caenorhabditis elegans] 7. 4 282 3322397 (AE001198) T. pallidum predicted coding region TP0130 1. 80E+00 283 3417412 (AL031261) putative superoxide dismutase 2. 9 284 2245121 (Z97343) hypothetical protein 0. 45 285 2924311 (AJ000882) steroid receptor coactivator le 8. 6 286 3323285 (AE001264) ABC transporter, ATP-binding protein 8. 5 287 4981435 (AE001755) hypothetical protein 2. 9 LIM and senescent cell antigen-like domains 1 >gi|1346721|sp|P48059|PINC_HUMAN PINCH PROTEIN (PARTICULARY INTERESTING NEW CYS-HIS 288 4826818 PROTEIN) >gil63 1281 lpirllJC2324 LIM protein-human 6. 5 troponin T, fast skeletal muscle, embryonic alpha (clone 501) Japanese quail >gil213628 (M26599) troponin T [Coturnix 291 104506 coturnix] 4. 8 (AF039048) similar to cdc25-like M-phase inducer 292 2736462 phosphatases [Caenorhabditis elegans] 2. 8 SPERM MITOCHONDRIAL CAPSULE SELENOPROTEIN 293 1708966 (MCS) 0. 74 294 4914378 (AC007584) hypothetical protein [Arabidopsis thaliana] 3E-10 295 5524931 (AL096842) hypothetical protein [Homo sapiens] 3E-64 Table 2B Nearest Neighbor (BlastX vs. Non-Redundant Proteins) SEQ ID ACC'N DESCRIP. P VALUE LOW-AFFINITY NERVE GROWTH FACTOR RECEPTOR PRECURSOR (NGF RECEPTOR) (GP80-LNGFR) (P75 296 128155 ICD) affinity-chicken 0. 00001 298 4205113 (AF000520) cell wall invertase [Fragaria x ananassa] 2. 7 (AL031765) MSK (EC 2. 7. 1.-) (HRT-20) (MYOCARDIAL 299 3702106 SNF I-LIKE KINAS... 0. 79 300 4325123 (AF119361) unknown [Frankia sp. EuIKI] 2. 8 MITOCHONDRIAL RIBOSOMAL PROTEIN S 14 301 417737 polymorpha=liverwort, Peptide Mitochondrial, 99 aa] 3. 6 302 2289030 (U53564) N-terminal region of the protein [Mus musculus] 2. 8 303 2318003 (U97553) unknown [murine herpesvirus 68] 0. 037 HYPOTHETICAL 43. 1 KD TRP-ASP REPEATS CONTAINING PROTEIN K04G 11. 4 IN CHROMOSOME X Genefinder ; Similarity to C. elegans Guanine nucleotide 304 3123176 binding protein (WP : C14B1.4) [Caenorhabditis elegans] 6E-09 (AFI 13615) FHI/FH2 domain-containing protein FHOS 305 5106956 [Homo sapiens] 1E-51 (AF151522) hairy and enhancer of split related-1 [Homo 311 5059323 sapiens] 0. 31 312 728831 ! ! ! ! ALU SUBFAMILY J WARNING ENTRY 4. 7 (AF125443) contains similarity to S. pombe phosphatidyl 313 4226073 synthase (GB : Z28295) [Caenorhabditis elegans] 2E-23 (AF016485) ORF H0532 [Halobacterium sp. NRC-1] 317 2822320 >gil2822445lgblAAC82951. 1 (AF016485) ORF H1831 7. 9 (AE000721) major facilitator family transporter [Aquifex 318 2983553 aeolicus] 3. 5 (AF118379) gamma-tubulin ring protein Dgrip84 [Drosophila 319 4689225 melanogaster] 0. 23 (U58746) coded for by C. elegans cDNA yk3bl 1. 5 ; coded for _ by C. elegans cDNA ykl3gl. 5 ; coded for by C. elegans cDNA yk3bl 1. 3 ; coded for by C. elegans cDNA CEESR37F ; coded for by C. elegans cDNA ykl3gl. 3 ; Similar to phospholipase. 322 1326337 [Caenorhab... 4. 5 323 2708738 (AC003952) hypothetical protein [Arabidopsis thaliana] 6E-10 326 4929629 (AF151838) CGI-80 protein [Homo sapiens] 8. 1 (AF103731) putative glycolipid transfer protein [Homo 327 4050073 sapiens] 2E-38 328 1905892 (L39835) Na/Ca exchange protein [Drosophilametanogasterl 0. 14 329 4972120 (AL078579) putative protein [Arabidopsis thaliana] 2E-08 Table 2B Nearest Neighbor (BlastX vs. Non-Redundant Proteins) SEQ ID ACC'N DESCRIP. P VALUE 330 4884202 (AL049953) hypothetical protein [Homo sapiens] lE-39 332 2981631 (AB012223) ORF2 [Canis familiaris] 0. 098 HYPOTHETICAL TRANSCRIPTIONAL REGULATOR IN GLVC-LIPB INTERGENIC REGION subtilis] >gil2633149lemblCABl2654l (Z99108) similar to transcriptional regulator (AraC/XylS family) [Bacillus 333 1723611 subtilis] 9. 9 (Z83246) predicted using Genefinder ; cDNA EST EMBL : M79771 comes from this gene [Caenorhabditis 334 3881873 elegans] 1. 3 335 3641352 (AF091234) putative transcription factor [Mus musculus] 2E-43 (Z78416) predicted using Genefinder ; Similarity to S. pombe RAD18 gene (TR : E198069) ; cDNA EST CEESX52R comes from this gene ; cDNA EST EMBL : D32785 comes from this gene ; cDNA EST EMBL : D35528 comes from this gene ; 336 3874427 cDNA EST EMBL : D37... 0. 0000006 341 1492037 (U60315) MC094R [Molluscum contagiosum virus subtype 1] 8. 5 342 3201625 (AC004669) hypothetical protein [Arabidopsis thaliana] 6. 2 (AP000059) 216aa long hypothetical protein [Aeropyrum 343 5103944 pernix] 3. 8 RNA REPLICATION PROTEIN (165 KD PROTEIN) (ORF 1) [CONTAINS : RNA-DIRECTED RNA POLYMERASE 344 139140 RNA-replicating protein [Potato virus X] >gil309911 5. 9 345 1085126 juvenile hormone esterase-related protein-cabbage looper 4. 9 346 1613846 (U71440) polyprotein [Rice tungro spherical virus] 0. 73 (X03614) alternative form of op-6 (aa I-1980) [Human 354 60900 parainfluenza virus 1] 0. 35 355 3287370 (AC002397) B [Mus musculus] 0. 003 (AE000909) serine/threonine protein kinase related protein 356 2622601 [Methanobacterium thermoautotrophicum] 2E-10 STRUCTURAL POLYPROTEIN [CONTAINS : MAJOR STRUCTURAL PROTEIN VP2 ; NONSTRUCTURAL PROTEIN VP4 ; MINOR STRUCTURAL PROTEIN VP3] >gil75451lpirllGNXSOH genome polyprotein-infectious bursal disease virus structural polyprotein [Infectious bursal 358 130489 disease virus] 9. 7 359 2996337 (AF053947) CobT homolog [Yersinia pestis] 0. 86 360 3644048 (AF091395) Trio isoform [Homo sapiens] 7. 1 363 3845280 (AE001418) hypothetical protein [Plasmodium falciparum] 0. 8 Table 2B Nearest Neighbor (BlastX vs. Non-Redundant Proteins) SEQ ID ACC'N DESCRIP. P VALUE (U49956) coded for by C. elegans cDNA yk57d5. 5 ; coded for by C. elegans cDNA cm20e2 ; coded for by C. elegans cDNA 364 1208844 cm06f2 [Caenorhabditis elegans] 4 366 3193245 (AF068709) No definition line found [Caenorhabditis elegans] 2. 9 368 5262568 (AL080129) hypothetical protein [Homo sapiens] IE-35 371 3261730 (Z92774) nhoA [Mycobacterium tuberculosis] 3. 5 373 2131482 hypothetical protein YDR426c-yeast 7. 7 hypothetical protein E30_orf352-Mycoplasma pneumoniae (SGC3) (ATCC 29342) >gil 1673872 (AE000021) Mycoplasma pneumoniae, E30orf352 Protein [Mycoplasma 374 2146218 pneumoniae] 7. 8 (AF047660) contains similarity to steroid/thyroid/retinoic nuclear hormone receptors : contains similarity to C4-type zinc 375 2911866 fingers 2. 7 377 3878117 (Z49068) mitochondrial carrier protein 5. 7 (AF043706) contains similarity to granulins [Caenorhabditis 378 2804500 elegans] 0. 18 (AE001471) ATP-DEPENDENT ZINC 380 4154882 METALLOPEPTIDASE 4. 7 (AF000198) Similar to cuticular collagen [Caenorhabditis 381 2047346 elegans] 0. 31 TUBULIN BETA-2 CHAIN Emericella nidulans >gil 168107 382 135454 (M17520) beta-tubulin beta [Emericella nidulans] 1. 5 (AP000001) 128aa long hypothetical protein [Pyrococcus 387 3256691 horikoshii] 3. 6 388 4033606 (AB008227) Extensin [Adiantum capillus-veneris] 0. 33 391 3036835 (AJ003243) bradykinin B2 receptor [Cavia porcellus] 7. 9 (AF160864) NADH dehydrogenase subunit 4 [Tetrahymena 392 5306171 pyriformis] 1. 6 hypothetical protein YDR409w-yeast CAI : 0. 12 393 2131472 [Saccharomyces cerevisiae] 0. 43 NADH dehydrogenase (ubiquinone) (EC 1. 6. 5. 3) chain 4- Crithidia oncopelti mitochondrion (SGC6) subunit 4 [Crithidia 394 418745 oncopelti] 3. 3 cyclodiene insecticide resistance protein-yellow fever mosquito >gil881590 (U28803) GABA receptor subunit 398 422408 [Aedes aegypti] 1. 1 400 4050089 (AF109907) hypothetical protein [Homo sapiens] 1. 6 Table 2B Nearest Neighbor (BlastX vs. Non-Redundant Proteins) SEQ ID ACC'N DESCRIP. P VALUE (Z73906) cDNA EST EMBL : M88866 comes from this gene 401 3875400 [Caenorhabditis elegans] 2. 1 (Z35641) cDNA EST yk273d8. 5 comes from this gene 402 3874821 [Caenorhabditis elegans] 9E-10 (AL034368) predicted using hexExon ; L779. 2, Hypothetical 404 4493761 protein, len : 4125 aa [Leishmania major] 6. 6 407 2598627 (AJ000870) histidine kinase [Streptococcus gordonii] 6 408 2842531 (AB004291) gamma-subunit of enolase 3. 5 409 728836 ALU SUBFAMILY SP WARNING ENTRY 0. 37 415 728832 ALU SUBFAMILY SB WARNING ENTRY 0. 95 (AF003131) C. elegans UNC-89 (GB : U33058) 416 2088675 (NID : gui 160355) 1. 2 417 102189 myosin I, high molecular weight-Acanthamoeba sp 0. 0005 418 2072961 (U93568) putative pl50 [Homo sapiens] 0. 008 P-TYPE CALCIUM CHANNEL ALPHA-1 SUBUNIT (RBA- I) >gil 111447lpirllA41098 calcium channel protein alpha-1 422 1705706 chain isoform A-rat >gil203111 norvegicus3 3. 6 (Y10290) formamidopyrimidine-DNA glycosylase 424 1781316 [Synechococcus elongatus] 4. 9 425 1183033 (D63821) polyprotein [Hepatitis C virus] 7. 5 426 3347920 (AF075261) orphan transporter [Mus musculus] 2. 9 428 1333929 (X66285) HCI ORF [Mus musculus] 0. 086 429 3121994 DNAJ PROTEIN japonicum] 1. 2 431 5689523 (AB029016) KIAA1093 protein [Homo sapiens] 0. 001 432 4887240 (AF064564) WSBI protein [Fugu rubripes] rubripes] 0. 013 RNA REPLICASE POLYPROTEIN 2. 7. 7. 48)-Ononis 433 130553 yellow mosaic virus >gil332574 virus] 0. 3 435 897917 (U28249) 11kD protein [Homo sapiens] 0. 25 441 2072958 (U93567) putative pl50 [Homo sapiens] 0. 002 444 728831 ! ! ! ! ALU SUBFAMILY J WARNING ENTRY 0. 008 446 4210496 (U61384) GAS41 protein [Homo sapiens] 9E-59 (U30261) G protein beta subunit-like ; Method : conceptual 447 1002672 translation supplied by author [Schistosoma mansoni] 1E-31 448 4680703 (AF132966) CGI-32 protein [Homo sapiens] 6E-67 (U53147) coded for by C. elegans cDNA yk34a9. 5 ; coded for by C. elegans cDNA yk34a9. 3 ; Similar to guanylate kinase. 450 1255371 [Caenorhabditis elegans] 4E-23 reverse transcriptase-Trypanosoma cruzi transcriptase 451 1078718 [Trypanosoma cruzi] 0. 91 452 728832 ! ! ! ! ALU SUBFAMILY SB WARNING ENTRY 0. 082 453 106323 hypothetical protein (L1H 5'region)-human 0. 58 Table 2B Nearest Neighbor (BlastX vs. Non-Redundant Proteins) SEQ ID ACC'N DESCRIP. P VALUE CHLORAMPHENICOL ACETYLTRANSFERASE acetyltransferase, CAT [Vibrio anguillarum=pJA7324, 454 1345693 Peptide Plasmid, 216 aa] [Vibrio anguillarum] 8. 4 455 3413884 (AB007930) KIAA0461 perotein [Homo sapiens] 8E-78 456 2072972 (U93572) putative pl50 [Homo sapiens] 0. 003 (D86984) similar to yeast adenylate cyclase (S56776) [Homo 458 1504042 sapiens] 7E-10 HEAT SHOCK FACTOR PROTEIN HSF30 STRESS TRANSCRIPTION FACTOR) >gil100265lpirllS25480 heat shock transcription factor HSF30-Peruvian tomato 460 729774 transcription factor HSF30 [Lycopersicon peruvianum] 8. 1 462 728831 !!!! ALU SUBFAMILY J WARNING ENTRY 0. 006 TESTIN 2 (TES2) [CONTAINS : TESTIN 1 (TES I)] 464 1351218 >gi|2137810|pir||148842 testin - mouse 7. 8 (AL008583) dJ327J16. (novel CHROMObox family protein) 465 4160198 [Homo sapiens] 1E-20 (AF070657) glutathione S-transferase subunit 13 homolog 466 4454690 [Homo sapiens] 2E-25 (Z81030) similar to citrate lyase beta chain ; cDNA EST 467 3873871 yk302b4. 5 comes from this gene 3E-41 (AE000788) conserved hypothetical protein [Borrelia 468 2690136 burgdorferi] 4. 7 469 3327192 (AB014589) KIAA0689 protein [Homo sapiens] 0. 000006 GASTRULA-SPECIFIC PROTEIN 17 African clawed frog >gil64733lemblCAA28842l (X05215) GS17 gene product (AA 470 121654 1-147) [Xenopus laevis] 0. 9 471 2506774 KERATIN, TYPE II CYTOSKELETAL 8 2E-42 472 4768838 (AF116910) putative ribonuclease III [Homo sapiens] 6E-74 473 4406551 (AF131739) Unknown [Homo sapiens] 2E-54 (AF070664) HSPC008 [Homo sapiens] protein [Homo 474 4454704 saplens 3E-39 475 4678836 (AL049701) hypothetical protein [Homo sapiens] 6E-43 477 3025319 ZINC FINGER PROTEIN 195 >gil2384653 sapiens] 3E-11 479 3327098 (AB014542) KIAA0642 protein [Homo sapiens] 5E-20 480 2506062 (D85196) cut4+ [Schizosaccharomyces pombe] 4. 7 481 220579 (D00570) open reading frame (196 AA) [Mus musculus] 1. 7 nucleosome assembly protein 1-like 1 >gi|1709337|sp|P55209|NPL1_HUMAN NUCLEOSOME ASSEMBLY PROTEIN l-LIKE I (NAP-I RELATED 482 4758756 PROTEIN) 2E-26 484 1778432 (U79660) Treacher Collins syndrome [Homo sapiens] 2. 9 Table 2B Nearest Neighbor (BlastX vs. Non-Redundant Proteins) SEQ ID ACC'N DESCRIP. P VALUE 485 4507455 transferrin receptor 2 sapiens] 3E-35 (U46068) von Ebner minor salivary gland protein [Mus 488 1184790 musculus] 0. 065 (Z81074) Similarity to Soybean 3-methylcrotonyl-CoA carboxylase (TR : Q42777) ; cDNA EST EMBL : M75819 comes from this gene ; cDNA EST EMBL : M89099 comes from this gene ; cDNA EST EMBL : D32737 comes from this gene ; 489 3876562 cDNA EST EMBL : D32763... 7E-41 490 746552 (U23523) F53A9. 1 gene product [Caenorhabditis elegans] 6. 7 491 2981631 (AB012223) ORF2 [Canis familiaris] 0. 037 492 1401210 (U58510) putative RNA polymerase II subunit 4. 8 493 3170180 (AF039690) antigen NY-CO-8 [Homo sapiens] 0. 26 496 1778838 (U83113) INS-1 winged-helix homolog [Homo sapiens] 2. 8 PUTATIVE MYCOCEROSYL TRANSFERASE IN MAS 5'REGION >gil3222481pirlIA441 10 orf 15'of mas- 497 549779 Mycobacterium tuberculosis >gil 149979 (M95808) ORF 8. 2 (Z48583) similar to ATPases associated with various cellular activities (AAA) ; cDNA EST EMBL : Z 14623 comes from this gene ; cDNA EST EMBL : D75090 comes from this gene ; cDNA EST EMBL : D72255 comes from this gene ; cDNA EST 498 3877493 yk200e4.... 3E-14 500 3879937 (Z68220) T20D3. 3 [Caenorhabditis elegans] 0. 0000003 MITOCHONDRIAL INNER MEMBRANE PROTEASE SUBUNIT 2 >gil I 078046lpirllS53952 proteinase 2 precursor, 501 1170551 mitochondrial inner membrane-yeast 4E-13 502 4210989 (AF121781) unknown [Homo sapiens] 0. 007 (Z93241) dJ222E13. 3. 2 (PUTATIVE partial isoform 2) 503 4826454 [Homo sapiens] 2E-46 504 5381426 (AF159046) SPANK-1 [Rattus norvegicus] 0. 12 505 3687833 (AF069737) notchless [Xenopus laevis] IE-65 506 2558501 (D63850) hepatoma-derived growth factor 3E-24 507 1061310 (M98326) valyl-tRNA synthetase [Homo sapiens] 2E-17 gene encoding a protein with coiled-coil alpha-helical 508 4503179 domains protein [Homo sapiens] 3E-35 (U33460) DNA-directed RNA polymerase I, largest subunit 509 4096591 [Homo sapiens] 6. 3 510 4836515 (AF124788) WS-3 protein [Mus musculus] SE-10 vessicle-associated membrane protein (VAMP)-associated 511 4507867 protein of 33 kDa >gil3320446 sapiens] 9E-33 512 5262560 (AL080125) hypothetical protein [Homo sapiens] 1E-41 Table 2B Nearest Neighbor (BlastX vs. Non-Redundant Proteins) SEQ ID ACC'N DESCRIP. P VALUE SMALL NUCLEAR RIBONUCLEOPROTEIN SM D1 (SNRNP CORE PROTEIN D 1) (SM-D 1) (SM-D AUTOANTIGEN) Sm-D [Homo sapiens] >gil1256741 513 134039 (M58558) Sm-D autoantigen [Mus musculus] 6E-13 (AL021397) dJ69E11. 3 (Yeast YPR037W and worm C02C2. 6 predicted proteins LIKE) [Homo sapiens] protein [Homo 514 4165247 sapiens] 2E-52 515 3327220 (AB014603) KIAA0703 protein [Homo sapiens] 5E-53 ribosomal protein L13 L13 (BREAST BASIC CONSERVED 516 4506599 PROTEIN 1) sapiens] 0. 0000003 (Z70780) cDNA EST yk465d 10. 3 comes from this gene ; cDNA EST yk465dlO. 5 comes from this gene ; cDNA EST 517 3877201 yk481d9. 5 comes from this gene [Caenorhabditis elegans] 0. 00002 cartilage-associated protein cartilage-associated protein 519 5453601 (CASP) [Homo sapiens] 8E-70 520 4633085 (AF102507) fizzy-related protein [Homo sapiens] 7E-60 (U91561) pyridoxine 5'-phosphate oxidase [Rattus 521 3237304 norvegicus] 6E-37 (AF000381) non-functional folate binding protein [Homo 522 2565196 sapiens] lue-17 (AF060539) channel interacting PDZ domain protein [Mus 523 3108057 musculus] 3E-63 524 4160432 (AF071592) kinesin superfamily motor KIF4 [Homo sapiens] 8E-62 525 423916 myosin-I, Myr lb (alternatively spliced)-rat 1E-66 (AF033201) clipper/cleavage and polyadenylation specificity 526 2687591 factor 30 kDa subunit homolog [Mus musculus] 4E-69 527 464555 RAS-RELATED PROTEIN RAB-12 >gil206531 6E-70 (U82992) envelope glycoprotein [Human immunodeficiency 529 2737967 virus type 1] 9. 6 530 1351047 SCAR1ET PROTEIN >gil 1079665 7. 9 531 2924445 (AL022022) PE PGRS [Mycobacterium tuberculosis] 7. 5 (U67264) AcMNPV ORF8/ORF1629 homolog [Helicoverpa 532 2078307 zea nuclear polyhedrosis virus] 4. 5 (U67264) AcMNPV ORF8/ORF1629 homolog [Helicoverpa 533 2078307 zea nuclear polyhedrosis virus] 4. 4 534 972711 (L47121) bacteriocin [Carnobacterium piscicola] 4. 2 535 2895941 (AF047011) prointerleukin-1 alpha [Canis familiaris] 2. 5 536 283868 collagen alpha 1 (XI) chain-chicken 2. 4 537 2052126 (Z94752) hypothetical protein Rv0992c 0. 17 Table 2B Nearest Neighbor (BlastX vs. Non-Redundant Proteins) SEQ ID ACC'N DESCRIP. P VALUE (U97553) complement regulatory protein [murine herpesvirus 538 2317926 68] 0. 0006 539 3242649 (AB015440) alpha 1 type I collagen [Rana catesbeiana] 0. 98 540 540952 hypothetical protein-Pseudomonas aeruginosa aeruginosa] 2. 6 542 4886288 (AL050300) putative protein [Arabidopsis thaliana] 0. 22 (AE001225) conserved hypothetical protein [Treponema 543 3322778 pallidum] 9. 6 (Y07850) neurofibromin [Hylobates concolor] >gil 1 772563lemblCAÅ69 1791 (Y07853) Neurofibromin 544 1772556 [Homo sapiens] >gi|1772576|emb|CAA69180| 9. 5 protein-tyrosine-phosphatase (EC 3. 1. 3. 48), receptor type 545 1083477 delta, splice form D precursor-mouse 0. 08 (U58736) Similar to cuticular collagen. [Caenorhabditis 546 1326298 elegans] 0. 005 547 4007418 (AF071538) Ets transcription factor PDEF [Homo sapiens] 2E-70 homeo box B5 homeotic protein Hox 2. 1-human >gil 184293 548 4504469 (M92299) homeobox protein [Homo sapiens] 0. 64 550 3367649 (Y16349) convulxin alpha [Crotalus durissus] 9. 7 551 2808634 (AJ001909) transcriptional activator 0. 69 553 1127550 (U18939) orfl [Battrachocottus baikalensis] 4. 6 LDLC PROTEIN protein LDLC-human 555 2498512 >gil575654lemblCAA84427l (Z34975) ldlCp [Homo sapiens] 6. 5 556 5579050 (AL096874) hypothetical protein 3. 5 557 3327421 (U97068) zonadhesin [Mus musculus] 4. 4 PROBABLE CALCIUM-TRANSPORTING ATPASE 8 >gil1078570lpirllS54520 probable membrane protein 558 2493011 YMR162c-yeast (Saccharomyces cerevisiae) cerevisiae] 3. 3 (AJ225122) hyperpolarization-activated cation channel, 559 3242240 HACI [Mus musculus] 1. 1 560 780367 (L41686) ORF [Rattus norvegicus] 1. 1 561 3327226 (AB014606) KIAA0706 protein [Homo sapiens] 0. 41 562 4886501 (AL050275) hypothetical protein [Homo sapiens] 1. 1 (AP000061) 111 aa long hypothetical protein [Aeropyrum 565 5105067 pernix] 0. 51 566 1079404 filamin, Mueller cell-chicken >gil392018 4. 2 567 4680264 (AF121977) odorant receptor S25 2. 4 570 4927208 (AF133913) ARL-6 interacting protein-6 [Mus musculus] SE-29 571 1749774 (Y10018) ANON-66Db [Drosophila melanogaster] 0. 079 (AP000060) 224aa long hypothetical protein [Aeropyrum 572 5104722 pernix] 9. 9 Table 2B Nearest Neighbor (BlastX vs. Non-Redundant Proteins) SEQ ID ACC'N DESCRIP. P VALUE carbonate dehydratase (EC 4. 2. 1. 1)-tiger shark (fragments) >gil226952lprfll1612265A carbonic anhydrase [Galeocerdo 573 320133 cuviers 5. 7 574 1839000 (Z85982) hypothetical protein Rv1648 4. 3 575 1839000 (Z85982) hypothetical protein Rv1648 4. 2 (U87863) SNAP-25 interacting protein hrs-2 [Rattus 576 1885385 norvegicus] 3. 2 (U40028) weak similarity to glycoprotein H precursor 577 1055150 K04H4. and C05B5. 5 ; glycine-rich [Caenorhabditis elegans] 2. 5 578 4262315 (AF075256) nonstructural polyprotein 1. 1 579 1001674 (D64002) hypothetical protein 0. 1 580 2224707 (AB002381) KIAA0383 [Homo sapiens] 0. 027 (S74099) polyprotein I (pl, p2, plO, pl5/PR=protease, p19-matrix protein, p27/CA=capsid protein, pl2/NC=nuclear capsid protein) [avian myeloblastosis virus AMV, Peptide, 581 765157 701 aa] [Avian myeloblastosis virus] 4. 3 582 1079438 ribonucleoprotein-chicken >gil550458 gallus3 0. 85 585 4584062 (AJ011380) polyprotein [porcine enterovirus 1] 7. 6 (Z70034) similarity to 35. 1KD hypothetical yeast protein (Swiss Prot accession number P38805) ; cDNA EST CEMSE65F comes from this gene ; cDNA EST EMBL : T01315 comes from this gene ; cDNA EST yk452e10. 3 comes from this gene ; cDNA ES... >git3877079emb) CAA90124) (Z499IO) similarity to 35. 1KD hypothetical yeast protein (Swiss Prot accession number P38805) ; cDNA EST CEMSE65F comes from this gene ; cDNA EST EMBL : T01315 comes from this gene ; cDNA EST 586 3874412 yk452e10. 3 comes from this gene ; cDNA ES... 0. 23 587 3123910 (AF039204) methyltransferase/helicase polyprotein 5. 7 589 4539761 (AF118391) salivary peroxidase 3. 2 COLLAGEN ALPHA 1 (VIII) CHAIN PRECURSOR (ENDOTHELIAL COLLAGEN) >gil899571pirlIA34246 590 115317 collagen alpha 1 (VIII) chain precursor-rabbit 0. 02 Homer, neuronal immediate early gene, 2 >gil3834619 591 4758548 (AF093264) homer-2b [Homo sapiens] 2E-18 PUTATIVE HELICASE C17H9. 02 IN CHROMOSOME I >gi|2330709|emb|CAB11211.1|(Z298597) putative helicase 592 3219961 [Schizosaccharomyces pombe] 7. 3 Table 2B Nearest Neighbor (BlastX vs. Non-Redundant Proteins) SEQ ID ACC'N DESCRIP. P VALUE (Y18285) mannose binding lectin-associated serine protease-2 594 5459418 [Rattus norvegicus] 3. 3 595 4127783 (AJ130871) Bazooka protein [Drosophila melanogaster] 23 596 563601 (X78602) hypothetical replicase [Peanut clump virus] 6. 6 599 1778663 (D83674) MesP1 [Mus musculus] 2.4 (L22756) GTG start codon ; ORFA [Bradyrhizobium 600 404789 japonicum] 0. 027 603 1743404 (Z83327) transport-associated protein 3 604 1438537 (U49058) rA4 [Rattus norvegicus] 2 (AL031863) 1-evidence=predicted by content ; 1. method=genefinder ; 084 ; 1-method score=68. 61 ; 1- evidenceend ; 2-evidence=predicted by match ; 2- matchaccession=AA541052 ; 2- matchdescription=LD20837. 5prime LD Drosophila 605 3929698 melanogaster... 0. 83 606 2708329 (AF038564) atrophin-I interacting protein 4 [Homo sapiens] 5E-14 608 4099321 (U86145) neuraminidase [influenza A virus 5. 8 609 3881475 (Z82083) ZK1010. 2 [Caenorhabditis elegans] 4E-12 612 220578 (D00570) open reading frame (251 AA) [Mus musculus] 0. 056 equilibrative nucleoside transporter 1 >gi 1845345 (U81375) equilibrative nucleoside transporter 1 [Homo sapiens] 613 4826716 >gil3694940 transporter [Homo sapiens] 0. 000008 (AF049885) Arg/Abl-interacting protein ArgBP2b [Homo 615 2952333 sapiens] 1. 9 618 727264 (U18791) hydroxyproline-rich glycoprotein precursor 4. 3 solute carrier family 25 member 14 >gi13851540 (AF078544) brain mitochondrial carrier protein-1 [Homo sapiens] 619 4507009 mitochondrial carrier protein-I (BMCP 1)) [Homo sapiens] 8E-36 620 4884108 (AL050089) hypothetical protein [Homo sapiens] 4E-41 ACETYLCHOLINE RECEPTOR PROTEIN, BETA CHAIN PRECURSOR >gil 12056pir)) S13873 nicotinic acetylcholine 622 113083 receptor beta chain precursor-rat beta-subunit [Rattus rattus] 3. 3 (AL031863) I-evidence=predicted by content ; 1- method=genefinder ; 084 ; 1-methodscore=66. 31 ; 1- 623 3757569 evidence_end [Drosophila melanogaster] 0. 65 Table 2B Nearest Neighbor (BlastX vs. Non-Redundant Proteins) SEQ ID ACC'N DESCRIP. P VALUE protein kinase (EC 2. 7. 1. 37)-Plasmodium faiciparum >gil9878lemblCAA47704l (X67288) protein kinase Plasmodium falciparum] >gil3845284 (AE001419) calcium- 624 422320 dept. protein kinase (C-term. EF hand) 7. 5 HYPOTHETICAL 131. 5 KD PROTEIN C02F12. 7 IN CHROMOSOME X >gil 109896 (U41545) coded for by C. elegans cDNA yk4b2. 5 ; coded for by C. elegans cDNA CEESN67F ; coded for by C. elegans cDNA yk94hl2. 5 ; coded for by C. elegans cDNA CEESD93F ; coded for by C. elegans 625 2496852 cDNA CEESG57F ; coded for by C. elegans cDNA yk4b2. 3 ;... 0. 0001 IgA-specific metalloendopeptidase (EC 3. 4. 24. 13) homolog 629 1361305 SepA precursor-Shigellaflexneriflexneri] 4. 2 (Z49128) similar to cAMP-dependant protein kinase ; cDNA EST EMBL : T00719 comes from this gene ; cDNA EST yk465d8. 3 comes from this gene ; cDNA EST yk465d8. 5 comes from this gene ; cDNA EST yk492f4. 3 comes from this 635 3878636 gene ; cDNA EST y... 1E-39 636 3649791 (AB012917) serine protease (TLSP) [Homo sapiens] 8E-42 637 868241 (U29488) C56C10, 3 gene product [Caenorhabditis elegans] 7E-14 640 2224593 (AB002324) KIAA0326 [Homo sapiens] 4E-25 642 4185794 (AF097025) cysteine desulfurase [Homo sapiens] 1E-64 643 1083755 phosphoprotein phosphatase (EC 3. 1. 3. 16) PPT 2E-15 (AL096844) probable 3-oxacyl- (acyl-carrier-protein) 644 5525067 reductase [Streptomyces coelicolor A3 (2)] 2E-19 645 4151929 (AF110377) PCAF-associated factor 400 [Homo sapiens] 0. 003 646 1174664 RHODOCOXIN >gil576672 (U17130) ThcC 0. 85 (AF038608) Contains similarity to Pfam domain : PF00046 (homeobox), Score=81. 5, E-value=5. 5e-21, N=1 648 2702397 [Caenorhabditis elegans] 1. 6 SET translocation (myeloid leukemia-associated) >gi|346361|pir||A45018 template activating factor-1, splice 649 4506891 form beta-human >gil338039 3E-10 chloride intracellular channel 3 chloride channel CLIC3 650 4758006 [Homo sapiens] 9E-13 (AL021366) clCK0721Q. 3 (Kinesin related protein) [Homo 651 3702453 sapiens] 5E-38 654 2276316 (Z96810) GLYT-1 LIKE [Homo sapiens] 7E-53 655 3599478 (AF085185) Myosin-IA [Acanthamoeba castellanii] 0. 18 657 2735147 (U87971) syntaxin 5 [Rattus norvegicus] 3E-08 Table 2B Nearest Neighbor (BlastX vs. Non-Redundant Proteins) SEQ ID ACC'N DESCRIP. P VALUE heat shock transcription factor 4 transcription factor 4 [Homo 658 4557651 sapiens] 3E-23 heat shock transcription factor 4 transcription factor 4 [Homo 659 4557651 sapiens] 3E-23 midkine (neurite growth-promoting factor 2) >gi| MIDKINE PRECURSOR (NEURITE OUTGROWTH-PROMOTING PROTEIN) (MK) OUTGROWTH-PROMOTING FACTOR 2) >gil88156lpirllJH0385 midkine precursor-human >gi|35087|emb|CAA38908| sapiens] >cyil 182651 (M69148) midkine [Homo sapiens] sapiens] >gi|219929|dbj|BAA01457| 661 4505135 (D10604) midkine [Homo sapiens] 2E-15 GLYPICAN-2 PRECURSOR (CEREBROGLYCAN) precursor-rat >gil440127 (L20468) cerebroglycan 662 1708021 cerebroglycan [Rattus norvegicus] 0. 00004 H3 histone, family 3A 3B (H3. 3B) >gi|122075|sp|P06351|H33_HUMAN ISTONE H3.3 rabbit >gi|90624|pir||S04186 histone H3. 3-mouse histone H3. 3- fruit fly (Drosophila melanogaster) histone H3. 3B-chicken >gi|2119023|pir||S61218 histone H3. 3-fruit fly (Drosophila hydei) histone (AA 1-136) [Oryctolagus cuniculus] 136) [Gallus gallus] >gij161190 (M17876) histone H3 sapiens] >gil306849 (M11353) H3. 3 histone [Homo sapiens] norvegicus] >gil761716lemblCAA88778l (Z48950) histone H3. 3 [Homo sapiens] >gi|963024|emb|CAA57078| (X81206) 663 4504279 histone H3. 3 [Drosophila hydei] >gil963026lembICAA570811 6E-47 coat assembly complex API sigma-lA subunit >gi|231555|sp|Q00382|AP19_MOUSE CLATHRIN COAT ASSEMBLY PROTEIN API9 (CLATHRIN COAT ASSOCIATED PROTEIN AP19) (GOLGI ADAPTOR AP-1 19 KD ADAPTIN) (HA1 19 KD SUBUNIT) (CLATHRIN ASSEMBLY PROTEIN COMPLEX 1 SMALL CHAIN) >gi|109674|pir||A40535 clathrin-associated protein 19-mouse 664 4557471 >gi|191983 AP-1 clathrin adaptor complex [Homo sapiens] 2E-64 671 410607 drebrin A [chickens, Peptide, 653 aa] 5. 4 (AF152396) beta-lactamase-like protein [Mycobacterium 672 5031433 fortuitum] 2. 3 Table 2B Nearest Neighbor (BlastX vs. Non-Redundant Proteins) SEQ ID ACC'N DESCRIP. P VALUE GROWTH/DIFFERENTIATION FACTOR 5 PRECURSOR (GDF-5) (CARTILAGE-DERIVED MORPHOGENETIC PROTEIN 1) (CDMP-1) >gi|1082279|pir||A55452 cartilage- derived morphogenetic protein 1 precursor-human >gil600732 (U13660) cartilage-derived morphogenetic protein 673 1346125 1 precursor [Homo sapiens] 1. 4 PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASE TYPE III (I-PHOSPHATIDYLINOSITOL-4-PHOSPHATE KINASE) (PIP5KIII) (PTDINS (4) P-5-KINASE C ISOFORM) I-phosphatidylinositol-4-phosphate 5-kinase (EC 2. 7. 1. 68) isoform C-human >gil 1042034lbbsl 169311 isoform C, PtdIns4P 5-kinase isoform C [human, peripheral blood 674 1730569 leukocytes, Peptide, 406 aa] [Homo sapiens] 1. 2 ENDOGLUCANASE A Bacillus sp >gij 142660 (M14781) 675 121781 cellulase (EC 3. 2. 1. 4) 0. 8 PUTATIVE MOLLUSCAN INSULIN-RELATED PEPTIDE (S) RECEPTOR PRECURSOR 676 2497556 >gi|1020140|emb|CAA59353| peptide (s) [Lymnaea stagnalis] 0. 28 677 1330328 (U50595) Rab8-interacting protein [Mus musculus] 0. 096 678 5689505 (AB029007) K1AA1084 protein [Homo sapiens] 4E-59 (Z79754) Similarity to some phosphatases and kinases ; cDNA 679 3876327 EST EMBL : Z14643 comes from this gene SE-10 680 4589530 (AB023160) KIAA0943 protein [Homo sapiens] lue-73 681 533891 (L36073) T-cell receptor antigen [Mus musculus] musculus] 0. 31 HYPOTHETICAL GENE 3 PROTEIN ictalurid herpesvirus 1 (strain auburn 1) >gil331213 4886-5794 [Ictalurid herpesvirus 683 137889 1] 1. 6 hypothetical protein-Escherichia coli plasmid R100 >gil42624lemblCAA39338l (X55815) open reading frame 684 421057 [Escherichia coli] 0. 26 Table 2B Nearest Neighbor (BlastX vs. No-Redundant Proteins) SEQ ID ACC'N I DESCRIP. P VALUE (Z72507) similar to Thrombospondin type I domain ; cDNA EST EMBL : D34389 comes from this gene ; cDNA EST EMBL : D37437 comes from this gene : cDNA EST EMBL : D64645 comes from this gene ; cDNA EST EMBL : D65908 comes from this gene ; cDNA... >gil3877441lembiCAA96654 EST EMBL : D34389 comes from this gene ; cDNA EST EMBL : D37437 comes from this gene ; cDNA EST EMBL : D64645 comes from this gene ; 685 3876064 cDNA EST EMBL : D65908 comes from this gene ; cDNA... 4. 5 686 2317934 (U97553) unknown [murine herpesvirus 68] 0. 02 689 1377886 (L46815) DNA binding protein Rc [Mus musculus] 4. 7 690 627570 phosphorylation regulatory protein HP-10-human 1. 6 cytochrome-c oxidase (EC 1. 9. 3. 1) chain III-Herpetomonas 691 480485 mariadeanei mitochondrion (SGC6) 1. 2 SKI-like SNON >gil68923lpirllTVHUSN transforming protein sno-N-human >gil36511lemblCAA33289l (X15219) snoN 692 4885599 protein (AA 1-684) [Homo sapiens] 0. 18 693 3927838 (AC005727) unknown protein [Arabidopsis thaliana] 0. 000007 (AP000061) 522aa long hypothetical protein [Aeropyrum 694 5104854 pernix] 2. 6 698 4240173 (AB020649) KIAA0842 protein [Homo sapiens] 4E-39 699 4096674 (U35833) ARX [Mus musculus] 5E-16 700 117525 LYCOPENE CYCLASE 6. 1 (AF063866) ORF MSV249 hypotehtical protein [Melanoplus 701 4049765 sanguinipes entomopoxvirus] 8. 1 702 4240203 (AB020664) KIAA0857 protein [Homo sapiens] 8E-43 (Z68159) Similarity to Yeast DNA repair protein RAD50 (SW : RA50_YEAST) ; cDNA EST EMBL : D37313 comes from this gene ; cDNA EST EMBL : D34285 comes from this 703 3874634 gene [Caenorhabditis elegans] 3. 4 704 201995 (M64866) thrombospondin [Mus musculus] 2. 3 LARIAT DEBRANCHING ENZYME debranching enzyme [Saccharomyces cerevisiae] >gil 172552 cerevisiae] >gil486256lemblCAA81990l (Z28149) ORF YKL149c 705 118288 [Saccharomyces cerevisiae ; l. 9 706 2654898 (AF016121) envelope protein 2 [Hepatitis GB virus C] 1. 6 707 5701582 (AF026205) No definition line found [Caenorhabditis elegans] 1. 5 708 2327063 (AF001305) protease 1 [Pneumocystis carinii f. sp. carinii] 0. 18 709 422761 basonuclin-human 0. 17 Table 2B Nearest Neighbor (BlastX vs. Non-Redundant Proteins) SEQ ID ACC'N DESCRIP. P VALUE 710 71403 collagen alpha 1 (1) chain-rat (fragments) 0. 007 (AP000064) 101 aa long hypothetical protein [Aeropyrum 714 5105952 pernix] 9. 7 717 1168479 APX-1 PROTEIN PRECURSOR >gi|473871 6. 3 718 4929024 (AF139719) unknown [Klebsiella oxytoca] 0. 49 GENOME POLYPROTEIN [CONTAINS : NUCLEAR INCLUSION PROTEIN B (NI-B) (NIB) (RNA-DIRECTED RNA POLYMERASE) ; COAT PROTEIN (CP)] >gil320062lpirllGNVSMB genome polyprotein-maize dwarf 719 417509 mosaic virus (strain B) protein [Maize dwarf mosaic virus] 0. 51 TROPOMYOSIN 1, FUSION PROTEIN 34 exons 720 1351287 [Drosophila melanogasterl 0. 11 (AF052433) katanin p80 subunit [Strongylocentrotus 721 3005601 purpuratus] 2E-16 DNA helicase-primase complex component-equine herpesvirus 2 >gil695213 (U20824) DNA helicase-primase 722 1360769 complex component [Equine herpesvirus 2] 2 723 5689525 (AB029017) KIAA1094 protein [Homo sapiens] IE-28 724 3876982 (Z81536) F40D4. 11 [Caenorhabditis elegans] 7. 7 neurofilament triplet M protein-Pacific electric ray 725 85437 (fragment) 0. 011 727 2978255 (AB007407) myeloid zinc finger protein-2 0. 42 (AF064823) NADH dehydrogenase subunit 5 [Sarcophyton 730 4091914 glaucum] 3. 5 731 2905612 (AF041845) gpl30pl [Xenopus laevis] 2. 7 732 2905612 (AF041845) gpl30pl [Xenopus laevis] 2. 7 733 2887499 (AC004143) R29893 1 [Homo sapiens] 2. 7 738 4587223 (AB021660) carbonic anhydrase VB [Homo sapiens] 3. 3 739 4886445 (AL050269) hypothetical protein [Homo sapiens] 1E-14 (AL079308) putative serine/threonine protein kinase 740 5102812 [Streptomyces coelicolor] 1. 1 741 4539386 (AL035526) extensin-like protein 0. 14 742 2496576 HYPOTHETICAL 32. 5 KD PROTEIN Y4AD 7. 8 743 3882265 (AB018315) KIAA0772 protein [Homo sapiens] 2E-13 744 3875383 (Z54284) D2085. 2 [Caenorhabditis elegans] 0. 000003 745 3116122 (AL023287) hypothetical protein 3. 8 749 3043716 (AB011168) KIAA0596 protein [Homo sapiens] 0. 28 (U88154) proline and glutamic acid rich nuclear protein 750 3168604 isoform [Homo sapiens] 0. 035 752 2429324 (AF015116) interleukin 6 receptor [Sus scrofa] 1. 3 Table 2B Nearest Neighbor (BlastX vs. Non-Redundant Proteins) SEQ ID ACC'N DESCRIP. P VALUE (M15972) The first atg start codon is the AA before the stop 753 808667 codon in ORF1 ; putative [Human herpesvirus 4] 1. 1 754 164840 (M10412) carbonic anhydrase I [Oryctolagus cuniculus] 0. 88 synapse-associated protein sap47-1-fruit fly (Drosophila 755 2133726 |melanogaster)>gi|929571|emb|CAA56416|melanogaster] 7E-22 HYPOTHETICAL PROTEIN UL7 cytomegalovirus (strain 756 136797 AD 169) >gil59612lembiCAA354401 7. 4 757 3881372 (Z81141) ZC47. 14 [Caenorhabditis elegans] 3. 3 759 3327160 (AB014573) KIAA0673 protein [Homo sapiens] 3E-57 761 1651655 (D90899) PNIL34 [Synechocystis sp.] 6. 3 env polyprotein-feline immunodeficiency virus >gil59290lemblCAA40321l (X57002) ENV [Feline immunodeficiency virus] >gil228554lprtl1805419A envelope 762 94228 glycoprotein [Feline immunodeficiency virus] 8. 2 (AL079308) putative serine/threonine protein kinase 763 5102812 |[Streptomyces coelicolor] 0. 94 transcriptional adaptor 2 complex) >gil3335555 (AF069733) 764 5454104 ADA3-like protein [Homo sapiens] 2E-54 (U55370) coded for by C. elegans cDNA CEESD82F ; coded 766 1280102 for by C. elegans cDNA CEESD82R [Caenorhabditis elegans] 4. 5 768 3875720 (Z50857) M79. 2 [Caenorhabditis elegans] elegans] 4. 9 769 4502247 armadillo repeat protein sapiens] 4. 8 770 3860231 (AF102887) thrombospondin-4 [Mus musculus] 3. 6 receptor tyrosine kinase c-kit-rat tyrosine kinase [Rattus 771 539999 rattus] 2. 9 773 3550638 (AJ006986) repeating unit transporter 6. 5 (AP000061) 124aa long hypothetical protein [Aeropyrum 775 5105066 pernix] 7. 7 (AE000916) tungsten formylmethanofuran dehydrogenase, 776 2622679 subunit A [Methanobacterium thermoautotrophicum] 4. 8 777 1086650 (U41015) Similar to serine/threonine protein kinase. 0. 4 probable finger protein YOL054w-yeast cerevisiae] >gil 1419863lembICAA990621 (Z74796) ORF YOL054w 778 1363837 [Saccharomyces cerevisiae] 0. 14 779 500858 (D14168) 50kDa lectin [Bombyx mori] 0. 0000004 780 4680659 (AF 132944) CGI-10 protein [Homo sapiens] 4E-67 785 4586844 (AB015633) type 11 membrane protein 3E-09 CYANAMIDE HYDRATASE (UREA HYDRO-LYASE) 786 117800 >gil 102020) pir)) A39365 cyanamide hydratase verrucaria] 1. 8 Table 2B Nearest Neighbor (BlastX vs. Non-Redundant Proteins) SEQ ID ACC'N DESCRIP. P VALUE 787 5689513 (AB029011) KIAA1088 protein [Homo sapiens] 3E-09 CARBON STARVATION PROTEIN A HOMOLOG 790 2829815 tuberculosis] 6. 9 791 2224671 (AB002363) KIAA0365 [Homo sapiens] 6. 6 (AF094519) diaphanous-related formin ; pi 34 mDia2 [Mus 792 3834629 musculus] IE-23 793 1572522 (U67194) upf54. 8 [Enterobacter aerogenes] 3. 3 (Z75536) similar to dynein heavy chain ; cDNA EST EMBL : D27549 comes from this gene ; cDNA EST EMBL : D34859 comes from this gene [Caenorhabditis 794 3876099 elegans] 0. 00001 797 3319990 (Y17267) ubiquitin-conjugating enzyme [Mus musculus] 4E-40 (M17619) NADH dehydrogenase subunit COIII [Asterina 799 473513 pectinifera] 2. 8 (L35031) Orfl59 ; Predicted integral membrane protein with 4 transmembrane sequences (method of Klein, Kanehisa, DeLisi in PCGene). One nucleotide overlap with upstream orf. ; 800 1460094 putative [Escherichia coli] 1. 6 801 4455041 (AFI 16463) unknown [Streptomyceslincolnensis] 0. 081 STAR PROTEIN >gi|472815 (L31886) amino acid feature : potential transmembrane domain, aa 280.. 302 [Drosophila 802 1174467 melanogaster] 0. 053 candidate tumor suppressor involved in B-CLL >gil3l33092lembICAA121361 (AJ224819) tumor suppressor 805 5031861 [Homo sapiens] 3E-15 807 1947168 (AF000299) No definition line found [Caenorhabditis elegans] 0. 24 808 5442104 (AF126467) Gag protein [Simian retrovirus SRV-2] 7. 8 (U20649) NADH dehydrogenase subunit [Cymbidium 809 1684987 atropurpureum] 6 PHOTOSYSTEM I P700 CHLOROPHYLL A APOPROTEIN Al >gil2147916lpirllS73205 photosystem I p700 chlorophyll A apoprotein A 1-Porphyra purpurea chloroplast >gil 1276750 (U38804) Photosystem I p700 chlorophyll A apoprotein Al 810 1709814 [Porphyra purpurea] 0. 74 MELANOCYTE STIMULATING HORMONE RECEPTOR (MSH-R) (MELANOTROPIN RECEPTOR) (MELANOCORTIN-I RECEPTOR) (MC I-R) >gil I I06901pirlIS25581 melanocyte-stimulating hormone 811 400280 receptor-mouse hormone receptor [Mus musculus] 10 Table 2B Nearest Neighbor (BlastX vs. Non-Redundant Proteins) SEQ ID ACC'N DESCRIP. P VALUE (AL031540) internalin-related, Leucine rich repeat containing 812 3581887 protein [Schizosaccharomyces pombe] 3. 6 813 2462671 (Z98529) putative RNA-binding protein 0. 002 ACTIN-LIKE PROTEIN ARP8 YOR141c-yeast 814 2492678 (Saccharomyces cerevisiae) I E-15 (Z77668) predicted using Genefinder ; Similarity to Mouse 815 3879157 selenium-binding protein 6 816 3668141 (AJ007398) PBK1 protein [Homo sapiens] 8E-57 (Z70750) similar to vanadate resistance protein 817 3875131 transmembranous domains [Caenorhabditis elegans] 5E-33 PUTATIVE FORKHEAD-RELATED TRANSCRIPTION FACTOR F26A 1. 2 >gil860690 (U27312) weak similarity to FKH-5 Protein (Mouse, PIR : S36074) and D. melanogaster 819 2494509 fork head domain protein FD4 9. 3 TRANSCRIPTION FACTOR HES-1 (HAIRY AND ENHANCER OF SPLIT 1) >gil539928lpirllA53336 transcription factor HES-1-mouse factor HES-1 [Mus 820 547625 musculus] 0. 69 821 113670 ! ! ! ! ALU CLASS E WARNING ENTRY !! ! ! 0. 23 822 3329124 (AE001337) S/T Protein Kinase [Chlamydia trachomatis] 2. 5 (AE001811) conserved hypothetical protein [Thermotoga 823 4982299 maritima] 0. 09 824 4530509 (AF124748) putative RNA-binding protein 3 825 75198 glycoprotein precursor-Uukuniemi virus 0. 59 MEMBRANE-ASSOCIATED ATPASE GAMMA CHAIN (SUL-ATPASE GAMMA) (ATP SYNTHASE, SUBUNIT D) 826 127477 3. 6. 1. 34) gamma chain-Sulfolobus acidocaldarius 0. 2 HYPERPLASTIC DISCS PROTEIN (HYD PROTEIN) 827 3915729 >gil2673887 (L14644) hyperplastic discs protein 0. 22 (AL034556) predicted using hexExon ; MAL3P5. 16 836 4493951 (PFC0650w), Hypothetical protein, len : 1282 aa 0.69 837 4884027 (AJ011655) hypothetical protein 2. 5 (Z46240) similar to endothelial actin-binding protein repeats ; cDNA EST EMBL : D27639 comes from this gene ; cDNA EST EMBL : D33624 comes from this gene ; cDNA EST EMBL : D33507 comes from this gene ; cDNA EST 838 3873691 EMBL : D36493 comes from thi... 9. 7 Table 2B Nearest Neighbor (BlastX vs. Non-Redundant Proteins) SEQ ID ACC'N DESCRIP. P VALUE teratocarcinoma-derived growth factor I >gi|117473|sp|P13385|CRI1_HUMAN TERATOCARCINOMA-DERIVED GROWTH FACTOR I (EPIDERMAL GROWTH FACTOR-LIKE CRIPTO PROTEIN CRI) (CRIPTO-I GROWTH FACTOR) (CRGF) >gil87385lpirllA30362 epidermal growth factor-like protein CR3-human >gi|30221|emb|CAA32467| factor I [Homo 839 4507425 sapiens] 0. 49 840 2271518 (AF009829) unknown [Mycobacterium bovis] 0. 082 * 841 4093025 (AF070836) NADH dehydrogenase subunit 4 1. 5 842 2662603 (AF036699) No definition line found 6. 4 (Z95621) similar to collagen : cDNA EST EMBL : D69870 comes from this gene : cDNA EST EMBL : D70498 comes from this gene [Caenorhabditis elegans] cDNA EST EMBL : D69870 comes from this gene ; cDNA EST EMBL : D70498 comes from this gene [Caenorhabditis 843 3880368 elegans] 3. 3 HYPOTHETICAL 73. 0 KD PROTEIN IN SEB 1-PTC2 INTERGENIC REGION >gil ! pirS5059I hypothetical protein YER088c-yeast (Saccharomyces cerevisiae) >gil603326 (U 18839) Yer088cp [Saccharomyces 844 731490 cerevisiae] 1. 7 852 4929605 (AF151826) CGI-68 protein [Homo sapiens] 1E-61 855 4996369 (AB021267) polyprotein [Arabidopsis thaliana] 2. 2 (AF001175) ribonuclease P protein subunit pl4 [Homo 856 4100563 sapiens] 2E-10 (U0663 1) homologous to mouse gene PC326 : GenBank 863 458692 Accession Number M95564 [Homo sapiens] 6 RNA POLYMERASE PRINCIPAL SIGMA FACTOR HRDA >gil807l7lpirlIS 17929 transcription initiation factor sigma hrdA-Streptomyces coelicolor subunit (AA 1-396) 864 123518 [Streptomyces coelicolor] 3. 1 LINE-1 REVERSE TRANSCRIPTASE HOMOLOG protein 865 126296 [Nycticebus coucang] 0. 0001 866 4972730 (AF132172) unknown [Drosophila melanogaster] 3E-19 HIGH-MOLECULAR WEIGHT COBALT-CONTAINING NITRILE HYDRATASE SUBUNIT ALPHA hydratase (EC 867 128169 4. 2. 1. 84)-Rhodococcus rhodochrous rhodochrous] 5 868 2809262 (AC002560) F21B731 [Arabidopsis thaliana] 1. 9 Table 2B Nearest Neighbor (BlastX vs. Non-Redundant Proteins) SEQ ID ACC'N DESCRIP. P VALUE four and a half LIM domains 3 LIM-protein FHL3 [Homo 869 4758374 sapiens] 0. 94 ACIDIC PHOSPHOPROTEIN PRECURSOR (50 KD ANTIGEN) >gil4772541pirlIA48455 acidic phosphoprotein PcEMAlq-Plasmodium chabaudi >gil160603 (M95789) 871 400784 acidic phosphoprotein [Plasmodium chabaudi] 3. 3 HYPOTHETICAL PROTEIN KIAA0129 product is novel. 872 2495704 Homo sapiens] 0. 0002 874 4514345 (AB013374) Ykok [Bacillus halodurans] 3. 7 875 5453794 nucleolar protein (KKE/D repeat) IE-18 877 2650666 (AE001107) A. fulgidus predicted coding region AF2427 0. 076 878 1572836 (U70858) similar to family 18 of glycosly hydrolases 2. 7 VITAMIN-K DEPENDENT PROTEIN C PRECURSOR (AUTOPROTHROMBIN IIA) (ANTICOAGULANT PROTEIN C) >gil 112216|pir||S18994 protein C (activated) 879 400853 (EC 3. 4. 21. 69) precursor-rat >gi856963lemblCAA456171 4. 7 880 113668 ! ! ! ! ALU CLASS C WARNING ENTRY !!!! 4. 9 (AJ133120) Proline rich synapse associated protein 2 [Rattus 881 5262748 norvegicus] 8. 6 CYTOCHROME C OXIDASE POLYPEPTIDE I subunit I 883 1352130 [Chondrus crispus] 9. 9 TRANSCRIPTIONAL REGULATOR IE63 human 886 547708 herpesvirus 1 (strain HFEM) 0. 31 dishevelled 2 (homologous to Drosophila dsh) >gil2291008lgblAAB65243. 1l (AF006012) dishevelled 2 887 4758216 [Homo sapiens] 0. 051 888 2291257 (AF016430) contains similarity to a BR-C/TTK domain 0. 016 889 2911858 (AF047659) No definition line found [Caenorhabditis elegans] 3E-26 890 1932813 (U88065) dsRNA adenosine deaminase [Xenopus laevis] 3. 4 893 728836 ! ! ! ! ALU SUBFAMILY SP WARNING ENTRY 0. 39 895 2580578 (AF000996) ubiquitous TPR motif, Y isoform [Homo sapiens] 0. 008 896 1869831 (Z86099) UL9 [human herpesvirus 2] 9. 9 897 2632151 (Y14493) PHOX2b protein [Mus musculus] musculus] 2. 6 GCR 101 protein-fruit fly (Drosophila melanogaster) >gi|510509|emb|CAA50795| (X71975) put. homologue to 898 1079078 S. cerevisiae GARS gene [Drosophila melanogaster] 0. 0000004 NADH dehydrogenase (ubiquinone) (EC 1. 6. 5. 3) chain 4- Crithidia oncopelti mitochondrion (SGC6) subunit 4 [Crithidia 900 418745 oncopelti] 4. 6 Table 2B Nearest Neighbor (BlastX vs. Non-Redundant Proteins) SEQ ID ACC'N DESCRIP. P VALUE (Z36719) cDNA EST yk208g3. 5 comes from this gene 901 3874002 [Caenorhabditis elegans] 0. 41 HYPOTHETICAL 50. 6 KD PROTEIN IN RPL14B-GPAI INTERGENIC REGION >gi|626594|pir||S46802 hypothetical protein YHR004c-yeast (Saccharomyces cerevisiae) 903 731630 >gil500822 (U10555) Yhr004cp [Saccharomyces cerevisiae] 0. 42 904 5081459 (AF124435) p55-related MAGUK protein DLG3 [Daniorerio] 6E-27 HYPOTHETICAL 26. 6 KD PROTEIN T19C3. 4 IN CHROMOSOME III >gi184923 8 (U28412) similar to 906 2497012 polyposis locus protein 1 (SP : DPI_HUMAN, Q00765) 3E-34 907 113671 ! ! ! ! ALU CLASS F WARNING ENTRY ! ! ! ! 0. 0002 909 5410448 (AF135183) Recq helicase 5 2E-52 910 1407655 (U58884) SH3P7 [Mus musculus] 0. 000002 912 2981631 (AB012223) ORF2 [Canis familiaris] 0. 000002 913 2289030 (U53564) N-terminal region of the protein [Mus musculus] 3. 6 914 4567179 (AC007228) BC37295_1 [Homo sapiens] 0. 000002 915 2842531 (AB004291) gamma-subunit of enolase 4. 4 916 1177607 (X92485) pval [Plasmodium vivax] 0. 33 (AC004877) sco-spondin-mucin-like ; similar to P98167 918 3638957 uncertain [Homo sapiens] 4. 3 919 5032163 transcription factor 17 lue-23 (Z37983) contains five copies ofthe EGF-like aspartic acid and asparagine hydroxylation site comes from this gene ; cDNA EST EMBL : D27753 comes from this gene ; cDNA EST 920 3873738... 4. 6 epithelial membrane protein 2 PROTEIN-2 (EMP-2) (XMP 921 4503561 PROTEIN) >gil2474096 (U52100) XMP 4E-08 primase, polypeptide I (49kD) SUBUNIT (DNA PRIMASE 922 4506051 49 KD SUBUNIT) (P49) p48) [Homo sapiens] 0. 064 (AF003534) putative tyrosine protein kinase [Chilo iridescent 923 2738451 virus] 5E-08 glutamine (Q)-rich factor 1, QRF-1-mouse factor 1, QRF-I 925 543222 [mice, B-cell leukemia, BCL1, Peptide Partial, 84 aa] 2E-44 927 961466 (D63777) adhesive plaque matrix protein 4. 9 Table 2B Nearest Neighbor (BlastX vs. Non-Redundant Proteins) SEQ ID ACC'N DESCRIP. P VALUE ANAEROBIC GLYCEROL-3-PHOSPHATE DEHYDROGENASE SUBUNIT B (G-3-P DEHYDROGENASE) subunit B [Escherichia coli] >gil 1788575 (AE000314) sn-glycerol-3-phosphate dehydrogenase (anaerobic), membrane anchor subunit [Escherichia coli] dehydrogenase (EC 1. 1. 99. 5) (anaerobic) 928 121404 chain B 0. 49 930 5640009 (AF167316) zinc finger protein ZFP109 [Mus musculus] 1. 2 931 4678836 (AL049701) hypothetical protein [Homo sapiens] 8E-43 U4/U6-associated RNA splicing factor >gil2708307 (AF016370 U4/U6 small nuclear ribonucleoprotein hPrp3 932 4758556 [Homo sapiens] 6E-09 CARBOXY-CIS, CIS-MUCONATE CYCLASE 3-carboxy- 933 729079 cis, cis-muconate cyclase [Neurospora crassa] 6. 4 934 5080758 (AC007842) BC331191 1 [Homo sapiens] 2E-08 protein phosphatase 1, regulatory subunit 10 >gi|2117159|emb|CAA73697|(Y13247)FB19 protein [Homo 936 4506009 sapiens] 8E-32 (U23175) similar to anion exchange protein [Caenorhabditis 937 726403 elegans] IE-25 (U23175) similar to anion exchange protein [Caenorhabditis 938 726403 elegans] 3E-26 RIBONUCLEASE S-4 PRECURSOR (STYLAR GLYCOPROTEIN 4) (S4-RNASE) 940 2500573 >gi(1405426|emb|CAA65320| 3. 2 941 2291171 (AF016420) No definition line found [Caenorhabditis elegans] 8. 7 UDP-N-ACETYLGLUCOSAMINE--PEPTIDE N- ACETYLGLUCOSAMINYLTRANSFERASE 110 KD SUBUNIT (O-GLCNAC TRANSFERASE P110 SUBUNIT) >gil1931579 (U76557) O-GlcNAc transferase, pl 10 subunit 942 3914191 [Rattus norvegicus] I E-17 MAJOR CAPSID PROTEIN Ll type 34 943 549341 >gil396996lemblCAA52560l (X74476) late protein 8. 1 944 4680673 (AF132951) CGI-17 protein [Homo sapiens] 3E-65 945 4191610 (AF (117107)IGF-II mRNA-binding protein 2 [Homo sapiens] 1 E-51 947 4589512 (AB023151) KIAA0934 protein [Homo sapiens] 5E-46 948 2193870 (D84391) reverse transcriptase [Mus musculus] 2E-09 949 3046871 (AB003753) high sulfur protein B2E [Rattus norvegicus] 5. 7 Table 2B Nearest Neighbor (BlastX vs. Non-Redundant Proteins) SEQ ID ACC'N DESCRIP. P VALUE HYPOTHETICAL 85. 7 KD PROTEIN (ORF C-792) 950 140130 >gi1767331pirlIS03232 hypothetical protein C-792 8 PERIODIC TRYPTOPHAN PROTEIN 1 HOMOLOG (KERATINOCYTE PROTEIN IEF SSP 9502) >gil 177765 951 2494897 sapiens] 2E-08 954 2465332 (U92819) unnamed HERV-H protein [Homo sapiens] 8E-14 (AF102777) FYVE finger-containing phosphoinositide kinase 955 4200446 [Mus musculus] 8E-15 956 3859560 (AF098668) acyl-protein thioesterase [Homo sapiens] 2E-61 958 4008551 (AL034490) pseudouridylate synthase 6. 7 zinc finger protein 91 (HPF7, HTF10) >gi|549839|sp|Q05481|ZY91_HUMAN ZINC FINGER 959 4508041 PROTEIN 91 (ZINC FINGER PROTEIN HTF10) (HPF7) 4E-19 961 1085397 taurine transporter-human >gil559853 2E-14 SERUM RESPONSE FACTOR ACCESSORY PROTEIN IB (SAP-1B) (ETS-DOMAIN PROTEIN ELK-4) protein-1 form . b, SAP-1 b-human >gi338035 (M85164) SAP-1B protein 962 134211 [Homo sapiens] 0. 038 (D63876) KIAA0154 gene product is related to mouse gamma 963 961444 adaptin. [Homo sapiens] 1E-20 general transcription factor IIF, polypeptide 2 (30kD subunit) FACTOR IIF, BETA SUBUNIT (TFIIF-BETA) (TRANSCRIPTION INITIATION FACTOR RAP30) >gil105393lpirllS18677 ATP-dependent RNA helicase 964 4758488 RAP30/74 chain RAP30-human RAP30 [Homo sapiens] 0. 00009 971 5262560 (AL080125) hypothetical protein [Homo sapiens] 2E-41 (U80931) strong similarity to class-III of pyridoxal-phoshate- 972 1707274 dependent aminotransferases 7E-31 (AL032684) conserved hypothetical zinc-finger protein 973 3810839 [Schizosaccharomyces pombe] 7E-12 (AF150755) microtubule-actin crosslinking factor [Mus 975 4887229 musculus] 5E-22 976 1675222 (U67203) ACF7 neural isoform 1 [Mus musculus] 4E-22 (X65335) lacZ [Cloning vector pSV-beta-Galactosidase 977 987050 Control] 3E-15 978 5052075 (AF074331) PAPS synthetase-2 8E-63 (AC004839) similar to IgD B-cell receptor-associated protein 979 3983573 (BAP) ; similar to S46997 (PID : gl085495) [Homo sapiens] 8E-58 Table 2B Nearest Neighbor (BlastX vs. Non-Redundant Proteins) SEQ ID ACC'N DESCRIP. P VALUE (AF060539) channel interacting PDZ domain protein [Mus 980 3108057 musculus] 1E-63 981 1755049 (U55042) myosin X [Bos taurus] 5E-55 (AB000170) endopeptidase 24. 16 type M3 endopeptidase 24. 16 type M3 [Sus scrofa] type M3 [Sus scrofa] >gi|1783130|dbj|BAA19065| type M3 [Sus scrofa] 982 1783123 >gi|1783134|dbj|BAA19067| type M3 [Sus scrofa] 2E-58 983 1098627 (U31079) 47 kDa heat shock protein [Danio rerio] 4. 5 984 3649791 (AB012917) serine protease (TLSP) [Homo sapiens] 6E-76 985 1177607 (X92485) pval [Plasmodium vivax] 0. 13 988 4106444 (AF085692) multidrug resistance-associated protein 3B 0. 97 (AL031863) 1-evidence=predicted by content 1- method=genefinder ; 084 ; 1-method score=66. 31 ; 1- 989 3757569 evidence_end [Drosophila melanogaster] 2. 5 COLLAGEN ALPHA I (VIII) CHAIN PRECURSOR (ENDOTHELIAL COLLAGEN) >gil899571pirlIA34246 990 115317 collagen alpha 1 (VIII) chain precursor-rabbit 0. 29 991 1743404 (Z83327) transport-associated protein 6. 2 (Z49128) similar to cAMP-dependant protein kinase ; cDNA EST EMBL : T00719 comes from this gene ; cDNA EST yk465d8. 3 comes from this gene ; cDNA EST yk465d8. 5 comes from this gene ; cDNA EST yk492f4.3 3 comes from this 992 3878636 gene : cDNA EST y... 3E-53 993 728837 ! ! ! ! ALU SUBFAMILY SQ WARNING ENTRY 4 994 1098627 (U31079) 47 kDa heat shock protein [Danio rerio] 4. 5 995 3649791 (AB012917) serine protease (TLSP) [Homo sapiens] 6E-76 COLLAGEN ALPHA 1 (VIII) CHAIN PRECURSOR (ENDOTHELIAL COLLAGEN) >gil89957lpirllA34246 996 115317 collagen alpha I (VIII) chain precursor-rabbit 0. 29 997 113668 ! ! ! ! ALU CLASS C WARNING ENTRY !!!! 0. 012 998 3722229 (AF058790) SynGAP-b [Rattus norvegicus] 3. 4 (Z79754) Similarity to some phosphatases and kinases ; cDNA 999 3876327 EST EMBL : Z14643 comes from this gene 6E-33 1000 4886288 (AL050300) putative protein [Arabidopsis thaliana] 0. 22 1001 4589530 (AB023160) KIAA0943 protein [Homo sapiens] 1E-73 1003 4063766 (D87895) chitinase [Emericella nidulans] 0. 016 peroxisomal biogenesis factor 3 PROTEIN PEX3 (PEROXIN- 3) >gi|3336882|emb|CAA04879 sapiens] 1004 4505727 >gil4218426lemblCAA08904i (AJ009866) Pex3p e-126 1005 2832671 (AL021712) hypothetical protein 1. 7 Table 2B Nearest Neighbor (BlastX vs. Non-Redundant Proteins) SEQ ID ACC'N DESCRIP. P VALUE HYPOTHETICAL PROTEIN HI1476 Haemophilus 1006 1175815 influenzae (strain Rd KW20) >gil 1574317 influenzae Rd] 7. 1 1007 4927208 (AF133913) ARL-6 interacting protein-6 [Mus musculus] 4E-28 1008 2327063 (AF001305) protease 1 [Pneumocystis carinii f. sp. carinii] 0. 18 1009 2384956 (AF022985) No definition line found [Caenorhabditis elegans] 3E-19 (Z48583) cDNA EST EMBL : T00483 comes from this gene ; cDNA EST EMBL : D64526 comes from this gene ; cDNA EST EMBL : D65147 comes from this gene ; cDNA EST EMBL : D68484 comes from this gene ; cDNA EST EMBL : D67548 comes from this gene ; c >gil3879229lemblCAA88749l EST EMBL : D64526 comes from this gene ; cDNA EST EMBL : D65147 comes from this gene ; cDNA EST EMBL : D68484 comes from this gene ; 1010 3877495 cDNA EST EMBL : D67548 comes from this gene ; cDN... 6. 7 1011 3355308 (AJ009695) wall-associated kinase 4 0. 74 1012 297922 (X66052) D-lactate dehydrogenase 2 (AF124490) ARF GTPase-activating protein GIT1 [Homo 1013 4691726 sapiens] 4E-68 1014 2384956 (AF022985) No definition line found [Caenorhabditis elegans] 3E-19 (D63483) The KIAA0149 gene product is related to Notch3. 1016 1469880 [Homo sapiens] 0. 58 1017 5678967 (AL109630) BACR7A4. ai [Drosophila melanogaster3 1. 4 VEGETATIBLE INCOMPATIBILITY PROTEIN HET-E-1 1018 3023956 >gil607003 (L28125) beta transducin-like protein 5E-28 1019 3882321 (AB018343) KIAA0800 protein [Homo sapiens] e-105 (U65891) protein tyrosine phosphatase CRYP-2 [Gallus 1020 1655907 gallus] 2. 5 1021 3540219 (D87686) KIAA0017 protein [Homo sapiens] 8E-70 ENTEROPEPTIDASE PRECURSOR enterokinase [Bos 1022 1352368 taurus] 7. 7 ribosomal protein S23 S23 >gil543449lpirllS41955 ribosomal protein S23-rat protein [Homo sapiens] >gil453281lemblCAA54584l (X77398) ribosomal protein S23 1023 4506701 [Rattus norvegicus] 9E-15 (AF151522) hairy and enhancer of split related-1 [Homo 1024 5059323 sapiens] 0. 31 (AE001339) ABC Transporter Membrane Protein [Chlamydia 1025 3329139 trachomatis] 1. 2 Table 2B Nearest Neighbor (BlastX vs. Non-Redundant Proteins) SEQ ID ACC'N DESCRIP. P VALUE synapse-associated protein sap47-1-fruit fly (Drosophila 1027 2133726 melanogaster) >gil929571 lemblCAA56416l melanogaster] 8E-25 solute carrier family 25 member 14 >gil3851540 (AF078544) brain mitochondrial carrier protein-1 [Homo sapiens] >gi|4678718|emb|CAB41251.1| protein-1 (BMCP1)) [Homo 1028 4507009 sapiens] e-121 1029 2662336 (D55702) ORF2 [Bombyx mori] 8. 2 transcriptional adaptor 2 complex) >gil3335555 (AF069733) 1030 5454104 ADA3-like protein [Homo sapiens] e-108 mucin (clone pGM7-1)-bovine repeats, clone pGBM7-1} 1031 1363044 [cattle, gall-bladder, Peptide Partial, 600 aa] [Bos taurus] 0. 21 (Z78416) predicted using Genefinder ; Similarity to S. pombe RAD 18 gene (TR : E 198069) ; cDNA EST CEESX52R comes from this gene ; cDNA EST EMBL : D32785 comes from this gene ; cDNA EST EMBL : D35528 comes from this gene ; 1032 3874427 cDNA EST EMBL : D37... 6E-09 GLYCYL-GLYCINE ENDOPEPTIDASE ALE-1 1033 3287732 PRECURSOR >gil 1890068ldbjlBAA 130691 (D86328) ALE-1 1. 7 glycoprotein-rat 986943 (L08134) glycoprotein [Rattus 1034 2143767 norvegicus] norvegicus] 0. 057 (AF 142440) BC1 [Indian mungbean yellow mosaic 1035 4929167 geminivirus] 0. 63 1036 2224593 (AB002324) KIAA0326 [Homo sapiens] 2E-41 1037 3820909 (AJ010642) Dof protein [Drosophila melanogaster] 1. 9 1038 4586844 (AB015633) type II membrane protein 3E-09 (AC003979) Contains similarity to ycf37 gene product gb|1001425 from Synechocystis sp. genome gblD63999. ESTs gb|T43026, gblR64902, gblZ18169 and gb|N37374 come from 1039 3287688 this gene. [Arabidopsis thaliana] 0. 036 heat shock transcription factor 4 transcription factor 4 [Homo 1040 4557651 sapiens] 3E-23 heat shock transcription factor 4 transcription factor 4 [Homo 1041 4557651 sapiens] 3E-23 Table 2B Nearest Neighbor (BlastX vs. Non-Redundant Proteins) SEQ ID ACC'N DESCRIP. P VALUE coat assembly complex API sigma-lA subunit >gi|231555|sp|Q00382|AP19_MOUSE CLATHRIN COAT ASSEMBLY PROTEIN AP19 (CLATHRIN COAT ASSOCIATED PROTEIN API 9) (GOLGI ADAPTOR AP-1 19 KD ADAPTIN) (HA1 19 KD SUBUNIT) (CLATHRIN ASSEMBLY PROTEIN COMPLEX 1 SMALL CHAIN) >gij 109674lpirllA40535 clathrin-associated protein 19-mouse 1042 4557471 >gi|191983 AP-1 clathrin adaptor complex [Homo sapiens] 4E-73 (AL031540) internalin-related, Leucine rich repeat containing 1043 3581887 protein [Schizosaccharomyces pombe] 3. 6 ACTIN-LIKE PROTEIN ARP8 YOR141c-yeast 1044 2492678 (Saccharomyces cerevisiae) 6E-21 HYPOTHETICAL PROTEIN KIAA0129 product is novel. 1052 2495704 [Homo sapiens] 0. 0002 1054 4680703 (AF132966) CGI-32 protein [Homo sapiens] 1E-91 reverse transcriptase-Trypanosoma cruzi transcriptase 1055 1078718 [Trypanosoma cruzi] 1. 1 1056 728835 ! ! ! ! ALU SUBFAMILY SC WARNING ENTRY 0. 16 1057 1932813 (U88065) dsRNA adenosine deaminase [Xenopus laevis] 5. 4 RNA helicase HELI 17-rat >gil897915 (U25746) RNA 1058 1363325 helicase [Rattus norvegicus] 3E-91 1059 631772 TEG-261 protein-mouse 2E-47 1062 2506774 KERATIN, TYPE II CYTOSKELETAL 8 2E-42 1063 4406551 (AF131739) Unknown [Homo sapiens] 2E-82 1064 4678836 (AL049701) hypothetical protein [Homo sapiens] 3E-13 1065 4567179 (AC007228) BC37295_1 [Homo sapiens] 0. 000005 1066 3953593 (AB020542) Zinc finger protein s 11-6 [Mus musculus] IE-32 1068 3170180 (AF039690) antigen NY-CO-8 [Homo sapiens] 0. 26 1069 4678836 (AL049701) hypothetical protein [Homo sapiens] 3E-13 1070 2558501 (D63850) hepatoma-derived growth factor 3E-24 1071 3327220 (AB014603) KIAA0703 protein [Homo sapiens] 5E-53 cartilage-associated protein cartilage-associated protein 1072 5453601 (CASP) [Homo sapiens] e-125 (U91561) pyridoxine 5'-phosphate oxidase [Rattus 1073 3237304 norvegicus] 3E-56 zinc finger protein 91 (HPF7, HTF10) >gi|549839|sp|Q05481|ZN91_HUMAN ZINC FINGER 1074 4508041 PROTEIN 91 (ZINC FINGER PROTEIN HTF10) (HPF7) IE-21 Table 2B Nearest Neighbor (BlastX vs. Non-Redundant Proteins) SEQ ID ACC'N DESCRIP. P VALUE (D63876) KIAA0154 gene product is related to mouse gamma 1075 961444 adaptin. [Homo sapiens] lue-20 (U80931) strong similarity to class-III of pyridoxal-phoshate- 1077 1707274 dependent aminotransferases 7E-31 1078 1546779 (U28789) PACT [Mus musculus] 0 1079 5052075 (AF074331) PAPS synthetase-2 8E-63 Table 3 SEQ ID NO : Profilename Start Stop Direction 97 Kazal 25 243 for 227 helicase C 212 389 for 242 EFhand 275 310 for 450 SH3 44 226 for 473 Zincfing_C2H2 211 273 for 505 WD domain 80 178 for 512 ZincfingS2H2 147 209 for 523 PDZ 168 395 for 527 ras 18 395 for 545 ANK 311 393 for 547 Ets Nterm 7 237 for 606 WW domain 120 209 for 635 protkinase 47 400 for 635 mkk 41 394 for 636 trypsin 147 381 for 640 ZincfingS2H2 122 184 for 693 Zincfing CCHC 135 185 for 721 WD domain 18 116 for 805 Zincfing C3HC4 263 406 for 918 BZIP 51 224 for 919 Zincfing C2H2 125 187 for 925 FKH 9 230 for 971 Zincfing C2H2 202 264 for 973 Zincfing CCHC 262 309 for 980 PDZ 241 468 for 992 mkk 0 708 for 992 protkinase 121 711 for 995 trypsin 202 760 for 984 trypsin 202 760 for 1018 WD domain 18 116 for 1028 pr55 24 1293 for 1035 ATPases 74 616 for 1036 Zincfing_C2H2 122 184 for 1053 14 3 3 63 619 for 1058 helicase C 212 448 for 1058 ATPases 59 442 for 1063 Zincfing_C2H2 211 273 for 1066 Zincfing_C2H2 125 187 for 1072 ATPases 808 1284 for 1078 protkinase 309 1022 rev 1078 neur chan 12 508 rev 1078 ZincfingCCHC 262309 for 1078 Zincfing_C3HC4 557 679 for Table 13 ES55 ES56 ES57 ES58 M00004170C : H06 M00004036B : C11 M00004288D : E07 M00023298B : G07 M00004170D : C06 M00004064B : G03 M00004318D:D07 M00026819B : E02 M00004171D : H10 M00004067C : E05 M00004356C : D02 M00026914C:H10 M00004174B : B12 M00004099C : F04 M00004391C:F12 M00027023B : H12 M00004175D : G10 M00004103A:E06 M00004386C : C03 M00027085A : G10 M00004176A : E07 M00004138B:H11 M00004414D : C11 M000027248D : DO ! M00001352D : A09 M00004167A:H04 M00004422C : A01 M00027546B : A11 M00001345C : B10 M00004158C:B01 M00004427D : H04 M000023299B : AOI M00001382D : F03 M00004165B : E03 M00004502B : G05 M000026857A : F02 M00001419A : E01 M00004181A:B05 M00004495D : A05 M000026858C : H05 M00001437D : A12 M00003993C : G I I M00005364C : A02 M000026861A : B05 M00001441D : G02 M00004046C:A04 M00005375B : H03 M00026846C : BOI M00001601D : A03 M00004034A : G03 M00005420C : E10 M000027131A : H02 M00001677B : GOI M00004036C : E10 M00005413B : B02 M00027396A : F07 M00001678A : B01 M00004043C : A06 M00005438D : A08 M000023301B : COI M00001675C : F05 M00004067C : C10 M00005453B : B06 M000023321B : F06 M00001360D : C12 M00004068A : A03 M00005446B : D10 M000023401C : D12 M00001389C : EOI M00004069A : E04 M00005493D : H12 M00026941C : E11 M00001390C : H05 M00004071C : B06 M00005476D : A I I M00027067A : B02 M00001399B : C04 M00004127C : C08 M00005482A : D08 M000027036B : D07 M00001507A : H06 M00004157C : E06 M00005485C : F09 M00027329A : H04 M00003747C : G12 M00004165D : H12 M00005563C : D05 M00027740C : C05 M00001358B : F12 M00003995B : C06 M00005569B : E04 M00023340A : A10 M00001360B : F09 M00004090A : B I 1 M00005621B : C09 M00026942C : A06 M00001392A : F02 M00004084C : F05 M00005628D : A10 M00027066A : A04 M00001397D : G04 M00004087A : H06 M00005629B : G06 M000027072C : A I I M00001463C : E12 M00004110A:G03 M00004866C : H08 M00027028A : B06 M00001531B : A03 M00004117D : F06 M00004872C : G03 M00023282B : H09 M00001507D : F09 M00004150A : B09 M00005358B : D10 M00023295B : C03 M00001513B : F05 M00004140C : D04 M00005385D : B08 M000026811A : ROI M00001514B : C02 M00004175D : D05 M00005392C : B03 M000026850B : F07 M00001576C : E03 M00004176A : H05 M00005395C : Ci ! M00026913D : G11 M00003756D : B09 M00004170C:A12 M00005396A : COI M00026936D : DO ! M00003907C : D02 M00004237B : GOI M00005435B : F01 M000027083C : F06 M00003926A : D01 M00004253A : E02 M00005464B : B08 M00027152D : H06 M00003928D : A04 M00003997D : G03 M00005505B : D10 M00027209D : B09 M00003935D : E04 M00003998C : D04 M00005509D : G05 M00027339D : E10 M00003985B : F06 M00004027C : E06 M00005614A : B07 M00027282D : G01 M00004063B : B12 M00004059D : A09 M00005721C:A12 M00023287A : D08 M00004101A : C12 M00004087B : D05 M00005705D : G09 M000026928A : B06 M00004104C : F06 M00004114C : B09 M00005709D : H05 M000027028B : C12 M00004107A : E02 M00004140B : C02 M00004859D : DO ! M00027115B : G04 M00004108B : D04 M00004149C:D11 M00005342D : E04 M00027096B:A01 M00003856A : H10 M00004168D:F05 M00005363D : C05 M00027154B : D05 173 Table 13 ES55 ES56 ES57 ES58 M00003908C : C04 M00004176B : H09 M00005353C : H01 M00027164A : A09 M00003895C : F05 M00004173A : D03 M00005386C : GO M00027218C : D06 M00003939B : C02 M00004209B : G01 M00005388B : B02 M00023343B : C08 M00003997A : C08 M00004253D : D04 M00005396C : H04 M00026871C : F12 M00004066D : C02 M00004275A : H07 M00005434A : F11 M00026882A : E07 M00004105C : C05 M00004269C : B10 M00005434C : E02 M00027067B : E09 M00003788B : C08 M00004298A : H09 M00005473C : F02 M00027062C : C04 M00003788C : C05 M00004347A : F10 M00005459B : A01 M00027131C : E07 M00003835B : C05 M00004337A : A07 M00005469A : D10 M00027137D : F05 M00003820B : G04 M00004372A : A08 M00005505D : H08 M00027204B : A08 M00003888C : G08 M00004406D : E11 M00005509B : E10 M00027188A : D12 M00003977D : H04 M00004449B : B05 M00005616B:E11 M00027190B : F06 M00004029D : H03 M00004507A : F11 M00005589B : H12 M00027193A : F07 M00004034A : A05 M00004276A : C06 M00005721D : B03 M00022362D : G11 M00004140D : E03 M00004270C:H05 M00005698A : H12 M00007947B : F07 M00003775C : C01 M00004343A : G07 M00006613C : C02 M00007948B : B07 M00003776B : F08 M00004344B : C06 M00006617A : A06 M00008003B : F09 M00003839D : C03 M00004373D : G10 M00006584D : D01 M00008054C : C03 M00003818C : D02 M00004368A : G11 M00006594B : D05 M00008075D : B01 M00003820C : E08 M00004371B:A05 M00006600D : G07 M00022074A : F05 M00003822A : D02 M00004403A : A02 M00006631D : G09 M00007943C:B02 M00003877C : GOI M00004445D : A04 M00006635A : C01M00008002B : F09 M00003880A : G10 M00004447A : A10 M00006726D : H10 M00021653C:B06 M00003919D : FOI M00004603D : D09 M00006874D : EOI M00021851D : H06 M00003960D : E09 M00004326D : D06 M00006882C : D03 M00022015D : C11 M00004081A : E11 M00004323B : G12 M00006925B : B02 M00022018B : E09 M00004085B : D12 M00004350A : C04 M00006946B : C08 M00022095C : F03 M00004142C : A06 M00004357A:B10 M00006949B : C07 M00007996C : B11 M00004135D : D01 M00004360B : B08 M00007026A : A03 M00007977B : C11 M00004198B : G08 M00004385D : D06 M00006712A : FOI M00008088D : BOI M00004185B : H03 M00004414D : A01 M00006727A : H12 M0002676B : B12 M00004187A : B05 M00004415A : A01 M00006815D:D11 M00021972A : C10 M00004251B : H12 M00004423A : B05 M00006805D : H12 M00022099C : A10 M00004232D : G I I M00004423C : F03 M00006934B : B I I M00022106D : B06 M00004240A : D03 M00004426B:H06 M00007019B : G01 M00007978B : C04 M00004285C : B06 M00004504C : G07 M00007038D : DOI M00008053D : E09 M00004292A : C08 M00004466A : E04 M00007041C : C05 M00021669B : G02 M00004335A : G05M00004498D : A11 M00006630A : E05 M00022118A : D08 M00004240C : A06 M00004292A : F03 M00006623C : G07 M00022251A : F07 M00004249A : C09 M00004280D : D10 M00006694D : G06 M00022235D : F07 M00004335D : D03 M00004286D : D02 M00006668D : B10 M00022240C : B03 M00004378A : H10 M00004870D : E05 M00006688A : F09 M000022406C : G03 M00004381A : E10 M00004871C : C04 M00006745B : C05 M00022459C : G05 M00004444C : H11 M00004872A:D07 M00006846A:B03 M00022627B : D01 174 Table 13 ES55 ES56 ES57 ES58 M00004225A : E03 M00005395D:D11 M00006823A : H06 M00022184D:F07 M00004284A : C09 M00005395D : B12 M00006925A : B09 M00022177D : G02 M00004264B : F03 M00005412D : G07 M00006894D : A07 M00022460C : E12 M00004404C : B03 M00005413D : G 12 M00006895D : A02 M00022627A : A02 M0000441OA : F06 M00005513A : H01 M00006991B : E05 M00022144D : D09 M00004412A : G05 M00005515D : G02 M00006994A : C12 M00022203B : A05 M00001340C : A08 M00005607A : C08 M00007046D : E10 M00022214C : C11 M00001340C : D09 M00005366D : E12 M00006577A : B01 M00022252C : A04 M00001395D : B04 M00005618C : H11 M00006630A : E09 M00022420B : C08 M00001466C : H11 M00005708C : D11 M00006619A:G11 M00022640B : G10 M00001528D : B12 M00005810B : C07 M00006704A : C11 M00022641C : H03 M00001517C : A10 M00006795C : B 12 M00022127C : E01 M00022652B : G06 M00001561A : G10 M00006755C : C03 M00022128A : C05 M00022216C : H02 M00001565C : F06 M00006756D : G07 M00022176D : F05 M00022199A : F09 M00001569A : H01 M00006779D : F03 M00022214A : H05 M00022214A : D01 M00001341A : H10 M00004821D : C03 M00022220B : B06 M00022273A : B03 M00001375C : C11 M00005358A : H03 M00022278C : E04 M00022256D : G11 M00001397C : FOI M00005480C : A04 M00022282A : A I 1 M00022261C : D06 M00001431A : F03 M00005481C : H05 M00022260C : H07 M00022490B : G12 M00001457D : E08 M00005490B : B02 M00022263A:C01 M00022648D : G11 M00001505C : C10 M00005820A : H11 M00022377A : E02 M00022709A : G02 M00001615A : D01 M00006621B : B06 M00022399C : B02 M00022701C : A05 M00001618C : E01 M00006752C : D04 M00022056C : D12 M00022826A : C08 M00001358C : D09 M00006757D : H04 M00022087A : D01 M00022963A : E07 M00001360B : B01 M00005000A : H05 M00022088B : E05 M00022904D : D04 M00001391C : B05 M00005296D : G03 M00022090D : B03 M00023095C : A09 M00001389B : B12 M00005378B : B04 M00022094A:A09 M00022684C : C12 M00001485A : C04 M00005461C : D11 M00022096B:D10 M00022765B:E03 M00001559D : E02 M00005464D : D07 M00022176A : F02 M00022898C : H07 M00001545D : F12M00005657B : F I I M00022217B : E03 M00022902B : F10 M00001549C : F10 M00006596D : H02 M00022259A : D04 M00023003A : HOI M00001579C : E07 M00005826B : F10 M00022381B : C12 M00022768A : A10 M00001630A : E08 M00006577B : F01 M00022399D : A07 M00022834A : H02 M00001386B : EOI M00006582A : F12 M00022401C:G07 M00023002A : C02 M00001389A : F03 M00006664A : C05 M00022407D : G07 M00023003C : C10 M00001418C : F06 M00006678C : B07 M00022417B : COI M00023012A : C06 M00001454D : H09 M00006840A : A12 M00022435C:C05 M00007973D : B03 M00001442D : D09 M00005020B : D10 M00022471D : A05 M00007939A : F06 M00001450D : H12 M00005296B : H07 M000224641) : F12 M00007941D : D07 M00001479D : B10 M00005403A : D12 M00022469A : A05 M00007948D : F08 M00001598C : F02 M00005376B : E08 M00022500B : D01 M00008012D : H04 M00001594A : HOI M00005378C : B12 M00022506D : B03 M00008014D : A11 M00001657D : D07 M00005397A : G08 M00022542A : B06 M00008048C : A08 M00003772C : F12 M00005449D:D04 M000225270 : A09 M00008099A : C12 175 Table 13 ES55 ES56 ES57 ES58 M00003844D : B02 M00005465A : A07 M00022568B : D03 M00021668D : G09 M00003845B : A04 M00005648C : C11 M00022561D : E06 M00021861C:B08 M00003845C : F08 M00006595C : B08 M00022687C : C11 M00021980A : F03 M00003848A : E08 M00006816D : D08 M00022695D : B02 M00007931A : B07 M00003880C : D06 M00006835D : C08 M00022425 A : F11 M00007948C:G01 M00001647D : A02 M00006914C : D07 M00022434D : B06 M00007969B : E10 M00001655C : F07 M00007177A : G07 M00022460D : C07 M00008012B : C05 M00003804D : F12 M00006920B : H07 M00022510A:B09 M00008012D : E07 M00003884C : G09 M00007161C : D12 M00022501D:A09 M00008014C:H01 M00003916D : A10 M00006968D : H02 M00022541D : G06 M00008016C : E06 M00003943B : C12 M00006936C : GAA M00022527B : H05 M00008052C : G11 M00003935A : C04 M00006945D:A07 M00022538D : B02 M00008054C : E07 M00003937D : F09 M00007047C : H04 M00022559D : F10 M00008093C : G08 M00001683B : F12 M00007065D : A03 M00022569D : H03 M00021614A : C09 M00001669B : H04 M00007079D : H01 M00022601A : A09 M00008094D : C02 M00003762D : C02 M00006968A : H05 M00022604A : F06 M00021667C : G10 M00003788D : E06 M00007078B : H04 M00022684B : F11 M00021674A : B07 M00003824A : B11 M00007186A : A 12 M00022702A : D10 M00021846B : F05 M00003865B : D10 M00004852B : H08 M00022691A : G01 M00021847B : A09 M00003870C : H03 M00005382A : G09 M00022696A : H03 M00021963C : H04 M00003901B : C02 M00005418C : B09 M00022444B : C04 M00007985C:G07 M00003893A : D03 M00005420C : E03 M00022447A : H06 M00008001D : Full M00003931A : G01 M00005450C : G09 M00022488C:H02 M00007992A : G04 M00003973A : D09 M00005444D : D01 M00022522B : A05 M00008000D : B06 M00001660A : B10 M00005494C : F08 M00022513C : G04 M00008001A : G11 M00003761C : C05 M00005479C : A05 M00022517C : B01 M00008044C : A05 M00003829C : G07 M00005486A : F07 M00022546B : F12 M00008085B : G01 M00003833D : F11 M00005538C : H11 M00022591C : F03 M00008082B : C05 M00003879D : A09 M00005648C : E10 M00022617B : A01 M00008083A : Hl I M00003880B : B08 M00005621A : B05 M00022681D:H10 M00021624B : E11 M00003861D : G10 M00004847D : GOI M00022659B : C01 M00021689A : G05 M00003876C : G11 M00005342B : G01 M00022664C : G10 M00021865B : F06 M00003877C : C11 M00005305A : H01 M00022711B : A05 M00021879B : CI1 M00003902C : D02 M00026906B : G03 M00022704A : H08 M00021958A : A03 M00003933A : B04 M00026872A : C10 M00022449D : B05 M00021945A : B04 M00003923D : A03 M00026964C : H02 M00022548A : F02 M00021981D : All M00003989D : A02 M00026982C : D08 M00022590D : E08 M00007987A : D10 M00003991A : D05 M00027069D : F02 M00022622A : E08 M00007998C : B04 M00004030C : E05 M00027042D : E02 M00022655A : F09 M00008001B : E11 M00004048A : E10 M00027056B : H07 M00022664A : E04 M00008045A : B05 M00006680D : A01 M00027137C : A03 M00022720A : C01 M00008023A:B03 M00006688C : C12 M00027184D : H02 M00022722D : C07 M00008027D : H09 M00006740A : A06 M00027189C : D04 M00022746D : D05 M00008044B : F07 M00006757A : C09 M00027196A : A10 M00022772A : A06 M00008089C : B08 176 Table 13 ES55 ES56 ES57 ES58 M00006859D : E11 M00027357D : A02 M00022813C : B09 M00021620D : B06 M00006917B : C05 M00027369A : B03 M00022853D : C05 M00021624B : D03 M00006919A : H12 M00027439B : A09 M00022843A : D02 M00021628C : B09 M00006993B : F02 M00027393D : FOI M00022844C : AOI M00021680D : H08 M00007093C : C11 M00027557D : B06 M00022968D : G06 M00021687C : A04 M00007047D : C02 M00027502C : H02 M00023023B:A05 M00021696C : E02 M00007064B : E09 M00027507C : C06 M00022716A : C01 M00021698A : H03 M00007121A : G04 M00027529B : B11 M00022725D : G05 M00021864C : C07 M00007107C : D02 M00027438D : A03 M00022817D : B09M00021958A : A04 M00007178D : A10 M00027388A : G05 M00022848D : H09 M00021949D : A05 M00007156D : E11 M00027396C : B06 M00022884D : A07 M00021951B : A01 M00007172D : H03 M00027551C : B07 M00022983A : H04 M00022001B : H10 M00007175D : G02 M00027518B : B07 M00023034B : B10 M00022001D:E06 M00007121D : AH M00027528A : G03 M00023038D : D04 M00022071D : C08 M00007101C : H01 M00027759B : E11 M00022743C : G05 M00022078B : B04 M00007104D : D10 M00027728A : B03 M00022734C : A03 M00022113B : A12 M00007116A : C08 M00027484A : G03 M00022737D : B02 M00022138C : B07 M00007152A : A10 M00027752B : E05 M00022801A : G04 M00022152A : G05 M00007179B : H04 M00022838B : E05 M00022158C : C08 M00007157B : B04 M00022856A : B09 M00022192B : H07 M00007167C : B10 M00022902C : F11 M00022233C : D11 M00007175B:B11 M00022893D : C06 M00022252A : COI M00007177B : C02 M00022922D : G06 M00022370A : G07 M00007141A : G08 M00022986B : C02 M00022300A : A05 M00007196D : D02 M00023002D : C12M00022386D : C04 M00007145C : B05 M00023096C:A03 M00022072D : E12 M00007126D : H01 M00023097A : C03 M00022102D : A10 M00007140C : G12 M00022743C : G06 M00022207C : COI M00007200A : B12 M00022736B : B03 M00022249C : G09 M00007203C : E06 M00022737B : F12 M00022383C : F05 M00022831C : F11 M00022384B : E06 M00022836C : A07 M00022067A : B03 M00022854D : C04 M00022056B : G12 M00022860A : A07 M00022084B : C03 M00022861C : B04 M00022087D : F12 M00023096A : F03 M00023096D:B11 M00023097C : D10 Table 14 ES59 ES60 ES61 ES62 M00001418A : A02 M00001477A : G02 M00004450A : G07 M00005515B : B08 M00003877C : A08 M00003853C : A09 M00004353D : C06 M00005385B : A10 M00003977C : D01 M00001694B : H12 M00004406A : H12 M00005516D : F12 M00004295A : C02 M00001664D : E02 M00004048C : C02 M00005822D : C05 M00001383C : C04 M3847B : H01 M00004170B:G04 M00004841C : H03 M00001500A : A02 M00001631D : G08 M00004108C : D07 M00005810B : G02 M00003880B : D03 M00004498D : F02 M00004125B : A02 M00007107A : H08 M00003803B : G12 M00001563A : F04 M00004109A : B07 M00004825A : G12 M00003819D : B02 M00001558D : E02 M00004123B : G05 M00005327C : G08 M00004178B : F07 M00004273C : H I I M00004152A : F03 M00005390C : E05 ES63 ES64 ES65 ES66 M00005520A : H11 M00006790D : F10 M000027175D : A05 M00026949A : F04 M00006814D : D09 M00006627C : C02 M00026910C : C05 M00023432D : F09 M00006918D : G08 M00027462D : A12 M00027280D : H01 M00027178B : E04 M00007197D : D12 M00026972A : F04 M00023289D : E06 M00027225B : D03 M00005497C : G08 M00027592D : C05 M00023373A : D01 M00023340B : B07 M00007109D : G01 M00026945B : C10 M00027231A : D01 M00027283C : H12 M00005377C : F07 M00027231C : D08 M00023321A : F07 M00027085C : H12 M00006813B : E04 M00027083D : F06 M00027266C : G12 M00027234C : B05 M00005825A:A10 M00027142A : COI M00023398D : F10 M00023390A : C04 M00005416B : A01 M00027607A : A09 M00027603C : E02 M00026810A : H04 ES67 ES68 ES69 ES70 M00023340B : H12 M00027642C : D11 M00022714B : D04 M00022709A : COI M00027237C : D04 M00027202B : B09 M00022838A : H05 M00022413B : D07 M00026809C : D10 M00027459A : G12 M00022392C : H06 M00022467C : H07 M00027386D : C02 M00027250A : C04 M00022363C : D03 M00022561B : B09 M00027343B : H05 M00027499B : G02 M00022205A : C02 M00022214C : E09 M00027356A : H02 M00027053C : B06 M00022717C : F05 M00022697A : C08 M00027363D : A08 M00027598C : D06 M00008015B : D08 M00022682A : F10 M00027364D : E08 M00006989C : BOI M00021625B : G07 M00021841A : E11 M00027618A : B08 M00006837B : H12 M00008100D : C08 M00021691B : E04 M00027628D : D08 M00007202A : A09 M00022669D : G07 M00022477C : C07 Table 14 ES71 ES72 ES73 ES74 M00022134D : D12 M00008028D : BOI M00022513C : E10 M00023363C : A04 M00022705B : F08 M00021931B : F04 M00022518C : C04 M00001401B : A02 M00022903D : H02 M00008097C : E04 M00022544C : D08 M00008023C : A06 M00022915C : C09 M00008082B : H10 M00022785C : B10 M00022077D : A12 M00007965C : B02 M00008006A : H02 M00022525C : E09 M00023284B : G06 M00022368C : C11 M00022167B : H02 M00022741D : F08 M00023369D : C05 M00007937C : E08 M00022509D : A12 M00022923A : A09 M00023413D : F04 M00021852C : D12 M00022169A : E11 M00026905A : G11 M00008000D : G11 M00022184D : H07 M00027169D : H06 M00021908B : F03 M00022441B : A06 M00005434D : H02